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The work outlined in this thesis explores the development of multi-component crystalline materials, in 
terms of the methods used for their preparation and how these materials can be applied so as to exploit 
their physicochemical properties. Focussing on co-crystals and salts, by combining two molecular 
entities within the same crystal lattice, the resultant multi-component system can present a different 
structure and, therefore, different physical attributes when compared to the starting materials. In many 
cases, these changes are beneficial, with implications for properties such as solubility, melting point 
and resolution processes. Like with many crystalline forms, multi-component materials can demonstrate 
structural variations. Here, these can manifest as either polymorphic, stoichiometric or enantiomeric 
variants, with the possibility of accessing each form depending upon the crystallisation conditions used. 
As such, each preparative method is reliant on the composition of material used and the kinetic 
parameters governing the process. These concepts, examples thereof and the methods of analysis used 
are detailed in Chapters 1-3.  
 
The research discussed within this volume was conducted at the University of Bath as part of the EPSRC 
Future Manufacturing Hub in Continuous Manufacturing and Advanced Crystallisation (CMAC), a 
collaboration between academia and industry. The aim is to explore the future manufacturing needs of 
key commercial bodies, particularly the pharmaceutical industry, concentrating on unit operations such 
as crystallisation, with a drive to facilitate the adoption of continuous processing techniques. 
 
Chapters 6-8 explore the potential of the chiral active pharmaceutical ingredient (API) naproxen (NPX) 
to form novel multi-component materials, with applications towards the preferential resolution of 
enantiomers via crystallisation. NPX preferentially forms a racemic crystalline phase at racemic 
compositions, rendering it unsuitable for direct resolution by crystallisation. Using a combined 
approach of mechanochemical and solution-based crystallisation methods, novel materials 
incorporating the API with a secondary molecule (co-former) were discovered, each displaying 
different chiral crystalline properties. These ranged from further racemic compounds, racemic solid 
solutions and that of metastable racemic conglomerates. Samples were phase characterised at 
enantiopure and racemic compositions using X-ray diffraction (Single Crystal X-ray Diffraction, 
SCXRD, and Powder X-ray Diffraction, PXRD), thermal methods (Differential Scanning Calorimetry, 
DSC, and Hot-Stage Microscopy, HSM) and Infrared (IR) spectroscopy.  
 
Chapter 6 focusses particularly on the system of NPX with the co-former 2-aminopyridine (2AP), a 
metastable conglomerate. This was determined using crystallographic and binary (melting point) phase 
diagram analysis. Despite the existence of a racemic solid at the corresponding compositions and 
through the design of initial cooling crystallisations, based upon ternary (solubility) phase diagram 
analysis, the homochiral phase was shown to crystallise at compositions tending towards racemic. This 
demonstrated a system with direct applications towards a preferential crystallisation process.   
 
Finally, in chapter 9, a variety of preparative methods were assessed in terms of their ability to 
selectively produce either of the stoichiometric co-crystals (1:2 or 1:1) of oxalic acid (OA) and urea (U). 
The methods used ranged from mechanochemical to slurrying to evaporation. Both phases could be 
accessed using these techniques depending upon the solvent or composition of material used. 
Furthermore, both co-crystals were shown to be selectively yielded from batch cooling crystallisations, 
with the (1:2) and (1:1) phases being accessed at room and higher temperatures, respectively. Selecting 
the more stable (1:2) phase and using the continuous crystallisation platforms based at the University 
of Bath, the Continuous Oscillatory Baffled Crystalliser (COBC) and the Kinetically Regulated 
Automated Input Crystalliser (KRAIC), it was further shown that this co-crystal could be consistently 
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1 Background and theory 
 
Across many industries, particularly the pharmaceutical industry, the ability to manufacture materials 
in the solid-state is of great importance, with the vast majority of pharmaceutical products being 
administered as solid dosage forms, be it through tablets, powders or capsules.1, 2 It is widely understood 
that the physicochemical properties of a material are directly related to its solid-state structure, with 
implications on properties such as solubility, stability and bioavailability.3, 4 In the case of 
pharmaceuticals, many compounds do not reach the marketplace owing to deficiencies in properties 
that can affect manufacturing or efficacy upon reaching the end-patient.5 As a result, the industry today 
is focussed on addressing these issues, through the manipulation of solid-state structures of active 
pharmaceutical ingredients (APIs), influencing properties, leading to materials that perform better 
throughout the pharmaceutical manufacturing and drug life cycles.6, 7 
 
In this introduction, many of the principles underpinning solid-state chemistry, particularly in the 
context of the pharmaceutical industry, will be outlined. The concept of structural variations within 
small organic molecule crystalline materials, including polymorphic, multi-component and chiral 
variants, will be introduced, along with the underlying theory of crystallisation and crystallisation 
techniques, exploring how crystallisation is currently utilised in industry and how it is being developed 
for the future. 
 
1.1 Solid-state materials – Crystalline and amorphous 
 
Solid materials7, 8 are divided into subcategories representing different degrees of order, either described 
as crystalline or amorphous. Amorphous materials7, 9 have little or no long-range order, but do exhibit 
short-range order similar to that of liquids. This short-range order stems from atoms or molecules being 
assembled and connected through a range of localised intermolecular interactions, comparable to that 
observed in crystalline phases. However, these local arrangements do not extend in a periodic manner 
throughout the structure, hence, minimising the overall order observed. This disparity between long and 
short-range order generally leads to less efficient packing and larger overall volumes, when compared 
to crystalline materials.  
 
In contrast, crystalline solids10, 11 show both short and long-range order, being built up through the 
regular and repeating arrangement of structural units in three-dimensions. These structural units can 
consist of individual or groups of atoms, molecules or ions, each related to each other through 
symmetry. These units interact through various interactions, from distinct chemical bonds, such as 
covalent or ionic bonds, to intermolecular bonds, like hydrogen bonds. For a more detailed description 
of crystalline materials, see Chapter 2. The homogeneous arrangement of units within crystals leads to 
reproducible and consistent properties, including melting point and solubility. 
 
The absence of long-range order in amorphous materials results in a higher free energy, with respect to 
crystalline materials, making amorphous solids comparatively less stable (Figure 1.1a).8 A 
characteristic phenomenon observed for amorphous materials is that of the glass transition (Tg)12, 
whereby, over a specific temperature range, the solid in question changes from a ‘glass’ to a viscous 
liquid phase, known as a ‘supercooled liquid’.12 With increasing temperature, the molar mobility 
continues to increase until the material reaches its melting point (Tm) and a liquid is formed.  This is not 
observed in crystalline materials which possess only a characteristic melt at a given temperature. 
 
Likewise, dissolution properties of crystalline and amorphous materials are also different. Due to the 
less favourable intermolecular interactions observed in amorphous phases, interactions with different 
solvent environments becomes increasingly favourable. Thus, amorphous materials are generally able 
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to dissolve more readily than crystalline solids. When an amorphous form of a material is present, 
dissolving it to excess of the equilibrium solubility exhibited by the crystalline phase results in so called 
‘supersatured’ solutions. With increasing supersaturation, the thermodynamic driving force for 
crystallisation increases and over time crystalline solid will begin to nucleate and grow (Figure 1.1b).8, 
9 Depending upon the discrepancy in dissolution rates between amorphous and crystalline solids, 





 Figure 1. 1 - (a) Gibbs free energy-temperature and (b) Dissolution comparison of amorphous and crystalline materials 
 
Whilst amorphous materials play an important role in many pharmaceutical formulations, given the 
inherent stability, order and applicability of crystalline materials as APIs, the rest of this introduction 
will focus on crystalline solid phases only. 
 
1.2 Small-molecule crystalline materials 
 
Crystals have a distinct advantage over other solid forms, due to their stability, reproducibility during 
manufacture and consistent physicochemical properties, arising from their inherent ordered structure.1, 
13 However, particularly with pharmaceutical products, many molecular materials have been shown to 
have structural variations that possess certain undesirable properties. Many common APIs, administered 
orally as tablets or powders, are made up of small molecular units that have the potential to form 
favourable interactions with receptors of choice to produce beneficial therapeutic effects. However, in 
many cases, these materials also exhibit unsuitable characteristics that can limit their performance, 
either for the patient or during manufacturing, and, for API materials in screening, hinder their progress 
to market. This can be seen through the ‘Biopharmaceutics Classification System’ (BCS), where 
therapeutic materials are assessed based upon their aqueous solubility and permeability.14 Although 
synthetic modification of APIs has shown promising results in addressing some of these issues, 
manipulation of the molecular structure itself can lead to undesirable changes in other factors, such as 
biological activity. Another route, therefore, to changing the physicochemical properties of a material 
is through the alteration of its intrinsic crystal structure. This can be achieved in a variety of ways, either 
through the discovery of new crystalline forms (polymorphism) or through the addition of secondary 
components in the crystal lattice to generate a multi-component system. 
 
1.2.1 Single and multi-component materials 
 
Upon crystallising an API as a single-component system, the molecules may occupy a variety of 
different crystalline assemblies, where the same molecular components are present, but the molecules 
themselves reside in different orientations in three-dimensional space. This phenomenon is known as 
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‘polymorphism’14, with each polymorph showing its own set of physical properties. This will be 
discussed in greater detail in Section 1.2.2.  
 
An API molecule can also be combined with a secondary (or ternary) molecular entity, interacting 
through non-covalent interactions, to form a novel crystalline structure. Such multi-component 
complexes13, 15 occur in a variety of forms, including salts, solvates, hydrates and, more recently, co-





Figure 1. 2 - Schematic diagram of some of the possible single and multi-component complexes used for physicochemical 
property enhanced with APIs 
 
Salt formation16, 17 has been one of the primary methods for pharmaceutical material property 
enhancement for several decades. In the case of multi-molecular complexes, this involves the 
interaction between an acid and a base, forming a network of electrostatic and intermolecular 
interactions; this interaction often occurs due to proton transfer. The main limitation in salt formation 
is the necessity for the species involved to possess ionisable sites, with a sufficient pKa difference to 
encourage proton transfer. 
 
In comparison, the formation of co-crystals18 does not require these ionisable sites, interacting primarily 
through neutral intermolecular interactions. Co-crystals can be described as “multiple component 
crystals in which all components are solid under ambient conditions … and co-exist as a stoichiometric 
ratio of a target molecule with a neutral molecular co-former”.19 For pharmaceutical co-crystals, the 
API is preferably combined with benign molecules from the GRAS (Generally Regarded As Safe) list.  
 
Solvates and hydrates1, 20, as for co-crystals, are made up from a combination of neutral molecular 
entities incorporated into a single crystal lattice. However, instead of existing as a solid under ambient 
conditions, the secondary component or guest molecule can be a liquid. As such, the formation of these 
materials arises from the amalgamation of a given API with the solvent used for the crystallisation, 
specifically water in the case of hydrates; these are also commonly known, inaccurately, as 
‘pseuodpolymorphs’. 
 
By generating beneficial physicochemical properties through structure manipulation21, 22, the 
development of multi-component API materials also offers opportunities for intellectual property.23 In 
order for a material to be patented, the substance must demonstrate novelty, usefulness and non-
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obviousness. The discovery of new multi-component materials between two (or more) molecular 
entities, defined by the unique arrangement of intermolecular contacts for the construction of a complete 
crystalline structure, is, by definition, novel, and the characteristic physicochemical properties arising 
from that structure also highlights the usefulness of these materials. The obviousness in the discovery 
and preparation of a given material can be related to its predictability. Despite continuing advances in 
this research area, the disparity between crystallisation and the resultant crystalline phase formed 
remains, showing that the ability to predict what solid state material will form still remains uncertain, 




Whilst molecular crystals are made up from an assembly of molecular entities held together by a 
network of intermolecular interactions, for a given system, the orientation and directionality of the 
molecules and their associated interactions can vary depending upon crystallisation conditions and 
relative stabilities of the structural variations.4  ‘Polymorphism’ in the solid state can be described as 
“the ability of a compound to crystallise in two or more crystalline phases with different arrangements 
and/or conformations of molecules in the crystal lattice”24, 25, with each different arrangement, or 
‘polymorph’, having a different set of physical properties. Polymorphism can be classified into the  
categories of packing and conformational polymorphism. Packing polymorphism occurs through the 
varied packing of rigid conformations of molecules in three-dimensions, whilst conformational 
polymorphism relies on the flexibility of the molecular components within crystalline materials. In 
reality, most polymorphic forms are classified as both having variations in packing and conformation. 
Selective preparation of individual polymorphs is of great importance for the pharmaceutical industry 
as each solid form for a particular compound brings its own physical properties, with implications for 
processing, formulation and drug availability.14 In addition, this can lead to regulatory concerns and can 
determine the development process used for a given material. As a result, polymorph screening1 is now 
a routine part of solid state development for most APIs. 
 
The relative stabilities of different polymorphic phases is dependent upon their relative free energies, 
with the most thermodynamically stable phase possessing the lower free energy.24-26 Under a given set 
of crystallisation conditions, only one polymorph will have the minimum free energy, with other phases, 
deemed ‘metastable’ polymorphs, having higher free energies and only being able to exist as solid 
forms as a result of slow transformation kinetics. The stability relationship and possible types of phase 
transitions between polymorphic forms are described thermodynamically using the terms 
‘enantiotropy’ and ‘monotropy’.27 Enantiotropic polymorphs (Figure 1.3a)24, 25 exhibit interconversion, 
with one phase transforming into another at a given transition temperature. Here, the form that possesses 
the lowest Gibbs free energy changes, resulting in a change in relative thermodynamic stability between 
polymorphs and thus interconversion. This transition is reversible, with the transition temperature being 
less than the melting point of either polymorphic phase. For monotropic systems (Figure 1.3b)24, 25, the 
Gibbs free energy curve of the liquid phase intersects the curves of the polymorphs at a temperature 
lower than that of the transition point. Here, melting of the more stable phase occurs before the point of 






Figure 1. 3 - Gibbs free energy curves for two polymorphic forms (α and β) and a liquid phase for (a) enantiotropic and (b) 
monotropic systems 
 
By relating the free energy of a polymorphic material to its solubility, it can be shown that the more 
thermodynamically stable form has a lower comparative solubility.26 For enantiotropic systems (Figure 
1.4a), the solubilities of the polymorphic forms are temperature dependent, highlighting that at a given 
temperature, the different forms can be interconverted, whilst for monotropic polymorphic materials 




Figure 1. 4 - Relative solubility curves for two polymorphic forms (α and β) for (a) enantiotropic and (b) monotropic systems 
 
Polymorphism is a constant issue within the pharmaceutical industry1, where the majority of API 
materials used are small organic molecules, many of which show polymorphic traits. Whilst common 
in single-component systems, polymorphic variations in multi-component materials, until recently, 
have had little scrutiny.3, 28 One intended advantage of co-crystals, salts, etc., is that by combining two 
or more molecular entities within the same crystal lattice, the variability in intermolecular interactions 
and, hence, polymorphism would be minimised. However, this hypothesis has, with increasing number 
of studies, been shown not to be true.28-30   
 
1.2.3 Stoichiometric variants in multi-component materials 
 
As well as showing polymorphic variability, whereby molecules pack together in a given stoichiometry 
within the same crystal lattice, multi-component materials can also show variation in structure by 
changing the ratio of the distinct molecular entities (Figure 1.5).31, 32 Stoichiometric variations are 
classified in a subtly different manner to polymorphs of a different stoichiometry, but for each set ratio 
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Figure 1. 5 - Schematic diagram comparing polymorphism and stoichiometric variations in multi-component materials 
 
1.2.4 Chiral crystalline materials 
 
Many molecules in nature, as well in the pharmaceutical industry, exhibit a particular form of isomerism 
called ‘stereoisomerism’.27, 33 Stereoisomers differ only in the spatial arrangement of their constituent 
atoms and possess no plane or centre of symmetry. The asymmetry associated with these molecules is 
usually localised about a specific atom, known as a ‘chiral’ centre (Figure 1.6).34 Chirality leads to 
molecules having mirror image forms, which are non-superimposable when overlaid. Different chiral 
forms of the same molecules are called ‘enantiomers’ and broadly possess the same properties, except, 
notably, their ability to rotate plane-polarised light, i.e. optical activity. Molecules of a specific chirality 
can rotate the light in a clockwise manner ((+)-dextrorotatory), whilst another form can rotate in an 
anti-clockwise direction ((-)-levorotatory). Classification of enantiomers, therefore, can be done in two 
ways; either based upon either their optical activity or their ‘handedness’33. The method of assigning 
the handedness of molecules is laid out based upon nomenclature outlined in the Cahn-Ingold-Prelog 
Rules. By following these rules, each enantiomer can be labelled as either ‘Rectus’ (R) or ‘Sinister’ (S): 
 
1. Assigning the atoms about the chiral centre in a ranked order based upon their atomic 
number 
2. Arranging the molecule so that the lowest priority atom is facing backwards 
3. Assessing the rotary direction of the larger substituents, labelling clockwise rotations as R 






Figure 1. 6 - Opposite chiral molecules, classified as either R or S, as defined by the Cahn-Ingold-Prelog Rules 
 
Whilst opposite enantiomers have the same overall physical properties, each chiral form does show 
significant differences in terms of their pharmacodynamics or pharmacokinetic activity, i.e. their ability 
to interact with different receptors within the body. This disparity can manifest itself to different 
degrees; from seeing little or no difference in the effects of enantiomeric molecules in biological 
systems, to catastrophic differences, as seen from the case of thalidomide.35 For this reason, many 
common APIs are prescribed as enantiomerically pure formulations. However, many synthetic 
processes yield mixtures of enantiomers that need to be separated36. A mixture of enantiomers, made 
up of 50% S and 50% R is known as a ‘racemic’ mixture and whilst a variety of methods are available 
for their complete resolution, crystallisation offers a convenient and cost effective way of separating 
out enantiomers. Broadly, there are two main chiral crystallisation separation techniques; 
‘preferential’37, 38 and ‘diastereomeric’.39, 40 The research outlined in later Chapters will focus on 
preferential crystallisation, though both methods are explained here. It should be noted that the efficacy 
of this crystallisation process is dependent upon the classification of the chiral crystalline phase formed 
from a racemic solution.  
 
Upon crystallisation of a single-component material (i.e. a chiral molecule at racemic compositions), 
three types of systems are possible; ‘racemic compounds, racemic conglomerates and racemic solid 
solutions’ (Figure 1.7a).35, 36, 41 Racemic compounds are by far the most common phase and consist of 
both enantiomers, related through symmetry, crystallising together within the same crystal lattice, to 
form a distinct phase from that of the homochiral. Racemic conglomerates and solid solutions are both 
comparatively rare. In the former case, both enantiomers crystallise individually, generating a physical 
mixture of enantiomerically pure crystals, whilst in solid solutions, both enantiomers crystallise 
together, but are distributed in a more random fashion throughout the structure. In order for individual 
enantiomers to be selectively crystallised from a racemic solution, a process otherwise known as 
‘preferential crystallisation’38, 42, the system in question must express specific properties, i.e. it must 
exhibit the characteristics of a racemic conglomerate forming system. 
 
Likewise, these classifications can also be applied to multi-component materials (Figure 1.7b)41, 43, 44. 
By introducing a secondary component (typically achiral) to a target molecule, composed at racemic 
compositions, a material has the potential, depending upon the nature of the interactions present, of 
being transformed from a racemic compound to a racemic conglomerate.  However, to date, few studies 
have been conducted exploring the potential of co-crystal or salt formation through which chiral 






Figure 1. 7 - Schematic diagram comparing the structures of racemic compounds, racemic conglomerates and racemic solid 
solutions for (a) single-component and (b) multi-component chiral crystalline systems 
 
The distinct advantage of preferential crystallisation is its simplicity; with a conglomerate forming 
system, opposite enantiomers can be directly resolved through a series of enrichments and seeding 
crystallisations. However, as previously stated, conglomerate systems are rare. The traditional method 
of chiral separation through crystallisation is from the preparation of ‘diastereomeric salts’ (Figure 
1.8).39, 45 Enantiomerically pure chiral resolving agents are added to a racemic solution, generating two 
distinct multi-component materials, typically salts. Due to the diastereomeric chiral relationship 
between the individual enantiomers and the single enantiomer resolving agent (e.g. R, S and S, S), two 
different crystalline materials are made, each with their own crystalline structure and hence, their own 
set of physicochemical properties. As a result, these diastereomeric materials have a disparity in 
solubility, through which the different enantiomers can be separated. Upon optimisation, this method 
can be a powerful resolution tool, but can require extensive salt screening and a significant enough 




 Figure 1. 8 - Classical resolution via the crystallisation of diastereomeric salts 
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1.3 Crystal engineering – Designing crystalline materials 
 
Molecular crystals consist of the ordered arrangement of discrete units, connected by a network of 
intermolecular interactions, which collectively determine the stability of the solid.3, 6, 19 Different 
polymorphic forms arise due to the multitude of possible interactions, individually giving rise to their 
own local free energy minimum assembly of molecules. As discussed previously, multi-component 
materials offer a route to physicochemical property manipulation by changing the intermolecular 
interactions through the addition of further components and, hence, altering the overall crystal structure 
for a material. These materials present a unique opportunity for the design of substances with desired 
attributes. However, predicting what structures will form remains an on-going issue.  
 
In the last few decades, attempts to address this issue have come about through the use of ‘crystal 
engineering’. Crystal engineering is “the understanding of intermolecular interactions in the context of 
crystal packing and the utilisation of such understanding in the design of new solids with desired 
physical and chemical properties”4. The basis of the method is to rationalise the structure of crystalline 
materials through an appreciation of the atomic, molecular and ionic components and accounting for 
their possible interactions. Through these considerations, predictions can be made about the structure 
of crystalline materials, allowing for an element of design to be introduced for novel solid-state 
assemblies. Once structures have been rationalised and prediction is possible, physical properties 
associated with a given structure can also be predicted. 
 
This process relies on an understanding of the functionalities within molecules and the interactions they 
can form. There are many possible intermolecular interactions, including hydrogen bonds46, halogen 
bonds47, π-π interactions6 and van der Waals interactions48, and once recognised, these can be 
categorised and applied in future crystal designs. 
 
1.3.1  Intermolecular interactions – Hydrogen bonding, halogen bonding and π-π 
interactions 
 
Crystalline solids can contain a variety of interactions, ranging from strongly bonded ionic49 and 
covalent33 networks to weaker interactions between molecules. As defined by Pauling, chemical bonds 
arise “between two atoms or groups of atoms in the case that the forces acting between them are such 
as to lead to the formation of an aggregate with sufficient stability to make it convenient for the chemist 
to consider it as an independent molecular species”48, 50, where the aggregates themselves result from 
the interplay between attractive and repulsive interactions. In order for bonds of any type to form, the 
overall interaction must be attractive. Despite being fundamentally weaker interactions than that of 
chemical bonds, this principle can also be applied to the intermolecular interactions6 between molecules.  
 
The focus of modern crystal engineering relies on intermolecular forces to predict and design the 
structure of molecular-based crystals. ‘Hydrogen bonds’ play a particularly important role and can be 
described as “an attractive interaction between a hydrogen atom from a molecule or a molecular 
fragment, X-H, in which X is more electronegative than H, and an atom or a group of atoms in the same 
or a different molecule, in which there is evidence of bond formation”.46, 51, 52  Broadly, in order for a 
hydrogen bond to form, a proton donor group (X-H) must interact with a proton acceptor (Y), where 
the donor has a local dipole moment orientated towards electron density associated with the proton 
acceptor group. Hydrogen bonding interactions can have a wide range of geometries and coordinations, 
from dimeric pairs to catemeric chains to shared bifurcated interactions, as well as intramolecular 
hydrogen bonds, each with an inherent set of stabilities and energetics. As such, these interactions can 




Table 1. 1 - The key differences between strong, moderate and weak hydrogen bonds, in terms of interaction types, bond 
lengths, angles and energies 
 
 Strong Moderate Weak 
X-H···Y interaction Mostly covalent Mostly electrostatic Electrostatic 
Bond lengths X-H ≈ H···Y X-H < H···Y X-H << H···Y 
H···Y (Å) ~1.2 – 2.5 ~1.5 – 2.2 2.2 – 3.2 
X···Y (Å) 2.2 – 2.5 2.5 – 3.2 3.2 – 4.0 
Bond angles (o) 175 – 180 130 – 180 90 – 150 
Bond energy (kcal mol-1) 14 – 40 4 – 15 <4 
 
In the case of strong hydrogen bonds, interaction formation is aided by either the hydrogen bond 
acceptor or donor groups having a greater electronegativity. Owing to the polarisation across the X-H 
bond, electron density is drawn away from the hydrogen atom, leaving a slight positive charge. This 
charge interacts with the electron density or distinct negative charge present on the acceptor atom, thus 
giving rise to the hydrogen bond. By increasing the electronegativity or electron deficiency of atom X 
or the electron density associated with atom Y, the polarisation of the X-H bond increases and the 
electrostatic interactions between the hydrogen atom and atom Y increases, thus giving a shorter and 
stronger bond. Whilst the increasing electrostatic nature of the interaction can strengthen the hydrogen 
bond, the position of the hydrogen atom itself becomes increasingly equidistant between the accepting 
and donating atoms, giving the stronger interactions more covalent characteristics. Typical strong to 
moderate hydrogen bonds include O-H···O, N-H···O and N-H···N interactions. Weaker hydrogen bonds 
span a wide energy range51, with some evidence of weaker interactions having  H···Y distances greater 
than the sum of the van der Waals radii. Such interactions include C-H···O, O-H···π and C-H···π 
bonds53, where the electronegativities of either the X or Y atoms are comparatively low.  
 
A more recent focus of intermolecular interactions has been on halogen bonds.4, 47 Halogen bonds are 
denoted as R-X···Y-Z and “occur when there is a net attractive interaction between an electrophilic 
region on a halogen atom (X) belonging to a molecule or molecular fragment (R-X), where R can be 
another atom, including X, or a group of atoms, and a nucleophilic region of a molecule, or molecular 
fragment (Y-Z)”.54 In many cases, halogen and hydrogen bonds are analogous in terms of their 
directionality and geometry. 
 
π-π stacking6 is a common feature of many small-organic molecule crystalline materials, be it single or 
multi-component, in which aromatic rings are present. These interactions form a dominant network of 
stabilising contacts and arise from maximised interactions between electron rich and electron deficient 
regions of aromatic functionalities within the crystals. In terms of orientation, π-π stacking can occur 
either as an offset face-to-face or edge-to-face aromatic ring interaction. 
 
1.3.2  Supramolecular synthons 
 
When trying to rationalise crystalline structures, two main issues arise.4, 51 Firstly, the probability of 
forming an intermolecular interaction depends upon, not only the individual functional groups, but also 
on their location and orientation with respect to all other functionalities in the immediate environment. 
Secondly, the process of crystallisation is, by definition, complex. In principle, in order for a crystal to 
develop, a molecule must come together with other molecules to form a cluster and then form nuclei. 
Once the size of the cluster is beyond a particular threshold, stable nuclei are able to form and crystal 
growth can take place. The regularity of this process is by no means definitive, affecting the 
predictability of crystalline materials from molecular units. 
 
In order to simplify matters, each functional group present and their relative intermolecular interactions 
can be condensed into individual contact units called ‘supramolecular synthons’.4, 50, 55 Supramolecular 
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synthons are structural units that can be used to build collective assemblies based upon the 
intermolecular interactions present. The main assumption is that the synthon is a reasonable 
approximation of the building blocks of the crystal structure, meaning that the method of piecing them 
together is evident. 
 
The most robust synthons are those that utilise the most directional and strongest interactions; the 
strongest synthons are used first, followed by the next strongest and so on. Due to the varying strengths 
of the interactions that make up each synthon, there is a degree of competition, giving rise to some 
unpredictability. However, the notion that a crystal structure can be described through a series of 
interactions that decrease in strength is a useful tool. By using the molecules as synthon nodes and the 
interactions between functionalities as synthon node connections, the three dimensional assembly of a 
crystal can be rationalised. As in organic retrosynthesis34, these structural units can be derived from a 
‘retroassembly’ analysis of previously studied structures and then applied to new systems with related 
molecular units. 
 
Based upon this synthon rationale, a series of guidelines for determining which intermolecular 
interactions will form were laid down by Etter et al..56 For hydrogen bonding interactions, this means 
that all suitable proton acceptors and donors are to be utilised, with intramolecular hydrogen bonds 
forming in preference to intermolecular bonds. For all other possible interactions, intermolecular 
hydrogen bonds may form in order of strength, meaning the best acceptors and donors interact first. 
Though a useful guide, these rules are by no means universal and should be applied with caution. 
 
Figure 1.9 outlines four common hydrogen bonding synthons; two homo and two heterosynthons, and 
can be characterised based upon their hydrogen bond donating and accepting abilities.4, 47 In examples 
(a) and (c), a homo and hetero-dimeric interaction is formed, respectively. In both cases, the two 
functional groups present consist of a proton acceptor and a donor. This is noted as a DA-AD 
interaction, where D denotes a proton donor and A a proton acceptor. In examples (b) and (d), the 
hydroxyl component of the carboxylic acid group acts as the proton donor, with the carbonyl and 
pyridine functionalities playing the role of the acceptor for the homo and hetero-synthon, respectively. 




 Figure 1. 9 - A set of common hydrogen bond based supramolecular synthons. (a) carboxylic acid dimer homo-synthon, (b) 





The hydrogen bonding pattern can be further described using the ‘graph set’ notation, as established by 
Etter et al. (Equation 1.1).4, 56 X represents the type of hydrogen bonding interaction present, of which 
there are four types: a ring (R), a chain (C), a non-cyclic dimer (D) and an intramolecular interaction 
(S). From the examples laid out in Figure 8, synthons (a) and (c) both have notations of 𝑅2
2(8), whilst 
examples (b) and (d) have the 𝐶1
1(4) and 𝐷1





 Equation 1. 1 - Graph set notation for hydrogen bonding interactions in supramolecular synthons, highlighting type of 
hydrogen bonded unit (X), the number of hydrogen bond acceptors (A) and donors (D), as well as the total number of atoms 
involved in the unit (n) 
 
1.3.3  pKa rule 
 
In multi-component materials, co-crystal and salt formation is dependent upon the acid-base 
relationship of the two interacting components1, 6. Depending upon pKa values, a proton can dissociate 
from an acidic species and transfer to a base, forming a conjugate acid and base, leading to the formation 
of a salt (Equation 1.2a). In order for a salt to form, the pKa difference (ΔpKa, Equation 1.2b) should be 
greater than 3, whereas co-crystals depend upon no proton transfer, thus require a minimum ΔpKa. 
Between the ΔpKa values 0 and 3, a region known as the ‘salt-co-crystal continuum’, the occurrence of 
proton transfer is uncertain, highlighting ambiguity in the pKa rule1, 57.  
 
(a) 𝐴𝐻 + 𝐵 → 𝐴− +  𝐵𝐻− 
(b) ∆𝑝𝐾𝑎 =  𝑝𝐾𝑎(𝑏𝑎𝑠𝑒) −  𝑝𝐾𝑎(𝑎𝑐𝑖𝑑) 
 
Equation 1. 2 - (a) Acid-base equilibrium and (b) ΔpKa, for determining salt or co-crystal formation 
 
1.3.4 CCDC Cambridge Structural Database 
 
Once possible synthons have been established for a given set of target materials, comparisons can be 
made with other crystal systems possessing similar synthons, giving an indication of the likelihood of 
the interactions.58 For co-crystal and salt screening, knowledge of previous interactions can be 
invaluable in determining likely salt or co-formers. The Cambridge Structural Database (CSD) from the 
Cambridge Crystallographic Data Centre (CCDC) contains all published organic and metal-organic 
small-molecule crystal structures, as determined by X-ray and neutron diffraction methods, with over 
800,000 structures as of 2015.59, 60 Within the database, both single and multi-component structures are 
deposited, making it invaluable for statistical studies of molecular complementarity and potential 
intermolecular interactions. 
 
1.4 Solid-state screening in the pharmaceutical industry 
 
Research, development and design of a manufacturing procedure for a pharmaceutical product is a 
lengthy process, typically taking between eight to twelve years, sometimes even longer (Figure 1.10).1, 
14 The process of drug development takes a discovered molecule of sufficient biological activity to a 
formulated drug that can be introduced to the market and, generally, can be divided into two main 
stages; first, discovery and research, and secondly, development, regulation and manufacture. In the 
initial discovery stages, screenings are conducted for the selection of molecules with appropriate 
sensitivity towards specific disease targets. These molecules are selected directly from synthesis or from 
a library of compounds, and once proven to have a degree of potency, are subjected to further 
characterisation, in terms of their physicochemical and pharmokinetic properties. Molecules that show 
particular promise are taken forward to ‘clinical’ trials, where the potential APIs are put through 
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toxicology and, for the first time, human testing, first with healthy volunteers and subsequently with 
larger patient populations. These steps are subject to a great deal of regulation and also provide an 
opportunity for the materials of interest to be put forward for drug registration. Assuming these stages 
yield promising results, synthesis and production methods are developed, scaled-up and refined, ready 
for complete registration and approval from the relevant regulatory body, such as the Food and Drugs 
Administration (FDA) in the USA or the European Medicines Agency (EMA) in Europe.  
 
Most drug products are administered orally, either as tablets, capsules or powders. Even for drugs 
delivered via solutions, leaving the material as a solid up to the point of use where it can be dissolved 
in the appropriate medium, due to the enhanced stability of the solid phase, can often be a preferred 
option. As well as for API delivery, most drug substances will, at some stage, be handled as a solid 
during the manufacturing process. As a result, solid-state form and properties are of paramount 





 Figure 1. 10 - An overview of the overall drug development process, highlighting key development steps, timescales and a 
focus on solid-state screening procedures (* = Human clinical trials) 
 
Typical solid screening2, 3, 61 involves several steps, from initial salt screening, for solubility 
enhancement, to assessment of the polymorphic landscape to the development of crystallisation 
processes. More recent pharmaceutical screenings have also included the examination of co-crystalline 
materials for physicochemical property enhancement, with each new phase (be it polymorphic, salt or 
co-crystal) offering new opportunities for property or process improvement, as well as patentability. 
This section will examine, in brief, the aims and methods of three types of solid-state screening; 





1.4.1 Polymorph screening 
 
As previously outlined, many crystalline API materials have the potential to show different polymorphs, 
each with its own unique stabilities and properties. For many polymorphic materials, the 
thermodynamically stable polymorph is the favoured phase for drug product development, owing to its 
inability to interconvert to other polymorphic phases, under given conditions14, 62. However, being the 
most stable form intrinsically means that this phase has the lowest solubility, leading to implications 
for processing and bioavailability. In many cases, the most stable polymorph is favoured, but depending 
upon the disparity in solubility, dissolution rates or patentability, it might be the case that the metastable 
phase is taken forward for drug formulation.1, 3, 24 In addition to polymorphs, the hydrate and solvate 
landscape20 is also assessed as part of the screening process. This might be to try and expand the library 
of solid-state materials for a given material, so as to avoid their crystallisation, or for the discovery of a 
more stable ‘pseudo-polymorphic’ phase.  
 
Polymorphic screening is vital for the reliable preparation of pharmaceutical materials and owing to the 
need for consistency in drug substance when transferring to clinical trials, the implementation of 
screenings must be early in the discovery and research process. The development of formulated drugs, 
in most circumstances, relies on the preparation of the most stable phase, but due to changing 
crystallisation conditions and improving impurity profiles during the development and scale-up steps, 
it is possible that the most stable phase could have been missed during initial screenings. A famous case 
when an unexpected polymorph appeared in later manufacturing stages is that of Ritonavir.14, 63 Hence, 
it is now common practice to conduction additional late-stage polymorph screenings. 
 
During screening, different polymorphs can be prepared through various crystallisation methods under 
different conditions. Screening conducted within the pharmaceutical industry utilises a wide range of 
techniques, from solution-based methods, like cooling and evaporative crystallisation, to 
mechanochemical preparations and crystallisations from the melt, amongst others.61, 64 Each method 
uses different pathways for cluster formation, nucleation and crystal growth, with every pathway 
potentially yielding different polymorphic forms. The principles underlining crystallisation and the 
various methods thereof are outlined in Sections 1.6 and 1.7. Preparation methods used for polymorph 
screening can also be translated to salt and co-crystal screening. 
 
Once a polymorphic form has been isolated, its physical, chemical and crystallographic properties need 
to be assessed.65-68 A variety of analytical techniques can be used for assessing the characteristics of 
individual polymorphs; structural information can be gained from single crystal X-ray diffraction 
(SCXRD), phase identification can be conducted through powder X-ray diffraction (PXRD), whilst 
thermal properties and temperature based phase transitions can be detected using differential scanning 
calorimetry (DSC) and hot-stage microscopy (HSM). Spectroscopic methods, particularly infrared 
spectroscopy (IR), can also be used for structural analysis, by probing the vibrational effects related to 
bonding and intermolecular interactions. These techniques are discussed in detail in Chapter 2 and can 
be used for the characterisation of any crystalline material, including salts and co-crystals. 
 
1.4.2  Salt screening 
 
If an API molecule forms a crystalline material that demonstrates unfavourable physicochemical 
properties, a traditional method of improving its characteristics is through the preparation of a salt.57, 69 
The reasons for salt selection can be due to a number of factors, in particular low aqueous solubility, 
low crystallinity, high hygroscopicity or low chemical stability.17  
 
In general, the formation of salts is made possible by the molecule in question possessing acidic or basic 
groups6, 70, a feature common to many APIs. Prepared predominantly through solution-based methods, 
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salt formation is dependent upon the pKa of the two species interacting with each other (see Section 
1.2). It should be noted that most pKa values are calculated with water as the solvent, though this can 
be used as an initial starting point for other solvent systems. 
 
If salt formation is deemed necessary, an appropriate salt selection strategy is required, with the 
chemical compatibility of the materials concerned being assessed.69, 71, 72 Once the API in question has 
been deemed amenable to salt formation, a suitable counter-ion needs to be found. This must be able to 
undergo acid-base interactions and be classified as safe.  
 
1.4.3  Co-crystal screening 
 
The use of co-crystals within the pharmaceutical industry has grown in recent years, with co-crystals 
showing a range of advantages over other solid phases, specifically as ionisable functionalities are not 
a prerequisite and the principles of crystal engineering are particularly amenable3. The process through 
which pharmaceutical co-crystals can be prepared is a multi-stage, involving interaction assessment, 
co-former selection, material screening, characterisation and scale-up (Figure 1.11).1, 3, 13, 70  
 
Having selected an API, the structure should be assessed for its possible intermolecular interactions, 
applying the rules and principles of crystal engineering4, with reference also to previous structures 
utilising that same API or related compounds. The same process should be carried out for potential co-
formers, assessing the prevalence of interactions that might be complementary to most of the API. 
Ideally, the co-former should be pharmaceutically acceptable i.e. using molecules that are ‘generally 




 Figure 1. 11 - Multi-step process for designing and preparing co-crystals 
 
Once a combination of API and co-former has been selected, small-scale co-crystallisation screenings 
can be conducted. These methods can be used to determine the propensity of whether or not a novel co-
crystalline form can be produced.18, 73 Common techniques used include solvent-based crystallisations, 
typically evaporative or cooling methods, or mechanochemical methods. If novel co-crystals are 
discovered, the material is characterised, as for polymorphs and salts, in terms of their physicochemical 





1.5  Phase equilibria 
 
An understanding of the equilibria between liquids and solids is of great significance in rationalising 
the thermodynamic basis of all crystallisation processes, either from the melt or solution. Based upon 
equilibrium information, graphical representations of the crystalline phases present for a given system 
can be generated, i.e. phase diagrams. Though often not known, particularly for new materials, 
knowledge of the phase diagram under a given set of conditions (temperature, pressure, composition, 
etc.) can be vital in designing selective crystallisation methods. In order to appreciate all aspects 
contributing towards a phase diagram, firstly, the phase rule must be understood. 
 
1.5.1  The Phase Rule and phase diagrams 
 
A phase is an individual constituent of a system that does not show variation in terms of its chemical 
composition and physical state.74, 75 Typical phases are either gaseous, liquid or solid and can exist 
purely in isolation from other phases (pure phase) or in combination with other phases (mixed phases). 
In this sense, any mixture of gases or miscible liquids can be classed as one phase. Similarly, an 
undersaturated solution of a solute in a solvent can also be a single phase, whilst a mixture of two 
immiscible liquids or a solid suspended in a solvent (solution crystallisation) are classed as having two 
phases.  
 
A system is said to be at the thermodynamic equilibrium when, at a specific temperature, pressure and 
composition, the phases present remain constant. By changing the conditions, the position of 
equilibrium can be shifted, thus changing the possible phases present. These systems can be defined by 
the ‘Phase Rule’ (Equation 1.3), which relates the number of components (C), phases (P) and degrees 
of freedom (F).26, 74, 76 For solid-liquid equilibria, pressure is often ignored, thus reducing the overall 
degrees of freedom, denoted as F’. 
 
𝑃 + 𝐹′ = 𝐶 + 2 
 
Equation 1. 3 - The Phase Rule for solid-liquid equilibria, linking the number of distinct phases (P) with the number of 
degrees of freedom (F’) and the relative number of chemical components (C) present  
 
The number of components is related to the number of distinct chemical compounds needed to describe 
the overall composition of a particular phase. For example, a system consisting of two enantiomers 
dissolved in a solvent can be described as a ternary system. For every system, the number of degrees of 
freedom represents the number of variables (e.g. temperature, pressure, composition) that must be fixed 
in order to define the phases present at the point of equilibrium. 
 
The phase rule can be used universally to understand phase behaviour exhibited at equilibrium, under a 
set of conditions. Phase diagrams depict, in two or three dimensions, the variation in phases at different 
equilibria, when temperature and composition or concentration are changed.75, 77 For equilibria between 
liquids and solids, phase diagrams give information relating to the different solid phases occurring, such 
as polymorphs and multi-component materials (co-crystals, salts, solvates and hydrates). In these 
systems, pressure is usually assumed to be constant. A simple binary phase diagram, highlighting the 
melts of two components, (A) and (B), is shown in Figure 1.12. A similar phase diagram can also be 






Figure 1. 12 - Simple melting point phase diagram for the binary mixture of components (A) and (B), where Tm,A and Tm, 
B represent the melting points of components A and B, respectively, highlighting the transition from liquid (point i) to the 
precipitation of the A (point ii) and then B (point iii) phases upon cooling 
 
In this two component system (C = 2), when only one phase is present (P = 1), e.g. a liquid (point i in 
Figure 1.12), the degree of freedom is two (F = 2), meaning the temperature and composition can be 
varied, independently, without changing the phase exhibited. As the temperature is lowered and the 
number of phases in equilibrium changes to two (point ii), the degree of freedom becomes one, making 
temperature and composition no longer independent of each other. When the number of phases that can 
exist together at equilibrium is three (point iii), the system no longer has any degrees of freedom, i.e. 
all three phases (solid A, solid B and liquid) can only coexist at one specific temperature and 
composition. This point is called the eutectic point, at temperature Te. 
 
1.5.2  Applications of the phase rule for polymorphic, multi-component and chiral materials 
 
The phase rule can be used to describe crystallisation phenomena, such as polymorphism, with each 
polymorph constituting different solid-state phases for a specific chemical entity (single component).75, 
77 For a system consisting of two polymorphic forms and given the phase rule at constant pressure, the 
equilibrium between the two phases would only have one degree of freedom. Figure 1.13a shows the 
binary phase diagram between the polymorphic material, A, and a given solvent, highlighting the 
transition temperature between forms (i.e. Tm, A – I to Tm, A – II). 
 
When combining two molecular species, A and B, within a single crystal lattice to make a multi-
component material, i.e. a co-crystal, salt, solvate or hydrate (Figure 1.13b),78, 79 there can be a change 
in the number of components. The formation of multi-component crystals occurs at mixed compositions 
of the pure starting material, giving rise to a distinct region in the phase diagram, characterised by the 
novel material melting point (Tm, CC). It should be noted here that the secondary component, B, can exist 






 Figure 1. 13 - Binary phase diagrams for (a) polymorphic and (b) multi-component materials, highlighting polymorphic 
transition temperatures, melting and (Tm) eutectic points (Te) 
 
Analysis of solid-liquid equilibria through binary phase diagrams can also be applied to chiral 
crystalline materials. Upon crystallisation of chiral molecules from various enantiomeric compositions, 
from the melt or otherwise, three types of material are possible; racemic compounds, racemic 
conglomerates or racemic solid solutions.35, 36, 41 Each class consists of two components, i.e. the two 
enantiomers, R and S, but, depending upon the composition, can vary in terms of the number of phases 






Figure 1. 14 - Binary phase diagrams for the three types of chiral crystalline material; (a) racemic compound, (b) racemic 
conglomerate and (c) racemic solid solution, which in turn can be subcategorised into (i) ideal, (ii) Roozeboom Type I and 
(iii) Roozeboom Type II solid solutions 
 
Due to the identical properties of both enantiomers, particularly with respect to melting point, the binary 
phase diagrams for all types of chiral material demonstrate symmetry, from racemic to enantiomerically 
pure compositions. Overall, the racemic compound can form three distinct phases, i.e. the racemic and 
two enantiomerically pure forms, whilst the conglomerate can produce two and for solid solutions, only 
one continuous phase is possible. These solid solutions can be subcategorised into three other groups; 
‘Ideal’, Roozeboom Type I and Roozeboom Type II.35, 41, 77 Each type differs in terms of their respective 
melting points when comparing the homochiral and heterochiral (50:50) phases. In ideal solid solutions, 
no matter the enantiomeric composition, there is no variation in the melting point, whilst the melting 
point of the racemic phase is higher and lower than that of the pure chiral phase for Roozeboom Type 
I and Type II materials, respectively. A key characteristic of solid solutions, when compared to racemic 
compound or conglomerate systems, is their lack of eutectic melting. 
 
Binary phase diagrams can account for two component systems, which can cover the dissolution of 
individual solutes in particular solvents, highlighting polymorphic variations, or the melting phenomena 
when two materials are combined. However, in order for systems with three components to be assessed, 
i.e. two solutes dissolved in a solvent, a different type of phase diagram must be used. Ternary phase 
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diagrams are of key importance when assessing solution crystallisations, at a specified temperature, that 
either contain impurities, involve the formation of multi-component materials or that of chiral 
crystalline systems.3, 36, 75, 80 Figure 1.15 shows several examples of ternary phase diagrams, for two 
simple multi-component material forming systems (a and b) and for the three types of chiral phases (c, 




Figure 1. 15 - Isothermal ternary phase diagrams of two solutes and a solvent, highlighting multi-component material 
formation for (a) equally soluble and (b) unequally soluble solutes, A and B, as well as that for chiral crystalline systems; (c) 
racemic compounds, (d) racemic conglomerates and (e) racemic solid solutions, with its three types (I-i, II-ii and III-iii) 
 
1.6  Crystallisation  
 
‘Crystallisation’ is an important operation in many fine chemical industries, as both a separation and 
purification technique. However, it holds particular significance within the pharmaceutical industry as 
many APIs are delivered as solid dosage forms. The process of crystallisation from solution refers to 
“the transfer of matter initially solvated to form crystallised particles”.77 Through crystallisation, 
critical properties such as crystal shape, size and form are determined, all of which have implications 
for the end product, as well as other manufacturing steps further downstream, such as filtration and 
milling. In order to control these properties, the principles of crystallisation must be understood. 
 
1.6.1  Supersaturation 
 
Whilst the equilibrium between a solid and liquid is determined by thermodynamics, crystallisation is 
a kinetic process26 driven by the relative ‘supersaturation’ of a solution.11, 26, 77, 81 A solution, at a 
specified temperature, is considered supersaturated when the concentration of a solute in a particular 
solvent exceeds its thermodynamic solubility but can be sustained as a solution over a finite 
concentration range without crystallisation occurring. This concentration range is called the ‘metastable 
zone’, existing between concentrations of solute above that of the solubility curve and an upper limit 
called the ‘metastable limit’.82 As shown by Figure 1.1681, the composition of a solution below the 
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solubility curve is considered ‘undersaturated’, with equilibrium favouring the liquid or solution phase, 
whilst compositions above the metastable limit favour the formation of the solid phase. In this ‘labile’ 
region, spontaneous nucleation is likely to occur. In a similar manner, supersaturation can be generated 
through the cooling of a saturated solution, at a given temperature. The time taken for nuclei to form, 




Figure 1. 16 - Solubility phase diagram, highlighting the equilibrium solubility, undersaturated, supersaturated and labile 
regions 
 
Though the equilibrium solubility is a thermodynamic property, the nature of the metastable zone is 
governed through kinetics and can vary greatly depending on experimental conditions11. A key factor 
that can affect the width of the zone is the rate at which supersaturation is achieved. This is dependent 
on the method of crystallisation and the environments present. Key factors that can affect this rate 
include variations in temperature, solvent composition, impurities or additives and mixing. 
 
Crystals can nucleate and grow only if the given solution is supersaturated. Supersaturation can be 
expressed in many ways (Equations 1.4a, b and c), each comparing supersaturation and equilibrium 
concentrations. These are absolute supersaturation (Δx), relative supersaturation (σ), and the 
supersaturation ratio (S)26, 27. 
 
(a) ∆𝑥 =  𝑥𝑠𝑠 −  𝑥𝑒𝑞 









Equation 1. 4 - Expressions for supersaturation, highlighting (a) absolute supersaturation, Δx, (b) relative supersaturation, σ, 
and (c) the supersaturation ratio, SS, with xss and xeq representing the supersaturation concentration and 
equilibrium/solubility concentration 
 
Whilst governed by the level of supersaturation, crystallisation itself can be broken down into two 
distinct kinetic processes; ‘nucleation’ and ‘growth’ (Figure 1.17).26 Upon exceeding the saturation 
limit, the kinetics of growth are dominant, with any initial nuclei present being given the opportunity to 
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grow, resulting in larger particle sizes. But as supersaturation increases and goes beyond the metastable 
limit, the rate of nucleation begins to surpass that of growth. This results in the formation of smaller 
crystals. These considerations, the careful balance between the kinetics of nucleation and growth, form 




Figure 1. 17 - Effect of supersaturation on particle size, nucleation and growth 
 
1.6.2  Nucleation 
 
The first step in the formation of new crystalline solids from the solution or liquid phases is nucleation, 
a key phenomenon in the control of particle size and number.2 Nucleation refers to initial particle 
formation and can occur via a number of routes, depending upon the presence of various growth 
interfaces (Figure 1.18).11, 26, 81 Primary nucleation involves the spontaneous formation of nuclei from 
solution: particles can form without the prior existence of any solute particles. This can occur either 
homogeneously, the completely spontaneous formation of nuclei from solution, or heterogeneously, 
whereby the initial particles form on a heterogeneous surface. Secondary nucleation, in contrast, only 
occurs heterogeneously and includes the formation of nuclei on previously formed solute particles. The 





Figure 1. 18 - Diagram differentiating the homogeneous and heterogeneous primary nucleation and heterogeneous secondary 
nucleation 
 
The study of homogeneous nucleation processes is difficult due to the inherent small size of the critical 
nucleus, with each nucleus being made up of only 10-1000 molecules, and short phenomena time scales, 
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though this varies from system to system.2 Current understanding of nucleation is based upon two main 
theories of cluster formation; ‘classical nucleation theory’ (CNT)2, 11, 81 and the ‘two-step’ approach.2  
 
CNT is a widely used theory and assumes that molecules add together sequentially until a cluster of 
sufficient size is formed (Figure 1.19). When these clusters are small, the free energy of the cluster 
surface dominates with respect to that of the bulk, with the molecules at the surface forming a greater 
proportion of interactions with surrounding solvent molecules. This leads to smaller clusters 
redispersing back into the solution. However, as the clusters get bigger, the disparity in free energy 
between the surface and the bulk decreases until a critical size (rC) is reached, whereby the free energy 
of the bulk stabilises the cluster. It should be noted that for spherical nuclei, the free energy of surface 




Figure 1. 19 - Free energy diagram of nucleation, highlighting the free energy of the surface, bulk and their sum, indicating 
the critical cluster size for stable nuclei 
 
The relative stability of an individual cluster is dependent upon the supersaturation of the system (Figure 
1.20). Systems are driven by the desire to lower their free energy. For smaller clusters, the free energy 
can only be minimised through dissolution, whilst for larger aggregations beyond a critical size, this is 
achieved through the growth of the cluster. With increasing supersaturation, this free energy barrier 
decreases, as well as the value of the critical cluster size leading to the eventual spontaneous nucleation 
of individual crystallites. An important consideration here is that of ‘Ostwald ripening’.11, 27 For the 
smaller molecular clusters, where the free energy of the surface dominates, resulting in destabilisation 
and redissolution, the molecules from these clusters are deposited back into the solution, enabling them 
to be used for the growth of larger clusters. Through this continual ripening of larger clusters, the overall 







Figure 1. 20 - Free energy as a function of cluster size (z) and supersaturation 
 
Though useful, CNT has several fundamental limitations.2, 81 It assumes that classical thermodynamics 
can be applied to small nucleating clusters. These considerations are based on the averages of very large 
groups of molecules and these often cannot be directly transferred to smaller units. CNT also assumes 
that cluster growth occurs through the step-wise addition of molecules, with the end crystal structure 
being built-up directly through this. As a result, only size is used as the limiting criterion for nucleation, 
this with this often being insufficient for many solution based crystallisations.  
 
An alternative is the two-step theory.2 Here it is proposed that solute molecules rapidly aggregate into 
initial fractional clusters and then progressively condense into structures resembling that of the end 
crystalline form. This gives rise to the two-step notion where the initial density of the structure fluctuates 
and eventually settles to a higher density ordered state. A great deal of study has gone into the two-step 
process and it is widely favoured as a more useful theory.83, 84 The differences between CNT and the 




Figure 1. 21 - Diagram comparing classical nucleation theory and the two-step model 
 
Whilst fundamental, homogeneous nucleation of a particular phase from a ‘clean’ solution is not always 
realistic. Heterogeneous nucleation occurs at the surfaces of pre-existing bodies, either as a primary or 
secondary process.85 Through a primary heterogeneous nucleation mechanism, nuclei develop on the 
surface of a foreign entity, be it an impurity or templating material, whilst in secondary processes, 
cluster formation occurs on surfaces of previously established crystals of the phase of interest, acting 
as a ‘seed’. The presence of these surfaces, foreign or otherwise, allows for the adsorption of molecules 
from solution, lowering the free energy barrier, and encouraging nucleation at lower supersaturation 
levels. The favourability of heterogeneous processes is dependent upon the overall free energy of the 
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system. If, through the introduction of these additional interfaces, the overall free energy is lowered, 
then spontaneous homogeneous nucleation is no longer favoured and nuclei form on pre-existing 
surfaces. 
 
Secondary heterogeneous nucleation is particularly significant in the control of many crystallisation 
processes. Here, a number of different mechanisms are possible, including initial seeding, needle 
breeding, fluid shear and contact nucleation. Initial seeding works through the addition of crystalline 
seeds to an already supersaturated solution. Here, micro-particles are shed from the surface of the seeds 
and become new centres for crystal growth. In these kinds of crystallisation, the shear forces generated 
from mixing can also have an impact on secondary nucleation. The flow of the surrounding solution in 
any crystallisation vessel can have an effect on what crystal faces can develop. 
 
The crystallisation of different crystalline phases (polymorphic, multi-component and chiral materials) 
is inherently controlled by the process of nucleation. The occurrence of various forms, e.g. polymorphs, 
which are not the most thermodynamically stable can be explained in terms of nucleation, by the 
principles laid out in ‘Ostwald’s rule of stages’.81, 86, 87 This rule states that the initial nucleating structure 
need not be the final, most stable phase, but rather that it represents the smallest change in free energy 
possible, as the system shifts from a supersaturated state to equilibrium. As a result, stepwise formation 
of different phases would occur before crystals of the thermodynamic form eventually appear.  
 
1.6.3  Growth 
 
Once a cluster of critical size and order has formed (a nucleus), a crystal can then begin to grow. When 
a crystal surface is exposed to a supersaturated environment, the movement of material to the surface 
exceeds the movement away: the net effect is the growth of the crystal surface.11, 26, 81 The ability of a 
surface to attract material and utilise this for growth is dependent upon the number of interactions 
possible, as well as their relative strengths. The classic picture of crystal growth involves the steady 
maturing of layers, where atoms, ions or molecules (or clusters thereof) arrive at a surface, shed 
themselves of their solvation layer, and bind to previously deposited material. The surface of a growing 
crystalline entity can be characterised in terms of three types of contact site; faces, steps and kinks 
(Figure 1.22).26, 27 For faces, particles can form one attachment with a surface, whilst for steps and kinks, 
two and three points of contact are possible, respectively. It should be noted that with increasing points 








The final crystal shape or ‘morphology’88 will thus depend upon the growth from the slowest growing 
site: the faces26. However, in order for crystals to grow at an appreciable rate, effective growth sites 
must be created. These growth sites generally utilise sites with a higher number of interactions: kinks 
and steps. The formation of such sites depends upon the nature of the interactions at the surface and the 
surrounding supersaturated solution. In order to describe how these key growth sites form and, hence, 
determine the mechanism for crystal growth, the ‘multi-layer’ model can be used (Figure 1.23).26 Here, 
hypothetical blocks are used to define solid and liquid phases, the solid being formed from a number of 
layers. By roughening the interface between the phases, the model can be used to predict the energy 




Figure 1. 23 - ‘Multi-layer’ model of the solid-fluid interface for surface roughening 
 
This energy change can be further used to express the α-factor, which reflects how well a surface can 
develop sites of multiple interaction (Equation 1.5). This gives an indication as to the ease of surface 







Equation 1. 5 - α-factor, indicating the relative ease of surface growth (k = Boltzmann constant, T = temperature) 
 
There are three common pathways, each of which exhibit an increasing tendency for multiple site 
formation; continuous growth method, surface nucleation and spiral growth.26, 27, 81 In some crystalline 
systems, the formation of higher interaction binding sites (kinks and steps) is comparatively easy; these 
systems undergo ‘continuous growth’ characterised by a low α-factor (less than 3). This continuous 
growth mechanism indicates that as long as growth species keep moving to the surface, they will find 
binding sites and the surface will grow. Therefore, the growth rate is proportional only to the level of 
supersaturation of the surrounding solution. 
 
Systems exhibiting continuous growth are rare, with the majority of materials not having sufficient 
roughness. In most cases, as the atoms, ions or molecules of interest approach the surface, they either 
bind directly to a pre-existing layer, are unable to bind and return to the surrounding fluid or adsorb to 
previously deposited species to form surface nuclei (Figure 1.24).81 Here, the outer ridges of the nuclei 
act as new kink or step sites. In this manner, these nuclei can grow and spread across a surface, with 
growth species adding from either the surrounding fluid or from species diffusing over the surface. This 
process is called ‘growth by surface nucleation’ and is characterised by an α-factor of between 3 and 
5.26 The growth rate for surface nucleation depends on the number of critical size nuclei formed at a 






 Figure 1. 24 - Formation of two-dimensional critical nuclei on a crystal surface 
 
In systems where α has a value great than 5, the formation of sites with a higher number of surface 
interactions is extremely difficult. For growth to occur, steps and kinks must be generated through a 
different process that requires the minimum amount of energy. The mechanism of ‘spiral growth’ 
utilises so-called ‘dislocations’, defects that are derived from primary and secondary heterogeneous 
nucleation processes, as a route to growth. Dislocations occur through a misalignment of crystal faces 
and can be built up to form a series of sequential steps, winding up through a spiral, extruding from the 




Figure 1. 25 - The development of spiral growth, showing a spiral dislocation build-up 
 
The rate of spiral growth can be expressed in terms of the height, the flux of material to the step and 
step density, which represents the nature of the spirals formed. The winding of the spiral becomes tighter 
with increasing supersaturation, increasing the step density. The rate is system dependent, as each 
system will has its own unique structure of dislocations. 
 
1.7  Crystalline material preparation 
 
When preparing any solid-state material, there is a balance between the thermodynamics and kinetics 
of crystallisation. Both nucleation and growth depend upon the notion of supersaturation, but subject to 
the rate at which this is achieved and its extent, it is possible to access a variety of phases, stable and 
metastable (Figure 1.26).1, 64 In order to control this, different crystallisation techniques can be used, 
each exploiting a different mechanism over various timescales.61 These methods can be described as 
being either from solution or not and include methods such as evaporative and cooling crystallisation, 







Figure 1. 26 - A selection of methods for producing different crystalline forms, highlighting timescales and material 
stabilities 
 
1.7.1  Crystallisation from solution – Evaporation, cooling and slurrying 
 
A method extensively used in solid-state screening is ‘evaporative’ crystallisation (Figure 1.27a).21, 64, 
89, 90 Held at a particular temperature, supersaturation is achieved by allowing solvent to be evaporated 
from a solution, transitioning from undersaturation to supersaturation.64, 77 Eventually enough solvent 
is driven off to reach the metastable limit, where nucleation occurs spontaneously. The rate at which 
supersaturation can be achieved can be varied depending upon the temperature of evaporation. This can 
have a direct impact on the solid-state forms that can be produced. Evaporation demonstrates several 
advantages, including ease of setup and its ability to be combined with additional crystallisation 
methods.81 As well as this, there is no prerequisite of solubility knowledge. However, despite these 






Figure 1. 27 - Solubility phase diagrams for (a) evaporative and (b) cooling crystallisation, seeded and unseeded 
 
In the pharmaceutical industry, evaporation can also be combined with ‘cooling’ crystallisation81, often 
for improving product yields. Cooling crystallisation (Figure 1.27b) is conducted by taking an initially 
undersaturated solution at a starting temperature and cooling at a given rate.64 Upon crossing the 
solubility line, the solution becomes supersaturated, with the metastable limit representing the point at 
which spontaneous nucleation can occur. This limit signifies the extent of supersaturation that can be 
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reached and can be varied depending upon the crystallisation conditions imposed, particularly with 
respect to the cooling rate and mixing profile. As a result of these different conditions, the crystallisation 
kinetics for a system can be altered, influencing the solid phase produced.91 
 
In order to instigate a degree of control, many cooling crystallisations can be ‘seeded’ so as to improve 
the crystal quality and allow for the formation of a particular crystalline phase.64, 92, 93 Through the 
introduction of a small quantity of end-product crystals, secondary nucleation can be induced well 
below the metastable limit, at lower supersaturations. By forcing crystallisation to occur within the 
metastable zone, where the kinetics of crystal nucleation and growth are more balanced, uncontrolled 
nucleation can be avoided, allowing for the formation of fewer, larger crystals.94 In addition, the end 
phase produced can also be controlled by seeding, as it allows for the nucleation of material akin to the 
seeds introduced. 
 
Both evaporative and cooling crystallisation work, through different processes, to achieve 
supersaturation; by allowing undersaturated solutions to go beyond the point of saturation, eventually 
enabling nucleation to occur. Another common method for not only generating new crystalline phases, 
but also for encouraging the formation of the most stable forms, is that of ‘slurrying’.64, 95, 96 Slurrying 
operates through the suspension of solid material in a quantity of solvent, insufficient to allow for 
complete dissolution, mitigating primary nucleation effects.42 Depending upon the composition of the 
suspended solid and the solvent utilised, different solid-state forms can be accessed, with the least stable 
forms nucleating first and maturing to the more stable phases over time, as dictated by Ostwald’s rule 
of stages. The key advantage of this method is its ability to access polymorphic forms of different 
stabilities over a period of time, simply by mixing a suspension. 
 
For all crystallisations conducted in solution, consideration of the process parameters is important in 
terms of supersaturation control. Solvent selection is key, with a material expressing different 
solubilities in each solvent environment, but in addition, the rate at which supersaturation is achieved 
is also significant. Cooling rates and evaporation temperatures directly affect how quickly 
supersaturation is achieved and the relative size of the metastable zone.  
 
1.7.2  Mechanochemical preparations 
 
An alternative to solution-based crystallisations is that of ‘mechanochemical’ methods. 
Mechanochemistry97, 98 refers to the transformation of materials in the solid-state through the application 
of mechanical force and has several advantages over other crystallisation techniques, with its inherent 
sustainability and ability to mitigate the bulk effects of solubility. Traditionally, grinding experiments 
were carried out on materials or combination of materials without the assistance of solvent, but more 
recently, the use of so-called ‘liquid-assisted’ grinding99-101 has taken greater prominence. By adding 
the minimum amount of solvent to the samples being ground, the formation of different solid phases 
can be facilitated, many of which are inaccessible through alternative methods. Furthermore, studies 
have also been conducted whereby changing the volume of liquid added can also have an impact on 
polymorphism and multi-component material formation.101 
 
Whilst mechanochemistry is not a fully understood process, on-going research in this area has proposed 
three possible mechanisms for its operation102, 103; through surface transportation104, liquid eutectic 
intermediates105 or via amorphous phase formation.106 The first mechanism considers systems where 
the molecular building blocks are only held at the surface loosely, hence with mechanochemical stress, 
they can be relocated and reconstructed into various other forms. For compounds or, in the case of 
multi-component systems, eutectic mixtures that express a low melting point, localised melting can 
occur, aiding in molecular transportation and phase crystallisation. The final route exploits materials 
that have initially strong lattices. However, when these materials are ground, a phase transition to an 
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amorphous form can occur and through Ostwald’s rule of stages, can allow for multiple crystalline 
structures to precipitate.  
 
Whilst utilising different processing routes, each of these mechanisms have several features in common. 
Firstly, upon the application of mechanochemical pressure, the particles in question are broken down 
into smaller particulates, generating larger surface areas. Combined with this, phase transitions are also 
aided by the efficient mixing of material inherent to the grinding process. Coupled with the potential 
for defect introduction and the localised heat of friction generated from grinding or milling, these 
phenomena are able to enhance or accelerate the process of crystallisation via mechanochemistry. No 
matter the mechanism, it can be said that under the conditions imposed, systems are not necessarily at 
equilibrium, offering routes to preparation of metastable phases.107  
 
Upon the addition of solvent in liquid-assisted grinding, many samples demonstrate higher crystallinity 
compared to those obtained from neat preparations. This can be rationalised through the enhanced 
molecular mobility and increased effect of solvation with the addition of solvent, though given that 
systems are always at high supersaturations, the crystallisation of metastable forms is still inherent. 
 
Mechanochemistry can be an attractive option for exploring the preparation of co-crystalline 
materials108, with a particular focus on variations in stoichiometry and polymorphic form. Often 
different stoichiometric co-crystals96 of the same starting components can be generated simply by 
grinding different molar ratios of the starting materials together. In a similar manner, polymorphic co-
crystals can also be accessed, depending upon conditions such as solvent type, quantity and grinding 
time.97, 101 
 
1.8  Industrial crystallisation 
 
As stated above, crystallisation processes are vital in the industrial production of many pharmaceuticals 
and fine chemicals.81, 92 The following section will focus on the two main classifications of process 
operation, batch and continuous, highlighting their setups and context in industry. 
 
1.8.1  Batch crystallisation 
 
‘Batch’ processing is used in a range of chemical industries for a variety of purposes.109 Due to its 
inherent simplicity and comparatively low start-up costs, batch operation can be applied to many unit 
operations (reaction, crystallisation, mixing, etc.) for the production of many different materials.  
 
Simple batch crystallisations from solution typically utilise setups such as individual ‘stirred tank 
reactors’, STRs (Figure 1.28).26 Such setups consist of a main reactor vessel, a temperature controlled 
jacket, a mixing element and an inlet. The solution of a given system is held in the body of the reactor, 
in which, by changing various process parameters, supersaturation can be induced, either by cooling or 
evaporation. For these methods, the temperature of the process is controlled using heated jackets and 
mixing achieved through mixing units, such as impellers. Once supersaturation is eventually reached, 






 Figure 1. 28 - Basic stirred tank reactor setup 
 
Despite its versatility, batch processing has inherent flaws, particularly in terms of poor heat and mass 
transfer with increasing scales110, which can lead to issues in the consistency of the end-product. These 
batch-to-batch inconsistencies can manifest themselves through variations in particle size, crystal shape 
and solid form, with implications for downstream processing steps such as filtration, drying and 
formulation.111 
 
1.8.2  Continuous crystallisation 
 
In contrast, ‘continuous’ operations offer a number of benefits, including shorter processing times, 
reduced energy costs and better mass-heat transfer, yielding more consistent product.110, 112 Historically, 
research into continuous methods has been focussed on flow synthesis113, but more recent work has 
applied these principles to other unit operations, including crystallisation, with motivation towards the 
development of fully integrated end-to-end production processes.114  
 
Continuous operations are characterised by “parameters which may be geographically distributed 
within the system but are unchanged with time”81. This means that whilst process conditions can vary 
at different stages of a reactor or crystalliser, due to the characteristic setup of such continuous 
platforms, the individual process parameters have far greater consistency and, hence, can be managed 
more effectively.115 The implications for materials moving through the system is that each molecule 
should experience the same conditions. As a result, continuous processes can be scaled-up and out more 
easily, by either increasing the throughput of material or running the process for longer.111 
 
The ideal operation of a continuous platform would be to operate at ‘plug flow’.110 Plug flow is defined 
as the regular movement of material through a reactor, whereby all the elements of the fluid flow in the 
same direction over the same time period, with perfect mixing. It is through this that process parameter 
consistency can be achieved. In reality, most reactors work at near-plug flow conditions, with the flow 






Figure 1. 29 - Types of flow; laminar flow, turbulent flow and plug flow 
 
Two conventional methods of achieving near plug flow conditions use a cascade of stirred tank reactors 
(cSTR)116 or a tubular reactor acting under turbulent flow.111 For cSTRs or mixed suspension mixed 
product removal (MSMPR)116-118 setups, a series of well-mixed batch STRs are connected in series, 
with plug flow achieved, in principle, when an infinite number of reactors are present. In practice, 5-10 
reactors are used, meaning the system is far from plug flow conditions, but with every additional reactor 
leading to an increase in inventory and associated capital cost. To date, the MSMPR platform has been 
used for the effective crystallisation of many API materials, with examples including cyclosporine, 
paracetamol and aliskiren hemifumarate.118 
 
In many tubular reactors, turbulent mixing is also introduced to try and improve mixing with a platform. 
The nature of turbulent flow only allows mixing through the net flow of material, resulting in tubular 
reactors being very long, even for short residence times. In practice, tubular reactors are altered111, 119 to 
promote more homogeneous mixing of material. An example of such a system is the ‘continuous 
oscillatory baffled crystalliser’ (COBC)120, 121, a jacketed tubular cooling crystalliser with periodically 
spaced orifice baffles. Material is moved via a net flow rate through the system but gentle mixing is 
induced through a superimposed oscillatory motion by which the solution moves back and forth through 
the baffles, generating eddies. The advantage of such a method is that the mixing can be decoupled 
from the net flow that is driven by turbulent action. With baffles situated along the crystalliser, mixing 
can be considered uniform in each interbaffle zone, leaving cumulative plug flow conditions along the 
length of the platform. To date, continuous crystallisation processes, either cascade tanks or tubular, 
have been used for the precipitation of a number of systems. A case of particular note was the selective 
crystallisation of the metastable polymorph of Paracetamol, Form II.120 
 
One of the newest directions for continuous crystallisation has been in the assessment and modification 
of the mixing parameters within the reactors themselves. Rather than using traditional mixing features, 
such as impellers and baffles, alternative methods have been explored for the efficient homogenisation 
of solution throughout the crystallisation process. One such method has been that of ‘solution 
segmentation’.122, 123 By mixing a crystallisation medium with an immiscible liquid and feeding them 
through a channel, the separation of phases can result in discrete and uniform segments, also known as 
‘slugs’. Once formed, these slugs can travel through a tubular reactor at a given rate, allowing for 
efficient mixing through the generation of internal vortices.  
 
An example of the application of solution segmentation in flow was demonstrated through the use of 
the ‘Kinetically Regulated Automated Input Crystalliser’, or KRAIC.124 This tubular crystalliser 
operates as cooling crystallisation reactor, whereby a solution, initially heated to ensure complete 
dissolution, is mixed with an appropriate immiscible carrier fluid at a mixing piece, generating the 
necessary slugs. Through the application of a carrier fluid with suitable wetting properties, the solution 
slug can be coated so as to minimise contact with the surrounding tube walls, reducing the possibility 
of heterogeneous nucleation. In the case illustrated in Figure 1.30, air was also introduced, resulting in 
three segments, allowing for the maximisation of throughput through the crystalliser. As the slugs move 
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through consecutive coils, the solution is gradually cooled to room temperature, achieving 
supersaturation and primary nucleation. Figure 1.30a outlines the general setup of the KRAIC, with 
Figure 1.30b emphasising the formation of the different segments within the crystalliser. To date, this 
platform has been used for the efficient crystallisation of a range of molecular and organometallic 




Figure 1. 30 - The Kinetically Regulated Automated Input Crystalliser (KRAIC), highlighting (a) the segment feeds and 




2 Analytical techniques 
 
Any product obtained from a crystallisation process should be characterised using a range of 
complementary analytical techniques, particularly in the case of novel materials. With particular 
emphasis on the crystalline phase, this section will cover the basic principles of some of the techniques 
used for solid-state characterisation, including microscopy, X-ray diffraction methods, thermal analysis, 
spectroscopic methods and solubility determination. 
 
2.1  Microscopy 
 
Optical microscopy126, 127 allows the user to observe materials down to dimensions of a few 
micrometres, depending upon the magnification, and can be divided into two sub-types; polarising and 
reflectance microscopy.128 Polarising microscopy is a transmission technique and can be used for the 
analysis of crystalline materials, fine powders or thin slices of material. It uses white or monochromatic 
light that is shone through a polariser which only transmits parallel components of the light with the 
same vibrational direction. The resultant ‘plane polarised light’ passes through a lens and onto a sample. 
Light is then transmitted by the sample to an objective lens and through an analyser, where only light 
90o in its vibrational direction to the polariser is transmitted and observed. When an analyser is present, 
a sample can be viewed between the cross polars of the polariser and the analyser, allowing the user to 
distinguish whether the same is ‘isotropic’ (dark) or ‘anisotropic’ (light or coloured). By varying the 
extinction direction, crystalline samples can be assessed for their quality depending upon their 
anisotropic nature. Reflectance light microscopes operate in a similar manner, except that the light 
source and objective lens are on the same side as the sample. By using optical microscopy, properties 
such as morphology, sample homogeneity, purity and crystal defects can be identified. 
 
2.2  X-ray crystallography 
 
X-ray diffraction methods are one of the most important family of techniques used in crystallisation 
science. Once a crystal has been prepared, it is necessary to characterise it in terms of its crystalline 
structure, assessing bond and interaction angles and lengths, which can be then related back to other 
physicochemical properties. The two techniques that utilise the diffraction of X-rays are ‘Single Crystal 
X-ray Diffraction’ (SCXRD)10, 129, 130 and ‘Powder X-ray Diffraction’ (PXRD).10, 131 Whilst broadly 
SCXRD is used for the determination of the 3-dimensional crystalline structure and PXRD is used as a 
method of phase identification, both rely on the same fundamentals for crystal analysis. This section 
will cover crystallographic definitions of crystalline structure and how it can be related to X-ray 
diffraction. From there, the unpinning principles of X-ray diffraction will be explored, assessing their 
application for structure determination and phase analysis, using SCXRD and PXRD respectively. 
 
2.2.1 Crystal symmetry 
 
Crystals are built up through the regular and repetitive arrangement of structural units in three-
dimensions.128, 132 These structural units can consist of individual atoms, a group of atoms, molecules 
or ions. The repetition of such species can be represented by a repeat unit called the ‘unit cell’, the 
smallest repeating volume that shows the full symmetry of the crystal structure (Figure 2.1).129, 133 The 
unit cell itself is made up from individual components that are related to each other through this 
fundamental symmetry. These components, also called ‘asymmetric units’, represent the most basic 
structural motif, expressing no internal symmetry themselves, from which the entire crystal structure 




Crystal structures comprise of the periodic arrangement of identical environments in three-
dimensions134. This repetition is defined in terms of an array of ‘lattice points’, which, when repeated, 
can be used to create an infinite array, or a ‘lattice’.10, 49 A lattice point can be used to denote an 
equivalent environment within an ordered material. Depending upon how these points are connected 
together, different unit cells can be made, the best of which are generally decided through a series of 
rules based upon the relative lengths and angles of the unit cell. The unit cell for a given system is 





Figure 2. 1 - The unit cell, defined by the axis lengths (a, b and c) and the angles (α, β and γ) 
 
A unit cell can be categorised into seven different crystal systems, based on its symmetry (Table 2.1), 
ranging from cubic, which is the most symmetrical, to triclinic, the least. There are four types of 
lattice128 that can be built up from the arrangement of lattice points and used for the construction of the 
unit cell; primitive (P), face-centred (F), body-centred (I) and side-centred (A, B or C, depending upon 
the face in question). In terms of contributions to defining the unit cell, P-lattices possess one lattice 
point in total, F-lattices four lattice points, I-lattice two lattice points and the A/B/C-lattice two lattice 
points (Figure 2.2). By combining the lattice types and crystal systems, 14 Bravais lattices can be 
generated. Certain Bravais lattices are not possible due to symmetry violations or can be reduced to 
give one of the other 14 lattices.  
 
Table 2. 1 - Seven crystal systems, unit cell parameters and Bravais lattices 
 
Crystal system Unit cell parameters Bravais lattice 
Cubic a = b = c, α = β = γ = 90o P, I, F 
Hexagonal a = b ≠ c, α = β = 90o,  γ = 120o P 
Trigonal a = b = c, α = β = γ ≠ 90o P 
Tetragonal a =  b ≠ c, α = β = γ = 90o P, I 
Orthorhombic a ≠ b ≠ c, α = β = γ = 90o P, C, I, F 
Monoclinic a ≠ b ≠ c, α = γ = 90o, β ≠ 90o P, C 







Figure 2. 2 - Lattice types; Primitive (P), Face-centred (F), Body-centred (I) and Side-centred (A, B or C) 
 
Whilst unit cells can only be related to each other through translational symmetry, the individual atoms, 
ions, molecules or groups thereof that make up a unit cell can be related through combinations of 
translational, rotational, inversion or reflection symmetries.129, 133 A ‘symmetry operation’ is a 
symmetry movement that moves a component into a new configuration that is equivalent to its original 
position. A ‘symmetry element’ defines the point, line or plane through which said symmetry operation 
can be performed. Through combinations of these symmetry elements, including ‘glide planes’ and 
‘screw axes’ that include translational elements, unit cells can categorised into ‘space groups’, of which 
230 are possible.  
 
2.2.2 X-ray diffraction – Bragg’s Law and intensities 
 
It has already been highlighted that crystalline structures can be described through lattice points and 
lattices. Due to the regularity of these points, it is also possible to define ‘planes’ in a range of 
orientations throughout the lattice. A lattice can have a number of planes, each defined by ‘Miller 
indices, hkl’.129, 131, 135 These indices represent a family of parallel planes that cut through arbitrary axes 
in reciprocal space. As well as these values, sets of planes can also be defined in terms of their 
interplanar distances, known as ‘d-spacing’. 
 
Due to the periodic nature of the lattice points in a given crystal, X-rays are able to interact with the 
components that make up these points in a coherent manner, resulting in constructive interference at 
specific angles. These interactions are manifest in the form of diffraction, where the waves of the X-ray 
radiation can interact in or out-of-phase, respectively. A geometrical interpretation of how X-ray 
diffraction works was proposed by W. H. Bragg and W. L. Bragg and relates the diffraction and 






Figure 2. 3 - A representation of Bragg’s Law, highlighting the reflection of X-ray radiation with lattice planes and the 
associated X-ray pathway difference 
 
Here, two incident X-rays are reflected by two adjacent planes, each X-ray having a different path 
length, travelling the additional distance AB + BC. ‘Bragg’s law’129 is used to define the conditions 
through which X-ray waves will occur in phase and for a reflection to be observed. In order for this to 
be so, the path difference must equal to integer numbers of wavelengths, as defined in Equation 2.1.68, 
129, 130 From this equation, the interplanar distances for a family of planes can be determined and hence, 
the unit cell parameters for a crystal system. 
 
𝑛𝜆 =  2𝑑ℎ𝑘𝑙 sin 𝜃 
 
Equation 2. 1 - The Bragg equation, highlighting the conditions necessary for in phase diffraction to occur (n = reflection 
order, λ = wavelength of X-ray radiation, dhkl = interplanar distance for a given set of Lattice planes, θ = angle of incidence) 
 
Routine crystallographic studies collect diffraction data from a range of angles and orientations of the 
crystal, sampling all the lattice planes that define a given material, generating a pattern of diffraction 
spots. The symmetry of a pattern is closely related to the symmetry and, therefore, structure within a 
crystalline sample. By rearranging the Bragg equation, it can be shown that the diffraction angle is 
related to the interplanar spacing in a reciprocal manner (i.e. sin θ = (nλ/2).(1/d)). As a result of this, 
the dimensions within a diffraction pattern is inversely related to that of the real structure. Therefore, 
the diffraction symmetry is defined through ‘reciprocal space’135, with dimensions on 1/d and units of 
Å-1. Analogous to crystal symmetry, the symmetry of the diffraction pattern in reciprocal space can be 
classified into different classes known as the 11 ‘Laue classes’. When looking at a diffraction pattern, 
it is sometimes observed that certain diffraction spots for a given crystal structure are missing. These 
are known as ‘systematic absences’129 and arise when a lattice is centred or a symmetry element 
possesses translational symmetry. Hence, by considering the positions of the diffraction spots, the size 
and shape of the unit cell can be defined. 
 
Whilst Bragg’s law dictates the conditions through which diffraction can occur, providing information 
as to the size and shape of the unit cell, from this alone, there is no indication as to what the contents of 
the unit cell might be. This information is contained in the intensities of the diffracted X-ray beam. 
Diffraction intensities rely on the relative in or out-of-phase nature of X-ray waves interacting with a 
crystalline material, the value of which are related to the crystal symmetry, atomic positions and their 




The atoms of each element exhibit characteristic scattering of X-ray radiation over various diffraction 
angles. At scattering angle of zero (2θ = 0o), waves are scattered completely in-phase by the electron 
density associated with each atom, but as the angle of diffraction increases, destructive interference also 
increases, causing a drop off in the diffraction intensity. The relationship between intensity and the 
angle of diffraction for a specific element is shown in Figure 2.4 and is known as the ‘atomic scattering 




Figure 2. 4 - X-ray atomic scattering factors (fi) for oxygen and carbon 
 
By taking all these parameters into consideration and through Fourier transform manipulation, the 
amplitudes and phases for a given set of reflections can be related to the individual atoms within the 
unit cell. This relationship is expressed through the ‘structure factor’ (Equation 2.2).  
 





Equation 2. 2 - The forward Fourier transform, highlighting the structure factor (F(hkl)) for a particular crystal structure, as 
defined by the summation of all amplitudes and phases (i) for diffracting X-rays, taking into account the ability of individual 
atoms (j) to scatter X-rays (fj) 
 
By only considering its magnitude, the structure factor is shown to be proportionally related to the 
intensity of the scattered X-ray beam, as shown in Equation 2.3.10 In turn, the magnitude can also be 
used to describe the relative amplitudes of a particular wave. 
 
𝐼(ℎ𝑘𝑙) ∝  |𝐹(ℎ𝑘𝑙)|2 
 
Equation 2. 3 - The relationship between diffraction intensity (Ihkl) and the amplitude of the diffracted wave (│Fhkl│), for a 
given set of lattice planes 
 
Once determined, the structure factor can be linked to the electron density and relative positions of the 
associated atoms within the unit cell. By conducting a reverse Fourier transform, an electron density 
map can be obtained directly from the diffraction pattern (Equation 2.4).129, 136 Here, the electron density 
is defined by taking all the diffracted X-ray waves together, taking into account their relative amplitudes 
and phases.  
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𝜌(𝑥𝑦𝑧) =  
1
𝑉




Equation 2. 4 - The reverse Fourier transform, highlighting the relationship between the electron densities (ρ(hkl)) associated 
with a unit cell of a given volume (V), the structure factors, relating to the amplitudes, and the relative phases of the 
incoming waves 
 
The mathematical description of the phases can be broken down into two components; the intrinsic 
phase, φ (hkl), of the waves themselves and their shift. Whilst the shift can be calculated based upon 
the different path lengths, intrinsic phasing cannot be determined directly from the diffraction 
experiment. In crystallographic terms, this is known as the ‘phase problem’.10, 130, 136 As a result, 
diffraction intensities cannot be directly related to the structure factor, and hence the electron density, 
based solely on experimental data.  
 
2.2.3 Structure solution 
 
Once diffraction data have been collected, the relative positions of the atoms within the unit cell and, 
hence, the overall structure of a crystal can be determined. Structures are generated based upon the 
initial assignment of atoms to positions of electron density on the electron density map, which can be 
derived from the reverse Fourier transform.136 Here, the amplitudes and phase shifts of the diffracting 
X-rays across all the lattice planes can be obtained directly from the experimental data. However, as 
highlighted above, knowledge of the intrinsic phasing must also be established. The phase problem 
cannot be resolved directly, so secondary methods need to be employed.  
 
When it comes to solving crystal structures, many methods are available. Whilst structure determination 
using the ‘Patterson synthesis’129 (identifying atoms with the highest electron density) is common for 
metal-organic and inorganic structure analysis, given that the focus here is on small molecular crystal 
systems, the structures in this project will be solved with either ‘direct’129, 137 or ‘dual space’138 methods. 
 
Direct methods is a family of techniques that solve the phase problem by defining a probabilistic 
relationship between the experimentally known structure factor amplitudes and the unknown phases. 
By ranking diffraction intensities, the most significant are selected first and their probable relationship 
to the correct phase can be determined. This process is repeated through a number of iterations, 
assigning phases and building up the electron density map. In order to achieve this, several assumptions 
are made, whereby the electron density is defined as being positive across the structure and localised to 
distinct atomic locations.  
 
Dual space or ‘charge flipping’139 methods operate by constraining the phases through combined 
observations from reflection intensities in reciprocal space and properties of the electron density in real 
space. This means defining constraints that relate the amplitudes of the electron density derived from 
the Fourier transform with those of the experimentally observed amplitudes, as well as treating all 
observed electron density as positive. 
 
2.2.4 Structure refinement 
 
Solving a crystal structure reveals the relative positions of the atoms present based upon their electron 
density. In the early stages of structure solution, a partial structure is obtained, with only some of the 
atomic positions determined. This generates an initial model that needs to be refined.  
 
Refinement involves the systematic adjustment of parameters governing the structure factor (atomic 
positions, thermal vibrational parameters, etc.) to give the best fit between the observed intensities (Fobs) 
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and those calculated for the modelled structure (Fcalc). The procedure through which this refinement is 
achieved is that of ‘least squares’.140 Typically, diffraction experiments generate more observed data 
points when compared to the number of parameters. As a rule, the more data points, the more reliable 
the refinement parameters, with a data-to-parameter ratio of >10 considered acceptable for a high 
quality structure determination.129, 141 To quantify this, each parameter has associated with it standard 
uncertainties (s.u.), which depend on the error related to the data, the agreement between the measured 
and calculated results and the overall quantity of the data. An initial reflection of the reliability of the 
data comes from the ‘goodness of fit’ value.129  
 
The relative disparity can be assessed in variety of ways, but most commonly through the residual ‘R’ 
factor (Equation 2.5).129, 142 As the phases cannot be taken directly from the experimental data, structure 
and refinement assessments must be based on amplitudes. This refinement indicator highlights the 
difference between the observed and calculated amplitudes, divided by that of the observed.   
 





Equation 2. 5 - Residual ‘R’ factor for assessing structure refinement 
 
Whilst useful, the ‘R’ factor does not take into account the relative importance of some diffraction 
intensities with respect to others. By incorporating a weighting scheme, the different contributions to 
the observed and calculated structure factors can be accounted for. Hence, a better statistical evaluation 
can be yielded through the use of the ‘wR2’ factor (Equation 2.6)129, 142, where the squared structure 
factors can be related directly to intensities. 
 











Equation 2. 6 - ‘wR2’ weighted factor for assessing structure refinement, where ‘w’ is the weighting factor 
 
For all structural refinements, the aim is to minimise the discrepancies between the observed and the 
calculated intensities. To achieve this, a range of parameters must be refined141. Amongst the most 
significant of these are those associated with the positioning and vibrations of atoms. Each atom has 
three positional coordinates (x, y and z) and a displacement parameter (U). The displacement of atoms 
can either be described ‘isotropically’, whereby atoms are represented with isotropic spherical thermal 
motion, or more commonly ‘anisotropically’. Here, atoms are defined by their movement in six 
different directions. For the best results, diffraction data is collected at lower temperatures (e.g. 150 K) 
so as to minimise thermal vibrations. Typically, most non-hydrogen atoms are assigned anisotropic 
displacement variables, resulting in up to nine parameters that can be refined for each atom. Owing to 
their inherently low electron density, the assignment and refinement of hydrogen atoms is conducted at 
later stages of the process, usually by incorporating isotropic ‘constraints’.143 Constraints are imposed 
refinement conditions, usually to fulfil symmetry requirements or to control refinement parameters that 
are poorly defined by the diffraction data. 
 
Once completed, a final structure is generated, demonstrating the accurate positions of atoms in the unit 
cell, together with their individual anisotropic thermal vibrations, providing estimates of bond lengths 





2.2.5 Considerations for single crystal X-ray diffraction (SCXRD) 
 
The most common method used for structure determination is SCXRD. Utilising the principles of X-
ray diffraction outlined above, the regular arrangement of atoms, ions and molecules can be determined 
from electron density maps, as derived from the diffraction pattern. The basic steps used in SCXRD are 




Figure 2. 5 - Schematic of the fundamental steps required for structure determination through SCXRD 
 
Once a crystal of sufficient quality has been selected, it can be mounted onto a ‘goniometer head’ and 
centred so as to be in the direct pathway of the X-ray beam. At this stage, an initial diffraction screen 
can be conducted. Whilst not always necessary, this initial assessment can provide important 
information as to the quality of the crystal being analysed. This can be in terms diffraction quality or 
for comparison with previously collected structures, via determination of the unit cell.  
 
One of the key decisions when designing any diffraction experiment is the choice of X-ray 
wavelength144. Although a wide range X-ray sources are available, the most common sources used in 
laboratory diffractometers are copper (Cu-Kα 1.54178 Å) and molybdenum (Mo-Kα 0.71073 Å). Whilst 
the use of molybdenum radiation can mitigate excessive X-ray absorption effects and give data at higher 
diffraction angles, the longer wavelength inherent to copper sourced radiation is particularly useful in 
yielding more intense diffraction patterns. This is of particular significance when analysing weakly 
diffracting materials, such as small molecular structures.  
 
As well as this, X-rays from copper sources are also widely used for determining the absolute structures 
of materials that possess chirality144. Single enantiomers are only able to crystallise within one of 65 
chiral space groups, where no symmetry elements that allow for the incorporation of the opposite 
enantiomer are present. These systems are described as ‘non-centrosymmetric’, whilst systems that do 
have mirror or inversion symmetry are known as ‘centrosymmetric’. 
 
When X-rays are generated, a series of filters and optics are used to remove all other wavelengths, apart 
from the desired wavelength135. At the ‘X-ray absorption edges’ that are key to this filtering, certain 
wavelengths are able to excite or eject electrons from atoms, resulting in a phase change in the X-rays 
scattered by specific atoms in the structure being analysed. This has implications for the intensity and, 
in non-centrosymmetric structures, can lead to the breakdown of ‘Freidel’s law’ and the observation of 
weak anomalous scattering.130, 144 Freidel’s law states that in the absence of anomalous scattering, 
diffraction in one direction will have the same intensities as those in the opposite, resulting in a 
centrosymmetric diffraction pattern. However, in the case of enantiomerically pure materials, this is not 
true. As a result, distinctions can be made between the diffraction patterns of the enantiomeric pairs and 
chirality can be resolved. This highlights the advantage of using copper radiation as it can allow for the 




Opposite chiral structures can be considered as inversions of each other. Upon structure solution and 
refinement, these inversion structures can be considered within the model and refined against each 
other. The ‘Flack’ parameter141, 145 is used to compare how close the model is to each of the inversion 
related structures and the correct chirality is assigned accordingly. Absolute structure determination142 
by X-ray diffraction is not always reliable, owing to the inherently weaker scattering effects used to 
observe the differences in phase between opposite diffractions. As a result, confirmation of the absolute 
configuration should be clarified by other means, either by referencing to the chirality of a known 
molecule used during crystallisation or through another analytical technique, such as chiral HPLC or 
circular dichroism spectroscopy (discussed below). 
 
When analysing crystalline samples, an important consideration is its homogeneity. To achieve the best 
diffraction data, single crystals are required. However, a common problem when determining a crystal 
structure is that of ‘twinning’.146 A crystal can be twinned when two or more orientations of the same 
structure reside together in a defined relationship. As a result, the overall diffraction pattern 
demonstrates the superposition of the different individual diffraction patterns of the constituent 
components. Common consequences of twinning include exaggerated intensities from overlapping 
diffraction spots and apparent alterations to the unit cell parameters. Although structures can be resolved 
from twinned materials, the process is by no means simple and has inherent complications with respect 
to conventional structure solutions.  
 
2.2.6 Powder X-ray diffraction (PXRD) 
 
Though useful in its own right, particularly for structure solution, one of the main drawbacks of SCXRD 
is the prerequisite of individual single crystals. In many cases, the growth of sufficiently homogeneous 
and large crystals is not always possible, with crystalline solids from synthesis or screening often being 
microcrystalline in nature. A common method for analysing bulk crystalline product is PXRD. 
 
Like with SCXRD, PXRD works on the principle of X-ray diffraction upon interaction with a crystalline 
material.10, 130 However, due to the nature of poly-crystalline samples, where many crystallites are 
arranged in a range of orientations, all lattice planes are exposed simultaneously. PXRD operates by 
sweeping through a range of diffraction angles. At any given position, a certain proportion of the 
crystallites present will have the necessary alignment to allow for X-ray waves to be diffracted, thus 
satisfying Bragg’s law. Unlike in SCXRD, the resultant diffraction pattern is made up of a series of 
concentric rings, otherwise known as ‘Debye rings’, rather than individual diffraction spots (Figure 
2.6a).10 These rings arise from the diffraction from individual lattice planes (defined by the Miller 
indices, hkl) common across the many crystallites present. The resultant pattern is recorded at 
characteristic 2θ values, corresponding the angle made between the diffracted and incident beams. This 
results in a range of peaks with given intensities, which can be indexed to the different planes present, 
their respective interplanar spacing and hence used to define the representative dimensions of the unit 
cell for that material .131 A schematic of a standard PXRD diffractometer is shown in Figure 2.6b.10 
 
An important consideration for PXRD analysis is that of ‘preferred orientation’.130 Often, 
polycrystalline materials deviate from the ideal random distribution of crystallite orientations. When 
samples contain larger individual crystals and depending upon their morphology, certain lattice planes 
can be expressed to a greater degree with respect to all of the other planes present. This results in the 
dominance of the peaks that correspond to these lattice planes, sometimes swamping the other 






Figure 2. 6 - Diagrams highlighting (a) the ring arising from the diffraction of a poly-crystalline sample and (b) a typical 
setup of a PXRD diffractometer 
 
One of the most important uses of PXRD is qualitative phase analysis, giving information as to which 
crystalline phases or combination of phases may be present.100, 147-149 Each material expresses its own 
unique pattern that can be used as a fingerprint for identification purposes. In the pharmaceutical 
industry, in particular, PXRD is commonplace, owing to its ability to rapidly assess polymorphism in 
the solid-state. Figure 2.7 outlines an example two-dimensional diffraction pattern for the racemic form 




Figure 2. 7 - An example PXRD pattern for the racemic API, naproxen (PAPTUX)150, highlighting intensities at respective 
values of 2θ 
 
2.3  Thermal analysis 
 
Thermal analytical techniques65, 68 work on the basis of measuring the changes observed in a material 
as a function of heat flow. By varying the temperature, thermal events can be recorded and subsequently 
interpreted in relation to physical and chemical properties for a given system. These thermal events can 
be classified as exothermic or endothermic processes, which incorporate phenomena such 
decomposition, solvent loss and a range of phase transitions (melting, crystallisation and solid-to-solid). 
A variety of thermal techniques are available, but the focus here will be on ‘differential scanning 




2.3.1 Differential scanning calorimetry (DSC) 
 
Differential scanning calorimetry (DSC)65, 68 is one of the most widely used thermal techniques for the 
analysis of pharmaceutical materials. Upon analysis with DSC, a sample is subjected to a regime of 
temperatures, from which heat flows can be recorded, highlighting any thermal induced phase 
transitions. Most commercially available DSCs operate through one of two mechanism; ‘power 
compensation’ or ‘heat-flux’. In power compensating devices, a sample and a reference are positioned 
on different heating elements, but the same temperatures are maintained for both. When a thermal event 
occurs, the energy taken in or given out by the sample is compensated for in the reference, therefore 
keeping the overall temperature between the two heating elements the same. This compensation is 
recorded in terms of heat flow and attributed to an observed thermal event. For heat-flux DSC 
instruments, the sample and reference are subjected to heating and cooling in two separate 
compartments in the same oven. Here, the temperature difference is measured as a function of 
temperature, from which the heat flow difference can then be calculated.  
 
In DSC, a variety of heating and cooling rates can be employed, from which thermal data can be 
obtained, including melting points and key enthalpies. DSC analysis is particularly important for the 
assessment of crystalline materials as it can differentiate between the melting points of polymorphic 
forms, as well as yield information relating to transitions between various phases.148, 151-153 Figure 2.8 




Figure 2. 8 - DSC trace showing common thermal phenomena, such as (a) a glass transition (baseline shift), (b) a 
recrystallisation from the melt (exothermic), (c) a phase transition (here, endothermic) and (d) a melting point (endothermic) 
 
2.3.2 Hot-stage microscopy (HSM) 
 
The ability to observe solids under a microscope often provides useful insight into the properties of a 
material. In hot-stage microscopy (HSM)65, samples can be observed whilst being exposed to different 
temperature profiles, similar to those used in DSC. Through these observations, thermal phenomena 
can be visually assessed and related back to quantitative data obtained from DSC.154 
 
2.4  Spectroscopy 
 
Spectroscopy76, 155 is a family of analytical methods that utilises either the absorption or transmission of 
specific energies of ‘electromagnetic’ radiation. These correspond directly to quantised energies for 
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excitations within a given atom, ion or molecule. From analysis of the different energetic transitions 
exhibited upon interaction with the various wavelengths of radiation, information relating to atomic and 
molecular structural features can be obtained. In terms of the different types of electromagnetic 
radiation, γ-rays possess the shortest wavelength and the highest energy whilst radio waves have the 
longest wavelength and lowest energy.  
 
Common laboratory spectrometers predominately operate by detecting absorption transitions, with that 
of ultraviolet visible (UV-vis) and infrared (IR) radiation being the most utilised, used to explore 
electronic, vibrational and rotational transitions, respectively. The techniques described here are 
‘infrared’ (IR) spectroscopy and the UV-vis based method of ‘circular dichroism’ (CD) spectroscopy.  
 
2.4.1 Infrared spectroscopy 
 
Infrared spectroscopy66, 155 refers to techniques that probe materials with wavelengths corresponding to 
the infrared region of the electromagnetic spectrum. Upon absorption of radiation, bonds within 
molecules are excited, demonstrating ‘vibrational’ excitation. These types of excitation manifest 
themselves as either higher energy stretches or lower energy bends. As a result, the absorption of certain 
wavelengths can be correlated to the bending and stretching of specific bond types, common to a large 
number of molecular structures. Although key to identifying individual bonds, single vibrations should 
not be considered in isolation. Upon absorption of infrared radiation, bonds throughout a molecular 
structure begin to oscillate, affecting the whole molecule and giving rise to overtones and other 
harmonics. 
 
Based upon these principles, infrared spectra can be used either quantitatively or, more commonly, 
qualitatively. By considering that bonds of greater strength will show greater vibrational frequencies, 
spectra can be analysed and judgements can be made as to the relative strengths of different bonds, the 
presence or absence of particular functionalities and the existence and directionality of intermolecular 
interactions, particularly hydrogen bonds. Broadly, infrared spectra can be categorised into three 
regions; 4000-2000 cm-1, 2000-1500 cm-1 and 1500-600 cm-1. The first two regions are synonymous 
with characteristic stretches for individual functional groups particularly those of the O-H, N-H and C-
O bonds, with the lower energy range of wavelengths being used to describe bond bending. These can 
be used as a unique fingerprint for a given molecular entity. Figure 2.9 outlines the example IR spectra 








2.4.2 Circular dichroism 
 
Circular dichroism spectroscopy156, 157 is a technique which measures the difference in absorption 
between left and right-handed ‘circularly polarised light’, typically utilising wavelengths associated 
with the ultraviolet and visible regions of the electromagnetic spectrum (Figure 2.10). The main 
application of this method is for the analysis of molecules and structures (e.g. proteins) that exhibit 
chirality. These systems exhibit ‘circular birefringence’, whereby a solution consisting of a chiral 
substance is able to propagate left and right circularly polarised light at different velocities. As a result, 
the waves rotate. It should be noted that this propagation effect does not result in strictly circular 
polarisation, but rather that of an ellipsoid. This phenomenon is common to both circular dichroism and 
‘polarimetry’, but whilst the latter deals exclusively with the degree of optical rotation, circular 
dichroism also incorporates the relative absorption of the different handed forms of polarised light. This 




Figure 2. 10 - Schematic diagram demonstrating the different absorptions of circularly polarised light by a chiral substance 
 
Polarised light can be represented as the combination of two linearly polarised states set at 90o to each 
other. At this point, both waves have the same amplitude and are in-phase. But by shifting the waves 
with respect to each other, they become out-of-phase resulting in non-linearly polarised light. 
Depending on the direction of this shift, the two waves of light now form a helix, spiralling in either a 
right or left-handed manner. This relationship is known as circular polarisation. 
 
In order to gain meaningful data from this technique, the material of interest must fulfil certain 
criteria.157 The substance should possess, not only chirality, but also a ‘chromophore’. These 
functionalities usually consist of conjugated (π) bonds and are responsible for the absorption of 
ultraviolet and visible light. Systems that exhibit strong circular dichroism typically have chromophores 
that are chiral.  
 
The output from circular dichroism spectroscopic experiments is usually reported in terms of 
absorbance (ΔA) or ‘ellipticity’ (millidegrees or m). Absorbance (Equation 2.7a) reflects the disparity 
in absorbance between the different handed forms of circularly polarised light, whilst ellipticity 
(Equation 2.7b) describes the degree to which the circularly polarised light forms an ellipsoid upon 
interaction with the chiral medium. Both of these units can be related to each other and using the ‘Beer-
Lambert law’, both can be corrected to be independent of solution concentration, in terms of ‘molar 





(a) ∆𝐴 = 𝐴(𝐿𝑒𝑓𝑡 𝐶𝑃𝐿) − 𝐴(𝑅𝑖𝑔ℎ𝑡 𝐶𝑃𝐿) 
 
(b) 𝜃 =  ∆𝐴. (32.98) 
 





(d) [𝜃] =  ∆𝜀. (3298) 
 
Equation 2. 7 - (a) Absorbance circular dichroism, (b) ellipticity, (c) molar absorbance circular dichroism and (d) molar 
ellipticity (32.982 is a scale factor between absorbance and the ellipticity) 
 
In practise, by measuring solutions of given concentration in terms of the molar ellipticity, the 
proportion of the enantiomers present can be measured. As shown in Figure 2.11, clear distinctions can 
be made between not only the individual two enantiomers, with each demonstrating a specific sign in 
terms of its molar ellipticity, but also the racemic composition, where the absorption associated with a 




Figure 2. 11 - Molar ellipticity plot, comparing the absorptions of both enantiomeric forms of the API, naproxen, as well as 
its racemic form 
 
2.5  Solubility determination 
 
In order to design efficient crystallisation processes from solution, the solubility of materials in a given 
solvent or combinations thereof must be known. By understanding the equilibrium solubility at a given 
temperature, initial investigations into the supersaturated region can be conducted. A variety of methods 
can be used to determine the solubility, including ‘gravimetric’158-160 and ‘temperature variation’ 
techniques.159, 161 
 
Gravimetric analysis is the most reliable method for determining the thermodynamic solubility, but is 
dependent upon the relative stability of particular phases (i.e. polymorphs) and can be experimentally 
time-consuming. Suspensions are prepared and mixed for an extended period of time, at a specified 
temperature, allowing the system to reach saturation. Here, the saturated solution is filtered and allowed 
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to evaporate, accounting for the mass of solvent and saturated solution (Figure 2.12a). From this, 
equilibrium concentrations can be determined.  
 
Due to the time-consuming nature of gravimetric analysis, most commercial equipment derives the 
solubility for a system based upon variations in temperature. Solutions of a known concentration are 
prepared and exposed to a temperature cycling regime. Typically, measurements are taken based upon 
turbidity, from which both the solubility and metastable limit can be found for a given concentration. 
Turbidity is a measure of the cloudiness of a fluid caused by particles being suspended in the solution. 
Upon cooling, the point at which nucleation occurs can be used to determine the metastable limit, whilst 
upon heating, the point at which there is complete dissolution can be taken as the solubility (Figure 
2.12b). Despite turbidity measurements having advantages in terms of being able to characterise various 
aspects of a solution undergoing dissolution and crystallisation, caution should be taken. In comparison 
to gravimetric methods, the system in question is not strictly allowed to equilibrate, meaning that in 










3 Material review 
 
Thus far, the principles of pharmaceutical solid-state chemistry, crystallisation and the methods for the 
analysis of the resulting solid products have been described in detail. The purpose of this chapter is to 
put these principles into context, focussing on a set of materials which form the basis of the research 
outlined in later sections of this thesis. Firstly, the API, naproxen, will be discussed, exploring its 
structure and related physicochemical properties, highlighting previous reported multi-component 
materials and their application to enantiomeric separation. This pharmaceutical ingredient will form the 
basis for the multi-component material screenings and characterisations conducted in Chapters 6, 7 and 
8. Secondly, the stoichiometrically diverse co-crystals of oxalic acid and urea will be introduced, 
emphasising the structural differences between the two forms and assessing previously studied methods 
for their respective preparation. These co-crystals are examined further in Chapter 9.   
 
3.1  Chirality and multi-component materials of the API, naproxen 
 
Naproxen (NPX), (2-(6-methoxy-2-naphthyl) propionic acid) is a non-steroidal anti-inflammatory drug 
(NSAID) used in the treatment of pathophysiological conditions, ranging from fevers and headaches, 
to degenerative diseases, such as osteo and rheumatoid arthritis.162-165 Typically administered orally, 
NPX is one of the most common NSAIDs and has a proven record of effectiveness. However, despite 
this, NPX has a dosage limit owing to side effects resulting from irritation and ulceration of the gastro-
intestinal tract. In addition, this API is categorised as a Class II drug166 under the ‘Biopharmaceutics 
Classification System’ (BCS), exhibiting high permeability across membranes but low aqueous 
solubility.  
 
NPX is made up of three principal functionalities; methoxy, naphthyl and propionic acid groups (Figure 
3.1). Key to its solid-state structure are the naphthyl and carboxylic acid groups, through which π-
stacking and hydrogen bonding can take place, respectively. NPX also possesses chirality about the 
methyl substituent adjacent to the carboxylic acid and naphthyl groups. Despite both showing 
therapeutic benefits, the S-enantiomer (sNPX) has been shown to demonstrate significantly higher 




 Figure 3. 1 - Schematic of the molecular structure of the API, naproxen (NPX), highlighting its chiral centre (*) 
 
Currently, enantiomeric separation is conducted post-synthesis, via a variety of means including chiral 
high performance liquid chromatography (HPLC) and classical diastereomeric resolution.168 The 
limiting factor for the application of NPX to a preferential crystallisation process is its inherent 
preference to form a racemic crystalline material at racemic compositions. As outlined in Chapter 1, 
preferential crystallisations can only be carried out when the material in question exhibits the properties 
of a racemic conglomerate at racemic compositions. Conglomerate systems arise when the like 
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enantiomers preferentially interact, resulting in a physical mixture of crystals precipitating, where each 
crystallite is composed of one single enantiomer. Figure 3.2 provides a structural comparison of the 
homochiral169-171 and heterochiral150 crystal structures of NPX, which crystallise in the P21 and Pbca 
space groups respectively. For the enantiomerically pure structure, the sNPX molecules form channels 
held together by extended hydrogen bonded backbones, utilising individual 𝐶1
1(3) interactions between 
the hydroxyl donors and carbonyl acceptors, whilst the racemic structure utilises 𝑅2
2(8) dimers between 




Figure 3. 2 - Crystal structures of sNPX169-171 and rsNPX150, highlighting their unit cells, (a) and (c), as well as the key 
hydrogen bonding motifs, (b) and (d), respectively (red = sNPX, blue = rNPX) 
 
Whilst synthetic derivatisation of NPX has been shown to allow for conglomerate formation172, in many 
cases, this can be an energy intensive process. Another technique for generating materials that are 
amenable to a preferential crystallisation (i.e. a racemic conglomerate) is through the preparation of 
multi-component materials. Previous studies have shown that through the addition of an achiral 
secondary component, novel co-crystal or salt forms can be made that demonstrate a change in the class 
of chiral crystalline material when compared to that of the starting materials. An example of this (Figure 
3.3a) is the co-crystal system of ibuprofen, another NSAID, with 4,4’-bipyridine.41 By co-crystallising 
different enantiomeric compositions of the API with the co-former in a 2:1 ratio, a solid solution is 
formed, whereby broadly the overall interaction motifs and packing remains the same, but the locations 
of R to S ibuprofen throughout the structure are continuous. This phenomenon is in contrast with 
ibuprofen, which forms a racemic compound. Likewise, upon combining 2,3-dichlorophenylacetic acid 
with (±)-trans-N,N’-dibenzyldiaminocyclohexane (Figure 3.4b)44, the resultant 2:1 salt form has been 





Figure 3. 3 - Crystal structures of the (a) 2:1 ibuprofen:4,4’-bipyridine co-crystal41 and (b) 2:1 2,3-dichlorophenylacetic 
acid:(±)-trans-N,N’-dibenzyldiaminocyclohexane salt44, highlighting solid solution and racemic conglomerate formation, 
respectively (red = S-enantiomer, blue = R-enantiomer) 
 
To date, most multi-component material screening incorporating NPX has been conducted either to 
enhance its aqueous solubility173 or for the preparation of diastereomeric materials.168, 174 Based upon 
searches of the CSD (conducted June 2018), 48 structures could be found including NPX either in its 
protonated or de-protonated state, excluding organometallic materials. Once the single-component 
sNPX and rsNPX structures had been discounted, the remaining 41 multi-component structures can be 
classified in terms of their salt or co-crystal properties, as well as in terms of the chirality of the salt or 
co-former being used (Table 3.1). Further crystallographic details can be found in the Appendix. 
 
Table 3. 1 - Classification of the previously report multi-component materials of NPX, based upon salt/co-former chirality 
and the ratio of salt to co-crystalline structures 
 
Salt/co-former chirality No. of salts No. of co-crystals 
Chiral (diastereomeric) 8 9 
Achiral 11 13 
 
It should be noted that the vast majority of the literature structures utilise enantiomerically pure NPX 
(R or S), with few studies exploring the chiral crystalline nature of the novel multi-component materials 
at racemic compositions. However, two studies that did explore this covered three sets of co-crystalline 
materials, where sNPX and rsNPX, respectively, were combined in 2:1 molar ratios with the co-formers 
nicotinamide175, 4,4’-bipyridine176 and piperazine176 (Figure 3.4). In each case, the co-crystals exhibited 
racemic compound-like behaviour, rendering them unsuitable for direct preferential crystallisation. 
Nevertheless, the study exploiting the NPX:nicotinamide co-crystals, counterintuitively, showed that by 
manipulating the crystallisation conditions (in this case, anti-solvent crystallisation with compressed 
CO2) to encourage rapid nucleation, a mixture of enantiopure and racemic co-crystal could be obtained 
at racemic compositions. In such scenarios, the homochiral phase is kinetically stabilised and, hence, 






Figure 3. 4 - Crystal structures of the homochiral and racemic co-crystals of NPX with (a) nicotinamide175, (b) 4,4’-
bipyridine176 and (c) piperazine176, whereby the first forms a metastable racemic conglomerate and the latter two form 
racemic compounds (red = sNPX, blue = rNPX) 
 
As such, the work discussed in Chapters 6, 7 and 8 explores the potential of NPX to form multi-
component materials with a range of salt and co-formers. From comparison of the materials prepared 
at racemic and enantiopure compositions, the chiral crystalline nature is assessed. Upon finding a 
system that demonstrated characteristics akin to that of a conglomerate or metastable conglomerate, 
further solution analysis is conducted so as to provide information useful for the design of preferential 
crystallisations. 
 
3.2  Stoichiometric co-crystals of oxalic acid and urea 
 
As discussed in previous chapters, multi-component systems, particularly co-crystalline materials, 
exhibit structural variations, not only in polymorphic terms, but also with respect to the stoichiometry 
of the constituent molecules within the crystalline structure. An example of this can be seen in co-
crystals of oxalic acid (OA) and urea (U). Both these simple molecules are readily available and have 
been applied in many co-crystal studies to date.177-180 OA (Figure 3.5a) itself can crystallise as one of 
two polymorphs (OA-α or β)181, but due to its high hygroscopicity (the ability to uptake water from the 
surroundings and incorporate it into the crystal lattice) it also readily forms a dihydrate (OAD)182, 183 
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under ambient conditions. In comparison, U (Figure 3.5b) forms only one polymorphic form (Form I) 
at room temperature and pressures184-186, though studies conducted at higher temperatures and pressures 
have shown the existence of further structures; Forms II-IV.187 The unit cell parameters for each of the 




Figure 3. 5 - Schematic of the molecular structures of (a) oxalic acid (OA) and (b) urea (U) 
  
Upon combining OA with U, under given crystallisation conditions, co-crystals have been shown to 
form. These co-crystals were first reported by Dalman188 in 1934, but only in the 1970s were the crystal 
structures of the OAU-1:2189 and OAU-1:1190 cocrystals determined via X-ray diffraction. Figure 3.6 
and Table 3.2 demonstrates the disparity between the stoichiometric co-crystals in terms of their crystal 
structures, hydrogen bonding and unit cell parameters. Both materials are made from two-dimensional 
hydrogen bonded networks built up into layers. In case of the OAU-1:1 co-crystal, the OA molecules in 
the plane are surrounded by alternating arrangements of equal number of OA and U molecules, whilst 
in the OAU-1:2 co-crystal, to account for the higher proportion of hydrogen bonding interactions, every 




Figure 3. 6 - Crystal structures of the OAU-1:1190 and OAU-1:2189 co-crystals, highlighting their respective unit cells, (a) and 
(b), packing arrangements, (c) and (d), and the hydrogen bonding motifs, (e) and (f) 
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Table 3. 2 - Unit cell parameters of the OAU-1:1190 and OAU-1:2189 co-crystals 
 
Co-crystal Space group a (Å) b (Å) c (Å) α (o) β (o) γ (o) Volume (Å3) 
OAU – 1:1 Monoclinic C2/c 13.06 6.64 6.84 90 92.47 90 593.72 
OAU – 1:2 Monoclinic P21/c 5.048 12.374 6.876 90 96.4 90 426.83 
 
To date, only three methods of preparation have been used for making either the 1:1 or 1:2 co-crystal 
of oxalic acid and urea; evaporative crystallisation189, 190, slurrying188, 191 and mechanochemistry192. The 
purpose of early studies was to obtain single crystals of sufficient quality for the determination of the 
crystal structures of each of the co-crystalline forms. For each diffraction study, evaporative 
crystallisation was preferred method used to yield suitable individual crystals. The focus of subsequent 
research shifted to the analysis of bulk properties (spectroscopic, thermal and thermodynamic data) of 
the respective co-crystals, thus slurry and mechanochemical methods were used. Table 3.3 highlights 
the key studies and the relevant preparation methods used to obtain each co-crystal. 
 
Table 3. 3 - Previous studies into the OAU-1:1 and OAU-1:2 co-crystals, outlining the relevant preparation methods utilised 
 
Author OAU co-crystal Preparation method 
S. Harkema et al. (1972)189 1:2 
1:2 molar ratio of OA to U dissolved in an 
aqueous solution and allowed to evaporate at 
room temperature 
V. Chithambaram et al. 
(2013)193 
1:2 
1:2 molar ratio of OA to U dissolved in distilled 
water and evaporated at room temperature, 
recrystallisation using seeds from evaporation 
in aqueous saturated solution maintained at 
30oC 
L. H. Dalman (1934)188 &  
Y. Feng et al. (2012)191 
1:2 
1:1/1:2 molar ratios of OA to U slurried in 
water at 40oC for 24 hours 
S. Harkema et al. (1979)190 1:1 
5:1 molar ratio of OAD to U dissolved in 
aqueous solution and allowed to evaporate at 
40oC 
L. H. Dalman (1934)188 &  
Y. Feng et al. (2012)191 
1:1 
4.5:1 molar ratio of OA to U slurried in water at 
40oC for 24 hours 
O. Onija et al. (2012)192 1:1 
1:1 molar ratio of OA to U ground in a mortar 
and pestle, with minimum distilled water added 
at room temperature 
 
The studies conducted thus far have broadly focussed on the structural and physical properties of the 
two OAU co-crystals, but few have assessed, in depth, the methods for their preparation. From the work 
that led to the initial discovery of these materials, Figure 3.7 outlines the ternary phase diagram upon 
the combination of OA and U in water. A key feature is the comparative stability of the OAU-1:2 co-
crystal over a large composition range, particularly when compared to that of the 1:1 system. It should 
be noted that this early research does not account for OAD, made readily under aqueous conditions. 
 
In the research outlined in Chapter 9, the co-crystals of OA and U are used as a model system through 
which the methods utilised in early phase screening could be assessed; mechanochemical, slurrying and 
evaporative crystallisation. Routes to the selective preparation of each co-crystal are determined, 
accounting for the solvent environment and stoichiometry, in terms of both molar contribution of OA 
to U and that of solute to solvent. From here, cooling crystallisations, previously unexplored for these 
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multi-component materials, are developed, translating from the standard batch environment to the 










4 Research outline and aims 
 
Various studies have shown that through the introduction of a secondary molecular component with 
complementary interactions, novel multi-component materials (co-crystals, salts, hydrates, and 
solvates) can be generated that exhibit different crystalline structures when compared to the constituent 
components and hence, altered physicochemical properties. This can have particular implications for 
pharmaceutical materials, offering a pathway to the tuning of material characteristics.  
 
In the research described in subsequent chapters, the selective preparation of various multi-component 
materials are studied as part of two main projects; the solid-state screening for novel multi-component 
materials of the API, naproxen, for application into a preferential crystallisation process, and the 
selective preparation and crystallisation of the stoichiometric co-crystals of oxalic acid and urea, 
driving towards continuous crystallisation. 
 
4.1 Solid-state screening for novel chiral multi-component materials of the API, 
naproxen, for application into a preferential crystallisation process 
 
As highlighted from previous chapters, chiral molecules can be separated by a variety of techniques. 
Preferential crystallisation offers a simple, efficient and economically viable route through which 
individual enantiomers can be resolved from a racemic solution. However, an important prerequisite is 
that the chiral system of interest crystallises as a racemic conglomerate at racemic compositions. This 
significantly limits the application of preferential crystallisation owing to the relative scarcity of 
conglomerates found in the literature. 
 
In the work outlined and discussed in Chapters 6, 7 and 8, the API naproxen (NPX), a racemic compound 
forming system, is subjected to extensive salt and co-crystal screenings, exploiting a range of potential 
achiral co-formers, so as to determine their chiral crystalline configuration. Chiral co-formers are not 
covered owing to the desire to focus on materials with the characteristic required for preferential 
crystallisation processes, as opposed to that of classical or diastereomeric resolution methods. The 
multi-component materials are prepared with racemic and enantiopure compositions of NPX, using a 
range of screening techniques, from mechanochemical to solution-based crystallisation methods, 
particularly evaporation and cooling. Each phase is characterised in terms of its crystalline structure, 
intermolecular interactions and thermal properties, from which they can be categorised in terms of their 
chiral crystalline nature. Systems that demonstrate interesting properties or that aid in development of 
a preferential crystallisation are explored further, developing initial crystallisation methods for 
preparation their respective phases at homo and hetero-chiral compositions. This work was carried out 
as part of an on-going collaboration between the Wilson group (University of Bath) and the ter Horst 
group (University of Strathclyde), looking towards the application of novel chiral multi-component 
materials into various preferential crystallisation setups. The work presented here is all that of the 
author. 
 
Chapter 6 focusses on the characterisation of NPX itself, establishing methods for distinguishing 
between its homo and heterochiral forms. Based upon CSD searches, a series of likely co-formers are 
selected and from the initial selection of 2-aminopyridine (2AP), multi-component materials thereof are 
screened and characterised. Cooling crystallisation methods are then developed for the materials of NPX 
and 2AP, exploring their applicability towards a preferential crystallisation. Further multi-component 
material screenings are discussed in Chapters 7 and 8, with the former focussing on direct 2-





4.2 Selective preparation and crystallisation of stoichiometric co-crystals of oxalic acid 
and urea, driving towards continuous crystallisation  
 
As with their single-component counterparts, multi-component materials can demonstrate structural 
variations, leading to distinctly different crystalline phases with their own set of physicochemical 
properties. Whist exhibiting classic polymorphism, these types of materials can also show variations in 
terms of constituent molecule stoichiometries. Producing a particular solid state phase is dependent 
upon the delicate interplay between the thermodynamics inherent to a given system and the kinetics 
governing a specific technique of crystallisation. 
 
To exemplify this, the work detailed in Chapter 9 focusses on the model co-crystalline system of oxalic 
acid and urea, which, to date, exhibits two stoichiometrically varying forms, OAU-1:1 and OAU-1:2. 
Using various preparation methods, ranging from methods that use minimal solvent 
(mechanochemical), to solid suspensions in solution (slurrying) to the direct crystallisation from 
solution (evaporative), the propensity for the formation of the two co-crystals, respectively, is assessed, 
determining the optimal parameters for their preparation in each case.  
 
From here, the focus is shifted to the more industrially scalable method of cooling crystallisation. Routes 
to the selective preparation of the respective co-crystals are initially carried out using batch methods, 
outlining the key conditions required for the transition into continuous crystallisation platforms. With 
particular emphasis on the 1:2 co-crystal, two continuous crystallisation setups, based at the University 
of Bath, are used; the continuous oscillatory baffled crystalliser (COBC) and the kinetically regulated 
automated input crystalliser (KRAIC). These initial studies are conducted in order to demonstrate the 





5.1 Solid-state screening for novel chiral multi-component materials of the API, 
naproxen, for application into a preferential crystallisation process 
 
5.1.1 Starting materials 
 
Naproxen, NPX, was purchased, in both its racemic, rsNPX (>98%) and enantiopure S-naproxen, sNPX 
(>99%) form, purchased from Tokyo Chemical Industry Ltd (TCI). The co-formers 2-aminopyridine, 
2AP (>99%), 2-amino-4,6-dimethylpyrimidine, 2ADMP (95%), acridine, A (97%), imidazole, I (99.5%) 
and benzimidazole, BI (98%) were obtained from Sigma-Aldrich Chemie GmbH, whilst 2-
aminopyrimidine, 2AMP (97%), 2-amino-3-chloropyridine, 2A3CP (98%), 2-amino-4-chloropyridine, 
2A4CP (99%), 2-amino-5-chloropyridine, 2A5CP (98%) and 2-amino-6-chloropyridine, 2A6CP (98%) 
were purchased from Fluorochem Ltd, UK. Laboratory grade (>99.8%)) solvents, including acetone, 
acetonitrile, chloroform, diethyl ether, ethanol, hexane, isopropanol, methanol and toluene were 
provided by VWR Ltd. Deionised water was obtained from an on-site water purification source. 
 
5.1.2 Co-former selection 
 
Co-formers were selected based upon on an initial assessment of key interactions derived from 
previously studied multi-component materials incorporating either homo or heterochiral NPX. Searches 
of the CCDC Cambridge Structural Database (CSD), using ConQuest version 1.22 © 2018 CCDC 
software194, were conducted for both protonated and deprotonated forms of NPX, to account for both 
co-crystal and salt forms. Single crystal diffraction data was selected only, with the NPX derivatives 
and organometallic structures being excluded from the search.  
 
For comparison purposes, the PXRD patterns for both the racemic and enantiopure API, as well as for 
each of the different co-formers, were taken from literature, accessed through the CSD. These patterns 
were generated based on published single crystal structures. 
 
5.1.3 Multi-component material screening 
 
5.1.3.1 Mechanochemical screening 
 
Initial multi-component material screenings were conducted through mechanochemical means, either 
neat or with application of minimum solvent, typically ethanol. sNPX or rsNPX, (25 mg, 0.11 mmol) 
were combined in either 2:1, 1:1 or 1:2 molar quantities with the given co-former and ground using a 
mortar and pestle for up to 10 minutes. Liquid-assisted grindings were carried out using the same 
procedure, but upon combining the materials, 3-4 drops of the desired solvent were added and the 
sample was ground until the solvent was deemed to have completely evaporated. Each sample was 
typically analysed using PXRD and DSC. 
 
5.1.3.2 Combined evaporative and (crash) cooling crystallisation screening 
 
Small-scale cooling crystallisations were setup to encourage single crystal growth for SCXRD analysis, 
as well as for comparison against the samples prepared through mechanochemical means. As 
determined from turbidity measurements, solutions of sNPX (0.09g, 0.39 mmol) or rsNPX (0.057g, 0.25 
mmol) in ethanol (1 g, 21.7 mmol), or sNPX (0.059g, 0.26 mmol) or rsNPX (0.039g, 0.17mmol) in 
isopropanol (1 g, 16.6 mmol) were prepared such that the solutions were saturated at 30oC with respect 
to their given enantiomeric composition and solvent. Quantities of each co-former, respectively, were 
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then added to give solutions, so as to yield either 2:1, 1:1 or 1:2 molar compositions of API to co-
former. The vials were then sealed and placed in a temperature controlled water bath, set at 45oC. 
Dissolution was encouraged through sonication and upon completion, the sealed vials were placed in a 
temperature controlled environment set at 4oC and allowed to cool. To aid in the growth of individual 
crystals, the solutions were not mixed. Each vial was monitored over the course of a few days to see 
whether crystallisation had occurred. 
 
If no crystallisation was observed after one week for a given sample, the lid of the vial was punctured 
several times so as to allow for slow evaporation of the solvent and encourage crystallisation. Several 
samples were also prepared using acetonitrile as the solvent. The same procedure was used as above, 
but owing to the unquantified solubility of rsNPX or sNPX in this solvent, the same quantities of homo 
and heterochiral API were used as for ethanol.  In specific cases where phases prepared via 
mechanochemistry could not be directly reproduced through solution crystallisation, saturated 
solutions, cooled to 4oC, were seeded with minimal quantities of mechanochemically prepared material.  
 
Upon crystallisation, images were taken under a microscope and individual crystals were picked out of 
solution and mounted onto a goniometer head for SCXRD screening and complete structure analysis. 
 
5.1.3.3 Binary phase diagrams 
 
Using either NPX starting material or NPX in combination with a co-former, so as to yield a multi-
component material with a given stoichiometry, further mechanochemical samples were prepared with 
varying enantiomeric compositions of NPX. Combinations of sNPX and rsNPX (total NPX mass: 25 
mg, 0.11 mmol) were combined, with or without co-former, so as to yield samples that represented 0.5, 
0.6, 0.7, 0.8, 0.9 and 1.0 mole fractions of sNPX to rNPX. Excess of only one enantiomeric form of 
NPX was used due to the excessive cost of the rNPX and the assumption that one side of the binary 
phase diagram would mirror the other. Samples were then ground for up to 10 minutes, either neat or 
with the addition of 3-4 drops of a selected solvent, typically ethanol. Each sample was subsequently 
analysed using PXRD, to confirm the different composition of phases, and DSC, taking onset and peak 
temperatures for each enantiomeric composition, so as to construct a binary (melting point) phase 
diagram. For each diagram, lines are added as a guide. 
 
5.1.4 Further crystallisation studies 
 
5.1.4.1 Bulk solvent-mediated (slurrying) preparation 
 
In order to collect solubility measurements, build a ternary phase diagram and conduct further cooling 
crystallisation experiments on the racemic and enantiopure salt form of NPX with 2AP, bulk 
preparations of sample were made. Solvent-mediated preparation, or slurrying, was used as a quick and 
efficient way of achieving this. 
 
Prior to bulk preparations, the necessary solvent environment for slurrying was screened. sNPX and 
rsNPX (0.15 g, 0.65 mmol) were weighed into vials, respectively, along with 2AP in a 1:1 molar ratio, 
to which minimum quantities of solvent were added, so as to generate a suspension of solid and avoid 
complete dissolution. The solvents used were ethanol, isopropanol and hexane. The suspensions were 
sealed and then mixed using a magnetic stirrer bar for 1 hour at 200 rpm.  
 
Subsequent bulk preparations of both the homo and heterochiral salt were prepared exclusively with 
hexane. sNPX and rsNPX (2 g, 8.69 mmol) were weighed into a 25 mL round bottomed flask (RBF), 
respectively, along with 2AP in a 1:1 molar ratio. Suspensions were generated with the addition of 




All preparations were done at room temperature (approximately 20oC) on a standard benchtop mixer-
heater plate in a laboratory fume cupboard. After mixing, the suspensions were filtered using a Buchner 
funnel and filter paper under vacuum, and allowed to dry for up to 12 hours. The solids yielded were 
analysed using PXRD and DSC to confirm their phase.  
 
5.1.4.2 Ternary phase diagrams 
 
Ternary (solution) phase diagrams were constructed to assess the impact of varying enantiomeric 
compositions on material solubility. Solubility measurements were taken based on gravimetric analysis. 
Initial sample preparations of single component NPX were made by combining sNPX and rsNPX (total 
NPX mass: 0.6 g, 2.61 mmol) starting material, so as to generate samples of mole fractions 0.5, 0.6, 0.7, 
0.75, 0.8, 0.85, 0.9, 0.95 and 1.0, corresponding to an excess of sNPX. These materials were suspended 
in ethanol (5 g, 1 mol) at either 20oC or 30oC for up to 3 days, mixed at 200 rpm using a magnetic stirrer 
bar. Using 1 mL syringes fitted with a suitable filter, to avoid excess solid being taken up, aliquots of 
liquor were taken from each suspension and deposited into individual pre-weighed vials. The combined 
mass of the vial and liquor was recorded and the solutions were allowed to evaporate to dryness at the 
same temperature at which they were slurried. The solubility for a given enantiomeric composition of 
NPX was determined upon comparison of the mass of dried solid and that of solvent evaporated. 
 
The same gravimetric procedure was also used for establishing the solubility of material at given 
compositions of the racemic and enantiopure salt of NPX and 2AP. Here, material was taken from bulk 
slurrying (see Section 5.1.4.1) and different combinations of homo and heterochiral salt were combined 
to generate mixtures with mole fractions corresponding to 0.5, 0.6, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95 and 
1.0, with respect to excess sNPX. For suspensions to be conducted at 20oC, the total mass of salt used 
exceeded 0.7 g (2.15 mmol) in 6 g (0.13 mol) of ethanol, whereas for preparations at 30oC, up to 1.3 g 
(4 mmol) of salt was suspended in 5 g (1 mol) of ethanol. In addition, the solid of the salt materials was 
also subjected to PXRD analysis. 
 
All slurrying was conducted on the Polar Bear Plus platform from Cambridge Reactor Design™ (Figure 
5.1). The platform operates through a thermoelectric Peltier with a working temperature range of -40oC 
to 150oC, allowing for the controlled heating and cooling of samples at a desired rate, from sample 
volumes of 1.5mL to 250mL. Samples can be also stirred through magnetic stirring capabilities. In order 
to build the above ternary diagrams, the Polar Bear Plus was used to maintain constant temperatures at 








5.1.4.3 Cooling crystallisations 
 
Cooling crystallisations were carried out to, first, demonstrate the reproducible formation of the racemic 
and enantiomerically pure NPX and 2AP salt forms from solutions of ethanol and, secondly, to probe 
different areas of the ternary phase diagrams, highlighting any interesting properties found. 
 
All crystallisation experiments were based upon solubilities derived from turbidity measurements. 
Initial cooling crystallisations were conducted at enantiomerically pure and racemic compositions, 
utilising bulk material made via slurrying (see Section 5.1.4.1). So as to saturate solutions at 30oC 
quantities of homochiral (0.13 g, 0.4 mmol) and heterochiral (0.12 g, 0.37 mmol) salt were weighed out 
into vials, respectively, to which ethanol (1 g, 0.022 mol) was then added. These initial suspensions 
were then heated to 45oC and held for 30 minutes, whilst being mixed using magnetic stirrer bars at 150 
rpm. Once all the solid was deemed to have completely dissolved, the solutions were then cooled to 
5oC, at a rate of either 1oC/minute or 0.1oC/minute. Upon reaching the end temperature, the samples 
were quickly taken off and filtered using a standard Buchner setup. 
 
Further cooling crystallisations were also conducted at given enantiomeric compositions to gauge the 
initial thermodynamic and kinetic stability of the homo and heterochiral phases. Using the saturation of 
the enantiopure salt form at 30oC (0.13 g, 0.4 mmol) in ethanol (1 g, 0.022 mol) as a guide, bulk 
preparations of the two NPX and 2AP phases were combined to yield solid mixtures that represented 
0.7, 0.75 and 0.8 mole fractions, with respect to sNPX. These mixtures were then dissolved in the 
appropriate amount of solvent and heated to 45oC at a given mixing rate (200 rpm). Upon complete 
dissolution, the samples were subjected to linear cooling regimes, at rates of either 1oC/minute or 
0.1oC/minute, ending at either 10oC, 5oC or 0oC. Samples were immediately filtered upon reaching their 
end cooling temperature. 
 
All crystallisations were performed on the Polar Bear Plus platform (detailed in Section 5.1.4.2), with 






5.2 Selective preparation and crystallisation of stoichiometric co-crystals of oxalic acid 
and urea, driving towards continuous crystallisation  
 
5.2.1 Starting materials 
 
Oxalic acid, OA (98%) and urea, U (Bioreagent) were both purchased from Sigma-Aldrich Chemie 
GmbH. Oxalic acid dihydrate, OAD, was prepared by slurrying OA in deionised water for an hour. OA 
was stored under with a desiccant in order to minimise the conversion to OAD under atmospheric 
conditions. Laboratory grade (>99.8%)) solvents, including ethanol, isopropanol and methanol were 
provided by VWR Ltd. Deionised water was obtained from an on-site water purification source. 
 
For comparison purposes, the PXRD patterns for the starting materials (OA (α)181, OA (β)181, OAD183 
and U Form I185), as well as that of the co-crystals of oxalic acid and urea189, 190, were taken from 
literature, accessed through the CSD. These patterns were generated based on published single crystal 
structures. 
 
5.2.2 Mechanochemical preparations 
 
Mechanochemistry was used as a minimal solvent or solvent free method of producing the two co-
crystals of OA and U. For all mechanochemical experiments conducted, the two starting materials were 
mixed in either 2:1, 1:1 or 1:2 molar stoichiometries. OA (25 mg, 0.27 mmol) was combined with U in 
each of these ratios and ground, initially, for 10 minutes using a mortar and pestle, either without solvent 
(neat) or with the assistance of a 3-4 drops of a given solvent (water, methanol, ethanol or isopropanol). 
If the solvent was not deemed to have evaporated fully, grinding was allowed to continue. 
 
Subsequent neat grindings, utilising the same stoichiometries, were carried out over a series of time 
periods (2, 5, 10, 20 and 30 minutes), with either anhydrous OA or OAD (25 mg, 0.02 mmol), so as to 
gauge the effects of water and extended grinding on the co-crystallisation process. In addition, further 
liquid-assisted grindings were carried out with varying quantities of water (0, 20, 40, 60, 80, 100, 120 
and 140 μL), with samples being ground until all the solvent appeared to have evaporated.  
 
Mechanochemistry was also used as a means of assessing the interconversion between the two co-
crystal forms of OA and U. Initial preparations with the two starting materials were prepared, using the 
same molar masses as above, so as to reflect the stoichiometry exhibited within the crystalline 
structures, i.e. either a 1:1 or 1:2 ratio. These samples were then ground either neat or with the same 
solvents as before (water, methanol, ethanol or isopropanol) for 10 minutes. After this, the stoichiometry 
of the samples was changed through the introduction of excess starting material, with additional U being 
added to the 1:1 combination and OA to the 1:2 preparation. Once added, the samples were ground for 
a further 10 minutes using the same solvent environments, respectively. 
 
For each sample prepared via mechanochemical means, phase analysis was conducted using PXRD. 
 
5.2.3 Solvent-mediated (slurrying) preparations 
 
Initial suspensions of OA and U were prepared by combining the starting materials in given 
stoichiometries in different solvent environments. OA (0.5 g, 5.55 mmol) was mixed with U in the 
corresponding 2:1, 1:1 and 1:2 molar quantities, and subsequently suspended in up to 7mL of solvent, 
either water, methanol, ethanol or isopropanol. The solvent-mediated preparations were then mixed 
using the Polar Bear Plus platform at 20oC at 200 rpm for 24 hours. The solid material was then filtered 




Using the same setup, bulk preparations of the oxalic acid:urea (1:2) co-crystal (OAU-1:2) were 
subsequently prepared via slurrying. OA (1 g, 11.11 mmol) was mixed with U in a 1:2 stoichiometry 
and suspended in up to 10 mL of water for up to 1 hour, mixing at 200 rpm at 20oC. After filtration, the 
material yielded from this preparation was used to determine the solubility of this co-crystalline phase 
using the turbidity method. 
 
Slurrying was also used to explore the different regions of the ternary phase diagram at 20oC, assessing 
its potential for the precipitation of the co-crystalline phases. Based upon the solubility of the OAU-1:2 
co-crystal at 30oC in water (0.063 g/g, 5.4 mmol/mol), suspensions were prepared at different 
stoichiometries of OA and U (5:1, 4:1, 3:1, 2:1, 1:1 & 1:2), utilising the same overall mass as for the 
1:2 case. The solid mass for 30oC was utilised as a reference so as to ensure the consistent establishment 
of a stable slurry. Furthermore, this reference mass was also used as a means to explore the effect of 
solid loading for the different stoichiometric compositions. As such, various solid loadings, 
corresponding to x2, x3, x4 and x5 that of the original masses, were prepared. The masses of OA utilised 
for the given molar ratios of starting materials, at the different solid loadings, are expressed in Table 
5.1. Upon combining the given amounts of OA and U, water (10 g, 0.56 mol) was added and the 
suspensions were mixed at 200 rpm for either 1, 4, 16 or 64 hours, after which the samples were filtered 
and analysed using PXRD. 
 
Table 5. 1 - Masses of OA (g) used in slurrying experiments with different stoichiometric (5:1, 4:1, 3:1, 2:1, 1:1 and 1:2) 
solutions of OA and U in water (10 g), highlighting increasing solid loading levels (x2, x3, x4 & x5 the saturation of the 




(OA to U) 
Solid loading 
w.r.t. the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC 
(OA g) 
x1 x2 x3 x4 x5 
1:2 0.2699 0.5398 0.8097 1.0796 1.2145 
1:1 0.3779 0.7558 1.1337 1.5116 1.7005 
2:1 0.4724 0.9448 1.4173 1.8897 2.1259 
3:1 0.5154 1.0308 1.5462 2.0616 2.3193 
4:1 0.5399 1.0799 1.6198 2.1598 2.4298 
5:1 0.5558 1.1117 1.6675 2.2234 2.7792 
 
 
5.2.4 Evaporative crystallisations 
 
Initial evaporative crystallisations were conducted either from aqueous solutions or from those of 
alcohols, specifically methanol, ethanol and isopropanol. OA (0.03 g, 0.33 mmol) was weighed out with 
the appropriate quantity of U, so as to generate solid mixtures that represented the 2:1, 1:1 and 1:2 molar 
stoichiometries required. The individual solvents were added dropwise, so as to allow for dissolution 
with the minimum amount, with the samples then being sealed. The vials were then sonicated at 40oC 
to ensure that all solid had dissolved and were then placed in temperature controlled environments to 
reflect evaporation at either 20oC or 40oC. The lids of the vials were partially exposed to the 
surroundings and allowed to evaporate to dryness.  
 
Further evaporative samples were prepared at given stoichiometries of OA to U and evaporated at a 
variety of different temperatures. Fixed quantities of OA (0.03 g, 0.33 mmol) were weighed out and 
combined with U in molar masses equating to the necessary 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1 and 1:2 
stoichiometries. These compositions were then dissolved in a minimum quantity of water (typically 1 
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g, 1 mL), sealed and sonicated at 40oC to allow for complete dissolution. Each sample was then placed 
in a temperature controlled environment, at either 4oC (fridge), room temperature (approximately 18oC) 
or 40oC (benchtop hot-plate), with the lid of each vial having been perforated in order to allow for 
evaporation. Subsequent samples were prepared through the same procedure, utilising only the 1:1 OA 
to U stoichiometry. Here, higher evaporation temperatures were used, including 60oC, 80oC, 100oC, 
120oC and 140oC. For each sample yielded from evaporation, images of the crystals were taken under 
the microscope and analysed for the solid phases present using PXRD.  
 
5.2.5 Batch cooling crystallisations 
 
Cooling crystallisations were initially carried out in a batch setup, where each experiment was 
conducted using the Polar Bear Plus platform from Cambridge Reactor DesignTM. The capabilities of 
this setup are detailed in Section 5.1.4.2. All crystalline materials yielded were analysed using PXRD.  
 
5.2.5.1 Cooling crystallisations from isopropanol 
 
Prior to conducting cooling crystallisations, the saturation of OA starting material in isopropanol at 20oC 
was established by gravimetric means. Suspensions of OA were prepared by mixing excess material in 
isopropanol at 20oC for 24 hours. From here, approximately 1g of the solution liquor was extracted, 
weighed and allowed to evaporate. The mass of the resultant solid was compared against that of the 
solvent dissipated off, providing a value for the quantity of solute dissolved in this solvent environment. 
This process was repeated three times, providing an average solubility of OA in isopropanol, that of 
0.22 g/g (0.15 mol/mol). 
 
Given this value, cooling crystallisations were conducted using a range of OA to U solution 
stoichiometries. Initial solutions of OA were prepared by mixing this starting component (2.2 g, 0.024 
mol) in isopropanol (10 g, 0.16 mol) with molar quantities of U, so as to create solution stoichiometries 
reflecting 4:1, 3:1, 2:1, 1:1 and 1:2 of OA to U. The subsequent mixtures were then heated to 65oC, to 
ensure complete dissolution, and cooled to 20oC. Each preparation was cooled and mixed at rates of 
0.1oC/minute and 200 rpm, respectively. Further crystallisations were then conducted using the same 
stoichiometries and crystallisation parameters, but with different degrees of saturation. These 
saturations represented x0.5, x0.25, x0.125 and x0.0625 the amount of OA used originally. The solid 
generated were filtered under a vacuum and allowed to dry. 
 
5.2.5.2 Cooling crystallisation of the oxalic acid:urea (1:2) co-crystal from water 
 
Based upon the solubility of the OAU-1:2 co-crystal in water at 30oC (0.063 g/g, 5.4 mmol/mol), initial 
cooling crystallisations were prepared, whereby OA (0.053 g, 0.59 mmol) was combined with U in a 
1:2 molar ratio with water (2 g, 0.11 mol). Four preparations were made, with each being heated to 
45oC and mixed at 200 rpm, using a magnetic stirrer bar, for 30 minutes to ensure complete dissolution. 
The samples were then cooled to either 25oC or 20oC, using cooling rates of 0.1oC/minute or 1oC/minute, 
respectively.  
 
Subsequent crystallisations were also established at various scales. Utilising the same saturation levels 
as before, further solutions were setup using 10 g, 30 g or 100 g of solvent (water), from which the 
samples were heated to 45oC and held for 1 hour, mixed at 200 rpm. The solutions were then cooled to 
20oC at a rate of 1oC/minute, maintaining the same degree of mixing. For each of the cooling 
crystallisation processes described, the solid material yielded was filtered using standard Buchner 





5.2.5.3 Cooling crystallisation of the oxalic acid:urea (1:1) co-crystal from water 
 
Further cooling crystallisations were conducted so as to devise a route to the selective preparation of 
the OAU-1:1 co-crystal. As for the exploratory suspension experiments in water, the total mass of solid 
required to saturate aqueous solutions with respect to the (1:2) co-crystal at 30oC was exploited as a 
reference from which preparations of increasing saturation (x2.5, x3 and x3.5) for a given stoichiometry 
could be established. As dictated by the masses outlined in Table 5.2, OA was weighed out and 
combined with molar ratios of U, establishing the 5:1, 4:1, 3:1 or 2:1 stoichiometries. Water (10 g, 0.56 
mol) was added and the suspensions were heated to 75oC and held for 30 minutes to ensure complete 
dissolution. The solutions were then cooled at either 0.1oC/minute or 1oC/minute to 20oC, with the 
resultant solid material being filtered off, dried and analysed. 
 
Table 5. 2 - Masses of OA (g) used in cooling experiments with different stoichiometric (5:1, 4:1, 3:1 and 2:1) solutions of 
OA and U in water (10 g), highlighting increasing saturation levels (x2.5, x3 & x3.5 the saturation of the oxalic acid:urea 




(OA to U) 
Saturation level 
w.r.t. the saturation of the oxalic acid:urea (1:2) co-crystal at 30oC 
(OA g) 
x1 x2.5 x3 x3.5 
2:1 0.4724 1.1811 1.4173 1.6535 
3:1 0.5154 1.2885 1.5462 1.8039 
4:1 0.5399 1.3499 1.6198 1.8898 
5:1 0.5558 1.3896 1.6675 1.9454 
 
Using the same procedure, additional cooling crystallisations were set up, cooling from 75oC to 30oC 
at a rate of 0.1oC/minute. The solid yielded was immediately filtered, dried and analysed. This procedure 
was conducted through five iterations. For each experiment, a constant mixing rate of 200 rpm was 
used. 
 
5.2.6 Continuous cooling crystallisations 
 
Following on from its reliable precipitation from batch cooling environments, the OAU-1:2 co-crystal 
was selected to assess the capabilities of the continuous cooling crystallisation platforms based at the 
University of Bath. These included the Continuous Oscillatory Baffled Crystalliser (COBC) and the 
Kinetically Regulated Automated Input Crystalliser (KRAIC), exploiting baffled and segmented flow 
mixing, respectively. The principles for the operation of both these setups can be found in Chapter 1. 
 
5.2.6.1 Continuous oscillatory baffled crystalliser (COBC) 
 
Initial continuous crystallisation experiments were conducted using the COBC. The setup consisted of 
12 individual jacketed tubes and five non-jacketed bends, each with an internal orifice diameter of 15 
mm. These units were constructed into six straights (numbered 1-6), orientated in a vertical geometry, 
and were fed from a feed vessel using a PTFE tube. The jacket temperature were controlled through 
four Grant R3 TX150 heater/chillers, setting the temperatures for straights 1, 2/3, 4/5 and 6 respectively, 
with water used as the heating medium. Thermocouples were used to monitor the temperature of each 
straight during each crystallisation run.  
 
For all experiments, the movement of solution throughout the system was modulated through combined 
pumping via a Watson Marlow peristaltic pump and an oscillating set of bellows. The pump was set at 
a standard rate of 4.1 rpm, whilst a frequency and amplitude of 2 Hz and 25 mm for oscillation were 
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employed, respectively, resulting in an overall flow rate of approximately 50 mL/minute. The residence 
time of solution within the crystalliser, including that of the feed pipe, was estimated to be 35 minutes. 
The pressure for the system was maintained at 1.5 bar, with any deviations away from this forcing a 
stop to any on-going experiment.  
 
Prior to each run, the platform was filled with water so as to maintain a homogenous environment and 
to ensure no air bubbles were present, thus minimising heterogeneous nucleation with surfaces other 
than that of the crystalliser internal walls. Feed solutions were prepared at the 5 L scale, whereby the 
solutions were saturated at either 30oC (0.063 g/g, 5.4 mmol/mol) or 35oC (0.078 g/g, 6.7 mmol/mol) 
with respect to the OAU-1:2 co-crystal in water. The solutions were prepared in a round bottomed flask 
of appropriate volume and heated to 60oC. The suspension was mixed at 200 rpm with a magnetic stirrer 
bar, with the solid being allowed to completely dissolve. Once ready, the solution was then fed into the 
body of the crystalliser, using the peristatic pump, through a feed tube. From there, the solution was 
pumped through the straights, gradually being cooled depending upon the cooling regime used, and 
mixed via oscillation through the baffles. A total of five runs were carried out, each using a different 
stepped cooling profile of the straights and different solution saturations. These parameters are 
highlighted in Table 5.3. 
 
Table 5. 3 - Solution saturations, with respect to the solubility of the oxalic acid:urea (1:2) co-crystal at 30oC in water, and 







Straight temperature (oC) 
1 2 3 4 5 6 
1 30 50 40 40 30 30 20 
2 30 50 40 40 25 25 20 
3 30 50 30 30 25 25 20 
4 30 50 20 20 20 20 20 
5 35 50 20 20 20 20 20 
 
The resultant crystalline materials were collected through an end piece of PTFE tubing and filtered from 
solution via a standard Buchner funnel setup. For each residence time or for any solid yielded, phase 
analysis was conducted using PXRD. Further to this, each run was monitored, observing the location 
of nucleation within the crystalliser, as well as that of any encrustation on its internal surface. 
 
5.2.6.2 Kinetically regulated automated input crystalliser (KRAIC) 
 
Based upon the outcomes from the COBC experiments, a further continuous crystallisation run was 
carried out using the KRAIC. This platform operated through the mixing of three distinct components 
through a purpose designed cross piece, so as to generate the necessary segmentation in flow; a heated 
feed solution, an immiscible carrier fluid and air. For the experiment conducted here, the carrier fluid 
used was that of the liquid polymer, perfluoropolyether Galden SV110.  
 
The feed solution was prepared by saturating a given volume of water (1 L, 55.5 mol) with OA and U 
in a 1:2 combination, reflecting a solution saturation at 35oC with respect to the (1:2) co-crystalline 
form. After being heated to 40oC and mixed at 200 rpm to allow for complete dissolution, the hot feed 
solution was fed through a heated PTFE tube (40oC) to the mixing piece at a rate of 3 mL/minute. Air 
and carrier fluid were also fed to the cross piece, at rates of 4.2 mL/minute and 2.1 mL/minute, 
respectively.  The characteristic segmentation for this system was generated upon the mixing of these 
three immiscible phases, which were subsequently fed into the body of the crystalliser at a collective 
rate of 9.3 mL/minute. The individual slugs were able to flow through 15 m of FEP tubing, with an 
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internal diameter of 3.2 mm, allowing for the solution to cool from 40oC to room temperature 
(approximately 20oC) over a residence time of 17 minutes. Upon reaching the end of the tubing, the 
individual segment components were separated and any solid yielded was analysed using PXRD. 
 




Micro-crystalline material, single crystals or otherwise were visualised using an optical microscope 
from Brunel Microscopes Ltd, complete with a camera accessory for capturing observations.  
 
5.3.2 Single crystal X-ray diffraction (SCXRD) 
 
Upon the growth of suitable individual crystals, SCXRD analysis was conducted to determine the 
crystal structure for a given sample. All analysis of this nature was conducted either using the Rigaku 
Oxford Diffraction SuperNova™ or Xcalibur™ diffractometers. Each instrument consists of an X-ray 
radiation source, area detector, Cryostream, goniometer and head, and an observation camera (Figure 
5.2). Whilst the SuperNova possesses a dual X-ray radiation source, for both Copper (Cu-Kα 1.54056 
Å) and Molybdenum (Mo-Kα 0.71073 Å) radiation, with micro-focussed beam for higher intensity X-
ray radiation, the Xcalibur only utilises Molybdenum sourced radiation. Both setups are equipped with 
a graphite monochromator and an Eos S2 Smart Sensitivity area detector, as well as a four-circle kappa 
goniometer. This allows for movement through four different rotation circles (φ, ω, χ, 2θ), allowing for 
all diffraction angles to be captured, generating a complete data set. Temperature regulation is achieved 
by Oxford Cryosystems 700 series Cryostreams, allowing for low and high temperature data collections. 





Figure 5. 2 - The Rigaku Oxford Diffraction SuperNova, highlighting X-ray sources, Cryostream, camera, area detector and 
goniometer head 
 
Individual crystals were mounted on the goniometer. Data were collected and processed using 
CrysAlisPro version 171.38.43 © 2014 Rigaku Oxford Diffraction software, allowing for data reduction 
and verification of the space group. Olex2 version 1.2 © 2004-2018 OlexSys Ltd software195 was used 
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to solve and refine each structure, utilising either Direct Methods in ShelXS196 or Dual Space in 
ShelXT138 for structure solution and Least Squares minimisation in ShelXL197 for structure refinement. 
All non-hydrogen atoms were located and refined with anisotropic thermal parameters. Hydrogen atoms 
were placed in either calculated positions or located and refined with isotropic thermal parameters, 
depending upon their contribution to hydrogen bonding. The resultant structures were visualised and 
assessed using Mercury CSD version 3.10.2 © 2001-2018 CCDC software194. The CIF files for each of 
the materials discovered can be found on the accompanying CD-ROM, with the file titles detailed in 
Appendix 5. 
 
Due to the importance of chirality to this research and the inherently weak diffraction properties of the 
materials in question, the Flack parameter145 could not be solely relied upon for absolute configuration 
confirmation. Hence, chirality was ultimately confirmed with reference to the starting materials used in 
the preparation to the given materials. 
 
5.3.3 Powder X-ray diffraction (PXRD) 
 
All PXRD data was collected using the Bruker D8 Advance laboratory diffractometer (Figure 5.3) at 
the University of Bath. The instrument was equipped with monochromatic Cu-Kα radiation source (λ = 




 Figure 5. 3 - The Bruker D8 Advance diffractometer, highlighting the X-ray source, sample holder (in flat-plate mode) and 
the area detector 
 
Typically, small quantities of the ground solid were placed onto a glass slide and pressed so as to 
produce an even surface. The slide was then mounted onto a flat-plate sample holder using a non-
diffracting adhesive material and exposed to X-ray radiation. Samples were scanned through 2θ angles 
ranging from 5o to 40o in 0.01o step sizes, with an exposure time of 0.3 seconds per step. The sample 
holder itself was rotated at 15 rpm to minimise the effects of preferred orientation. Experimental 
parameters were applied using the Bruker DIFFRACplus XRD Commander Version 2.6.1 © 2000 
Bruker-AXS GmbH software. All analyses were conducted at room temperature. Patterns were plotted 
in terms of intensity, in arbitrary units (a.u.), and 2θ (o). In each case, patterns are plotted with reference 
to those collected from the CSD or simulated from SCXRD for the relevant starting or comparative 
materials. 
 
All mechanochemically prepared samples were analysed using PXRD, along with all materials obtained 
from the controlled cooling crystallisation experiments. In addition, selected samples obtained from the 
combined evaporative/cooling crystallisation screening method were also assessed using this technique. 
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Where necessary, the materials were ground using a mortar and pestle in order to achieve homogeneous 
crystalline samples.  
 
5.3.4 Differential scanning calorimetry (DSC) 
 
DSC analysis was carried out using a Thermal Advantage Q20 instrument from TA Instruments, set up 
with the Thermal Advantage Cooling System 90, operating under a dry nitrogen purge at a flow rate of 
18 mL/min (Figure 5.4). Samples were weighed (2-4 mg) into Tzero aluminium pans, sealed and placed 
on a heating plinth, alongside an empty reference pan, after which, the materials in question were 
exposed to a heating/cooling regime. Typically, samples were heated at a rate of 10oC/minute, sweeping 
from 20oC up to 200-250oC, unless otherwise stated. Temperatures and ramp rates were calibrated 
against an Indium standard (melting point 156.6oC). Thermal traces were processed and analysed using 
the TA Advantage version 5.5.22 © 2001-2011 and TA Universal Analysis 2000 version 4.5A © 1998-
2007 software (TA Instruments-Waters LLC), respectively, from which thermal onsets, end points and 
enthalpies were taken. For all DSC plots, downward and upward phenomena are taken as endothermic 




Figure 5. 4 - The Thermal Advantage Q20 DSC from TA, highlighting heating/cooling unit, temperature stage, sample and 
reference pan positions 
 
All samples prepared via mechanochemical means, i.e. samples from screening or for binary phase 
diagram analysis, were analysed using DSC. Single crystals derived from crash cooling were also 
assessed so as to confirm the melting point for a given crystalline material. Samples taken from slurrying 
and controlled cooling crystallisation processes were also analysed by DSC. 
 
5.3.5 Hot-stage microscopy (HSM) 
 
HSM was used to corroborate and visualise thermal phenomena initially observed in DSC. HSM was 
carried out with the Mettler Toledo FP82 hot-stage equipped a Leica DM1000 microscope. Crystalline 
samples, individual crystals or polycrystalline, were mounted onto glass slides, subjected to similar 
temperature regimes used during DSC analysis, as controlled by the FP90 Central Processor and filmed 
using a Lumenera Infinity 2 microscopy camera. Media data was processed using Studio Capture 




Typically, individual crystals taken from the samples prepared by the combined evaporative and cooling 
method were analysed using HSM and, where possible, compared to the DSC traces taken for 
comparable mechanochemical samples. 
 
5.3.6 Infrared spectroscopy (IR) 
 
The assessment of key bonds and intermolecular interactions was conducted through infrared 
spectroscopy. Fourier transform infrared (FTIR) spectra of the mechanochemically prepared samples 
were collected using a Perkin Elmer FTIR Spectrometer at room temperature with an attenuated total 
reflectance (ATR) sampling accessory, scanning through a range from 4000 to 800 cm-1. Spectroscopic 
data was collected and processed through Spectrum version 10.400.0190 © 2013 PerkinElmer Inc. 
software. This technique was used for the analysis of materials in the solid-state only, both 
polycrystalline and single crystal samples. 
 
5.3.7 Circular dichroism (CD) 
 
Ethanol solutions of NPX with given enantiomeric mole fractions, with respect to sNPX (0.5, 0.6, 0.7, 
0.8, 0.9 and 1.0), and concentration (0.00075M, 0.0005M and 0.0001M) were analysed for their circular 
dichroism (CD) using the Chirascan™ Circular Dichroism Spectrometer from Applied Photophysics. 
The instrument utilises of a nitrogen-cooled 150 watt Xenon arc lamp coupled with a dual polarising, 
dual dispersing monochromator, as well as a photomultiplier detector. Samples were syringed into 1 
cm path-length Quartz curvettes and placed into a single cell, Peltier controlled sample holder within 
the spectrometer. For each experiment, the samples were held at 20oC and scanned over a 250 to 380 
nm wavelength range, with a step size of 1 nm and a bandwidth of 2 nm. The CD and UV-visible 
absorption was collected for each sample, from which the molar ellipticity could be calculated. Using 
these data, calibration plots could be generated so as to ascertain solution enantiomeric composition. 
 
5.3.8 Turbidity measurements (Crystal16) 
 
Dissolution and turbidity measurements were conducted for the starting materials and related multi-
component materials in either water, ethanol or isopropanol using the Technobis Crystal16, based at 
the University of Strathclyde. The instrument consists of 16 parallel wells, each capable of holding 1 
mL vials, and uses the percentage transmissivity of a laser beam through a solution to determine to clear 
(solubility) and cloud point (metastable limit) of a given solvent-solute system. Suspensions with given 
concentrations were prepared and were initially allowed to equilibrate at 0oC for 30 minutes. From here, 
each sample was subjected to three iterations of temperature cycling, noting the points of dissolution 
and crystallisation; heated from 0oC to 50oC, held for 30 minutes, cooled back to 0oC and held for 
another 30 minutes, each ramp conducted at 0.2oC/minute (Figure 5.5). Data were collected and 











6 Chiral multi-component materials of naproxen with 2-aminopyridine 
(2AP) 
 
As discussed in Chapter 3, the non-steroidal anti-inflammatory drug naproxen (NPX) exhibits not only 
poor permeability properties, but solid state structures at racemic compositions that demonstrate little 
applicability to the direct resolution of the two chiral forms of the API from solution. In this chapter, 
the properties of NPX were assessed, in both the solid state and in solution. From here, the techniques 
used in multi-component material screening were used in the development of novel molecular 
complexes incorporating the achiral co-former, 2-aminopyridine (2AP). Furthermore, based upon the 
results of solution analysis, initial cooling crystallisations were designed, highlighting the formation of 
a metastable conglomerate material with direct implications for the separation of the different 
enantiomeric forms.  
 
6.1 Characterisation of racemic and enantiopure naproxen (NPX) 
 
In this section, the physical properties of NPX, both as a solid and when allowed to dissolve in a solvent 
(ethanol or isopropanol), were assessed. The information detailed below was used to make comparisons 
and to inform subsequent multi-component material experiments. 
 
6.1.1 Solid state characterisation 
 
As previously highlighted from the material literature review (Chapter 3), NPX can precipitate as 
different crystalline phases depending upon the composition of enantiomers present. Figure 6.1 
highlights the crystal structures of homo (COYRUD169) and heterochiral (PAPTUX150) NPX, with the 




Figure 6. 1 - Crystal structures and key hydrogen bonding interactions of (a) sNPX and (b) rsNPX  
(sNPX in red, rNPX in blue) 
 
 Table 6. 1 - Unit cell and crystallographic parameters for sNPX and rsNPX 
 






S-naproxen169 7.7354(11) 5.7181(8) 13.3641(18) 90 93.737(2) 90 589.861 P21 C14H14O3 
RS-
naproxen150 
25.8301(13) 15.4939(4) 5.9465(2) 90 90 90 2379.84 Pbca C14H14O3 
 
Due to the fact that two distinct structures are generated upon transitioning from racemic to enantiopure 
contributions, the system of NPX can be described as that of a racemic compound. This means that two 
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discrete phases are yielded at racemic and enantiopure ratios, respectively, with the heterochiral form 
expressing a greater degree of stability in the solid state, shown from DSC analysis of the respective 
starting materials, as outlined in Table 6.2. The individual thermal traces are depicted in Appendix A6.1. 
The melting point of the racemic phase was shown to be higher, though only marginally, than that of 
the single enantiomeric case. This suggested that the interactions utilised, a combination of hydrogen 
bonding and π stacking contacts, were collectively stronger. 
 
Table 6. 2 - Onset and peak temperatures for the melting of sNPX and rsNPX 
 
Material Melting onset (oC) Melting peak (oC) 
S-naproxen 155.1 156.6 
RS-naproxen 156.2 157.6 
 
Using this information and by exploiting mechanochemical preparation techniques, a binary (melting 
point) phase diagram was generated (Figure 6.2). Grinding was used as a simple method of preparing 
mixtures of the required enantiomeric composition (0.5, 0.6, 0.7, 0.8, 0.9 and 1.0 mole fractions with 
respect to sNPX), where minimal quantities of solvent were added to aid in homogenisation. Upon 
grinding for up to 10 minutes, the samples were analysed for their thermal properties, highlighting the 
presence of significant melting or eutectic phenomena. This phase diagram showed which of the two 
structures were stable, with respect to melting, when the composition of the enantiomers changed. As 
shown, the trajectory of the points at the liquid-solid equilibrium outlined distinct regions, highlighting 
that at compositions greater than the sNPX mole fraction 0.8 the homochiral material was the more 
stable phase, and from 0.5 to 0.8, the racemic phase was the most stable. Due to the inherent likeness 
of enantiomers, the melting point of the rNPX crystalline phase was assumed to be the same as that of 




Figure 6. 2 - Binary (melting) point phase diagram, with changing enantiomeric composition of rNPX and sNPX, 
highlighting the liquidus (Δ) and the eutectic (▲) points 
 
In addition to the liquidus line, the other key observation was that of the eutectic melt. Shown to take 
place between 147-150oC, the eutectic point represents the point at which a number of phases (the 
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racemic solid, enantiopure solid and liquid) were in equilibrium. In this case, it was shown to reside at 
a sNPX mole fraction of 0.8. The location of this thermal event, in terms of enantiomeric contribution, 
could be used for comparison purposes when contrasting against the multi-component materials 
prepared in this Chapter and Chapters 7 and 8. By confirming the presence of the distinct regions of 
stability for the respective homo and heterochiral phases, and noting the presence of the eutectic point, 
the existence of a stable racemic compound forming system was confirmed for this API. The 
corresponding DSC and PXRD data for the different compositions can be found in Appendix A6.1. 
 
6.1.2 Solution characterisation 
 
As outlined above, in the solid state, this API was shown to form a racemic crystalline material at the 
corresponding composition of enantiomers. This phase had greater stability to that of the homochiral 
phase, which can be emphasised by their comparative melting points, but also from their individual 
solubilities in a given solvent environment. Figure 6.3 demonstrates the trends of the solubility of the 
two respective crystal forms in ethanol and isopropanol, with Table 6.3 showing the concentrations of 
materials dissolved at 20oC and 30oC for the given solvent systems. These initial measurements were 
collected using turbidity analysis, assessing the point of complete dissolution at concentrations of 
material ranging from 3-30 mmol/mol. Using the Technobis™ Crystal 16, samples with the pre-
specified solid loadings were heated from 0oC to 50oC and monitored in terms of their transmissivity of 
a beam of light passing through the solution. At a given temperature, the solid was deemed to have 




Figure 6. 3 - Solubility data of sNPX and rsNPX in ethanol and isopropanol, as determined from turbidity measurements 
(% standard error no greater than 1.5% across the range) 
 
Table 6. 3 - Saturation points of sNPX and rsNPX in ethanol and isopropanol, respectively, at 20oC and 30oC 
 
Material Solvent 
Saturation at 20oC 
(NPX mmol/mol) 




Ethanol 12.1 18.1 
Isopropanol 10.2 15.8 
RS-naproxen 
(rsNPX) 
Ethanol 7.6 11.6 




As is common in many small organic systems, the solubilities for the different materials of NPX were 
shown to increase with temperature. In each case, the solubility was shown to increase in excess of 1.5 
times upon raising the temperature from 20oC to 30oC. Furthermore, as expected, the solubility of the 
racemic solid was shown to be consistently lower than that of the homochiral across the different solvent 
environments. This highlighted that there was an enhanced stabilisation effect of the enantiopure phase 
by solvation, corresponding to comparative stability of these phases in the solid state. Knowledge of 
the solubilities at these temperatures were later used as a guide from which to plan solution based 
crystallisations for the screening of novel multi-component materials. 
 
Selecting ethanol as the solvent, the relative solubilities for different enantiomeric compositions at 20oC 
and 30oC could be determined. Based upon gravimetric analysis, the ternary (solubility) phase diagram, 
shown in Figure 6.4, was constructed. This two-axis representation of the ternary phase diagram could 
be directly related to that of the three-axis plot, with the contribution of solvent made relative to the 
respective enantiomers present. The individual saturation points for these two temperatures can be 




Figure 6. 4 - Ternary (solubility) phase diagram, corresponding to the saturation of different enantiomeric combinations of 
NPX (mole fractions of sNPX highlighted) in ethanol at 20oC and 30oC, respectively 
 
The observations made from this analysis support the findings from that of the solid state, highlighting 
a clear change in solubility from racemic to enantiopure, with an inflection point, i.e. the eutectic point, 
discernible at sNPX mole fractions of 0.9-0.95 and 0.95 for the lower and higher temperature 
preparations, respectively. This emphasised the degree to which the racemic phase remained stable in 
solution with changing contributions of enantiomers. Given the large solubility difference between the 
racemic and enantiopure states, as well as the distinctive trend in solubility exhibited upon changing 
the chiral composition of the solutions, resolution of the two enantiomers was not deemed possible via 
crystallisation in its current crystalline form.  
 
In addition to assessing the characteristics of NPX, various methods were explored that could account 
for the different contribution of enantiomers in solution. The method selected, with potential future 
applications into preferential crystallisation processes, was that of Circular Dichroism Spectroscopy. 
Prepared solutions of given compositions of the different chiralities of NPX (sNPX mole fractions of 
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1.0, 0.9, 0.8, 0.7, 0.6, 0.5 and 0.0) were analysed for their absorption behaviour with circularly polarised 
light. Samples of varying solution concentrations were assessed over a given wavelength range, from 
which the molar ellipticity could be calculated and correlated to the different enantiomeric 
compositions. The result was a calibration plot, as shown in Figure 6.5. The specific molar ellipticity 
versus wavelength spectra can be found in Appendix A6.1.  
 
Given the correct dilution, this plot could be used confirm the combination of the two chiral forms of 
the API in solution. Circular dichroism was thus used to check the findings from the ternary phase 
diagram and formed the basis of an on-going collaboration for the use of CD in monitoring the 
crystallisation of chiral multi-component materials, between the Universities of Bath (Wilson group) 




Figure 6. 5 - Calibration plot of molar ellipticity with changing enantiomeric composition of NPX in ethanol, at three 





6.2 Material screening with racemic and enantiopure naproxen with 2-aminopyridine 
(2AP) 
 
As emphasised above, NPX forms two distinct crystalline phases at the corresponding enantiopure and 
racemic compositions, resulting in a material unsuited to chiral resolution processes. To mitigate this, 
the API was combined with molar quantities of a variety of secondary molecular entities so as to screen 
for novel multi-component materials, i.e. co-crystals and salts. Screening was conducted using 
mechanochemical and solution crystallisation, assessing and comparing materials derived from homo 
and heterochiral preparations so as to determine the racemic crystalline nature of the material being 
studied.  
 
6.2.1 Co-former selection 
 
Prior to screening, the molecular structure of NPX was evaluated for the functional groups capable of 
forming key intermolecular interactions, such as hydrogen bonding. Whilst the methoxy group could 
act as a weak hydrogen bond acceptor, the most important supramolecular synthon was shown to be 
that of the carboxylic acid (COOH). This group has the capability of performing the role of an acceptor 
and a donor, through the C=O and O-H groups, respectively. Both of these were exploited differently 
in the homochiral and racemic crystal structure, with the former utilising individual 𝐷1
1(3) O-H···O 
contacts, forming extended chains, and the latter consisting of both the enantiomers dimerising together 
through a 𝑅2
2(8) interaction.  
 
As shown from the literature review conducted in Chapter 3, a number of multi-component materials, 
salts and co-crystals, containing this API had been researched previously. From an assessment of these 
structures, the most common interactions formed between NPX and the co-formers were that of the 
carboxylic acid functionality interacting with a pyridine, amine or related salt forms. A summary of this 
initial CSD search can be found in Appendix A3. The interaction synthons most commonly shared 




Figure 6. 6 - Key interaction synthons common with multi-component materials of NPX, highlighting (a) the O-H···N and 
(b) N-H···O interactions 
 
One structure found from the previous screening198 studies was that of the homochiral API interacting 
with the secondary molecular component 2-aminopyridine (2AP). This co-former, the molecular 
structure of which is outlined in Figure 6.7, consisted of a heterogeneous nitrogen and an amine bound 
at the two or ortho position. As such, this molecule expressed both the common functionalities from 
which many of the previous multi-component systems had been established. Furthermore, this material 
had only one known crystalline form (CSD reference: AMPYRD199), exhibiting a melting point at 57-
59oC. Given the pKa values of the API and co-former were given as 4.2162, 198 and 6.68198, respectively, 
salt-co-crystal formation prediction could not be reliably ascertained. However, noted from the previous 






Figure 6. 7 - The molecular structure of the co-former 2-aminopyridine (2AP), highlighting potential hydrogen bond donors 
and acceptors 
 
Hence, it was clear that 2AP possessed the necessary qualities required to form further novel multi-
component materials with NPX. As such, this combination of materials, at racemic and enantiopure 
compositions of the API, formed the basis of the initial mechanochemical and solution crystallisation 
screenings. The aim of the screening was to confirm the preparation of the homochiral material via 
these methods, whilst also exploring the materials that could be made at racemic proportions. This 
process formed the basis of subsequent screenings carried out on different types of co-formers, as well 
as that with various 2AP derivatives. These are discussed in Chapters 7 and 8.  
 
6.2.2 Material screening 
 
6.2.2.1 Mechanochemical screening 
 
Screening was initially conducted through the application of mechanochemistry, whereby the API and 
co-former were ground together, neat, in different stoichiometries (2:1, 1:1 and 1:2) using a mortar and 
pestle. These stoichiometries were selected given the most likely ratio of molecular units possible within 
crystalline structures, allowing for different areas of the phase landscape to be probed. After being 
ground for 10 minutes, the samples were then analysed using PXRD and DSC so as to ascertain whether 
or not a new phase had formed.  
 
The PXRD patterns for the enantiopure combination of NPX with 2AP are shown in Figures 6.8. For 
each molar ratio preparation, uncomplexed starting material was noted for each sample, but in addition, 
diffraction peaks were detected that did not correlate to those of the starting materials. With a particular 
focus on the 2θ region between 10o and 14o, three distinct intensities were observed, indicating 
diffraction from three discrete planes of a crystal lattice attributed to a new material of long-range order. 
Furthermore, these peaks were consistent across the patterns of the three preparations, with each 
showing direct correlation to structure obtained from subsequent SCXRD analysis of the crystals grown 
from solution.  
 
These samples were also assessed using thermal analysis, depicted in Figure 6.9. In each case, an initial 
melt/recrystallisation event was observed between 50-52oC, corresponding to the melt of the 2AP 
starting component and the formation of a different phase. The 1:1 preparation showed a further 
endothermic event at 102-104oC, which was taken as the melt of the novel multi-component phase. The 
2:1 preparation expressed two sequential phenomena, at 88-91oC and 92-95oC respectively, most likely 
relating to the melt of the complex and excess NPX, whilst the 1:2 phase showed a broad thermal process 
between 78-93oC. This latter observation could, again, could be related to the gradual melt of an impure 




Subsequent neat grindings at the 1:1 composition, ground for 30 minutes, yielded a PXRD pattern clear 
of additional starting material and a DSC with a single endothermic event, occurring between 104-
105oC. Collectively, the unique diffraction pattern and melting demonstrated the formation of a new 
phase. Furthermore, mechanochemical samples prepared with the aid of minimum quantities of solvent, 
including ethanol, were all shown to allow for the formation of this novel complex of sNPX and 2AP. 
The relevant PXRD and DSC plots can be found in Appendix A6.2.   
 
Mechanochemical processing was also used for the preparation of materials with racemic NPX. The 
same stoichiometries were utilised as before, with the combinations being ground neat. All attempts to 
yield material suitable for analysis from liquid-assisted samples failed, with the resultant materials 
displaying amorphous character, i.e. sticky or oily.  
 
The PXRD patterns for the three stoichiometric samples of rsNPX and 2AP are shown in Figure 6.10. 
The patterns produced for the preparations made in non-equimolar quantities showed diffraction peaks 
that could be directly related to those of the raw starting components, with the addition of some further 
peaks. The 1:1 sample showed a distinctive pattern, matching not only to that of the additional 
intensities observed in the other preparations, but that simulated from SCXRD data of the crystals 
obtained from parallel solution crystallisations (discussed below).  
 
Common to all the DSC traces for these samples (Figure 6.11), an initial melt/recrystallisation process 
occurring between 50-52oC was observed, with only the 1:1 sample exhibiting an additional single 
endothermic process. This was taken to occur from 97-100oC. The additional thermal events noted in 
the other preparations could be attributed to the melting of either excess starting material or a depressed 
melt of the new racemic material. Subsequent grindings conducted for 30 minutes with the 1:1 
combination produced a pure preparation of this new phase, with the melting point taken at 98-101oC. 
 
In both cases, mechanochemistry was shown to be able to yield novel materials, at the given 
enantiomeric compositions, particularly without the need for solvent. The fact that no solvent was 
required highlighted the relative favourability of complex formation in each case. However, the 
formation of sticky, amorphous materials from the further mechanochemical preparations at racemic 






Figure 6. 8 - PXRD patterns from mechanochemically prepared samples of sNPX and 2AP, ground neat in either 2:1, 1:1 or 














Figure 6. 10 - PXRD patterns from mechanochemically prepared samples of rsNPX and 2AP, ground neat in either 2:1, 1:1 




Figure 6. 11 - DSC traces from mechanochemically prepared samples of rsNPX and 2AP, ground neat in either 2:1, 1:1 or 





6.2.2.2 Combined evaporation & cooling crystallisation screening 
 
Parallel to the materials made via mechanochemistry, individual crystals were grown from solution, to 
generate crystals suitable for SCXRD studies. Solutions were prepared by dissolving the necessary 
quantities of sNPX and rsNPX, respectively, into ethanol or isopropanol, so that they may be saturated 
at 30oC, and combining them in 2:1, 1:1 and 1:2 stoichiometric amounts with 2AP. After allowing for 
complete dissolution, the solutions were placed in a temperature controlled environment, set at 4oC, and 
allowed to cool. If crystals were not observed after a period of time, the samples were exposed to the 
atmosphere, encouraging evaporation, increasing the supersaturation and, eventually, letting nucleation 




Figure 6. 12 - Microscope and mounted images of crystals yielded from 1:1 ethanol solutions of (a) sNPX and (b) rsNPX 
with 2AP 
 
The crystals grown from 1:1 ethanol solutions for both the enantiomerically pure and racemic 
complexes with 2AP are shown in Figure 6.12. In the homochiral case, long flat blocks with distinctive 
edges were shown to precipitate, with the colour of the bulk material shown to be off-white. Despite 
agglomeration being evident, individual crystals of suitable quality for analysis could be selected. By 
contrast, the crystals grown from the corresponding racemic solution were shown to agglomerate, with 
only small crystallites being generated. The morphology resembled that of a block shape, though were 
by no means uniform, with the bulk colour of this material observed to be pale yellow. It was also noted 
that the time required for the racemic phase to precipitate was substantially greater than that for the 
enantiopure phase. 
 
Highlighted in the previous section, the crystals obtained from these crystallisations were shown to 
correlate directly to those materials made from the corresponding mechanochemical experiments. This 
was gauged based upon the comparison of the collected PXRD patterns and that simulated from the 
SCXRD structure. Further confirmation was obtained via HSM. Individual crystals were selected from 
their respective solutions, placed on a slide and heated, whilst being observed under a microscope. 
Figures 6.13 and 6.14 show the thermal transitions expressed by the respective homo and heterochiral 
crystals. It was shown that the crystals melted between 100-106oC and 101-104oC, respectively. 
Accounting for the discrepancies between DSC analysis of bulk powder and HSM measurements of 
individual crystals, the melting point of the homochiral phase was taken to be higher than that of the 





Figure 6. 13 - HSM images corresponding to the thermal phenomena exhibited by crystals selected from the 1:1 ethanol 




Figure 6. 14 - HSM images corresponding to the thermal phenomena exhibited by crystals selected from the 1:1 ethanol 





6.2.3 Material characterisation 
 
The combination of mechanochemical and solution cooling crystallisation screening demonstrated the 
reproducible preparation of novel materials by combining NPX and 2AP at racemic and enantiopure 
quantities. The next step was to characterise the complexes generated, in terms of their solid state 
structure and chiral crystalline nature.   
 
6.2.3.1 Phase, thermal and spectroscopic analysis 
 
As shown below (Figure 6.15), the simulated PXRD patterns derived from diffraction analysis of the 
individual crystals of the complexes formed are compared and contrasted to those of the starting 
materials. The diffraction data for the multi-component materials showed distinct peaks from those of 
the initial components, emphasising that unique complexes had been generated. Further to this, the 
patterns yielded at racemic and enantiopure compositions were also shown to be substantially different 
to each other. This showed that two discrete phases were produced and presented the first indication 
that upon multi-molecular structure formation between NPX and 2AP at racemic quantities, a racemic 




Figure 6. 15 - PXRD patterns of the S-naproxen:2-aminopyridine & RS-naproxen:2-aminopyridine (1:1) salts, as derived 
from SCXRD data, compared to that of the starting materials 
 
The disparate nature of the materials yielded from the two enantiomeric combinations was also shown 
from their individual thermal phenomena. The DSC traces, depicted in Figure 6.16, show the major 
thermal events taken for the starting materials, as well as those of the novel complexes. The melting 
points of the multi-component samples were taken from the excessive neat grindings of sNPX and 
rsNPX, respectively, with the co-former in a 1:1 molar ratio. As shown, the endothermic events of the 
complexes resided between that of 2AP and the NPX materials, indicating that upon interaction, there 
was a stabilisation with respect to the co-former and a destabilisation when compared to the API. It was 
also confirmed that the melting point of the enantiopure was greater (104-105oC) than that of the 
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heterochiral phase (98-101oC). Whilst only slight, this indicated that in the solid state, the interactions 
associated between like enantiomers were of greater strength than those found in the racemic case. 
Given that it had already been established that a different phase could be yielded at racemic 
compositions when compared to that at homochiral, this observation suggested that the enantiopure 




Figure 6. 16 - Traces of the S-naproxen:2-aminopyridine & RS-naproxen:2-aminopyridine (1:1) salts, prepared via 
mechanochemistry, compared to that of the starting materials 
 
Before complete structural analysis could be conducted via SCXRD, an initial assessment of the 
structural features of the two novel multi-component materials of NPX and 2AP was undertaken using 
infrared (IR) spectroscopy. The diagram shown in Figure 6.17 highlights the spectra of each of the 
starting components, as well as that of the individual complexes, prepared mechanochemically. The 
spectrum of 2AP presented a variety of features, with the absorptions at 3444 cm-1 and 3285 cm-1 
indicating the vibrational modes for the N-H bonds. The two spectra of sNPX and rsNPX both presented 
broadly similar characteristics, with a broad absorption occurring at 3104 cm-1 and 2987 cm-1, 
respectively, indicating the O-H group forming hydrogen bonding interactions. A key functionality was 
that of the C=O stretch, with the racemic NPX phase showing a single peak at 1705 cm-1 and the 
enantiopure demonstrating two peaks at 1725 cm-1 and 1681 cm-1. This indicated that the carbonyl group 
associated with the homochiral form possessed a greater degree of freedom than in the racemic case. 
Furthermore, it was also noted that the racemic phase exhibited two small peaks from 2700-2500 cm-1, 
highlighting the dimeric nature of the interactions exhibited within its crystalline structure. 
 
In contrast, the spectra of the complexes presented distinct differences to those of the starting materials. 
Focussing on the carbonyl functionality, the main peaks for the enantiopure and racemic cases were 
taken as 1655 cm-1 and 1632 cm-1, respectively. In comparison to the NPX materials, both of these 
systems expressed red shifting, suggesting that the interactions formed between NPX and 2AP in each 





Figure 6. 17 - IR spectra for the mechanochemically prepared samples of S-naproxen:2-aminopyridine (1:1) and RS-
naproxen:2-aminopyridine (1:1) salts, compared to that of the starting materials 
 
6.2.3.2 Binary (melting point) phase diagram analysis – Classification of chiral crystalline materials 
 
To clarify the chiral crystalline nature of this system when changing the composition from equal 
quantities of rNPX and sNPX to that of entirely enantiopure, binary (melting point) phase diagrams 
were prepared. Using mechanochemical means, two different types of sample preparation were carried 
out. Each preparation utilised a constant 1:1 stoichiometry of API to co-former, with the first set of 
samples using combinations of rsNPX with excess sNPX, and the second using the individual 
enantiomers, whereby rNPX was combined with extra sNPX to facilitate the change in the chiral 
composition. Samples were ground neat and analysed using DSC (Appendix A6.2). The thermal events 
were assessed and used to construct the different aspects of the phase diagrams shown in Figure 6.18. 
 
Focussing initially on the ground combinations of rsNPX, sNPX and 2AP, a clear trend was shown, 
highlighting distinct regions towards racemic and enantiopure compositions. Peaking at the melting 
points of the respective phases, as shown above, the trajectory from that of the sNPX and rsNPX 
complexes converged to exhibit a single thermal event at the sNPX molar fraction of 0.7. This was taken 
as the eutectic point and was consistent across several of the compositions, occurring between 94-97oC. 
The presence of the distinct regions, corresponding to the racemic and enantiopure multi-component 
phases, along with the eutectic point, confirmed that this system could be classified as a racemic 
compound.  
 
However, upon grinding the two individual enantiomers together with 2AP, rather than producing the 
thermal phenomena observed as in the above case, a contrasting phase diagram was generated. Here, 
the path of the liquidus line, representing the thermodynamic boundary between the liquid and solid 
states, demonstrated that the regions present upon transitioning from hetero to homochiral 
compositions, corresponded to that of a single phase. This type of phase diagram is common for 
conglomerate systems, suggesting that upon combination with 2AP, the two uncoupled enantiomers 
could form opposing enantiopure complexes, which could remain stable with increasing temperatures. 
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For this preparation, it was demonstrated that the homochiral phase could be accessed at compositions 




Figure 6. 18 - Binary (melting point) phase diagram, highlighting the melting and eutectic phenomena associated with 
mechanochemically prepared samples constituting either sNPX & rNPX (Χ, ♦) or sNPX & rsNPX (▲, Δ), with NPX in a 1:1 
stoichiometry with 2AP 
 
6.2.3.3 Crystallography – Crystal structure analysis 
 
Having established the existence of two discrete forms at racemic and homochiral compositions, 
respectively, and their metastable relationship in the solid state, the next step was to determine the 
crystalline structures of these materials. Individual crystals were selected from the previously prepared 
crash cooling crystallisations and analysed using SCXRD. The corresponding CIF files (1, 2) can be 
found on the accompanying CD-ROM.  
 
The arrangement of molecules from the complex of sNPX and 2AP, in terms of its unit cell, hydrogen 
bonding motifs and long range molecular assembly, is shown in Figure 6.19. The unit cell dimensions 
can be found in Table 6.4, along with further information describing the refinement of the diffraction 
data. Each of the asymmetric units consisted of one molecule of the enantiopure API and that of the co-
former. These compounds were found to crystallise in the non-centrosymmetric monoclinic space group 
P21.  
 
Hydrogen bonds were shown to be the key intermolecular interactions, forming between the relative 
accepting and donating groups of sNPX and 2AP, respectively. The key atoms utilised in these 
interactions, as well as the defining lengths and angles, can be found in Appendix A6.2. The API and 
co-former were shown to form a heterodimeric interaction unit, consisting of two 𝐷1
1(3) hydrogen 
bonds, collectively making a 𝑅2
2(8) ring. Given the pKa difference between the molecules, salt 
formation was deemed to be possible and as such, for this complex, proton transfer was observed from 
the Fourier electron density difference map. As a result, the two hydrogen bonding contacts of the 
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heterodimer consisted of a charge assisted interaction from the donating pyridinium moiety of the co-
former to the accepting carboxylate functionality of the API, as well as that between the neutral amine 
and carboxyl groups. The formation of a salt allowed for this system to be described as a S-naproxen:2-




Figure 6. 19 - Crystal structure of the S-naproxen:2-aminopyridine (1:1) salt, highlighting (a) the unit cell, (b) hydrogen 
bonding synthon and (c) packing arrangement (sNPX in red) 
 
Table 6. 4 - SCXRD data for the S-naproxen:2-aminopyridine (1:1) salt 
 
Material S-naproxen:2-aminopyridine  
(1:1) salt 
Empirical formula C19H20N2O3 
Formula weight 324.37 
Temperature (K) 150.01(10) 
Crystal system monoclinic 
Space group P21 
a (Å) 9.6568(5) 
b (Å) 6.0822(4) 
c (Å) 14.4228(8) 
α (°) 90 
β (°) 96.340(5) 
γ (°) 90 
Volume (Å3) 841.94(8) 
Z, Z’ 2, 1 
ρcalc (g/cm3) 1.279 
μ (mm-1) 0.087 
F(000) 344.0 
Crystal size (mm3) 0.166 × 0.121 × 0.082 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 6.708 to 51.356 
Index ranges -7 ≤ h ≤ 11, -7 ≤ k ≤ 7, -17 ≤ l ≤ 17 
Reflections collected 5562 
Independent reflections 3167 [Rint = 0.0355, Rsigma = 0.0633] 
Data/restraints/parameters 3167/1/219 
Goodness-of-fit on F2 1.063 
Final R indexes [I>=2σ (I)] R1 = 0.0467, wR2 = 0.0941 
Final R indexes [all data] R1 = 0.0620, wR2 = 0.1024 
Largest diff. peak/hole  (e Å-3) 0.14/-0.23 
Flack parameter -1.2(10) 
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Taking the key interaction unit described above, the extended structure of this salt form can be built up. 
Exploiting the additional N-H bond not already utilised in the dimerised motif, an additional D11(3) N-
H···O was able to form, connecting neighbouring interaction moieties and allowing for a chain to be 
generated. This chain takes on a three-dimensional spiral arrangement. Overall, the crystalline structure 
can hence be built up through a series of these chains, all interlocking and running parallel to each other.  
 
For the material prepared from the racemic mixture of API with 2AP in a 1:1 ratio, the crystal structure 
was solved and assessed as before. The important aspects, including the unit cell, hydrogen bonding 
synthon and the overall packing arrangement, are shown in Figure 6.20. As for the homochiral case, the 
unit cell consisted of two asymmetric units, each consisting of a single enantiomer and co-former 
molecule. The dimensions of the unit cell and refinement parameters are shown in Table 6.5. Upon 
combing the starting components and given the crystallisation conditions, the asymmetric units were 





Figure 6. 20 - Crystal structure of the RS-naproxen:2-aminopyridine (1:1) salt, highlighting (a) the unit cell, (b) hydrogen 
bonding synthon and (c) packing arrangement (sNPX in red, rNPX in blue) 
 
Once again mirroring that of the enantiopure complex, the key hydrogen bond motif noted was that of 
the heterodimer between the deprotonated carboxylic acid functionality of NPX and that of the 
protonated pyridine and amine groups of 2AP. Given proton exchange and the stoichiometry observed, 
this system could be classified as a RS-naproxen:2-aminopyridine (1:1) salt. However, despite utilising 
the same initial dimer, the extended structure of the racemic phase was different to that of the 
homochiral complex. The further N-H hydrogen bond donor of 2AP, rather than being used to form a 
chain, was used to bind two of the key interaction units together, each exploiting a different chiral form 
of NPX. Each heterodimeric unit formed bridging 𝐷1
1(3)) contacts with its opposing unit, forming a 
dimer of dimers, characterised as a 𝑅4
2(8) ring. 
 
These structural motifs can, hence, be used to describe the overall packing arrangement of the racemic 
salt form. Given the kinked plane existing through the co-former molecules of the interaction unit, the 
body of the different enantiomers (i.e. naphthyl and methoxy groups) were shown to protrude from 
opposite sides of this plane, allowing for the motif to express a three-dimensional herring-bone 
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structure. Utilising this, the overall long range assembly of the material was shown to consist of 
interlocked interaction units, forming distinct layers, each offset from the other. 
 
Table 6. 5 - SCXRD data for the RS-naproxen:2-aminopyridine (1:1) salt 
 
Material RS-naproxen:2-aminopyridine  
(1:1) salt 
Empirical formula C19H20N2O3 
Formula weight 324.37 
Temperature (K) 292.63(10) 
Crystal system triclinic 
Space group 𝑃1̅ 
a (Å) 8.6586(4) 
b (Å) 8.9635(3) 
c (Å) 11.5676(6) 
α (°) 78.553(4) 
β (°) 83.951(4) 
γ (°) 68.062(4) 
Volume (Å3) 815.72(7) 
Z, Z’ 2, 1 
ρcalc (g/cm3) 1.321 
μ (mm-1) 0.730 
F(000) 344.0 
Crystal size (mm3) 0.098 × 0.08 × 0.062 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection (°) 7.802 to 146.716 
Index ranges -10 ≤ h ≤ 10, -11 ≤ k ≤ 11, -14 ≤ l ≤ 14 
Reflections collected 26157 
Independent reflections 3229 [Rint = 0.0383, Rsigma = 0.0194] 
Data/restraints/parameters 3229/0/219 
Goodness-of-fit on F2 1.044 
Final R indexes [I>=2σ (I)] R1 = 0.0458, wR2 = 0.1250 
Final R indexes [all data] R1 = 0.0540, wR2 = 0.1321 
Largest diff. peak/hole  (e Å-3) 0.25/-0.21 
Flack parameter N/A 
 
 
Given the crystal structures of these two salt forms, the previous finding of a racemic compound forming 
system upon the combination of NPX with 2AP at different enantiomeric compositions was confirmed. 
Both were shown to exploit different hydrogen bonding interactions, from which different crystalline 
structures could be generated. In the case with 2AP, the respective structures of the homochiral and 
racemic salts were shown to form interactions akin to that of single-component NPX, though with the 





6.3 Multi-component material cooling crystallisation 
 
Having established that at enantiopure and racemic combinations, novel complexes corresponding to 
these compositions could be obtained, and given that the homochiral phase demonstrated a certain 
metastability under certain conditions, with respect to the racemic form, bulk methods were established 
for the reproducible preparation of each of the respective materials. From here, the different salts were 
characterised for their behaviour in solution, from which initial cooling crystallisations were derived so 
as to confirm the metastability of the single enantiomeric phase towards racemic compositions.  
 
6.3.1 Bulk material preparation – Slurrying 
 
It was shown from the initial screening experiments, detailed in Section 6.2, that the salts of sNPX and 
rsNPX with 2AP, respectively, could be prepared via both mechanochemical and cooling crystallisation 
means. These experiments were carried out on relatively small scales, requiring excessive mechanical 
stress in the case of grinding or generating larger crystallites, when grown from an unmixed solution, 
which were deemed unsuitable for conducting further solution characterisation. Therefore, before more 
refined cooling crystallisation practices could be developed, ‘solvent-mediated’ or slurrying techniques 
were utilised for the bulk preparation of the respective complexes. 
 
Slurrying entailed the suspension of excess solid in a given solvent, at a specific temperature, with the 
material being continually mixed for a set amount of time. As such, three solvent systems were selected 
to ascertain their applicability for the bulk preparation of the two salts; ethanol, isopropanol and hexane. 
The alcohols were chosen to mimic the initial cooling crystallisations conducted in screening, whilst 
hexane was used as a contrast, being a non-polar solvent and showing minimal dissolution compatibility 
with the API. Suspensions were prepared and mixed for up to one hour at room temperature.  
 
The PXRD patterns depicted in Figures 6.21 and 6.22 demonstrate the phases made in the three solvent 
environments for the individual enantiopure and racemic combinations of NPX with 2AP, in comparison 
with the starting materials. For the homochiral preparations, the corresponding salt was shown to form 
in each case, with particular purity in the isopropanol and hexane systems. In the ethanol case, excess 
starting material was also shown to precipitate. For the racemic preparations, the heterochiral salt was 
shown to form consistently in each of the different solvent environments. However, the amorphous 
content of the material generated from hexane was shown to be slightly greater than that observed in 
either of the alcohol solutions. This concurred with previous observations made for this system from 
mechanochemical experiments   
 
These slurrying experiments were conducted with low quantities of solvent and solid, but to provide a 
route to the bulk scale preparation of the two salts, larger volumes of solvent were required. Therefore, 
hexane was selected as a suitable solvent medium, owing to its ability to yield the necessary phases, 
with sufficient crystallinity. Furthermore, the solubility of the given materials in hexane was 
significantly lower than that of the other solvents, allowing for a greater quantity of solid to be 
suspended and, subsequently, collected. Hence, samples of each of the salt forms were prepared via 
slurrying in hexane, with the quantity of solvent and solid used substantially increased. The diffraction 
patterns and DSC traces were collected for three iterations of both the homo and heterochiral materials. 
These can be found in Appendix A6.3. Both forms were shown to be consistently prepared, with the 
materials yielded exhibiting bulk melting points at 103-105oC and 99-101oC for the enantiopure and 
racemic complexes, respectively, corresponding to those found from screening.  
 






Figure 6. 21 - PXRD patterns for the bulk preparation of the S-naproxen:2-aminopyridine (1:1) salt, slurried in either 




Figure 6. 22 - PXRD patterns for the bulk preparation of the RS-naproxen:2-aminopyridine (1:1) salt, slurried in either 





6.3.2 Material solubility 
 
As highlighted in the previous section, slurrying could be used to reliably produce bulk quantities of 
the two salt forms of NPX and 2AP at racemic and enantiopure contributions. This allowed for solubility 
analysis to be carried out. As before, these measurements were conducted based upon turbidity 
measurements, taking the clear point as the point of dissolution with increasing temperature, for a given 
concentration of material. Figure 6.23 shows the solubility curves taken for the respective salt forms in 
ethanol, with Table 6.6 demonstrating key solubilities determined for 20oC and 30oC. For information 




Figure 6. 23 - Solubility data of the S-naproxen:2-aminopyridine (1:1) and RS-naproxen:2-aminopyridine (1:1) salts in 
ethanol, as determined from turbidity measurements (concentration taken with respect to NPX) (% error no greater than 
2.5%) 
 
Table 6. 6 - Saturation points of the S-naproxen:2-aminopyridine (1:1) and RS-naproxen:2-aminopyridine (1:1) salts in 
ethanol, at 20oC and 30oC (concentration taken with respect to NPX) 
 
Material 
Saturation at 20oC 
(NPX mmol/mol) 
Saturation at 30oC 
(NPX mmol/mol) 
S-naproxen:2-
aminopyridine (1:1) salt 
15.5 23.7 
RS-naproxen:2-
aminopyridine (1:1) salt 
13.3 22.1 
 
In comparison with the single-component forms of NPX, whether at racemic or enantiopure 
compositions, the solubility of both the multi-component forms was shown to be consistently higher 
over the temperature range explored. For the homochiral materials, the salt form was shown to be 
around 1.28 and 1.31 times higher at 20oC and 30oC, whilst the racemic salt exhibited solubilities 1.75 
and 1.9 times higher for the same temperatures. This emphasised the advantages of using multi-
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component materials, in this case salts, for developing systems with enhanced physicochemical 
properties with respect to their starting components.   
 
Further to this, both of the complexes displayed higher solubilities than that of single component sNPX, 
the enantiomeric composition of the API with the greater solubility. This observation was deemed to be 
key when considering developing future cooling crystallisation experiments as it demonstrated distinct 
regions where only the multi-component phase could be crystallised. This was in contrast to the 
solubility measurements taken for isopropanol. Here, the solubility of the multi-component materials 
was shown to coincide with that of sNPX and rsNPX, rendering this solvent system inappropiate for the 
selective crystallisation of the different NPX phases over the temperature range explored. 
 
Finally, the solubility disparity between the two salt forms was shown to be smaller than that observed 
for NPX on its own, emphasising a smaller stability difference between the novel materials. Though by 
no means definitive, the trends of the solubility curves suggested that with increasing temperature the 
solubility gap between the homo and heterochiral multi-component materials decreased, providing an 
indication that the enantiopure salt had potential stability upon crystallisations at higher temperatures. 
 
6.3.3 Ternary (solution) phase diagram analysis 
 
To further explore the solubility relationship between the sNPX and rsNPX salts, providing further 
information for the design of cooling crystallisations, a ternary phase diagram was developed for the 
ethanol solvent system. Figure 6.24 shows the phase diagram, derived from gravimetric analysis, for 
different enantiomeric compositions of the API, combined in a 1:1 ratio with 2AP, at 20oC and 30oC. 
The PXRD patterns of each of the slurried preparations, as well as the individual solubility points taken 




Figure 6. 24 - Ternary (solubility) phase diagram, corresponding to the solubility of different enantiomeric combinations of 




As shown, with particular evidence at 30oC, the trend of the solubility points represented that of a 
racemic compound system, demonstrating specific regions that could be attributed to the either the S-
naproxen:2-aminopyridine (1:1) or RS-naproxen:2-aminopyridine (1:1) salt. These regions were 
separated by a distinctive inflection point, the eutectic point, shown to occur at a sNPX mole fraction 
of 0.85. In order to test the hypothesis that this system truly represented a metastable conglomerate, it 
was established that cooling crystallisations should be developed that probed enantiomeric 
compositions from racemic to those below that indicated by the eutectic point.  
 
The preparation of this diagram also highlighted some further interesting features of this system. The 
gravimetric samples were prepared via slurrying, for which diffraction analysis was conducted on the 
left over solid residue. For the solid yielded from lower temperature slurrying, the PXRD patterns 
demonstrated consistent preparation of the two distinct multi-component crystalline phases, either pure 
or as a mixture. However, for the higher temperature preparations, the complexes were also shown to 
crystallise along with excess starting material, predominately NPX. This could be attributed to either 
difficulties in salt formation at higher temperature or the evaporation of additional mother liquor from 
the solid sample, with a high concentration of NPX.  
 
A further observation was that relating to the higher than expected solubility of the sample generated at 
purely racemic compositions at 30oC. After slurrying, the mother liquor was extracted and allowed to 
evaporate at the given solvent-mediation temperature. This allowed for solid to crystallise and the 
solubility could be determined. In the racemic case at the higher temperature, the initial material 
generated post-evaporation was amorphous in nature, given its sticky and oily texture. Cooling 
crystallisation experiments for preparations at racemic compositions were thus deemed unnecessary.  
 
6.3.4 Initial cooling crystallisations 
 
Thus far, it has been demonstrated that both the racemic and enantiopure multi-component salts of NPX 
and 2AP could be prepared through mechanochemical, slurrying or static cooling crystallisation means. 
For the most part, these were conducted at either purely homochiral or racemic compositions, with 
varying combinations of the different enantiomeric forms only being used in the development of the 
ternary phase diagram. In this final section, designed cooling crystallisation experiments were explored, 
establishing a definitive route to the preparation of the two complexed phases via cooling and exploring 
the potential of crystallising the enantiomerically pure salt at compositions tending towards racemic.  
 
The first controlled cooling crystallisations were designed to reliably prepare the respective novel 
phases. Saturated solutions at 30oC with respect to racemic and enantiopure contributions of the API, 
with the corresponding amount of co-former, were setup and heated to 45oC so as to allow for complete 
dissolution. Mixed at a given rate, the solutions were then cooled at either 0.1oC/minute (slow) or 
1oC/minute (fast) to 5oC. Upon reaching the end temperature, the solid material yielded was analysed 
by PXRD. The diffraction patterns for these samples are shown in Figures 6.25 and 6.26.  
 
For each of the respective preparations, the individual multi-component materials of the different 
corresponding enantiomeric composition were produced. This emphasised that both forms could be 





Figure 6. 25 - PXRD patterns for initial cooling crystallisation experiments for the preparation of the S-naproxen:2-
aminopyridine (1:1) and RS-naproxen:2-aminopyridine (1:1) salts at enantiopure and racemic compositions, saturating the 




Figure 6. 26 - PXRD patterns for initial cooling crystallisation experiments for the preparation of the S-naproxen:2-
aminopyridine (1:1) and RS-naproxen:2-aminopyridine (1:1) salts at enantiopure and racemic compositions, saturating the 





Having established that cooling could be used for the reproducible preparation of both multi-component 
phases, further crystallisations were carried out utilising different enantiomeric compositions. Based 
upon the findings from the ternary phase diagram analysis, cooling crystallisations were conducted at 
compositions below sNPX mole fractions of 0.85. Hence, mole fractions of 0.8, 0.75 and 0.7 were 
selected. The same cooling rates were utilised as previously, with mixing rate and end temperature 
being varied, either at 150 (slow) or 600 (fast) rpm and 10oC, 5oC and 0oC, respectively. Upon reaching 
the temperature, each sample was filtered immediately. The solid phases produced were analysed again 
using PXRD, the data for which can be found in Appendix A6.3.  
 
Upon analysing the materials generated at the slow cooling rate, it was noted that no matter the 
composition or the mixing rate, both crystalline salt forms were shown to precipitate to different extents. 
In the specific set of crystallisations where the samples were cooled to 10oC, mixed at 600 rpm, no 
crystallisation was observed. In contrast, by cooling the solutions at the faster rate, mixing slowly at 
150 rpm and only cooling to 10oC, the enantiopure salt could be exclusively accessed at all the 
compositions used. The solids were collected immediately after precipitation and analysed, as 
highlighted in Figure 6.27. These observations could be rationalised by considering the mechanism of 
crystallisation taking place. By mixing at the slower rate at the given enantiomeric compositions, the 
collective metastable zone width for the two salts was deemed to be sufficiently wide so as to allow for 
the distinct nucleation of both of the multi-component phases. In addition, by cooling at the faster rate 
and given the kinetic stability of the homochiral form towards racemic contributions, the corresponding 
enantiopure salt was able to crystallise preferentially with respect to its racemic counterpart. 
 
It was also shown that with the related coolings to 5oC and 0oC, the composition at which the homochiral 
complex could be obtained exclusively shifted towards compositions with higher contributions of 
sNPX. Furthermore, by increasing the mixing rate, the racemic phase was once again shown to 




Figure 6. 27 - PXRD patterns of the solid yielded from cooling crystallisations, utilising 1:1 ethanol solutions of NPX to 
2AP, with varying enantiomeric compositions (80:20, 75:25 and 70:30, excess sNPX), cooled at 1oC/min from 45oC to 10oC, 




The solubility line, as dictated through the ternary phase diagram, represents the thermodynamic 
equilibrium between not only the solution and solid phases, but also that of the different NPX-2AP salt 
forms. Highlighted from the above cooling crystallisations, it has been shown that given the correct 
kinetics, the homochiral complex could be accessed at compositions closer to that of racemic. This 
confirmed the metastability of this phase and existence of a metastable conglomerate, with potential 
applications towards preferential crystallisation.   
 
6.4 Summary, conclusions and future work 
 
In this chapter, the API naproxen (NPX) has been re-evaluated in terms of its crystalline structure and 
melting point, at either enantiopure or racemic compositions. Based upon this, its binary (melting point) 
phase diagram was constructed and rationalised, emphasising the existence of a racemic compound 
system. This was supported by the solubility data for the different phases, showing a significant 
disparity in their respective solubilities, thus highlighting the relative stability of NPX at the two 
enantiomeric contributions. Furthermore, by assessing the solubility of the various heterochiral 
combinations at given temperatures, the characteristic trend of a racemic compound system was shown 
through the preparation of ternary (solubility) phase diagram. Together, these observations reiterated 
the impracticality of using this API, in its current form, in preferential crystallisation processes. 
 
The chiral composition of the solutions of NPX was analysed using Circular Dichroism (CD) 
spectroscopy, a method that could account for not only solution concentration through the measurement 
of UV-vis light, but also enantiomeric mole fraction by accounting for the absorption of different 
circularly polarised light. Calibration plots were established and used to quantify future crystallisation 
outcomes. However, a limitation to CD spectroscopy was that it can be limited by concentration effects. 
This could be attributed to a detection limit associated with the detector. Hence, an effective dilution 
was necessary for each sample prior to analysis. However, the use of this analytical method formed the 
basis of a collaboration with the University of Strathclyde (ter Horst group), exploring its potential for 
in-line monitoring of chiral crystallisation processes, as well as establishing modifications to the 
technique to allow for its use with multi-component systems.  
 
Given the impracticality of using NPX for the separation of its chiral forms, it was decided that by 
manipulating the crystalline lattice of the API through the introduction of a second, complementary 
molecular entity, a system could be generated that could be applied to preferential crystallisation 
processes. Based upon an assessment of the relative interactions exploited by NPX with other molecules, 
as determined from CSD searches, specific co-formers could be selected. One particularly promising 
co-former was that of 2-aminopyridine (2AP). This molecule exhibited the pyridine and amine 
functionalities deemed most likely to form a multi-component complex with NPX. 
 
Various screening methods were used in the preparation of materials of NPX with 2AP at both 
enantiopure and racemic compositions, including mechanochemical and preliminary crash cooling 
crystallisation methods. Mechanochemistry offers a quick and easy route to the development of novel 
multi-component complexes, be they co-crystals or salts. This technique allows for the direct 
assessment of stoichiometry, providing early indications of the ratio of molecular components in the 
structure. The role of solvent can also be evaluated, with minimum quantities being used in the 
preparations. Whether solvent is used or not, also provides an understanding of the propensity of the 
molecular entities to interact and hence form novel structures. However, the crystalline structure of a 
given material could not be directly obtained from the samples derived from mechanochemistry, due to 
their microcrystalline nature. Using the initial solubility data of one of the starting materials, saturated 
solutions can be set up and rapidly cooled with a specific stoichiometry of starting components. In this 
way, single crystals were able to be grown that were suitable for SCXRD analysis. In many cases, the 
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materials generated through mechanochemical means could also be correlated to the crystals grown 
from solution, potentially highlighting the stability of a given crystalline phase.  
 
In the specific case of NPX and 2AP, both preparation methods were shown to reproducibly yield 
distinct materials at homo and heterochiral compositions with characteristic diffraction patterns distinct 
from each other, as well as those of the starting materials. Thermal analysis indicated melting points at 
103-105oC and 99-101oC for the enantiopure and racemic complexes, respectively. Utilising 
mechanochemical means, binary phase diagram analysis confirmed the existence of two discrete phases, 
providing an initial indication of that this combination yielded a racemic compound chiral crystalline 
system. Subsequent structural analysis highlighted that the two forms corresponded to that of a S-
naproxen:2-aminopyridine (1:1) salt and a RS-naproxen:2-aminopyridine (1:1) salt. 
 
Upon grinding racemic contributions of the API with the co-former, the amorphous content of the 
samples prepared were shown to be greater than that observed for the enantiomerically pure case. The 
melting point of the racemic phase was thus taken to be lower, an atypical phenomenon for many 
racemic compounds. This provided the first indication as to the potential metastability of the homochiral 
salt. The narrowing in the relative stabilities of the two forms was also emphasised from solubility 
analysis of the two materials, with the difference between them being substantially smaller than that 
observed for the enantiomeric compositions of just NPX. Whilst the ternary phase diagram of this 
system, again, demonstrated the existence of a racemic compound system, it was noted that at higher 
temperatures, the racemic salt tended towards the amorphous phase, highlighting its comparative 
instability and presenting an opportunity to crystallise the homochiral salt form at compositions closer 
to racemic.  
 
Finally, the possibility of crystallising both phases using controlled cooling crystallisations was 
explored, with the aim to manipulate the enantiomeric composition and determine the conditions 
required for the precipitation of the homochiral salt at more even quantities of the two chiral forms. 
Having demonstrated that slurrying could be used to generate both of the novel phases, initial cooling 
crystallisations were carried out at fast and slow cooling rates to emphasise that both the enantiopure 
and racemic salts could be crystallised via this method. With this established, it was then shown that 
with immediate filtration, the enantiomerically pure complex could be obtained at compositions up to 
and including the sNPX mole fraction of 0.7. This represented a point beyond the thermodynamic 
eutectic boundary in solutions of ethanol, showing that the homochiral salt could be kinetically 
stabilised at compositions that tended towards racemic. As such, the complexes of NPX and 2AP can 
be described a metastable conglomerate material, presenting opportunities for future preferential 
crystallisation processes.  
 
Several aspects of the system of NPX and 2AP should be explored further. Firstly, the stability of the 
racemic multi-component phase at higher temperatures should be established, assessing potential 
opportunities for the crystallisation of the homochiral material under these conditions. Additional 
cooling crystallisations should also be conducted, exploiting enantiomeric contributions even closer to 
racemic quantities, i.e. sNPX mole fractions of 0.65 and 0.6. Initial seeding experiments should also be 
carried out to ensure the crystallisation of the correct form at these compositions and to maximise yield. 
 
As part of an on-going collaboration between the Wilson (University of Bath) and ter Horst (University 
of Strathclyde) groups, the development and application of multi-component materials for separation 
of chiral molecular forms from racemic solutions via crystallisation has been explored further. With the 
enantiopure combination of NPX and 2AP expressing the characteristics of a metastable conglomerate, 
initial plans have been established for its application into a preferential crystallisation process, using 
the setup depicted in Figure 6.28. Here, a feed tank containing a racemic solution of NPX with 2AP can 
be fed into a temperature controlled secondary vessel, where cooling crystallisation is allowed to take 
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place. In the crystallisation unit, the racemic solution is initially enriched through an enantiopure feed, 
so as to favour the crystallisation of only one of the enantiomeric forms of the API and to minimise the 
chance of the racemic phase precipitating. From this point, the system is cooled fairly rapidly at a given 
mixing rate until spontaneous nucleation occurs and the solid material is filtered and analysed. The 
solution dynamics, in terms of its enantiomeric composition and the crystallisation activity, can be 
monitored by in-line polarimetry and ‘Focus Beam Reflectance Measurements’ (FBRM), respectively. 
Polarimetry establishes the composition of enantiomers within solution based upon the relative degree 
of optical rotation of light, whilst FBRM monitors the scattering of a beam of laser light so as to 
determine the point of nucleation. The point to which the system should be enriched is dependent upon 
the desired area of operation, as dictated by the ternary phase diagram for a given system, and the 
crystallisation conditions used. Together, these can both determine the degree of kinetic stabilisation 
awarded to the homochiral salt phase as the system is composited towards racemic contributions. As 
well as these experiments, seeded crystallisation should also be conducted, so as to further control the 





Figure 6. 28 - A schematic of the preferential crystallisation setup used by the ter Horst group (University of Strathclyde), 
highlighting the feed and crystallisation vessels, in-line polarimetry and FBRM, as well as the filtration units 
 
In addition, this collaboration is exploring various aspects of chiral crystallisation, including exploring 
methods for the in-line determination the enantiomeric composition of solutions. Currently, polarimetry 
has been used to monitor the solution composition of the two enantiomers, but through the use of CD 
spectroscopy, both the composition and concentration can be monitored. Further studies are currently 
underway so as to assess the capability of this form of analysis in the characterisation of multi-




7 Chiral multi-component materials of naproxen with derivatives of 2-
aminopyridine 
 
Based upon the initial assessment and robust cooling crystallisations for the racemic and homochiral 
multi-component materials of NPX and 2AP, further co-crystal and salt screenings were conducted 
using appropriate derivatives of the co-former. As discussed from the initial CSD search described in 
the previous chapter, it was determined that the key hydrogen bonding interactions, common to many 
systems incorporating NPX, were that of the carboxylic acid-pyridine, carboxylate-pyridinium and 
carboxylic acid-amine interactions. Given the propensity for 2AP to form a heterodimeric interaction 
unit with NPX, the initial molecules selected were chosen to mimic these types of contacts. Hence, as 
shown in Figure 7.1, the molecules selected included 2-aminopyrimidine (2APM), 2-amino-4,6-
dimethylpyrimdine (2ADMP), 2-amino-3-chloropyridine (2A3CP), 2-amino-4-chloropyridine 
(2A4CP), 2-amino-5-chloropyridine (2A5CP) and  2-amino-6-chloropyridine (2A6CP). For the unit 




Figure 7. 1 - Molecular structures for the derivatives of 2AP selected for the co-crystal and salt screening with NPX, 
highlighting 2-aminopyrimidine (2APM), 2-amino-4,6-dimethylpyrimdine (2ADMP), 2-amino-3-chloropyridine (2A3CP), 2-
amino-4-chloropyridine (2A4CP), 2-amino-5-chloropyridine (2A5CP) and  2-amino-6-chloropyridine (2A6CP) 
 
This chapter will outline the screening carried out with each of these co-formers with both racemic and 
enantiopure NPX, utilising mechanochemical and solution crystallisation methods, assessing their 
efficacy and compatibility in the preparation of particular phases. The relationship between the homo 
and heterochiral phases will be explored, establishing the relationship between the solid state structures 
at these enantiomeric compositions. This was done primarily through binary phase diagram analysis 
and exploration of crystalline structures of each of the respective materials.   
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7.1 Materials of racemic and enantiopure naproxen with 2-aminopyrimidine (2APM) 
 
7.1.1 Material screening 
 
Co-crystal and salt screening was conducted by combining both racemic and enantiopure NPX, 
respectively, with the co-former 2-aminopyrimidine (2APM). This co-former, obtained as an off-white 
powder, has only one known polymorphic form (CSD reference: AMPYRM10200), with a melting point 
between 124-126oC. 2APM, a symmetrical molecule, has similar functionalities to 2AP, with both the 
amine and pyridine groups providing options for hydrogen bond donation and acceptance. However, 
unlike 2AP, 2APM possesses heterocyclic nitrogen atoms, one either side of the amine moiety (ortho), 
offering additional opportunities to accept hydrogen bonds. This co-former has weak basic properties201, 
with a pKa of 3.81, limiting the likelihood of proton transfer and salt formation with NPX. 
 
7.1.1.1 Mechanochemical screening 
 
The initial screening for novel multi-components of NPX and 2APM was carried out through liquid-
assisted grinding, where a few drops of ethanol were added to the material in the mortar and pestle. The 
co-former was ground in either 2:1, 1:1 or 1:2 stoichiometries with either sNPX or rsNPX. Phase and 
thermal analysis was then conducted on each of the preparations. 
 
Assessment of the PXRD patterns for the enantiopure samples, shown in Figure 7.2, indicated the 
formation of a novel phase with respect to that of the starting materials, with particular evidence in the 
1:1 and 1:2 mechanochemically combined samples. Whilst the presence of excess starting material was 
also noted, distinct peaks could be matched to the subsequent simulated pattern generated from SCXRD 
data of the 1:1 multi-component phase, as crystallised from solution (see Section 7.1.2). 
 
Analysis of the DSC traces (Figure 7.3) highlighted that for the 1:1 preparation an initial 
melt/recrystallisation occurred approaching 80oC, after which a minor endothermic event (101-103oC) 
was followed by a major endotherm (109-112oC). This indicated that complexation could be achieved 
not only through grinding, but with the aid of heating. The subsequent series of endothermic peaks 
highlighted solid-to-solid transitions for the various multi-component forms of sNPX and 2APM, be 
that polymorphic or stoichiometric.   
 
The PXRD patterns for the materials derived from the grinding of rsNPX and 2APM, as shown in Figure 
7.4, again highlighted the formation of a new phase, consistent across all three stoichiometric 
combinations. Preparation from the 1:1 stoichiometry, in particular, demonstrated the formation of this 
novel form free from excess starting material, again matching that taken from SCXRD (see below).  
 
Traces taken from DSC analysis (Figure 7.5) validated that a novel multi-component phase was 
produced at racemic compositions. The thermal plot for the 1:1 stoichiometric preparation exhibited a 
small broad thermal event, peaking at 68oC, followed by a minor endotherm (93-97oC) and then a major 
endotherm (110-112oC). The event occurring at the lower temperature could be attributed to the 
evaporation of excess solvent, followed immediately by either the melt of an additional impurity, related 
phase or that of a solid-to-solid transition. The final major endotherm was related to the melting of the 






Figure 7. 2 - PXRD patterns from mechanochemically prepared samples of sNPX and 2APM with ethanol, ground in either 




Figure 7. 3 - DSC traces from mechanochemically prepared samples of sNPX and 2APM in ethanol, ground in either 2:1, 1:1 







Figure 7. 4 - PXRD patterns from mechanochemically prepared samples of rsNPX and 2APM in ethanol, ground in either 




Figure 7. 5 - DSC traces from mechanochemically prepared samples of rsNPX and 2APM in ethanol, ground in either 2:1, 





7.1.1.2 Combined evaporation & cooling crystallisation screening 
 
Initial cooling crystallisations, aided by slow evaporation, were conducted in ethanol, whereby 2:1, 1:1 
and 1:2 solutions of sNPX and rsNPX with 2APM, respectively, were prepared and placed in a 
temperature controlled environment, set at 4oC. Figure 7.6 shows the crystals produced from three 1:1 
preparations of NPX and 2APM, highlighting those from seeded and non-seeded homochiral solutions, 
and from heterochiral solutions. For each sample, the resultant crystals were elongated blocks, 




Figure 7. 6 - Microscope and mounted SCXRD images of crystals yielded from (a) 1:1 and (b) seeded 1:1 solutions of sNPX 
and 2APM, as well as (c) 1:1 solutions with rsNPX 
 
HSM thermal analysis was conducted on the crystallites taken from each crystallisation. The images 
taken for those prepared solely from racemic solutions, as well as those from seeded enantiomerically 
pure solutions are shown in Appendix A7.1. For these samples, the thermal events observed could be 
related back to those demonstrated from DSC analysis.  
 
Figure 7.7 shows the crystals taken directly from the unseeded 1:1 combination of sNPX and 2APM. 
Initial melting occurred prior to 108oC continuing to 115oC, followed by the subsequent melt of further 
crystallites between 115oC and 119oC. Recrystallisation and crystal growth was then noted, with the 
crystals being sustained until 150oC, after which further melting was observed. These observations 
indicated the presence of several novel forms, melting consecutively, followed by the recrystallisation 




Figure 7. 7 - HSM images of the thermal events attributed to crystals taken from the straight crash cooling of sNPX and 
2APM in a 1:1 solution molar ratio (10oC/min & 100μm scale) 
 
Subsequent diffraction experiments with the crystals yielded from the direct cooling of the 1:1 ethanol 
solution with sNPX and 2APM showed that a new phase was generated when compared to that produced 
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mechanochemically. This phase was shown to have the API and co-former in a 2:1 stoichiometry, 
showing that the crystals observed for the corresponding HSM analysis represented a mixture of 
different crystalline phases. In order to obtain single crystals corresponding to that derived from 
grinding, a small quantity of mechanochemically prepared seed was added to solutions of the same 
composition at 4oC. This yielded the necessary crystals required for assessing the structure of the 
material generated using the mortar and pestle. 
 
7.1.2 Material characterisation 
 
After establishing routes for the initial preparation of the respective racemic and enantiopure phases by 
both mechanochemical and solution crystallisation, further solid state analysis was conducted to define 
the phases present in terms of their thermal and structural properties. The analysis used included that of 
PXRD, DSC and SCXRD. Additional IR analysis was also carried out, the spectra of which can be 
found in Appendix A7.1. 
 
7.1.2.1 Phase, thermal and spectroscopic analysis 
 
The screening using both mechanochemical and solution crystallisation methods produced three distinct 
forms; two homochiral multi-component materials and one at racemic compositions. The sNPX form 
obtained from spontaneous nucleation, based upon HSM, exhibited a marginally higher melting point 
(115-119oC) to that prepared via mechanochemistry or seeded crystallisations, indicating slightly 
stronger interactions within the crystalline structure. Figure 7.8 shows the PXRD patterns of the two 
stoichiometric co-crystals of sNPX and 2APM, the racemic co-crystal and the individual starting 
materials (taken from the CSD150, 171, 200), whilst thermal data, obtained using DSC, for the two 1:1 co-
crystals are highlighted in Figure 7.9. No clear traces could be obtained for the crystals of the initial 
enantiopure multi-component material derived from the unseeded solution.  
 
Comparison of the two mechanochemically prepared substances at the disparate enantiomeric ratios 
highlighted distinctly similar melting phenomena, whilst still displaying different diffraction patterns. 
Further HSM studies using single crystals (see Appendix A7.1) confirmed the melting point of the 
homochiral co-crystal, but indicated that the racemic had a slightly higher melting point, between 112-
116oC. This highlighted the benefits of conducting analysis on single crystal samples and crosschecking 
against the results obtained from mechanochemically acquired samples. Despite this, the discrete 
patterns of the two phases indicated the formation of a racemic compound chiral crystalline system, 
with the interactions in the forms of similar energy. 
 
The IR spectra obtained for the solid-state materials made either via mechanochemistry or crash cooling 
showed similarities in their stretching and vibrational frequencies, indicating the presence of the same 
functionalities as in the starting materials. However, differences were noted between the carbonyl 
stretches associated with each of the novel multi-component forms. Whilst the homochiral material 
collected directly from solution exhibited a major peak with an associated shoulder at 1694 cm-1, that 
of the mechanochemically obtained materials demonstrated a single and double peak, respectively for 
the homochiral and racemic phases, occurring at 1685 cm-1 and 1645 cm-1. This suggested that upon 
building the overall structures of the materials, different intermolecular interactions were utilised, 






Figure 7. 8 - PXRD patterns of the S-naproxen:2-aminopyrimidine (2:1) & (1:1) co-crystals, the RS-naproxen:2-
aminopyrimidine (1:1) co-crystal, as derived from SCXRD data, compared to that of the starting materials 
 
 
Figure 7. 9 - DSC traces of the S-naproxen:2-aminopyrimidine (1:1) and the RS-naproxen:2-aminopyrimidine (1:1) co-





7.1.2.2 Binary (melting point) phase diagram analysis – Classification of chiral crystalline materials 
 
As highlighted above, the PXRD patterns of the ground samples and those generated from SCXRD for 
individual single crystals showed sufficient differences to indicate the existence of two discrete co-
crystalline phases at racemic and enantiopure compositions of NPX, when combined with 2APM. Using 
DSC, the thermal events of different mechanochemically prepared samples of the API and co-former 
were recorded with the enantiomeric mole fraction of rNPX to sNPX increased from racemic to 
enantiopure, with respect to the S-enantiomer. From these, a binary phase diagram was made, as shown 
in Figure 7.10. The supporting DSC traces and PXRD patterns for each of the individual compositions 
can be found in Appendix A7.1. 
 
The phases form defined regions, highlighting the temperature and composition ranges at which only 
either the racemic or homochiral phases remained solid upon heating. The rsNPX-2APM phase was 
shown to be solely stable between the molar compositions of 0.3 to 0.7, whilst the sNPX-2APM was 
stable at higher molar compositions of sNPX, at fractions greater than 0.7. In addition, a eutectic melt 
was also observed over the enantiomeric range, between 106-107oC, with the single eutectic 
phenomenon being most pronounced at the 0.7 mole fraction.  Due to the presence of the eutectic event 
and the evidence of the two clear regions of stability for the two phases, the relationship between the 
mechanochemically prepared materials of NPX and 2APM can be definitively described as a racemic 
compound forming system, similar to that of single-component NPX. Therefore, this multi-component 




Figure 7. 10 - Binary (melting) point phase diagram, with changing enantiomeric composition of rNPX and sNPX, for the 1:1 
co-crystals incorporating the co-former 2APM, highlighting the liquidus (Δ) and the eutectic (▲) points 
 
However, upon forming their respective multi-component forms, the stability range over which the 
racemic solid is prevalent, was reduced when compared to that of single component NPX. This 
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emphasises the ability of multi-component materials to manipulate properties, with the potential of 
working towards a racemic conglomerate.  
 
7.1.2.3 Crystallography – Crystal structure analysis 
 
Once crystallised via cooling crystallisation, crystals of sufficient quality were selected, mounted and 
assessed in terms of their crystalline structure using SCXRD. For all hydrogen bonding information for 
the three co-crystalline forms, see Appendix A7.1. The corresponding CIF files (3-5) can be found on 
the accompanying CD-ROM.  
 
Shown in Figure 7.11, the crystal structure of the crystal derived from the combined crash cooling and 
evaporative crystallisation of sNPX and 2APM in a 1:1 molar ratio in ethanol confirmed the formation 
of novel phase between the two starting materials. However, rather than crystallising in a 1:1 ratio 
within the crystal lattice, the resultant co-crystal was shown to form in a 2:1 stoichiometry between the 
API and co-former. Whilst through X-ray diffraction data the ability to definitively define the location 
of hydrogen atoms is limited, this structure showed no evidence of proton transfer, suggesting the 
formation of a co-crystal, as opposed to a salt. This material can, hence, be denoted as a S-naproxen:2-




Figure 7. 11 - Crystal structure of the S-naproxen:2-aminopyrimidine (2:1) co-crystal, highlighting (a) the unit cell, (b) 
hydrogen bonding synthon and (c) packing arrangement (sNPX in red) 
 
The molecules of sNPX and 2APM crystallised in the non-centrosymmetric monoclinic P21 space group, 
with each unit cell (parameters outlined in Table 7.1) consisting of four sets of sNPX and 2APM (2:1) 
units. As such, each asymmetric unit could be made up from two of these units, giving rise to Z’ value 
of 2. The key interaction unit was held together through hydrogen bonding, whereby the 2APM 
molecule bridges between the two sNPX entities, forming a sNPX:2APM:sNPX motif. Each of the 
individual API molecules forms a 𝑅2
2(8) synthon with the central co-former, with the amine and 
hydroxyl groups of 2APM and sNPX acting as hydrogen bonding donors to the accepting carboxyl and 
pyridine groups, respectively. These units then interlock and stack in order to build up the whole 








Empirical formula C32H33N3O6 
Formula weight 555.61 
Temperature (K) 150.01(10) 
Crystal system monoclinic 
Space group P21 
a (Å) 16.9054(4) 
b (Å) 5.70540(10) 
c (Å) 29.5031(7) 
α (°) 90 
β (°) 100.160(2) 
γ (°) 90 
Volume (Å3) 2801.01(11) 
Z, Z’ 4, 2 
ρcalc (g/cm3) 1.318 
μ (mm-1) 0.749 
F(000) 1176.0 
Crystal size (mm3) 0.261 × 0.057 × 0.033 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection (°) 6.086 to 140.114 
Index ranges -19 ≤ h ≤ 20, -6 ≤ k ≤ 6, -29 ≤ l ≤ 35 
Reflections collected 19107 
Independent reflections 10548 [Rint = 0.0329, Rsigma = 0.0475] 
Data/restraints/parameters 10548/9/768 
Goodness-of-fit on F2 1.061 
Final R indexes [I>=2σ (I)] R1 = 0.0428, wR2 = 0.0964 
Final R indexes [all data] R1 = 0.0514, wR2 = 0.1015 
Largest diff. peak/hole  (e Å-3) 0.21/-0.19 
Flack parameter 0.02(10) 
 
In contrast, the crystals prepared via the seeding of 1:1 ethanol solutions with mechanochemically 
prepared preparations of sNPX and 2APM yielded a different crystalline form. Structural analysis 
demonstrated the formation of another new phase, but in this case, the homochiral form of the API 
forms interactions with the co-former in a 1:1 relationship (Figure 7.12). The two molecular moieties 
crystallised in an orthorhombic P212121 space group, with the unit cell possessing eight molecular units 
of sNPX and 2APM in a 1:1 molar ratio. Thus, the asymmetric unit was deemed to consist of sets of two 
interaction motifs (Z’ = 2). Similarly to the 2:1 co-crystal, the key interaction motifs formed from the 
hetero-dimerised 𝑅2
2(8) interaction between the amine and pyridine groups of the co-former molecule 
and the carboxylic acid group of the homochiral API. However, unlike for the stoichiometric variant, 
the symmetrical nature of the 2APM molecules was not exploited, leaving a pyridine functionality 
devoid of hydrogen bonding. Instead, two dimerised interaction units were connected together through 
a further ring, where the second N-H amine constituted a hydrogen bond donor, forming a contact with 
carboxyl group associated with the other dimer. Taking into account all the interactions, this connecting 
ring can be described as a  𝑅4
2(8) hydrogen bonding synthon, generating an overall dimer of dimers. 
The zig-zagged configuration of these units allowed for stacking, forming distinct channels of 
homochiral API. 
 
Upon assessment of the crystals obtained from racemic solutions, crystallographic analysis 
demonstrated the formation of a further multi-component material, where both enantiomeric forms of 
the API were shown to crystallise within the same monoclinic P21/c lattice, as shown and detailed in 
Figure 7.13 and Table 7.3. Here, each asymmetric unit was made up of the NPX and 2AP molecules in 
a 1:1 ratio, with the unit cell reflecting both chiral forms. As for the related homochiral phase, the 
racemic form was shown to allow for the API and co-former to crystallise in a 1:1 relationship, with no 
proton transfer being exhibited. As a result, this phase can be described as a RS-naproxen:2-






Figure 7. 12 - Crystal structure of the S-naproxen:2-aminopyrimidine (1:1) co-crystal, highlighting (a) the unit cell, (b) 
hydrogen bonding synthon and (c) packing arrangement (sNPX in red) 
 




Empirical formula C18H19N3O3 
Formula weight 325.36 
Temperature (K) 149.9(4) 
Crystal system orthorhombic 
Space group P212121 
a (Å) 5.93398(16) 
b (Å) 15.2065(5) 
c (Å) 36.4930(7) 
α (°) 90 
β (°) 90 
γ (°) 90 
Volume (Å3) 3292.96(15) 
Z, Z’ 8, 2 
ρcalc (g/cm3) 1.313 
μ (mm-1) 0.744 
F(000) 1376.0 
Crystal size (mm3) 0.472 × 0.083 × 0.06 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection (°) 6.296 to 140.104 
Index ranges -7 ≤ h ≤ 6, -15 ≤ k ≤ 18, -31 ≤ l ≤ 44 
Reflections collected 12767 
Independent reflections 6232 [Rint = 0.0364, Rsigma = 0.0522] 
Data/restraints/parameters 6232/2/442 
Goodness-of-fit on F2 1.050 
Final R indexes [I>=2σ (I)] R1 = 0.0477, wR2 = 0.1098 
Final R indexes [all data] R1 = 0.0604, wR2 = 0.1191 
Largest diff. peak/hole  (e Å-3) 0.19/-0.21 
Flack parameter -0.1(2) 
 
This racemic co-crystal showed structural similarities to that of the 1:1 enantiopure phase, with both 
forms exploiting the same dimer of dimers interaction motif. In the racemic case, the respective API 
molecules in the motif possessed opposing chirality. This likeness in intermolecular interaction goes 
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some way to explaining the minor differences observed in their respective melting temperatures. The 
relative stability of these phases can also be highlighted through the similarities in their calculated 
packing densities. The homochiral and racemic co-crystals expressing densities of 1.313 g/cm3 and 
1.311 g/cm3, respectively.   
 
Despite this, as shown in Figure 7.14, the overall packing arrangement of these units was distinctly 
different. Whilst the homochiral structure showed alternating periods of API and co-former, the racemic 
form demonstrates continuous channels of NPX and 2APM, with the repeated alternations between 
chiral forms. This difference in the overall packing assembly of the two 1:1 co-crystals, emphasised the 
formation of two discrete phases at the different enantiomeric compositions and therefore the formation 





Figure 7. 13 - Crystal structure of the RS-naproxen:2-aminopyrimidine (1:1) co-crystal, highlighting (a) the unit cell, (b) 









Empirical formula C18H19N3O3 
Formula weight 325.36 
Temperature (K) 149.9(4) 
Crystal system monoclinic 
Space group P21/c 
a (Å) 15.2222(4) 
b (Å) 5.84020(10) 
c (Å) 19.1479(5) 
α (°) 90 
β (°) 104.399(2) 
γ (°) 90 
Volume (Å3) 1648.79(7) 
Z, Z’ 4, 1 
ρcalc (g/cm3) 1.311 
μ (mm-1) 0.743 
F(000) 688.0 
Crystal size (mm3) 0.134 × 0.087 × 0.049 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection (°) 5.994 to 140.14 
Index ranges -15 ≤ h ≤ 18, -7 ≤ k ≤ 6, -23 ≤ l ≤ 19 
Reflections collected 9917 
Independent reflections 3127 [Rint = 0.0198, Rsigma = 0.0205] 
Data/restraints/parameters 3127/1/223 
Goodness-of-fit on F2 1.041 
Final R indexes [I>=2σ (I)] R1 = 0.0394, wR2 = 0.1007 
Final R indexes [all data] R1 = 0.0470, wR2 = 0.1061 
Largest diff. peak/hole  (e Å-3) 0.29/-0.22 





Figure 7. 14 - A comparison of the extended packing arrangements of the (a) S-naproxen and (b) RS-naproxen:2-








7.2 Materials of racemic and enantiopure naproxen with 2-amino-4,6-
dimethylpyrimidine (2ADMP) 
 
7.2.1 Material screening 
 
The next co-former used in salt and co-crystal screening was 2-amino-4,6-dimethylpyrimidine 
(2ADMP). Related to 2APM, 2ADMP is a derivative of 2AP, exhibiting two pyridine groups either side 
of the amine functionality. In addition, the co-former possesses methyl groups about the aromatic ring, 
adding to the steric bulk of the molecule. 2ADMP has only one known polymorphic form (CSD 
reference: NEQLOM202), exhibiting a melting point between 151-153oC, and was obtained as an off-
white powder. As derived from literature203, the pKa for this material was taken as 4.4. Due to the 
minimal acidity difference, it was deemed unlikely that, upon combination, NPX and 2APM would 
undergo salt formation. 
 
7.2.1.1 Mechanochemical screening 
 
Initial grinding experiments were conducted using sNPX and 2ADMP in 2:1, 1:1 or 1:2 molar ratios 
with the aid of a mortar and pestle. These were initially carried out using no solvent (Appendix A7.2), 
but with no novel materials shown to be evident, minimal amounts of ethanol were subsequently added 
to the grinding mix. The PXRD patterns and DSC traces of those samples prepared with the assistance 
of solvent can be found in Figures 7.15 and 7.16, respectively.  
 
Upon combining the two starting components in equal quantities, phase analysis conducted by PXRD 
highlighted the formation of a new phase, distinct from the patterns of the starting material. Little or no 
excess starting material was noted, suggesting the formation of a 1:1 multi-component form in high 
purity. By comparing with the diffraction pattern simulated from SCXRD data (see Section 7.2.2), there 
was significant likeness to confirm that liquid-assisted mechanochemistry was a reliable method of 
generating the homochiral multi-component phase. Thermal analysis of the 1:1 preparation showed only 
one exothermic event between 139oC and 141oC, confirming the direct formation of a single novel phase 
through liquid-assisted grinding.  
 
Likewise, mechanochemical preparations of rsNPX with 2ADMP were also made in the same molar 
ratios, either neat (Appendix A7.2) or with ethanol. When the two starting components were ground in 
equimolar quantities with a few drops of ethanol, phase analysis (Figure 7.17) again highlighted a 
PXRD pattern of sufficient difference to that of the raw starting materials, so as to suggest the formation 
of another novel multi-component phase. Evidence taken from DSC analysis (Figure 7.18) supported 
this finding, with the 1:1 preparation showing a minor endotherm (124-130oC) followed by a significant 
thermal phenomenon between 153oC and 155oC. These were taken as a eutectic event between the NPX 
and 2ADMP, and the melting point of a novel phase, respectively. 
 
From this initial mechanochemical screening, novel multi-component crystalline materials were shown 
to have been made consistently with a high degree of purity via this technique. In contrast, the neat 
grinding with the two different enantiomeric compositions was shown to have little or no success in the 
preparation of such complexes, with only the starting materials evident from the initial phase analysis. 
Preparation of the novel phases could be achieved, in each case, upon heating, with the DSC traces for 
each enantiomeric composition showing the expected melting features. To date, no further evidence has 






Figure 7. 15 - PXRD patterns from mechanochemically prepared samples of sNPX and 2ADMP in ethanol, ground in either 




Figure 7. 16 - DSC traces from mechanochemically prepared samples of sNPX and 2ADMP in ethanol, ground in either 2:1, 







Figure 7. 17 - PXRD patterns from mechanochemically prepared samples of rsNPX and 2ADMP in ethanol, ground in either 




Figure 7. 18 - DSC traces from mechanochemically prepared samples of rsNPX and 2ADMP in ethanol, ground in either 2:1, 





7.2.1.2 Combined evaporation & cooling crystallisation screening 
 
Single crystals were grown from 1:1 API to co-former saturated solutions of ethanol, for racemic and 
enantiopure NPX, respectively, through the combined crash cooling and evaporative crystallisation 
technique outlined previously. Both multi-component forms showed individual off-white crystals with 
needle morphologies (Figure 7.19). Individual crystals were selected for structural analysis and for each 





Figure 7. 19 - Microscope and mounted SCXRD images of crystals yielded from 1:1 ethanol solutions of (a) sNPX and (b) 
rsNPX with 2ADMP, respectively 
 
Crystals were also selected, from each enantiomeric solution, for HSM analysis (see Appendix A7.2) 
as a comparison to the thermal phenomena found for the mechanochemical samples from DSC. Whilst 
overall the same melting characteristics were found for both chiral multi-component crystals, the actual 
melting range was found to be over a broader range when compared to DSC, particularly for the racemic 
crystals. An initial darkening of the crystal was noted as the temperature approaches 115oC, with the 
final melting occurring from 145oC to 154oC. These observations can be accounted for through an 
appreciation of how the samples were prepared for HSM when compared to DSC, with particular focus 





7.2.2 Material characterisation 
 
The results of the initial mechanochemical and solution crystallisation screenings demonstrated the 
reproducibility in preparation of both the homochiral and racemic multi-component phases. The nature 
of these materials were compared and contrasted with further characterisation using PXRD, DSC, 
SCXRD and phase analysis. IR spectra were also collected for the two materials, highlighting a number 
of similarities (Appendix A7.2). 
 
7.2.2.1 Phase, thermal and spectroscopic analysis 
 
PXRD patterns were simulated from the SCXRD structures (150 K) for the racemic and enantiopure 
multi-component were compared against the respective starting materials, as shown in Figure 7.20. This 
showed that 2ADMP formed novel complexes with both sNPX and rsNPX. The patterns of both 
materials showed striking similarities to each other, possessing many of the same peaks. Despite certain 
shifts (e.g. the peak corresponding to the 111̅ plane moving from 18.3o to 18.7o with increasing 
enantiopurity), it could be said that two phases appeared to be very similar and were intrinsically related.  
 
Despite this, thermal analysis highlighted certain disparities between these crystalline forms. As shown 
in Figure 7.21, the melting point of the homochiral multi-component form (139oC-141oC) was more 
than 13oC lower than that of the material consisting of rsNPX and the co-former (153oC-155oC). In 
isolation, this difference could suggest the formation of another racemic compound, but owing to the 
observations made from X-ray diffraction, racemic solid solution was also possible, with the materials 
towards racemic compositions expressing greater stability to melting in the solid state. 
 
The nature of the bonding and intermolecular interactions in the two multi-component phases was also 
assessed using the IR spectroscopy. As highlighted from their respective spectra, the vibrational and 
stretching modes associated with the homo and heterochiral forms were similar, indicating similarities 
between crystalline forms. This was particularly evident upon assessing the peaks associated with 
carbonyl functionality, where, in both cases, two peaks were observed from 1700-1660 cm-1.  This 







Figure 7. 20 - PXRD patterns of the S-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) and RS-naproxen:2-amino-4,6-





Figure 7. 21 - DSC traces of the S-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) and RS-naproxen:2-amino-4,6-




7.2.2.2 Binary (melting point) phase diagram analysis – Classification of chiral crystalline materials 
 
Owing to the reproducibility of the phases observed through single crystal growth using 
mechanochemical preparation, a binary phase diagram assessing the melting point of the naproxen:2-
amino-4,6-dimethylpyrimidine (1:1) complexes with varying compositions of enantiomer was 
prepared, as shown in Figure 7.22. The corresponding PXRD patterns and DSC traces can be found in 
Appendix A7.2. 
 
As shown, with increasing contribution of sNPX from racemic compositions, the melting points of the 
ground samples gradually decreased. In addition, inspection of the DSC data showed no evidence of 
any eutectic phenomena, with the PXRD patterns showing only subtle changes in the peaks observed. 
Given these observations, rather than being a racemic compound, it could be said that the multi-
component material of NPX and 2ADMP better expressed the characteristics of a racemic solid solution, 
particularly that of a Roozeboom Type II. Whilst interesting in its own right, this type of system has no 




Figure 7. 22 - Binary (melting) point phase diagram, with changing enantiomeric composition of rNPX and sNPX, for the 1:1 
co-crystals incorporating the co-former 2ADMP, highlighting the liquidus (Δ) point 
 
7.2.2.3 Crystallography – Crystal structure analysis 
 
The unit cell parameters and refinement information for both the homochiral and racemic structures of 
NPX and 2ADMP can be found in Table 7.4, with further details as to the hydrogen bond dimensions 
and disorder detailed in Appendix A7.2. The corresponding CIF files (6, 7) can be found on the 
accompanying CD-ROM.  
 
In the case of the enantiomerically pure multi-component material, sNPX was shown to crystallise with 
the co-former molecule in a 1:1 ratio, with the unit cell being made up from four of these motifs. 
Therefore, each asymmetric unit was deemed to consist of four molecules (Z = 4, Z’ = 2). The molecular 
components crystallised in a monoclinic P21 lattice, highlighted in Figure 7.23, and in accordance with 
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the minimal pKa difference between the API and co-former, no proton transfer was not observed. As 
such, the S-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal was shown to form. 
 








Empirical formula C20H23N3O3 C20H23N3O3 
Formula weight 353.41 353.41 
Temperature (K) 150.01(10) 150.01(10) 
Crystal system monoclinic monoclinic 
Space group P21 P21/c 
a (Å) 8.8020(3) 8.8993(5) 
b (Å) 5.65999(14) 5.7686(4) 
c (Å) 37.2977(10) 36.301(2) 
α (°) 90 90 
β (°) 95.650(2) 94.554(5) 
γ (°) 90 90 
Volume (Å3) 1849.11(9) 1857.65(19) 
Z, Z’ 4, 2 4, 1 
ρcalc (g/cm3) 1.269 1.264 
μ (mm-1) 0.087 0.699 
F(000) 752.0 752.0 
Crystal size (mm3) 0.204 × 0.051 × 0.039 0.373 × 0.095 × 0.052 
Radiation MoKα (λ = 0.71073) CuKα (λ = 1.54184) 
2Θ range for data collection (°) 5.488 to 51.36 9.778 to 140.148 
Index ranges -10 ≤ h ≤ 10, -6 ≤ k ≤ 6, -45 ≤ l ≤ 32 -7 ≤ h ≤ 10, -6 ≤ k ≤ 6, -44 ≤ l ≤ 44 
Reflections collected 11996 13562 
Independent reflections 6993 [Rint = 0.0293, Rsigma = 0.0590] 3485 [Rint = 0.0406, Rsigma = 0.0382] 
Data/restraints/parameters 6993/5/479 3485/7/251 
Goodness-of-fit on F2 1.063 1.134 
Final R indexes [I>=2σ (I)] R1 = 0.0509, wR2 = 0.0993 R1 = 0.0681, wR2 = 0.1549 
Final R indexes [all data] R1 = 0.0719, wR2 = 0.1109 R1 = 0.0856, wR2 = 0.1634 
Largest diff. peak/hole  (e Å-3) 0.14/-0.19 0.24/-0.25 




Figure 7. 23 - Crystal structure of the S-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal, highlighting (a) the unit 
cell, (b) hydrogen bonding synthon (* referring to a pseudo-inversion point) and (c) packing arrangement (sNPX in red) 
 
As with many of the 2AP derivatives, the key interaction unit between sNPX and 2ADMP consisted of 
the hydrogen bonded dimer between the API carboxylic acid and the co-former pyridine-amine groups, 
yielding the 𝑅2
2(8) synthon. However, the opposite amine and pyridine functionalities of the 
symmetrical 2ADMP molecule formed an additional ring hydrogen bond dimer, bridging between the 
two main heterosynthons. This homosynthon could also be classed as a 𝑅2
2(8)interaction, with the 
144 
 
overall interaction unit consisting of a sNPX:2ADMP:2ADMP:sNPX moiety. Whilst inversion 
symmetry was not present, the main body of the interaction unit could be described through a point of 
pseudo-inversion, with the only discrepancies arising from the atoms located about the chiral centres. 
Using these units, the macro-crystalline assembly can be constructed, whereby the zig-zagged 
interaction motifs can be stacked and connected using side-on C-H···π contacts. 
 
With changing enantiomeric contribution so as to reflect a racemic composition, no significant change 
in the co-crystalline structure was noted. As in the enantiopure form, the unit cell contained four 
molecular entities (Z = 4, Z’ = 1) consisting of NPX and 2ADMP in a 1:1 molar ratio. Each of these 
represented an asymmetric unit, whereby both enantiomers were evenly represented. As such, these 
units crystallised in a monoclinic P21/c crystalline space group.  
 
With no evidence of proton transfer, the RS-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal 
(Figure 7.24) was shown to utilise the same combination of hydrogen bonding interactions as exploited 
in the homochiral form, with two heterodimers, each specifying opposite enantiomers, being bridged 
by a homosynthonic interaction. The interaction unit could hence be described as a 
sNPX:2ADMP:2ADMP:rNPX unit, whereby the enantiomers were related through inversion symmetry. 
However, detailed in Appendix A7.2, disorder was noted, localised about the chiral centres, suggesting 
a fluidity of the enantiomeric composition throughout the structure. The structural similarities of these 
interaction units is highlighted in Figure 7.25. Further to this, the packing of the racemic interaction 
units was shown to express a great deal of similarity to that of the sNPX co-crystal, with the discrete 





Figure 7. 24 - Crystal structure of the RS-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal, highlighting (a) the 
unit cell, (b) hydrogen bonding synthon (* referring to an inversion point) and (c) packing arrangement (sNPX in red, rNPX 
in blue) 
 
The similarity between the RS-naproxen and S-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-
crystals was attributed to the favourability of the key hydrogen bonded unit responsible for holding the 
molecular entities together and allowing for limited flexibility for the overall configuration. The 
exception to this was that about the chiral centres. The interchangeability of NPX enantiomers 
highlighted the continuous nature of the chiral composition throughout the structure, confirming the 





Figure 7. 25 - An overlap of the two interaction units for both the racemic and enantiopure co-crystalline form of NPX and 





7.3 Materials of racemic and enantiopure naproxen with 2-amino-3-chloropyridine 
(2A3CP) 
 
7.3.1 Material screening 
 
2-aminochloropyridines (2ACPs) were also utilised as co-formers, where chlorine atoms were 
substituted at each of the available positions on the aromatic pyridine ring, respectively. With the aim 
to introduce a functionality that was able to contribute addition electron density and steric bulk, to 
explore their effects on the hydrogen bonding capabilities, as well as for the formation of different chiral 
crystalline materials.  
 
The molecule of 2-amino-3-chloropyridine (2A3CP) presents opportunities to influence the hydrogen 
bonding expressed from the secondary N-H bond, pointing away from the heterodimeric interaction. 
To date, only one structural form of 2A3CP (CSD reference: URAXER204) has been found, with a low 
melting point between 59-62oC. The basicity of the co-former, pKa, was shown to be 4.8 in 
water/ethanol systems at 25oC205, giving an initial indication that proton transfer with NPX was not 
likely.   
 
7.3.1.1 Mechanochemical screening 
 
Mechanochemical screening was conducted in 2:1, 1:1 and 1:2 molar stoichiometries, with minimum 
quantities of ethanol. As shown from the initial phase analysis conducted with sNPX and 2A3CP (Figure 
7.26), equimolar ground samples and that with increased amounts of the co-former both highlighted the 
formation of a novel crystalline form with respect to that of the starting materials. Given that little to 
no excess starting material was evident from these patterns, preliminary interpretations suggested the 
formation of a new homochiral multi-component phase. Subsequent comparison with the PXRD 
patterns generated using SCXRD data (see Section 7.3.2) highlighted that the same novel complex of 
sNPX and 2A3CP could be made consistently by either method.  
 
Thermal analysis confirmed the presence of a discrete phase, particularly for the sample prepared from 
a 1:1 combination. As shown in Figure 7.27, a single endothermic event was noted for this composition, 
with a melt evident between 107oC and 109oC.  
 
Likewise, the ability to prepare materials of rsNPX and 2A3CP via grinding was also shown to be 
possible, with particular emphasis on the samples made in equal molar quantities. PXRD analysis 
(Figure 7.28) indicated that a form distinct from that of the starting components could be made, with its 
DSC trace (Figure 7.29), again, emphasising the formation of a pure novel material, with only a single 
thermal phenomenon being noted. This represented a melting point at 123-125oC. As with the 
homochiral case, phase comparison between the mechanochemical sample and that of individual 






Figure 7. 26 - PXRD patterns from mechanochemically prepared samples of sNPX and 2A3CP, ground, with ethanol, in 




Figure 7. 27 - DSC traces from mechanochemically prepared samples of sNPX and 2A3CP, ground, with ethanol, in either 







Figure 7. 28 - PXRD patterns from mechanochemically prepared samples of rsNPX and 2A3CP, ground, with ethanol, in 




Figure 7. 29 - DSC traces from mechanochemically prepared samples of rsNPX and 2A3CP, ground, with ethanol, in either 





7.3.1.2 Combined evaporation & cooling crystallisation screening 
 
In parallel to the above mentioned liquid-assisted grinding experiments, single crystals were grown 
from equimolar solutions of ethanol using the previously described evaporative and cooling method. 
For both the homochiral and racemic cases, blocky needle crystals were prepared, each showing an off-
white colour when in the bulk (Figure 7.30). Upon selecting suitable individual crystals, SCXRD 
analysis was conducted, showing the unique crystalline structure of each chiral form and confirming 




Figure 7. 30 - Microscope and mounted SCXRD images of crystals yielded from 1:1 ethanol solutions of (a) sNPX and (b) 
rsNPX with 2A3CP, respectively 
 
7.3.2 Material characterisation 
 
The results of the initial mechanochemical and solution crystallisation screenings demonstrated the 
reproducibility in preparation of both the homochiral and racemic multi-component phases. The nature 
of these materials were compared and contrasted with further characterisation using PXRD, DSC, 
SCXRD and phase analysis. IR spectra were also collected for the two materials, highlighting a number 
of similarities (Appendix A7.3). 
 
7.3.2.1 Phase, thermal and spectroscopic analysis 
 
As highlighted in Figure 7.31, the novel multi-component phases showed different diffraction patterns 
to that presented by the starting materials, confirming the formation of new crystalline entities. 
However, distinct differences were noted between the patterns of the enantiopure and racemic 
complexes, indicating that upon varying the enantiomeric composition, a transition is made from one 
crystal phase to another. These observations suggested that upon combining the two respective starting 
components at racemic quantities of API, like with single-component NPX, a racemic compound was 
formed. 
 
DSC traces were taken and compared for the single and multi-component phases. As shown from Figure 
7.32, both the racemic and enantiopure complexes expressed lower melting points than those of the 
enantiomeric materials of NPX, but higher than that of 2A3CP. This suggested that whilst the 
interactions between NPX and the co-former were favourable, they were not necessarily preferential 
when compared to single-component API, in the solid state. Upon comparing the melting points of the 
homo and heterochiral multi-component forms, the phase yielded from racemic composition 
demonstrated a higher melting point (123-125oC) when compared to the phase containing a single 
enantiomer (107-109oC). This observations supported the findings made from phase analysis, 






Figure 7. 31 - PXRD patterns of the S-naproxen:2-amino-3-chloropyridine (1:1) and RS-naproxen:2-amino-3-chloropyridine 




Figure 7. 32 - DSC traces of the S-naproxen:2-amino-3-chloropyridine (1:1) and RS-naproxen:2-amino-3-chloropyridine 




Infrared spectroscopy was also carried out on mechanochemical preparations of the novel multi-
component complexes and compared to that of the starting materials (see Appendix A7.3). The spectra 
for the freshly prepared samples showed obvious differences to those of the initial components, again 
indicating the formation of novel materials with a diverse variety of interactions. However, it was also 
evident that the racemic and enantiopure complexes possessed striking similarities, suggesting that both 
solid phases have similar molecular conformations and interactions. Of particular note was that of the 
split vibrational modes of the carbonyl functional group of the API molecules, indicating the 
involvement of that moiety in several intermolecular interactions.  
 
7.3.2.2 Binary (melting point) phase diagram analysis – Classification of chiral crystalline materials 
 
Confirmation of the existence of a racemic compound upon combining NPX and 2A3CP at racemic 
quantities was obtained through the construction of a binary phase diagram. The melting points of 1:1 
mechanochemical combinations of API to co-former, where the enantiomeric composition was varied 
from racemic to enantiopure (sNPX), were taken and plotted, noting the presence of any eutectic 
phenomena. The PXRD patterns and DSC traces for each composition can be found in Appendix A7.3. 
As shown from Figure 7.33, discernible regions are observed, corresponding to regions of stability to 
melting for both the homochiral and racemic complexes, respectively. The enantiopure phase was 
shown to remain the stable solid phase only at high enantiomeric excesses (mole fraction of sNPX 
greater than 0.9), whilst the stability range of the racemic material was far greater, with this phase being 
stable to heating from racemic compositions to a 0.9 mole fraction of sNPX. In addition, consistent 
eutectic melting was also observed between 105oC and 107oC, with the key eutectic composition being 
evident at 0.9 contributions of sNPX. This culmination of phase and thermal analysis confirmed the 





Figure 7. 33 - Binary (melting) point phase diagram, with changing enantiomeric composition of rNPX and sNPX, for the 1:1 
co-crystals incorporating the co-former 2A3CP, highlighting the liquidus (Δ) and the eutectic (▲) points 
152 
 
7.3.2.3 Crystallography – Crystal structure analysis 
 
Individual crystals of both novel crystalline phases were taken from solution crystallisations and 
analysed by using SCXRD. Details of the hydrogen bonding dimensions and, where necessary, atomic 
occupancies, can be found in the Appendix A7.3. The corresponding CIF files (8, 9) can be found on 
the accompanying CD-ROM.  
 
The homochiral multi-component crystal was found to consist of sNPX and 2A3CP interacting through 
hydrogen bonding interactions in a 1:1 molar relationship. The unit cell was shown to contain two 
asymmetric units, each consisting of one API and one co-former molecule (Z = 2, Z’ = 1). As such, 
these units crystallised in a monoclinic P21 space group, a non-centrosymmetric system.   
 
As highlighted by Figure 7.34, proton transfer was not evident, showing that the combination of these 
molecular entities allowed for the formation of the S-naproxen:2-amino-3-chloropyridine (1:1) co-
crystal. The presence of the substituent chlorine atom at the three-position demonstrated no hindrance 
in hydrogen bond formation, with the API and co-former forming the 𝑅2
2(8) heterosynthon common to 
many 2AP derivatives. Further contacts, utilising a 𝐷1
1(3) interaction motif, connect these dimers, 
forming extended hydrogen bonded chains, similar to that seen in the structure of the S-naproxen:2-
aminopyridine (1:1) salt. The overall crystal structure can then be described through an arrangement of 
these expansive chains.  
 




Empirical formula C19H19N2O3Cl 
Formula weight 358.81 
Temperature (K) 150.01(10) 
Crystal system monoclinic 
Space group P21 
a (Å) 8.71920(10) 
b (Å) 6.12300(10) 
c (Å) 16.7639(2) 
α (°) 90 
β (°) 97.3880(10) 
γ (°) 90 
Volume (Å3) 887.56(2) 
Z, Z’ 2, 1 
ρcalc (g/cm3) 1.343 
μ (mm-1) 2.077 
F(000) 376.0 
Crystal size (mm3) 0.4 × 0.1 × 0.02 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection (°) 10.23 to 140.128 
Index ranges -10 ≤ h ≤ 10, -7 ≤ k ≤ 7, -14 ≤ l ≤ 20 
Reflections collected 6200 
Independent reflections 3372 [Rint = 0.0116, Rsigma = 0.0139] 
Data/restraints/parameters 3372/2/229 
Goodness-of-fit on F2 1.073 
Final R indexes [I>=2σ (I)] R1 = 0.0246, wR2 = 0.0675 
Final R indexes [all data] R1 = 0.0249, wR2 = 0.0678 
Largest diff. peak/hole  (e Å-3) 0.14/-0.21 







Figure 7. 34 - Crystal structure of the S-naproxen:2-amino-3-chloropyridine (1:1) co-crystal, highlighting (a) the unit cell, 
(b) hydrogen bonding synthon and (c) packing arrangement (sNPX in red) 
 
In the racemic case, NPX was shown to crystallise with the 2A3CP co-former in 1:1 stoichiometry, as 
part of an orthorhombic Pna21 space group. The unit cell contained four asymmetric units (Z = 4, Z’ = 
1), each consisting of one API molecule and one co-former molecule, with both enantiomeric forms 
being reflected equally. The defining parameters of unit cell and crystallographic refinement are 
highlighted in Table 7.7. Despite this system being non-centrosymmetric (like in the homochiral 
material), the presence of mirror symmetry still allows for the presence of both enantiomers within the 
structure, making it non-enantiomorphic.   
 
No proton transfer was observed, confirming the formation of a RS-naproxen:2-amino-3-chloropyridine 
(1:1) co-crystal. Here, the key interaction units utilised (Figure 7.35) the same hydrogen bonding 
interactions as seen in that of the homochiral co-crystal, i.e. the 𝑅2
2(8) dimer and 𝐷1
1(3)connecting 
chain. This was in contrast to structure observed for the racemic salt of NPX and 2AP, where a dimer 
of dimers was able to form. The structure, comparable to that of the homochiral co-crystal, indicated 
that with the introduction of the chlorine atom at the meta position, the closed hydrogen bonded 







Figure 7. 35 - Crystal structure of the RS-naproxen:2-amino-3-chloropyridine (1:1) co-crystal, highlighting (a) the unit cell, 
(b) hydrogen bonding synthon and (c) & (d) packing arrangements (sNPX in red, rsNPX in blue) 
 
By extending the hydrogen bonding interactions, chains selective to one chiral type were observed. 
These chains made up the main structure of the racemic co-crystal, with the enantiomeric homogeneity 
of these channels changing in an alternating fashion. As shown in Appendix A7.3, the racemic co-
crystal was modelled with disorder about the chiral centre of every NPX molecule, with relative 
occupancies of approximately 0.81:0.19, in terms of the S and R enantiomers. Given the non-
enantiomorphic nature of this system, this disorder was most likely averaged across the structure. With 
this disorder being consistent across all the API molecules, the chiral consistency of the individual 
hydrogen bonded chains was deemed constant, emphasising the defined enantiopurity of these 
alternating channels. 
 
The complementary intermolecular interactions exhibited by both the homo and heterochiral co-
crystalline materials supported the initial interpretation of the IR spectra. The main discrepancy between 
the two structures could be attributed to the enantiomeric composition of the individual hydrogen 
bonded channels. It can be said that due to the alternating chiral make-up of these chains in the RS-
naproxen:2-amino-3-chloropyridine (1:1) co-crystal, they can pack together with greater efficiency than 
that observed in the enantiopure co-crystal. This was reflected by the higher structure density calculated 
from SCXRD for the racemic multi-component form, i.e. 1.343 g/cm3 and 1.360 g/cm3. As such, this 










Empirical formula C19H19ClN2O3 
Formula weight 358.81 
Temperature (K) 149.9(4) 
Crystal system orthorhombic 
Space group Pna21 
a (Å) 16.2100(5) 
b (Å) 17.3936(5) 
c (Å) 6.2135(2) 
α (°) 90 
β (°) 90 
γ (°) 90 
Volume (Å3) 1751.91(9) 
Z, Z’ 4, 1 
ρcalc (g/cm3) 1.360 
μ (mm-1) 2.105 
F(000) 752.0 
Crystal size (mm3) 0.58 × 0.076 × 0.032 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection (°) 7.454 to 177.238 
Index ranges -21 ≤ h ≤ 21, -19 ≤ k ≤ 19, -5 ≤ l ≤ 7 
Reflections collected 9587 
Independent reflections 2673 [Rint = 0.0405, Rsigma = 0.0332] 
Data/restraints/parameters 2673/8/240 
Goodness-of-fit on F2 1.132 
Final R indexes [I>=2σ (I)] R1 = 0.0563, wR2 = 0.1415 
Final R indexes [all data] R1 = 0.0581, wR2 = 0.1427 
Largest diff. peak/hole  (e Å-3) 0.22/-0.24 








7.4 Materials of racemic and enantiopure naproxen with 2-amino-4-chloropyridine 
(2A4CP) 
 
7.4.1 Material screening 
 
Different enantiomeric compositions of NPX were also screened with the co-former 2-amino-4-
chloropyridine (2A4CP), an isomer of 2A3CP. To date, no crystalline structures of 2A4CP have been 
submitted to the CSD, so the number of polymorphic forms is currently unknown. As such, the reference 
PXRD pattern for 2A4CP was taken directly from that of the starting material, as well as the melting 
point, taken as 129-131oC. In addition, no pKa data could be found from the literature, but owing to the 
combined electron donating ability of the chlorine atom combined with its positioning with respect to 
aromatic nitrogen, it can be anticipated that this co-former expresses increased basicity with respect to 
that of its 2A3CP relative. Therefore, salt formation may be possible.  
 
7.4.1.1 Mechanochemical screening 
 
Figure 7.36 shows the PXRD patterns taken from mechanochemically prepared samples of sNPX with 
2A4CP. Whilst it was event that novel phases were prepared via this method, with respect to the starting 
materials, the phases formed from the 1:1 and 1:2 combinations do not reflect the findings from the 
subsequent solution-based crystallisations (see Section 2.4.2). Further liquid-assisted grindings were 
conducted using a range of different solvents (shown in Appendix A7.4) to explore the potential of 
mechanochemistry to produce the phases seen from cooling. It was highlighted that whilst neat grinding 
yielded a physical mixture, preparations utilising either methanol, isopropanol, acetonitrile or ethyl 
acetate demonstrated the reproducible formation of the original phase found from the initial screening 
experiments with ethanol. Samples made with toluene and hexane showed a physical mixture of both 
the forms produced, thus far, exclusively through mechanochemical means and that of the phase 
produced from solution. This emphasised that for certain systems, solvent could play a significant role 
in the mechanochemical processing. 
 
DSC analysis (Figure 7.37) of the initial samples confirmed the formation of a unique material at the 
1:1 stoichiometry, with its thermal trace highlighting only one endothermic event, occurring between 
92oC and 96oC. Thermal analysis of further mechanochemical preparations with methanol, ethanol, 
isopropanol, acetonitrile and ethyl acetate showed consistency in this melting, whilst the case with 
toluene showed two consecutive melts, one at 89-92oC and another 95-96oC. These can be attributed to 
heating-assisted complexation and subsequent melting of a distinct phase. 
 
In contrast, ground preparations of racemic API with the co-former were shown to produce a novel 
phase at 1:1 compositions. In addition, consistency was shown to be possible between the materials 
made through mechanochemical methods to that made by solution cooling crystallisation (Figure 7.38). 
As well as this, the DSC trace, shown in Figure 7.39, showed a clear single endothermic event, occurring 






Figure 7. 36 - PXRD patterns from mechanochemically prepared samples of sNPX and 2A4CP, ground, with ethanol, in 




Figure 7. 37 - DSC traces from mechanochemically prepared samples of sNPX and 2A4CP, ground, with ethanol, in either 








Figure 7. 38 - PXRD patterns from mechanochemically prepared samples of rsNPX and 2A4CP, ground, with ethanol, in 




Figure 7. 39 - DSC traces from mechanochemically prepared samples of rsNPX and 2A4CP, ground, with ethanol, in either 





7.4.1.2 Combined evaporation & cooling crystallisation screening 
 
Single crystals were prepared from ethanol solutions, with varying stoichiometries and enantiomeric 
compositions, and were viewed under a microscope (Figure 7.40). Long thin needle agglomerates were 
shown to form for 1:1 solutions of sNPX and 2A4CP, whilst non-uniform elongated planks were yielded 
from racemic preparations. As determined from SCXRD characterisation, the crystals from the 
homochiral sample generated a material that was different to that made via grinding. Despite using 
small amounts of mechanochemical sample as a seed to force the nucleation and growth of the desired 
form, the crystals selected and assessed were shown to only be that of the initial material made without 
seeding. This was later shown to correspond to a (1:1) homochiral salt. To date, efforts are continuing 




Figure 7. 40 - Microscope and mounted SCXRD images of crystals yielded from 1:1 ethanol solutions of (a) sNPX and (b) 
rsNPX with 2A4CP, respectively 
 
7.4.2 Material characterisation 
 
7.4.2.1 Phase, thermal and spectroscopic analysis 
 
By using mechanochemical and solution crystallisation techniques, novel materials of either sNPX or 
rsNPX with 2A4CP were prepared. Figure 7.41 shows the PXRD patterns taken either from subsequent 
simulations produced via structure determination or directly from analysis of mechanochemically 
prepared samples. The patterns of the newly discovered phases emphasise the production of different 
crystalline forms and, with particular significance when assessing the racemic and homochiral materials 
prepared via grinding, this provided the first indication that with multi-component material formation, 
a racemic compound was produced.  
 
This was supported by comparing the melting points of the mechanochemically prepared samples at the 
racemic and enantiopure combinations (Figure 7.42). The transition from a solid to the molten state for 
the homochiral phase (92-96oC) was lower than that for the racemic (102-104oC), suggesting that the 
interactions exhibited when both chiral forms of NPX were present was greater than when only one 
form was present, again highlighting the formation of a racemic compound.  
 
IR spectroscopic analysis of the ground samples (Appendix A7.4) showed different carbonyl vibrational 
modes, respectively, suggesting that the interactions exploited between these two materials utilise a 





Figure 7. 41 - PXRD patterns of the S-naproxen:2-amino-4-chloropyridine co-crystal (prepared mechanochemically), as well 
as its stoichiometric (2:1) salt, and RS-naproxen:2-amino-4-chloropyridine (1:1) co-crystal, as derived from SCXRD, 




Figure 7. 42 - DSC traces of the S-naproxen:2-amino-4-chloropyridine (prepared mechanochemically) and RS-naproxen:2-




7.4.2.2 Binary (melting point) phase diagram analysis – Classification of chiral crystalline materials 
 
Further phase analysis was carried out so as to confirm the relationship between homo and heterochiral 
phases generated via mechanochemical means. Data collected from DSC and PXRD analysis (see 
Appendix A7.4) was used to construct the diagram shown in Figure 7.43. As shown, towards racemic 
compositions a different solid-state material showed thermal stability compared to that towards 
enantiopure. Recognition of the characteristic racemic region, coupled with the presence of eutectic 




Figure 7. 43 - Binary (melting) point phase diagram, with changing enantiomeric composition of rNPX and sNPX, for the 1:1 
co-crystals incorporating the co-former 2A4CP, highlighting the liquidus (Δ) and the eutectic (▲) points 
 
7.4.2.3 Crystallography – Crystal structure analysis 
 
For detailed crystallographic data for the structures containing 2A4CP, see Appendix A7.4. The 
corresponding CIF files (10, 11) can be found on the accompanying CD-ROM.  
 
Despite not representing the material made through direct grinding of sNPX and 2A4CP, crystals 
obtained from initial crash cooling crystallisations were investigated so as to confirm their crystalline 
structure. As shown in Figure 7.44, two molecular units of sNPX were able to interact with the co-
former in a 2:1 molar ratio, with these motifs making up the asymmetric units of the unit cell (Z = 2, Z’ 
= 1). The details of the unit cell, as well as further refinement parameters, can be found in Table 7.8. 
Hence, the molecules were shown to crystallise in a monoclinic P21 space group, a non-centrosymmetric 
system. 
 
The key interaction unit consisted of the classic 𝑅2
2(8)dimer motif, between one API molecule and a 
co-former molecule. It was noted that proton transfer had occurred, resulting in charge assisted 
hydrogen bonding interactions. Further contacts were utilised, connecting individual dimers through a 
𝐷1
1(3) motif, forming an extended chain, similar to that seen in the homochiral structure with 2A3CP. 
162 
 
However, a secondary sNPX molecule was shown to coordinate to the deprotonated oxygen atom of the 
original sNPX moiety, forming another 𝐷1
1(3) interaction. For this contact, no further proton transition 
took place. The overall assembly of the S-naproxen:2-amino-4-chloropyridine (2:1) salt was generated 
through a collection of these extended enantiopure chains. The presence of the chlorine atom at the para 
position presented no steric hindrance to hydrogen bond formation, but in this case, aided in the creation 




Figure 7. 44 - Crystal structure of the S-naproxen:2-amino-4-chloropyridine (2:1) salt, highlighting (a) the unit cell, (b) 









Empirical formula C33H33ClN2O6 
Formula weight 589.06 
Temperature (K) 150.01(10) 
Crystal system monoclinic 
Space group P21 
a (Å) 16.2086(15) 
b (Å) 5.4036(5) 
c (Å) 17.029(2) 
α (°) 90 
β (°) 95.882(10) 
γ (°) 90 
Volume (Å3) 1483.6(3) 
Z, Z’ 2, 1 
ρcalc (g/cm3) 1.319 
μ (mm-1) 0.177 
F(000) 620.0 
Crystal size (mm3) 0.221 × 0.098 × 0.042 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 5.37 to 51.362 
Index ranges -19 ≤ h ≤ 18, -6 ≤ k ≤ 6, -20 ≤ l ≤ 17 
Reflections collected 10522 
Independent reflections 5608 [Rint = 0.0388, Rsigma = 0.0714] 
Data/restraints/parameters 5608/314/387 
Goodness-of-fit on F2 1.030 
Final R indexes [I>=2σ (I)] R1 = 0.0755, wR2 = 0.1821 
Final R indexes [all data] R1 = 0.0978, wR2 = 0.2021 
Largest diff. peak/hole  (e Å-3) 0.99/-0.31 
Flack parameter 0.04(5) 
 
For the material prepared both mechanochemically and from solution crystallisation at racemic 
quantities, NPX was shown to crystallise in a 1:1 stoichiometry with 2A4CP in a centrosymmetric 𝑃1̅ 
triclinic space group. The asymmetric units within the unit cell (Z = 2, Z’ = 1) consisted of one molecule 
of the API and one molecule of the co-former, with both enantiomers being accounted for. The 
arrangement of the molecules within this system are shown in Figure 7.45., with the parameters defining 
the unit cell and crystallographic refinements detailed in Table 7.8. 
 
In this case, no proton transfer was exhibited, meaning that a RS-naproxen:2-amino-4-chloropyridine 
(1:1) co-crystal had formed. As with the racemic structure exhibited between NPX and 2AP, the key 
interaction unit consisted of the dimerisation (𝑅4
2(8)) of the main heterodimer (𝑅2
2(8)), incorporating 
an inversion operation to account for both enantiomers. These zig-zagged units can be stacked in order 
to build up the whole crystal lattice, forming channels of a given enantiomeric form.  
 
To date, no single crystals have been grown that represent that of the enantiopure multi-component 
phase first prepared via grinding. Despite this, upon comparison with racemic phase and the 
observations made from spectroscopic techniques, it could be suggested that this unknown phase is co-







Figure 7. 45 - Crystal structure of the RS-naproxen:2-amino-4-chloropyridine (1:1) co-crystal, highlighting (a) the unit cell, 
(b) hydrogen bonding synthon and (c) packing arrangement (sNPX in red, rNPX in blue) 
 





Empirical formula C19H19ClN2O3 
Formula weight 358.81 
Temperature (K) 150.0(4) 
Crystal system triclinic 
Space group P1̅ 
a (Å) 5.4593(4) 
b (Å) 10.9119(9) 
c (Å) 14.7360(7) 
α (°) 80.310(5) 
β (°) 86.609(5) 
γ (°) 80.965(6) 
Volume (Å3) 854.10(10) 
Z, Z’ 2, 1 
ρcalc (g/cm3) 1.395 
μ (mm-1) 0.245 
F(000) 376.0 
Crystal size (mm3) 0.287 × 0.104 × 0.068 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 7.29 to 50.7 
Index ranges -6 ≤ h ≤ 6, -13 ≤ k ≤ 10, -17 ≤ l ≤ 17 
Reflections collected 5589 
Independent reflections 3121 [Rint = 0.0263, Rsigma = 0.0556] 
Data/restraints/parameters 3121/1/232 
Goodness-of-fit on F2 1.049 
Final R indexes [I>=2σ (I)] R1 = 0.0476, wR2 = 0.1002 
Final R indexes [all data] R1 = 0.0739, wR2 = 0.1123 
Largest diff. peak/hole  (e Å-3) 0.25/-0.23 
Flack parameter N/A 
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7.5 Materials of racemic and enantiopure naproxen with 2-amino-5-chloropyridine 
(2A5CP) 
 
7.5.1 Material screening 
 
The co-former 2-amino-5-chloropyridine (2A5CP) exhibits its chlorine atom meta to the pyridine 
functionality, making its electron donating contributions similar to that of 2A3CP. Searches of the CSD 
have highlighted only one polymorph (CSD reference: AMCLPY12206), an off-white solid, with a 
melting point between 135oC and 136oC. Further to this, its pKa has been estimated to be approximately 
4.7, highlighting weak basicity and the likelihood of co-crystal formation with NPX.  
 
7.5.1.1 Mechanochemical screening 
 
Enantiopure samples of NPX and 2A5CP, prepared mechanochemically with minimum quantities of 
ethanol, were assessed using PXRD, the patterns of which are shown in Figure 7.46. With particular 
emphasis on the patterns generated from analysis of the 1:1 and 1:2 API to co-former preparations, the 
diffraction data demonstrated the formation of a novel crystalline phase, distinct from that of the starting 
materials. Comparison with the simulated PXRD pattern generated from subsequent SCXRD analysis 
of crystals obtained from solution crystallisation (see section 7.5.2) demonstrated the reproducibility of 
the enantiopure multi-component phase over the different methods. The DSC trace for this combination, 
shown in Figure 7.47, stressed the formation of a new phase, highlighting the presence of a single 
endothermic peak at 89-91oC.  
 
As with the homochiral case, samples were also made via grinding consisting of the racemic 
combination of API and the co-former. Depicted in Figure 7.48, PXRD analysis showed the formation 
of a distinct crystalline phase across all three stoichiometric combinations. For the 2:1 and 1:2 
preparations, the unknown phase was found to be in a physical mixture with excess starting material. 
The consistency in preparation of this racemic multi-component phase across the preparation techniques 
was highlighted by the concurrency of diffraction patterns generated for the mechanochemical and 
cooling crystallisation samples. Thermal analysis, shown in Figure 7.49, confirmed the existence of a 







Figure 7. 46 - PXRD patterns from mechanochemically prepared samples of sNPX and 2A5CP, ground, with ethanol, in 




Figure 7. 47 - DSC traces from mechanochemically prepared samples of sNPX and 2A5CP, ground, with ethanol, in either 






Figure 7. 48 - PXRD patterns from mechanochemically prepared samples of rsNPX and 2A5CP, ground, with ethanol, in 




Figure 7. 49 - DSC traces from mechanochemically prepared samples of sNPX and 2A5CP, ground, with ethanol, in either 





7.5.1.2 Combined evaporation & cooling crystallisation screening 
 
Individual crystals were grown via the combined evaporative and crash cooling method, from solutions 
of ethanol, with the three defined stoichiometries of NPX to co-former (2:1, 1:1 and 1:2), for both 
racemic and enantiopure compositions of the API. Figure 7.50 shows the crystals formed from 1:2 
solutions of sNPX and rsNPX with 2A5CP, respectively. The crystals in both cases were shown to be 
off-white in colour and displayed long thin plate-like morphologies. It should be noted that for both 
crystallisations, the individual crystallites formed agglomerates. In addition, the shapes of the racemic 
multi-component crystals were far less uniform compared to its enantiopure counterpart. Single crystals 
were selected from each preparation and mounted for a diffractometer so as to ascertain their crystalline 





Figure 7. 50 - Microscope and mounted SCXRD images of crystals yielded from 1:2 ethanol solutions of (a) sNPX and (b) 
rsNPX with 2A5CP, respectively 
 
7.5.2 Material characterisation 
 
7.5.2.1 Phase, thermal and spectroscopic analysis 
 
Upon combining either rsNPX or sNPX with the co-former, 2A5CP, mechanochemically or via solution 
crystallisation, novel crystalline phases were prepared. Figure 7.51 shows the simulated PXRD patterns 
of these multi-component phases, also showing that these phases differ from each other, demonstrating 
that by varying the enantiomeric composition from racemic to enantiopure, maintaining the required 
stoichiometry of API to co-former, a transition occurs. The presence of a unique phase at racemic 
compositions indicates that upon complexation with this given co-former, a racemic compound chiral 
crystalline system can be formed. 
 
Comparison of the thermal traces of these materials suggested the existence of a racemic compound. 
Outlined in Figure 7.52, the melting points of both the homo and heterochiral materials were shown to 
be lower than that of the respective starting components, with the racemic form displaying a higher 
melting point (103-105oC) than the homochiral phase (89-91oC). For the structure using both 
enantiomeric forms of NPX, along with 2A5CP, greater stability can be achieved when compared to 







Figure 7. 51 - PXRD patterns of the S-naproxen and RS-naproxen:2-amino-5-chloropyridine (1:1) co-crystals, as derived 




Figure 7. 52 - DSC traces of the S-naproxen and RS-naproxen:2-amino-5-chloropyridine (1:1) co-crystals, compared to that 




Based upon data obtained from IR spectroscopy (for the spectra, see Appendix A7.5), it was shown that 
each of the novel chiral materials utilised similar intermolecular interactions, but with some subtle 
differences. With a focus on the carbonyl functionality, both phases exhibited a main vibrational mode 
at 1737 cm-1 with a shoulder at a slightly lower wavenumber. This would suggest that the carbonyl 
group formed a constituent part of two different hydrogen bonding interactions for both multi-
component forms. Upon closer examination of the spectra for the homochiral material, the broad peak 
unique to this phase at 2430 cm-1 was noted and attributed to the amine group undergoing hydrogen 
bonding interactions in the solid state. The presence of this phenomenon exclusively for the enantiopure 
form suggested that one of the amine N-H bonds forms a more flexible contact than when compared to 
that of the racemic material. These observations provided further evidence that two distinct phases exist, 
collectively resulting in a racemic compound system. 
 
7.5.2.2 Binary (melting point) phase diagram analysis – Classification of chiral crystalline materials 
 
A culmination of the phase and thermal analysis for the system incorporating both NPX and 2A5CP can 
be described using the binary (melting point) phase diagram shown in Figure 7.53. The corresponding 
DSC and PXRD data can be found in Appendix A7.5. Upon transitioning from racemic to enantiopure 
compositions, clear regions were evident, emphasising the stability of the homo and heterochiral phases, 
respectively. In addition, eutectic melting was also observed at 87-89oC. The combined evidence of the 
distinct phases, higher racemic material melting and the existence of eutectic events upon changes in 




Figure 7. 53 - Binary (melting) point phase diagram, with changing enantiomeric composition of rNPX and sNPX, for the 1:1 





7.5.2.3 Crystallography – Crystal structure analysis 
 
The crystal structures for the multi-component materials were determined from the X-ray diffraction 
patterns of single crystals taken from the respective racemic and enantiopure solutions. Visual 
representations of the key structural and interaction units for the materials utilising either sNPX or 
rsNPX with the co-former, can be found in Figures 7.54 and 7.55, respectively. The unit cell and 
refinement parameters in each case are outlined in Tables 7.10 and 7.11. Further information, including 
details of the hydrogen bond dimensions, can be found in Appendix A7.5. The corresponding CIF files 
(12, 13) can be found on the accompanying CD-ROM.  
 
Crystals prepared from enantiopure solutions showed a 1:1 arrangement of sNPX to 2A5CP molecules, 
with this unit constituting the asymmetric unit (Z = 2, Z’ = 1). From this, the molecular entities were 
shown to crystallise in the non-centrosymmetric monoclinic P21 space group. No proton transfer was 




Figure 7. 54 - Crystal structure of the S-naproxen:2-amino-5-chloropyridine (1:1) co-crystal, highlighting (a) the unit cell, 
(b) hydrogen bonding synthon and (c) packing arrangement (sNPX in red) 
 
The key interaction motif between the sNPX and 2A5CP molecules was the hydrogen bonded 
heterodimer, whereby the hydrogen bond donors were represented by the amine and hydroxyl 
functionalities, and the acceptors by the carbonyl and pyridine groups. Collectively, this dimer could 
be defined as a 𝑅2
2(8) synthon. These dimerised units were further connected to other dimers through 
an additional single hydrogen bond interaction between the secondary amine donor and the carbonyl 
group on an adjacent API molecule. This synthon can be described in terms of a 𝐷1
1(3) contact. 
Resultant chains were built up in parallel so as to generate the overall crystalline assembly of this S-
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naproxen:2-amino-5-chloropyridine (1:1) co-crystal. This material was structurally akin to that of the 
homochiral multi-component phases incorporating the co-formers 2AP and 2A3CP.  
 




Empirical formula C19H19ClN2O3 
Formula weight 358.81 
Temperature (K) 150.00(10) 
Crystal system monoclinic 
Space group P21 
a (Å) 9.05850(10) 
b (Å) 5.92910(10) 
c (Å) 16.7511(2) 
α (°) 90 
β (°) 90.4220(10) 
γ (°) 90 
Volume (Å3) 899.66(2) 
Z, Z’ 2, 1 
ρcalc (g/cm3) 1.325 
μ (mm-1) 2.049 
F(000) 376.0 
Crystal size (mm3) 0.476 × 0.115 × 0.062 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection (°) 5.276 to 144.242 
Index ranges -6 ≤ h ≤ 11, -7 ≤ k ≤ 7, -20 ≤ l ≤ 20 
Reflections collected 10457 
Independent reflections 3563 [Rint = 0.0243, Rsigma = 0.0187] 
Data/restraints/parameters 3563/2/232 
Goodness-of-fit on F2 1.037 
Final R indexes [I>=2σ (I)] R1 = 0.0318, wR2 = 0.0861 
Final R indexes [all data] R1 = 0.0319, wR2 = 0.0863 
Largest diff. peak/hole  (e Å-3) 0.15/-0.23 
Flack parameter 0.002(12) 
 
Upon changing crystallisation medium to reflect that of a racemic composition, individual molecules 
of the API, of both chiralities respectively, were shown to precipitate with the 2A5CP co-former in a 
1:1 molar ratio in monoclinic P21/c space group, a centrosymmetric system. With each asymmetric unit 
consisting of one molecule of the respective component materials, four units could be packed into the 
unit cell (Z = 4, Z’ = 1) with the individual chiral forms being accounted for. As with the enantiopure 
form, no proton transfer was noted, allowing for this phase to be described as a RS-naproxen:2-amino-
5-chloropyridine (1:1) co-crystal.  
 
The racemic phase was shown to form a key interaction unit that utilised a combination of two 𝑅2
2(8) 
heterodimers between the NPX and 2A5CP molecules, each exploiting a different enantiomer. These 
units were held together through subsequent 𝐷1
1(3) contacts, allowing for the formation of a 𝑅4
2(8) ring, 
resulting in dimer of dimers common to several racemic forms with 2AP derivatives. This supports the 
findings of the IR spectroscopic analysis. The overall structure can then be constructed through the 
stacking of these core interaction units. This assembly is fundamentally related to that exhibited for the 
racemic salt form of NPX and 2AP, but differs from that observed for 2A3CP.  
 
As confirmed by the crystallographic structures outlined above, two distinct phases can be generated at 
racemic and enantiopure compositions of NPX with the co-former 2A5CP, respectively. The structures 
exhibited are structurally alike to those found upon combining the API with 2AP, indicating that the 
positioning of the chlorine atom, meta to the pyridine group and para to that of the amine group does 
not hinder hydrogen bond formation, allowing for these specific interactions to form. However, as 
demonstrated from DSC analysis, the melting point of the racemic phase was higher than that of the 
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homochiral co-crystal. This was in contrast to the observations made for the 2AP salts. By adding the 
halogen atom to the co-former molecule at this given position, the packing efficiency of the racemic 
material is enhanced (calculated packing density of the homochiral co-crystal, 1.325 g/cm3, and that of 
the racemic co-crystal, 1.376 g/cm3), aiding in its stabilisation relative to the S-naproxen:2-amino-5-




Figure 7. 55 - Crystal structure of the RS-naproxen:2-amino-5-chloropyridine (1:1) co-crystal, highlighting (a) the unit cell, 










Empirical formula C19H19ClN2O3 
Formula weight 358.81 
Temperature (K) 149.9(4) 
Crystal system monoclinic 
Space group P21/c 
a (Å) 17.6584(8) 
b (Å) 5.7923(2) 
c (Å) 17.9151(7) 
α (°) 90 
β (°) 109.095(5) 
γ (°) 90 
Volume (Å3) 1731.58(13) 
Z, Z’ 4, 1 
ρcalc (g/cm3) 1.376 
μ (mm-1) 2.130 
F(000) 752.0 
Crystal size (mm3) 0.191 × 0.095 × 0.037 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection (°) 10.052 to 144.214 
Index ranges -17 ≤ h ≤ 21, -7 ≤ k ≤ 6, -19 ≤ l ≤ 22 
Reflections collected 10109 
Independent reflections 3395 [Rint = 0.0343, Rsigma = 0.0360] 
Data/restraints/parameters 3395/0/232 
Goodness-of-fit on F2 1.123 
Final R indexes [I>=2σ (I)] R1 = 0.0560, wR2 = 0.1482 
Final R indexes [all data] R1 = 0.0676, wR2 = 0.1576 
Largest diff. peak/hole  (e Å-3) 0.61/-0.49 





7.6 Materials of racemic and enantiopure naproxen with 2-amino-6-chloropyridine 
(2A6CP) 
 
7.6.1 Material screening 
 
The final chlorine derivative of 2AP to be used in the screening for novel multi-component materials 
with NPX was that of 2-amino-6-chloropyridine (2A6CP). Searches of the CSD highlighted only one 
known structure of this co-former (CSD reference: XONQAU207), exhibiting a melting point between 
69oC and 71oC. pKa data could not be found, but salt formation was deemed unlikely. 
 
7.6.1.1 Mechanochemical screening 
 
Upon grinding enantiopure compositions of the API with the co-former, in a variety of different 
stoichiometries, incorporating minimum quantities of ethanol as a mediating solvent, it was shown that 
a novel phase could be prepared. As shown from the PXRD patterns in Figure 7.56, each preparation 
demonstrated diffraction intensities unique from those of the starting materials, with particular emphasis 
on the sample made from equimolar contributions of sNPX and 2A6CP. In each case, excess starting 
material was noted, with this being the least evident for the 1:1 sample. Comparison of the material 
made mechanochemically with that crystallised from solution highlighted distinctly similar patterns, 
emphasising the transferability of the preparation of this homochiral complex.  
 
Thermal analysis, conducted via DSC and shown in Figure 7.57, showed an initial melt and 
recrystallisation (exhibited through an endothermic and subsequent exothermic process), followed by a 
major endotherm observed at 100-103oC. This phenomenon was particularly evident for the 1:1 
preparation, again showing the ability of mechanochemistry to allow for the screening of novel 
materials.  
 
In contrast, mechanochemistry with ethanol was shown to not yield any new phases with respect to the 
raw starting components. Figure 7.58 shows the PXRD patterns for the ground samples of racemic NPX 
with the co-former, 2A6CP. Across the three stoichiometries used, no new peaks were accounted for 
that did not correspond to either of the starting components. The thermal traces taken for these 
preparations, depicted in Figure 7.59, each showed an initial endothermic event between 47oC and 55oC, 
followed by a series of minor thermal phenomena. First interpretations could attribute these to an initial 
melt of the co-former, followed by melting of excess NPX. In the case of the 1:2 preparation, an 
additional small endotherm was noted at 82-87oC. 
 
Further 1:1 mechanochemical preparations of rsNPX and 2A6CP were made using not only ethanol, but 
also isopropanol and acetonitrile. The PXRD and DSC traces for these samples can be found in 
Appendix A7.6. As for the original ground materials, the samples made showed a great deal of similarity 
to that of the starting materials. However, assessment of the PXRD pattern of that utilising isopropanol 
demonstrated extra peaks, with a significantly intense peak at 19.5o. The thermal traces of the samples 
made with the assistance of isopropanol and acetonitrile both showed a more significant 
recrystallisation phenomenon, followed by a minor then a major event, between 74-79oC and 84-89oC 
respectively. This gave an indication that with the aid of heating, a new phase had the potential to 
precipitate from the melt.  
 
Overall for the mechanochemical screenings utilising racemic compositions of NPX, no direct evidence 
of the formation of a novel multi-component materials was evident, though this could have dependence 
upon the solvent environment used. This could indicate that at racemic combinations, complexation 






Figure 7. 56 - PXRD patterns from mechanochemically prepared samples of sNPX and 2A6CP, ground, with ethanol, in 




Figure 7. 57 - DSC traces from mechanochemically prepared samples of sNPX and 2A6CP, ground, with ethanol, in either 







Figure 7. 58 - PXRD patterns from mechanochemically prepared samples of rsNPX and 2A6CP, ground, with ethanol, in 




Figure 7. 59 - DSC traces from mechanochemically prepared samples of rsNPX and 2A5CP, ground, with ethanol, in either 





7.6.1.2 Combined evaporation & cooling crystallisation screening 
 
Single crystals were grown from homochiral solutions of sNPX and 2A6CP, in a range of 
stoichiometries and solvent environments. The crystals used for diffraction studies of the enantiopure 
multi-component phase were taken from ethanol solutions, with a 1:1 molar ratio of API to co-former, 
and were shown to correspond to the same material generated via mechanochemistry. The individual 





Figure 7. 60 - Microscope and mounted SCXRD images of crystals yielded from 1:1 ethanol solutions of sNPX with 2A6CP 
 
Whilst a multitude of cooling crystallisation samples were prepared in the racemic case, utilising 
ethanol, isopropanol and acetonitrile, again varying a number of stoichiometric and environmental 
parameters, to date all crystals screened via SCXRD were shown to be products from the 
recrystallisation of starting material.  
 
7.6.2 Material characterisation 
 
7.6.2.1 Phase, thermal and spectroscopic analysis 
 
As highlighted from the mechanochemical and solution crystallisation screening, a novel multi-
component phase could be prepared via both methods when the chiral composition tends towards 
enantiopure. This was not the case at racemic quantities. The simulated PXRD and thermal analysis of 
the homochiral phase along with those of the starting materials are shown in Appendix A7.6. The 
combined phase of sNPX and 2A6CP demonstrated a discrete crystalline phase from that of the starting 
materials, whereby the transition from solid to liquid could be made at 84-89oC. This was midway 
between the corresponding melting points of the two starting materials, suggesting a stabilisation of the 
intermolecular interactions in the solid state with respect the co-former and a destabilisation compared 
to the NPX.  
 
Whilst no direct evidence of complexation between racemic contributions of the API with the co-former 
were observed, there were some indications that it was possible. Undefined thermal phenomena from 
the DSC traces taken from the mechanochemical preparations made with isopropanol and acetonitrile 





7.6.2.2 Binary (melting point) phase diagram analysis – Classification of chiral crystalline materials 
 
Due to the lack of distinction between the potential novel multi-component materials using the grinding 
preparation technique, a binary phase diagram could not be directly made for this system. However, as 
shown from the DSC traces in Figure 7.61, as the enantiomeric contributions shift toward racemic, the 
position of the melting endotherms shift gradually towards lower temperatures, though this trails off at 
compositions of sNPX below 70%. This could give an indication of the formation of a racemic 




Figure 7. 61 - DSC traces, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystal of NPX and 
2A6CP, with increasing molar contributions of sNPX, prepared mechanochemically with ethanol 
 
7.6.2.3 Crystallography – Crystal structure analysis 
 
Individual crystals were taken from the 1:1 enantiopure solutions of NPX and 2A6CP and the crystalline 
structure for the co-crystalline material was determined via SCXRD. The corresponding CIF file (14) 
can be found on the accompanying CD-ROM. The structure of this homochiral phase, along with the 
key hydrogen bonding interactions, are shown in Figure 7.62, with the defining interaction dimensions 
found in Appendix A7.6. The unit cell parameters are shown in Figure 7.12.  
 
The molecules of sNPX were shown to crystallise with the co-former in a 1:1 relationship in an 
orthorhombic P212121 space group. The asymmetric unit was shown to be made up from the respective 
molecules, with four units occupying the unit cell (Z = 4, Z’ = 1). Having demonstrated no proton 
transfer, this system could be described as a S-naproxen:2-amino-6-chloropyridine (1:1) co-crystal. 
 
The co-crystal exhibited the same key interaction unit common to many of the NPX-2AP derivative 
homochiral multi-component materials, that of the 𝑅2
2(8) heterodimer. The synthon acted through the 
carboxylic acid group of the API and the combined amine and pyridine functionalities of the co-former. 
These dimers were then used to form the backbone of an extended chain, whereby each co-former was 
connected through a further 𝐷1
1(3) hydrogen bond, acting between the carboxyl acceptor and the second 
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amine interaction, from sNPX and 2A6CP, respectively. These chains extend to form elongated channels 
that can be packed together to form the overall crystalline lattice. This configuration again shows 




Figure 7. 62 - Crystal structure of the S-naproxen:2-amino-6-chloropyridine (1:1) co-crystal, highlighting (a) the unit cell, 
(b) hydrogen bonding synthon and (c) packing arrangement (sNPX in red) 
 





Empirical formula C19H19ClN2O3 
Formula weight 358.81 
Temperature (K) 150.00(10) 
Crystal system orthorhombic 
Space group P212121 
a (Å) 5.71330(10) 
b (Å) 8.4990(2) 
c (Å) 37.3574(8) 
α (°) 90 
β (°) 90 
γ (°) 90 
Volume (Å3) 1813.98(7) 
Z 4, 1 
ρcalc (g/cm3) 1.314 
μ (mm-1) 2.033 
F(000) 752.0 
Crystal size (mm3) 0.211 × 0.121 × 0.069 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection (°) 9.47 to 140.098 
Index ranges -5 ≤ h ≤ 6, -9 ≤ k ≤ 10, -39 ≤ l ≤ 45 
Reflections collected 6628 
Independent reflections 3435 [Rint = 0.0199, Rsigma = 0.0266] 
Data/restraints/parameters 3435/0/232 
Goodness-of-fit on F2 1.191 
Final R indexes [I>=2σ (I)] R1 = 0.0377, wR2 = 0.0917 
Final R indexes [all data] R1 = 0.0399, wR2 = 0.0926 
Largest diff. peak/hole  (e Å-3) 0.23/-0.23 
Flack parameter 0.012(8) 
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To date and despite extensive screening, no crystalline structures have been found for an equivalent 
racemic phase. These initial findings suggested an agreement with those found from mechanochemical 
screenings. As shown above, the location of the chlorine atom at the six-position did not hinder 
formation of the conventional elongated channels observed in many of the enantiopure forms of NPX 
with a 2AP derivative. The methyl group, key to defining the chirality for a given API molecule, faced 
away from the halogen atom of the interacting co-former, indicating that steric hindrances were 
minimised when a single enantiomeric form was present. Whilst no racemic structures were found, the 
most likely form was thought to resemble that of the racemic form with 2A3CP, with the overall 
structure forming from concurrent channels of these chains, each channel alternating in terms of its 
chirality. 
 
Upon changing the composition to that of racemic, no structure correlating to the expected double dimer 
was observed. This could again be explained through the positioning of the chlorine atom relative to 
other functional groups and neighbouring atoms within the structure. The dimerised dimer synthon, 
seen in many racemic structures with 2AP derivatives (2AP, 2A4CP and 2A5CP), was used as a main 
building block, through which the collective crystalline assembly could be constructed. As such, these 
units can be offset to each other and stacked. By introducing the chlorine atom at the ortho position to 
the pyridine functionality, steric stress between the halogen atom and a neighbouring NPX molecule 




Figure 7. 63 - Visual representation of the hypothetical dimer of dimer structure formed between racemic NPX and 2A6CP, 
highlighting the possible steric hindrance between the key interaction motifs   
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7.7 Summary, conclusions and future work 
 
Throughout this chapter, the API naproxen (NPX) has been screened with a range of potential co-
formers using a combined preparation approach of mortar and pestle grinding and crash cooled solution 
crystallisation. The aim was to conduct an initial assessment of the combination of materials, over a 
range of different stoichiometries and solvent environments, using mechanochemical means, seeing 
whether any novel phases were prepared and translating the process towards the growth of individual 
crystals. This combined approach attempted to provide a relatively quick method of screening, 
accounting for the existence of any novel phases, their melting points, their chiral crystalline nature and 
their individual crystal structures. To date, this method has allowed for the discovery of 12 novel multi-
component forms of NPX with the six 2AP derivatives discussed here, at both racemic and enantiopure 
compositions, highlighting the formation of several racemic compounds, racemic solid solution and an 
interesting system with the potential of being a racemic conglomerate. It should be noted that even 
through the development of multi-component materials, no conglomerate systems could be directly 
found, emphasising the rarity of their formation and occurrence.  
 
In the case of the pyrimidine based co-formers, i.e. 2-aminopyrimidine (2APM) and 2-amino-4,6-
dimethylpyrimidine (2ADMP), both were shown to form novel co-crystalline forms with the API. In 
the case of the former, three distinct species were found, an enantiopure and racemic (1:1) pair, as well 
as that of a (2:1) homochiral stoichiometric variant. The equimolar co-crystals were both shown to 
utilise the same dimer of dimer interaction motif as in the racemic salt of NPX with 2AP, but with each 
system expressing a different packing arrangement, therefore forming a conventional racemic 
compound. For the 2ADMP co-former, further (1:1) co-crystals were found, with both the racemic and 
enantiomerically pure phases expressing broadly the same interactions and packing arrangements, with 
the only variation occurring about the chiral centre of the API. Given the fluidity of chirality throughout 
the structure and the improved packing density at racemic compositions, it was shown that this 
combination of molecules represented a Roozeboom Type II racemic solid solution.  
 
Additional screenings were conducted using further 2AP derivatives, this time incorporating additional 
chlorine atoms as substituents. Broadly, it was shown that no matter the position of the halogen atom 
about the pyridine ring, particularly for the meta and para positioned species, racemic compound co-
crystalline systems were produced. For each of the (1:1) homochiral co-crystals discovered, it was 
shown that the same hydrogen bonding motifs were exploited as in the sNPX-2AP salt, that of the 
heterodimer between the carboxylic acid and pyridine-amine groups, with the second N-H bond forming 
a contact with a neighbouring unit, establishing the elongated spiralled chain arrangement. Whilst the 
(1:1) co-crystal of the API with the 2-amino-4-chloropyridine (2A4CP) co-former has yet to have its 
structure fully resolved, it was thought that the enantiopure and racemic materials obtained via grinding 
were structurally related so as to generate a racemic compound forming system. For this para 
substituent, an additional stoichiometric salt form was also found, the only structural variant found for 
these types of derivatives. In contrast, the intermolecular interactions used for racemic (1:1) co-crystals 
was shown to vary depending upon the relative positioning of the chlorine atom around the pyridine 
ring. Transitioning from the three site to four and five sites, respectively, the interactions utilised 
changed from that mimicking the chain arrangement seen for the homochiral species, to that resembling 
the dimer of dimer motif exploited by the rsNPX-2AP salt.  
 
In each of the above cases, the location of the chlorine atom was deemed inconsequential as to the 
formation of either the enantiopure or racemic multi-component phase with NPX, except in the case of 
the 2-amino-6-chloropyridine (2A6CP) co-former. Here, the chlorine atom was placed adjacent to the 
pyridine nitrogen atom and whilst a homochiral structure similar to those observed for the other 
derivatives was found, to date no evidence has been found of a racemic multi-component material 
incorporating this co-former. Though there could still be a racemic material, an initial suggestion is that 
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these initial observations could be due to the fact that the chlorine atom, a bulky substituent, at the ortho 
position has the potential to block the interactions required to allow for the efficient packing of both 
enantiomers of NPX within the same crystal lattice. As such, this particular co-former could have 
potential applications towards the development of a racemic conglomerate material capable of being 
applied into a preferential crystallisation setup.  
 
For the systems detailed above, further screening should be carried out utilising a greater range of 
crystallisation conditions so as to find and characterise any polymorphic or stoichiometric multi-
component variations. The crystallographic structure of the homochiral (1:1) phase of NPX with 2A4CP 
should also be collected in order to confirm the spiralled chain arrangement, as hypothesised. Moreover, 
a detailed assessment of the system with 2A6CP should be carried out, checking for the existence of a 
racemic (1:1) co-crystalline material and if it is absent (i.e. a conglomerate system), developing early 
stage crystallisations for the development of the direct enantiomeric resolution methods.  
 
To extend the scope of this research, further derivatives of 2AP could also be explored. Common to 
every structure discussed in this chapter was that of the heterodimer hydrogen bond motif between the 
carboxylic acid and pyridine-amine groups. By shifting the position of the amine group about the 
pyridine ring, different interactions can be accessed. Two potential co-formers that could be used are 3-
aminopyridine (3AP) and 4-aminopyridine (4AP), as shown in Figure 7.64a. Alternatively, rather than 
changing the fundamental heterodimer, the substituents about the ring could also be changed. Different 
halogen substituents could be used, be it fluorine, bromine or iodine (Figure 7.64b). This could allow 









8 Chiral multi-component materials of naproxen and polymorphic co-
formers 
 
When screening for novel multi-component materials, co-former selection is of particular importance. 
Based upon intermolecular interactions, crystalline materials can be constructed, with each form 
exhibiting their own set of defined characteristics. A key consideration when selecting which 
complementary molecules to use is that of their polymorphic nature. Polymorphism arises when a 
material possesses a number of different functionalities, each capable of forming intermolecular 
interactions. These interactions are in competition with each other and all, respectively, lead to different 
crystal forms. Therefore, the crystallisation of each form is dependent upon the flexibility of the given 
molecule and the crystallisation conditions used.  
 
In multi-component systems, polymorphism or stoichiometric variance in this case is reliant on the 
interactions that form, their number and the orientations of the different molecular entities relative to 
each other. Whilst a given co-former may exhibit a range of polymorphic variants, upon crystallisation 
with a secondary molecule, this phenomenon does not necessarily translate to being demonstrated in 
multi-component materials. As in previous chapters, screenings for such materials were conducted with 
the API naproxen (NPX), using a range of co-formers. However, in the systems outlined here, the co-
formers selected each demonstrate their own set of structural variations. These co-formers include 
imidazole (I), benzimidazole (BI) and acridine (A), which demonstrate two (CSD reference: 
IMAZOL21/22), three (CSD reference: BZDMAZ02/03/05) and five (CSD reference: ACRDIN) 
polymorphic forms, respectively. The molecular structures are shown in Figure 8.1 and further 




Figure 8. 1 - Molecular structures for the co-formers selected for the co-crystal and salt screening with NPX, highlighting 
imidazole (I), benzimidazole (BI) and acridine (A) 
 
Using both mechanochemical and solution crystallisation methods, different enantiomeric compositions 
of NPX, enantiopure and racemic, were screened in combination with these three co-formers. As before, 
the aim was to gauge whether or not novel multi-component materials could be generated, assessing 
their structural and thermal properties, so as to ascertain the classification of chiral crystalline material 
generated. These materials were also explored in terms of their polymorphic behaviour, with a 





8.1 Materials of racemic and enantiopure naproxen with imidazole (I) 
 
8.1.1 Material screening 
 
The first co-former to be selected in this context was imidazole (I). A diazine five-membered ring, I 
demonstrates two main functional groups; that of an amine and an aromatic nitrogen. In its neutral form, 
these functionalities act as a hydrogen bond donor and acceptor, respectively, the interactions from 
which form the basis of the two polymorphic phases of I208; the α and β forms. The α polymorph (CSD 
reference: IMAZOL21) is the most common form under standard atmospheric conditions, with a 
melting point of 89-91oC, whilst, to date, the β polymorph (CSD reference: IMAZOL22) has only been 
prepared from the melt under high pressure. The pKa of I has been shown to be 6.9209, so whilst this is 
an increase from some of the derivatives of 2AP, the acidity difference between the co-former and API 
is such that the predicted co-crystal-salt nature of any multi-component materials is uncertain.  
 
8.1.1.1 Mechanochemical screening 
 
Initial mechanochemical screenings of I with homochiral compositions of NPX were prepared using a 
mortar and pestle, where the API and co-former were ground in either 2:1, 1:1 or 1:2 molar ratios with 
a few drops of ethanol. It should be noted that for the 1:1 and 1:2 combinations, the resultant materials 
were sticky and amorphous in nature. These samples did not crystallise when left and were deemed too 
difficult to handle for PXRD and DSC analysis. However, the combination of the components in a 2:1 
did generate a material suitable for analysis, the diffraction pattern and thermal trace of which are shown 
in Figures 8.2 and 8.3, respectively. 
 
As shown from the PXRD pattern of the 2:1 mechanochemically prepared sample, a distinct crystalline 
phase was prepared, exhibiting a different set of diffraction peaks to that of the starting materials. Upon 
comparison with that obtained subsequently from SCXRD, accounting for temperature dependent 
shifts, the phase made at this composition mechanochemically could be matched to those crystals grown 
from solution, emphasising the reproducibility of this phase. Thermal analysis highlighted two 
endothermic events; the first, a minor phenomenon, occurring at 84-89oC and the second, a major event, 
taking place at 124-127oC. These represented melting of excess I starting material and that of a novel 
multi-component phase, respectively.   
 
Neat mechanochemical samples were also prepared and analysed, the PXRD patterns and DSC traces 
of which can be found in Appendix A8.1. Preparations made in the 2:1 ratio again showed the evidence 
of the formation of the same multi-component material made with the assistance of solvent, highlighted 
by the similarity between their diffraction and thermal characteristics. Further to this, the material 
obtained from the 1:1 mechanochemical preparation was taken to consist of a mixture of the 2:1 phase 
and an additional novel phase. This second phase corresponded directly to the peaks observed in the 
1:2 neat sample. For the 1:1 sample, the thermal trace demonstrated a sharp endotherm (90-93oC) 
followed by a broad one (101-110oC), whilst that of the 1:2 phase presented an initial 
melt/recrystallisation phenomenon (69-72oC) with a further major endotherm at 92-94oC. The peak at 
92oC suggested the formation of a different form to that observed from the 2:1 preparation, supporting 
the findings from PXRD. 
 
When combining I with racemic compositions of NPX and grinding them together, as with the 
homochiral case, only the 2:1 sample was shown to form a crystalline form suitable for analysis. This 
was also seen for the neat combinations of the starting materials (see Appendix A8.1 for PXRD and 
DSC data). The PXRD patterns in Figure 8.4 indicated that a novel crystalline material was prepared, 
distinct from the individual starting materials and again matching the pattern simulated from SCXRD. 
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Figure 8. 2 - PXRD patterns from mechanochemically prepared samples of sNPX and I with ethanol, ground in either 2:1, 










Figure 8. 4 - PXRD patterns from mechanochemically prepared samples of rsNPX and I with ethanol, ground in either 2:1, 









8.1.1.2 Combined evaporation & cooling crystallisation screening 
 
Saturated solutions of NPX, racemic and enantiopure, were prepared with either ethanol or isopropanol 
in a range of API to co-former stoichiometries. These were then cooled, allowing for crystal growth. 
Where necessary evaporation was introduced to aid in this process. Figure 8.6 shows the crystals 
obtained from the homochiral and racemic crystallisations. In the enantiopure case, crystals were 
obtained from a 1:1 solution of API to co-former, whilst for the racemic, the same ratio of materials 
was used but in isopropanol. For both scenarios, flat elongated blocks were yielded, with the bulk 
material showing a white colour. SCXRD analysis was conducted to obtain the crystal structures for 
these novel materials, from which it was confirmed that the crystalline phases grown from solution 




Figure 8. 6 - Microscope and mounted SCXRD images of crystals yielded from (a) a 1:1 sNPX-I ethanol solution and (b) a 
1:1 rsNPX-I isopropanol solution 
 
8.1.2 Material characterisation 
 
Having established routes to the reproducible preparation of both the enantiopure and racemic multi-
component forms via mechanochemical and solution crystallisation means, further solid state analysis 
was conducted to ascertain the chiral crystalline relationship of the species. This included PXRD, DSC 
and SCXRD analysis, culminating in the construction of a binary (melting point) phase diagram. IR 
spectroscopy was also carried out on the ground samples, to determine the key interactions acting in 
these given structures. These IR spectra can be found in Appendix A8.1. 
 
8.1.2.1 Phase, thermal and spectroscopic analysis 
 
A comparison of the X-ray diffraction patterns (simulated from SCXRD data) and the thermal traces of 
both the 2:1 phases of NPX and I at homo and heterochiral compositions, as well as those of the starting 
materials, are shown in Figures 8.7 and 8.8. As shown from the diffraction data, both forms express 
discrete patterns with respect to not only the starting materials, but also to each other. Their melting 
points reside between that of the I and the different enantiomeric combinations of NPX, with the 
homochiral material expressing a higher melt (124-127oC) than that of the racemic (113-117oC). This 
would suggest that the interactions between the API and co-former are stronger in the solid state at 
enantiopure compositions. These collective observations indicated that whilst a different phase forms 
at racemic quantities than that observed for just sNPX, the melting points demonstrated the possible 
existence of a metastable racemic conglomerate system. For these types of materials, the homochiral 





Figure 8. 7 - PXRD patterns of the S-naproxen:imidazole & RS-naproxen:imidazole (2:1) salts, as derived from SCXRD 




Figure 8. 8 - DSC traces of the S-naproxen:imidazole & RS-naproxen:imidazole (2:1) salts, prepared via mechanochemistry, 
compared to that of the starting materials 
 
The IR spectra of the novel multi-component materials showed similar vibrational and stretching 
characteristics. This would indicate that both phases showed a similar range of intermolecular 
interactions and, therefore, structures. With a particular focus on the carbonyl stretch expressed for both 
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systems, a broad mode could be seen at 1703-1705 cm-1. This ill-defined peak suggested that the 
carbonyl group was involved in a number of interactions. 
 
8.1.2.2 Binary (melting point) phase diagram analysis – Classification of chiral crystalline materials 
 
Due to the reliability of the mechanochemical methods to yield both of the novel crystalline forms, 
further samples were prepared via grinding, maintaining the same stoichiometry of NPX to I, but with 
variations in the enantiomeric composition. PXRD and DSC analysis were conducted (Appendix A8.1), 
from which the necessary data was taken so as to construct the binary phase diagram, shown in Figure 
8.9. As highlighted from the phase diagram, distinct regions were noted, defined by the existence of 
both racemic and enantiopure multi-component materials, respectively. The melting points taken from 
racemic and homochiral compositions were shown to converge towards a common point, that of a 
eutectic point between 108oC and 112oC. This cumulative evidence supports the notion of a racemic 
compound system, with the lower melting point of the racemic phase suggesting the possibility of 




Figure 8. 9 - Binary (melting) point phase diagram, with changing enantiomeric composition of rNPX and sNPX, for the 2:1 
salts incorporating the co-former I, highlighting the liquidus (Δ) and the eutectic (▲) points 
 
8.1.2.3 Crystallography – Crystal structure analysis 
 
SCXRD data was collected from individual crystals so as to determine the crystal structures of both the 
homo and heterochiral multi-component materials. For further crystallographic information, including 
details of the key lengths and distances for hydrogen bonding interactions, as well as that for any 
disordered atoms present, see Appendix A8.1. The corresponding CIF files (15, 16) can be found on 
the accompanying CD-ROM.  
 
For the homochiral case, the API and co-former molecules were shown to crystallise in a 2:1 ratio, with 
two molecules of sNPX forming contacts with one molecule of I. Collectively these molecular entities 
crystallised in a non-centrosymmetric monoclinic P21 space group. This 2:1 combination formed the 
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basis of the asymmetric unit, of which two were used to construct the unit cell (Z = 2, Z’ = 1). Figure 
8.10 highlights the unit cell and the key interactions that were used to build up the whole crystal 
assembly. Table 8.1 shows the unit cell parameters for this homochiral multi-component system.   
 
 
Figure 8. 10 - Crystal structure of the S-naproxen:imidazole (2:1) salt, highlighting (a) the unit cell, (b) hydrogen bonding 
synthon and (c) packing arrangement (sNPX in red) 
 
Table 8. 1 - Unit cell and crystallographic parameters for the S-naproxen:imidazole (2:1) salt 
 
Material S-naproxen:imidazole (2:1) salt 
Empirical formula C31H32N2O6 
Formula weight 528.58 
Temperature (K) 150.00(10) 
Crystal system monoclinic 
Space group P21 
a (Å) 6.5408(2) 
b (Å) 5.6125(2) 
c (Å) 37.0129(13) 
α (°) 90 
β (°) 91.009(3) 
γ (°) 90 
Volume (Å3) 1358.54(8) 
Z, Z’ 2, 1 
ρcalc (g/cm3) 1.292 
μ (mm-1) 0.090 
F(000) 560.0 
Crystal size (mm3) 0.341 × 0.151 × 0.067 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 6.23 to 52.044 
Index ranges -8 ≤ h ≤ 8, -6 ≤ k ≤ 6, -45 ≤ l ≤ 45 
Reflections collected 15487 
Independent reflections 5303 [Rint = 0.0382, Rsigma = 0.0382] 
Data/restraints/parameters 5303/26/386 
Goodness-of-fit on F2 1.083 
Final R indexes [I>=2σ (I)] R1 = 0.0452, wR2 = 0.1030 
Final R indexes [all data] R1 = 0.0504, wR2 = 0.1067 
Largest diff. peak/hole  (e Å-3) 0.43/-0.34 




The key interaction unit was shown to consist of three 𝐷1
1(3) hydrogen bonding interactions, with 
contacts forming between the two API entities, one of the API and co-former molecules, as well as 
between neighbouring interaction units. The API-to-co-former contact arose through a hydrogen bond 
between the hydroxyl group of the first NPX molecule and the I aromatic nitrogen. Here, the 
intermolecular interaction was enhanced through proton transfer, forming a salt. Hence, this system can 
be defined as S-naproxen:imidazole (2:1) salt. In addition to this charge-assisted interaction, a further 
hydrogen bond was shown to form between the amine group of I and the carboxyl group of a sNPX 
molecule in an adjacent interaction unit. This chain of alternating API and co-former molecules forms 
the core backbone from which the main structure was built. The final interaction formed between the 
deprotonated API moiety and that of a second, neutral API molecule, from a hydrogen bond across the 
hydroxyl group of the neutral species and the carbonyl component of the charged entity. Collectively, 
these interactions formed a branched chain, built up into channels, from which the whole crystal 
structure could be constructed.  
 
This structure was modelled with disorder, with the charged sNPX entity being anchored, additional 
flexibility was observed about the carboxylic acid group of the neutral API molecule and the whole co-
former species. Enough space was observed within the structure to allow for these groups to rock about 
an axis. This disorder highlighted the dynamic nature of the structure, with a variations expected upon 
changes in temperature. Although disorder was noted about some of the key functionalities, not 
occupancy disparities were noted around the chiral centres of the API molecules, emphasising the 
enantiopure nature of the structure. 
 
As in the homochiral system, the complex prepared with rsNPX and I was shown to utilise a 2:1 
stoichiometry. The relationship was represented within the asymmetric unit, two of which formed the 
unit cell (Z = 2, Z’ = 1). As such, these units were shown to crystallise in a centrosymmetric triclinic 
𝑃1̅ space group, accounting for both enantiomeric forms of the API to be accounted for. Proton transfer 
was noted, demonstrating the formation of a RS-naproxen:imidazole (2:1) salt. Figure 8.11 highlights 
the key structures and interactions for this material, with Table 8.1 outlining the unit cell and refinement 
parameters. 
 
In a similar manner to that observed in its enantiopure counterpart, the predominant interactions with 
this complex were that of three 𝐷1
1(3) hydrogen bonds, linking the charged and neutral API species 
with that of the co-former. Two of these interactions were the same as observed for the other structure, 
with a charge-assisted contact forming between one of the NPX molecules and the co-former, as well 
as that forming between the NPX themselves. In contrast, however, the hydrogen bond connecting 
individual interaction units was shown to take place not between the co-former and the deprotonated 
species, but from the amine functionality of the co-former to the accepting carbonyl group on the neutral 
API molecule present in the interaction unit. As such, the combination of these interactions resulted in 
a zig-zagged continuous chain, with the I molecules residing down the centre of the chain, alternating 
between orientations between units. The chains were then packed together in order to generate the whole 
crystal structure. 
 
These chains consisted of both enantiomeric forms, with the one form consistently undertaking proton 
transfer and the other remaining neutral. The composition of enantiomers either side of the co-former 
spine alternated moving along the chain, with the charged and uncharged forms remaining the same. 
For a given crystal, the overall construct maintains this relationship, but due to the disorder about the 
chiral centre of respective forms of NPX, alternation between enantiomers, in terms of the charged and 





Figure 8. 11 - Crystal structure of the RS-naproxen:imidazole (2:1) salt, highlighting (a) the unit cell, (b) hydrogen bonding 
synthon and (c) packing arrangement (sNPX in red, rNPX in blue) 
 
Table 8. 2 - Unit cell and crystallographic parameters for the RS-naproxen:imidazole (2:1) salt 
 
Material RS-naproxen:imidazole (2:1) salt 
Empirical formula C31H32N2O6 
Formula weight 528.58 
Temperature (K) 150.01(10) 
Crystal system triclinic 
Space group P1̅ 
a (Å) 6.01873(16) 
b (Å) 12.2567(4) 
c (Å) 18.3581(5) 
α (°) 90.876(2) 
β (°) 96.959(2) 
γ (°) 92.853(3) 
Volume (Å3) 1342.32(7) 
Z, Z’ 2, 1 
ρcalc (g/cm3) 1.308 
μ (mm-1) 0.742 
F(000) 560.0 
Crystal size (mm3) 0.305 × 0.091 × 0.058 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection (°) 7.222 to 136.498 
Index ranges -7 ≤ h ≤ 5, -14 ≤ k ≤ 14, -22 ≤ l ≤ 22 
Reflections collected 14853 
Independent reflections 4923 [Rint = 0.0187, Rsigma = 0.0172] 
Data/restraints/parameters 4923/14/379 
Goodness-of-fit on F2 1.039 
Final R indexes [I>=2σ (I)] R1 = 0.0568, wR2 = 0.1534 
Final R indexes [all data] R1 = 0.0657, wR2 = 0.1615 
Largest diff. peak/hole  (e Å-3) 0.47/-0.37 
Flack parameter N/A 
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8.2 Materials of racemic and enantiopure naproxen with benzimidazole (BI) 
 
8.2.1 Material screening 
 
Further to the screening with I, its benzene derivative, benzimidazole (BI), was also utilised as a 
potential co-former for combinations with the NPX. Exhibiting the same aromatic nitrogen and N-H 
functionalities, BI has three polymorphic forms210; α, β and γ. The first two phases can be prepared 
under ambient conditions from aqueous or ethanol solutions, with β polymorph (CSD reference: 
BZDMAZ03) a metastable relationship to that of the α form (CSD reference: BZDMAZ02). The γ 
polymorph (CSD reference: BZDMAZ05), to date, can only be accessed under higher pressures. Raw 
material of BI can be purchased as an off-white powder as the α phase, with a melting point of 168-
171oC. The pKa value of the co-former was taken from literature as 5.5209 and making proton transfer 
unlikely.  
 
8.2.1.1 Mechanochemical screening 
 
Samples combining sNPX and BI were prepared using mechanochemical means, where 2:1, 1:1 and 1:2 
stoichiometries were ground together with minimum quantities of solvent. Phase and thermal analyses 
were conducted using PXRD and DSC, highlighted in Figure 8.12 and 8.13, respectively.  
 
The diffraction patterns of these homochiral combinations showed the presence of a novel crystalline 
form common across all stoichiometries. Though minimum starting material was also noted, the 1:1 
pattern demonstrated the clearest signs of the formation of a distinct multi-component phase. DSC 
analysis of the 1:1 preparation highlighted two endothermic events, the first at 120-123oC and the 
second at 128-130oC. For the other stoichiometries, a single thermal phenomenon was observed, at 121-
124oC and 118-122oC for the 2:1 and 1:2 samples, respectively. For the equimolar combination, the 
initial thermal event could be attributed to a possible phase transition from a low temperature form to 
that of high temperature form, followed by a melt.  
 
Parallel neat grindings showed no direct complexation from any of the stoichiometries used (PXRD and 
DSC data in Appendix A8.2), with novel material formation only being derived from heating. After an 
initial phase transition between 77-85oC, the two further thermal events were witnessed, at 119-123oC 
and 128-130oC, respectively, correlating to that observed from the liquid-assisted preparations.  
 
Upon grinding racemic proportions of NPX with BI in a variety of molar ratios with ethanol, as with the 
enantiopure case, a novel multi-component phase was shown to form. The diffraction patterns for these 
combinations can be found in Figure 8.14. The formation of such a material was consistent over all 
stoichiometries used, omitting excesses in the starting material, with particular evidence in the 1:1 
sample. DSC traces were also taken, shown in Figure 8.15. These mirrored the observations made for 
the homochiral 1:1 sample, with two distinct thermal events, occurring at 120-126oC and 128-131oC, 
respectively. The trends in thermal behaviour for the 2:1 and 1:2 samples also closely followed that of 
the enantiopure samples, exhibiting broader melting phenomena at 124-127oC and 119-123oC, 
respectively.  
 
Neat grinding once showed little capability of preparing the novel material demonstrated in the liquid-
assisted case, with heating the only route possible to allow for complexation. For the complete PXRD 






Figure 8. 12 - PXRD patterns from mechanochemically prepared samples of sNPX and BI with ethanol, ground in either 2:1, 




Figure 8. 13 - DSC traces from mechanochemically prepared samples of sNPX and BI in ethanol, ground in either 2:1, 1:1 or 






Figure 8. 14 - PXRD patterns from mechanochemically prepared samples of rsNPX and BI with ethanol, ground in either 




Figure 8. 15 - DSC traces from mechanochemically prepared samples of rsNPX and BI in ethanol, ground in either 2:1, 1:1 






8.2.1.2 Combined evaporation & cooling crystallisation screening 
 
Individual crystals were grown using crash cooling crystallisation for racemic and enantiopure solutions 
of NPX, where the API and co-former were combined in either 2:1, 1:1 or 1:2 molar ratios, in ethanol 
or isopropanol. Figure 8.16 depicts the single crystals made and analysed, through SCXRD, for both 
enantiomeric compositions. Crystallites taken from 1:1 solutions were shown to only be that of the 
starting components, whilst most crystals selected from the 1:2 racemic solutions with ethanol were 
deemed to be unsuitable for structural analysis. The crystals chosen were shown to directly correlate 
with the material made via mechanochemistry, with both entities exhibiting the same bulk white colour 
and elongated block morphology. For the racemic entity, it was noted that the crystals were shown to 




Figure 8. 16 - Microscope and mounted SCXRD images of crystals yielded from (a) a 1:2 sNPX-BI ethanol solution and (b) 
a 1:2 rsNPX-BI isopropanol solution 
 
To explore the thermal events indicated in the mechanochemical preparations, crystals of suitable 
quality were selected and monitored using HSM, whilst the temperature was ramped. Figures 8.17 and 
8.18 show images of crystals taken from the multi-component preparations with homochiral and 
racemic NPX, respectively. For both cases, no physical transformations were observed until beyond 
117oC. Upon reaching this point, the crystals of the different chiral compositions were shown to subtly 
darkening and become speckled between 117oC and 123oC. Prior to complete melting at temperatures 
beyond 131oC, the crystals seemed to lighten. These observations corresponded to that seen from DSC 






Figure 8. 17 - HSM images of individual crystals obtained from homochiral ethanol solutions, with 1:2 molar ratio of NPX to 




Figure 8. 18 - HSM images of individual crystals obtained from racemic isopropanol solutions, with 1:2 molar ratio of NPX 





8.2.2 Material characterisation 
 
To determine the chiral crystalline relationship between the materials generated upon combining 
different enantiomeric contributions of NPX with BI, further analysis was conducted. This included 
comparisons of the relevant PXRD and DSC data, brought together to yield a binary phase diagram, as 
well as that of the relevant crystal structures, derived from SCXRD data. 
 
8.2.2.1 Phase, thermal and spectroscopic analysis 
 
Based upon the findings from mechanochemical screening and initial single crystal growth, it was 
shown that both the homo and heterochiral multi-component forms of NPX and BI could be 
reproducibly generated via the above mentioned techniques. Figure 8.19 allows for the comparison of 
the simulated PXRD patterns of each of the novel materials, as well as that of the different crystalline 
forms for the starting materials. As shown, the combinations of the API and the co-former produced 
distinctly different patterns to that of the single-component entities, emphasising the formation of new 
multi-component crystalline phases. However, it was noted that the diffraction arrays for both 
preparations expressed the exact same patterns, suggesting that both materials exhibited the same 
crystalline structure. This provided the first indication of either a racemic conglomerate or racemic solid 




Figure 8. 19 - PXRD patterns of the S-naproxen:benzimidazole & RS-naproxen:benzimidazole (1:1) co-crystals, as derived 
from SCXRD data, compared to that of the starting materials 
 
As previously explored, the mechanochemical preparations of the racemic and enantiopure multi-
component combinations both expressed thermal traces with two clear subsequent endothermic events. 
Whilst it was most likely that these phenomena represented a phase transition of some kind, as 
highlighted in Figure 8.20, the similarity in the thermal properties of these two systems suggested that 
the interactions exploited were alike. This likeness in melting resembled the characteristics of a racemic 






Figure 8. 20 - DSC traces of the S-naproxen:benzimidazole & RS-naproxen:benzimidazole (1:1) co-crystals, prepared via 
mechanochemistry, compared to that of the starting materials 
 
IR spectroscopy was used to provide a first indication as to the intermolecular interactions and 
vibrational modes exhibited by for a given structure. Comparison of the rsNPX-BI and sNPX-BI 
materials using this technique (Appendix A8.2) demonstrated the same set of vibration and stretching 





8.2.2.2 Binary (melting point) phase diagram analysis – Classification of chiral crystalline materials 
 
Taking advantage of the capabilities of mechanochemistry to reliably produce the enantiomerically 
varying multi-component forms, different compositions of sNPX and rNPX were ground together with 
the co-former, BI, in a set molar ratio of 1:1. Minimum quantities of ethanol were used. The PXRD and 
DSC data for each sample can be found in Appendix A8.2. By taking the final melting point observed, 
the binary (melting point) phase diagram, shown in Figure 8.21, was constructed. 
 
Despite changing the relative ratio of enantiomers for each preparation, little variation was noted in 
melting points from sample to sample. This indicated that the interactions holding the structure together 
did not change significantly with changing enantiomeric composition. The phase diagram reinforced 




Figure 8. 21 - Binary (melting) point phase diagram, with changing enantiomeric composition of rNPX and sNPX, for the 1:1 
co-crystals incorporating the co-former BI, highlighting the liquidus (Δ) point 
 
8.2.2.3 Crystallography – Crystal structure analysis 
 
Single crystals were grown from solution (as previous discussed) and analysed to ascertain their 
crystalline structure using SCXRD. The arrangement of the molecular entities within the assemblies, as 
well as the key interaction units, for the homo and heterochiral multi-component forms are shown in 
Figure 8.22 and 8.23, respectively. The unit cell parameters for these materials are detailed in Table 
8.3. For further crystallographic information with particular emphasis on the hydrogen bonding and 
disorder exhibited, see Appendix A8.2. The corresponding CIF files (17, 18) can be found on the 
accompanying CD-ROM.  
 
In the case of the enantiopure material, the S-enantiomer of NPX was shown to crystallise with BI in a 
1:1 stoichiometry in a non-centrosymmetric monoclinic P21 space group. No proton transfer was noted, 
allowing for this system to be described as a S-naproxen:benzimidazole (1:1) co-crystal. The 
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asymmetric unit was constructed using two sets of the original 1:1 molecular combination (Z = 4, Z’ = 
2), collectively reflecting the individual contributions to key interaction unit. This unit was held together 
by four 𝐷1
1(3) hydrogen bonds, collectively set as a 𝑅4
4(16) ring. These contacts were classified into 
two distinct types; N-H···O and O-H···N interactions. With both enantiomeric forms contributing to this 
unit, the relationship between the molecules could not be defined using mirror or inversion symmetry, 
but could be described using a pseudo point of inversion, with the main body the molecular entities 
being related in this manner and remaining rigid. The only variation in structure that was noted was that 
about the chiral centre. Disorder was used to model the methyl group, emphasising the distinct mobility 
of this group within the crystalline structure, allowing for different chiral forms to be present. Here, the 
disorder was only such that a single enantiomer was present. Using these interaction units, the overall 
crystalline structure could be constructed, whereby the methyl functionalities line up, demonstrating a 




Figure 8. 22 - Crystal structure of the S-naproxen:benzimidazole (1:1) co-crystal, highlighting (a) the unit cell, (b) hydrogen 
bonding synthon (* = pseudo-inversion symmetry) and (c) packing arrangement (sNPX in red) 
 
Upon introducing the opposite enantiomer of the API, it was shown that, as for the homochiral material, 
NPX was able to crystallise with the co-former in a 1:1 molar relationship. In the centrosymmetric 
monoclinic P21/n space group, each of the asymmetric units within the unit cell reflected the 1:1 
stoichiometry of API to co-former, though here both enantiomers were accounted for (Z = 4, Z’ = 1). 
 
Like that seen in the enantiomerically pure phase, no proton transfer was noted, allowing for this 
material to be described as a RS-naproxen:benzimidazole (1:1) co-crystal. A similar interaction unit 
was utilised, exploiting the same hydrogen bond interactions, with near identical orientations, but both 
enantiomers present within the motif, now related by inversion symmetry. Whilst the main body of the 
BI and NPX molecules were set to defined positions, the presence of disorder indicated variations about 
the chiral centres, demonstrating that there was enough space about each of the asymmetric carbon 
atoms to allow for variation in the enantiomeric composition. The units are then packed as before, 
showing distinct channels of interlocking motifs, central to which were the chiral centres, highlighting 






Figure 8. 23 - Crystal structure of the RS-naproxen:benzimidazole (1:1) co-crystal, highlighting (a) the unit cell, (b) 
hydrogen bonding synthon (* = inversion symmetry) and (c) packing arrangement (sNPX in red, rNPX in blue) 
 
Table 8. 3 - Unit cell and crystallographic parameters for the S-naproxen:benzimidazole (1:1) and RS-






Empirical formula C21H20N2O3 C21H20N2O3 
Formula weight 348.39 348.39 
Temperature (K) 150.01(10) 150.00(10) 
Crystal system monoclinic monoclinic 
Space group P21 P21/n 
a (Å) 11.8180(2) 11.7490(2) 
b (Å) 7.52380(10) 7.56745(17) 
c (Å) 19.8809(3) 19.8873(4) 
α (°) 90 90 
β (°) 93.0030(10) 93.2125(15) 
γ (°) 90 90 
Volume (Å3) 1765.31(5) 1765.41(6) 
Z, Z’ 4, 2 4, 1 
ρcalc (g/cm3) 1.311 1.311 
μ (mm-1) 0.716 0.716 
F(000) 736.0 736.0 
Crystal size (mm3) 0.229 × 0.15 × 0.127 0.524 × 0.187 × 0.113 
Radiation CuKα (λ = 1.54184) CuKα (λ = 1.54184) 
2Θ range for data collection (°) 7.49 to 140.096 8.538 to 140.142 
Index ranges -13 ≤ h ≤ 14, -9 ≤ k ≤ 9, -24 ≤ l ≤ 21 -14 ≤ h ≤ 14, -9 ≤ k ≤ 8, -24 ≤ l ≤ 22 
Reflections collected 13257 17819 
Independent reflections 6670 [Rint = 0.0311, Rsigma = 0.0368] 3348 [Rint = 0.0228, Rsigma = 0.0149] 
Data/restraints/parameters 6670/11/497 3348/8/253 
Goodness-of-fit on F2 1.038 1.042 
Final R indexes [I>=2σ (I)] R1 = 0.0380, wR2 = 0.1014 R1 = 0.0502, wR2 = 0.1243 
Final R indexes [all data] R1 = 0.0402, wR2 = 0.1048 R1 = 0.0521, wR2 = 0.1259 
Largest diff. peak/hole  (e Å-3) 0.20/-0.17 0.64/-0.45 





Further to the similarity in the unit cell dimensions, by overlaying the interaction units of both the homo 
and heterochiral co-crystals, as depicted in Figure 8.24, the distinct similarities between the crystalline 
materials could be emphasised, with the only region of difference that about the chiral centres, 
confirming the existence of a racemic solid-solution. In this case, despite changes in the enantiomeric 
composition of the co-crystal, the packing efficiency was shown not to change, highlighted by the same 
calculated packing density for each structure (1.311 g/cm3). This emphasised the ideal nature of this 




Figure 8. 24 - The overlapped key interaction units of the enantiopure and racemic (1:1) co-crystals of NPX and BI, 





8.3 Materials of racemic and enantiopure naproxen with acridine (A) 
 
8.3.1 Material screening 
 
Acridine (A) was also used in combination with NPX, as part of the search for a racemic conglomerate. 
A exhibits a single hydrogen bond acceptor functionality, that of the aromatic nitrogen atom. Due to its 
extensively conjugated structure, the main intermolecular interaction possible is that of π-π stacking or 
C-H···π contacts. As such, this co-former expresses seven known structural variations; one hydrate211 
and six single-component polymorphs212, 213 (II-VII). Despite the most stable form being reported as 
Form II (CSD reference: ACRDIN01), the raw material purchased for the purposes of screening was 
that of Form III (CSD reference: ACRDIN). This form is yellow in colour, with a melting point between 
109-111oC. The pKa value of A was taken from the literature as 5.3 and, upon comparison with that of 
NPX, suspected to not undergo salt formation.  
 
8.3.1.1 Mechanochemical screening 
 
As for the previous co-formers, mechanochemical screening was conducted with sNPX and A, to gauge 
their potential for multi-component material formation. This was conducted using minimum quantities 
of solvent, in this case ethanol, as well as neat. The PXRD patterns and DSC traces for the liquid-
assisted grindings are shown in Figures 8.25 and 8.26, respectively, with that of the neat preparations 
in Appendix A8.3.  
 
Having combined the materials in given quantities (2:1, 1:1 and 1:2), phase analysis showed that for 
the equimolar sample ground with ethanol, a unique diffraction pattern was yielded when compared to 
the starting components. This demonstrated that a novel crystalline material could be prepared 
mechanochemically at a 1:1 stoichiometry. This was classified later as the (1:1) co-crystal, Form I. In 
the samples constituting excess of the co-former, the same novel peaks were also noted, along with 
those corresponding to A (Form III), whilst that with more API expressed a combination of peaks related 
to sNPX and that of a different phase generated from the equimolar preparation. This evidence of 
different distinct diffraction patterns at the varying stoichiometries of sNPX and A provided the first 
signs that structural variations with this combiantion of materials were possible.  
 
The DSC traces showed major endothermic events at 88-91oC, 90-94oC and 87-89oC for each of the 
stoichiometric samples, in descending quantities of sNPX, respectively. The 2:1 preparation also 
exhibited a broad phenonenon between 114oC and 125oC that could be attributed to the melting of the 
excess API, whereas the 1:2 showed a small endotherm at 75-80oC that represented a possible phase 
transition to one of the newly discovered multi-component materials. Due to the relative impurities 
highlighted in the PXRD data, these melts, particularly for the 2:1 and 1:1 preparations, could not be 
directly taken as those of the actual novel complexed materials. However, the materials being analysed 
clearly showed significantly different melts to that of the starting material, indicating they are new 
crystalline forms consisting of sNPX and A.  
 
For the corresponding neat preparations, the PXRD patterns for each sample was shown to only be a 
physical mixture of the starting materials, with the only evidence of complexation coming after heating. 
The DSC traces for each stoichiometry demonstrated the same thermal phenonema, to different extents, 
with an initial event occurring at 80-83oC, followed by a second at 86-88oC with a subsequent 
recrystallisation and major endothermic melt occuring from 93oC to 96oC. These observations could 
attributed to an initial complexation, followed by solid-to-solid transitions and a melt of the stable phase. 
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Again, this highlighted that with this combination of materials, polymorphic or stoichiometrically 




Figure 8. 25 - PXRD patterns from mechanochemically prepared samples of sNPX and A with ethanol, ground in either 2:1, 




Figure 8. 26 - DSC traces from mechanochemically prepared samples of sNPX and A with ethanol, ground in either 2:1, 1:1 
or 1:2 molar ratios 
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Racemic combinations of NPX and A were also ground in the same combinations as in the homochiral 
case. These grindings were conducted either neat (see Appendix A8.3 for analysis) or with minimum 
amounts of ethanol. Figures 8.27 and 8.28 show the PXRD and DSC data for the samples prepared via 
liquid-assisted mechanochemistry.  
 
Phase analysis of these samples showed that upon combining the two consistent starting materials, a 
unique pattern could be generated, particularly for the 1:1 stoichiometry. The 2:1 and 1:2 sample 
showed the same diffraction patterns as for the equimolar preparation, but also with excess starting 
material noted. It should be noted that in terms of the excess contributions of the co-former present, 
distinction could not be made between that of Forms II and III.  
 
 
Figure 8. 27 - PXRD patterns from mechanochemically prepared samples of rsNPX and A with ethanol, ground in either 2:1, 
1:1 or 1:2 molar ratios (top three patterns) 
 
The DSC traces taken for these materials highlighted significantly different thermal events than 
compared to that of the starting materials, again, emphasising the formation of a novel crystalline phase. 
For the 2:1 and 1:1 samples, both showed a major melting phenomenon between 107-110oC, with the 
preparation consisting of uneven contributions of the starting components showing an additional broad 
endotherm at 125-131oC. This secondary event was attributed to that of excess NPX. The 1:2 sample 
demonstrated several endothermic processes. After excess solvent was driven off, two concurrent 
endothermic events were shown to occur at 86-88oC and 87-90oC, respectively, followed by a further 
broad endotherm, from 96-103oC. Collectively, these events could be related to the melt of the novel 
multi-component material and of excess A.  
 
Neat grinding was shown to only partially allow for complexation to occur, the 1:1 combination 
showing the strongest signs of a novel form being made. As with the enantiopure grindings, the racemic 
combinations showed similar thermal properties across the stoichiometries, with an initial 
melt/recrystallisation occurring between 89oC and 91oC, followed by the melt at 108-110oC. Together, 
these findings showed that the same novel multi-component material could be prepared either with 






Figure 8. 28 - DSC traces from mechanochemically prepared samples of rsNPX and A with ethanol, ground in either 2:1, 1:1 
or 1:2 molar ratios 
 
To explore the possibility of preparing different polymorphic forms, homochiral and racemic 
compositions of NPX were ground with A in a 1:1 stoichiometry, in a variety of different laboratory 
solvents, including water, methanol, ethanol, isopropanol, acetonitrile, ethyl acetate, toluene and 
hexane. The respective PXRD and DSC data can be found in Appendix A8.3.  
 
For the enantiopure preparations, the (1:1) multi-component phase, yielded initially from grindings with 
ethanol, was shown to be consistently made with the assistance of water, methanol, acetonitrile, ethyl 
acetate, toluene and hexane, each exhibiting a consistent melt between 93-96oC. Samples prepared with 
water, toluene and hexane were also shown to have excess starting material, which gave rise to 
additional endothermic events. The PXRD pattern of the material produced with isopropanol 
highlighted the presence of a number of crystalline entities, both single and multi-component. It was 
noted that not only was the (1:1) Form I phase present, but also that corresponding to those observations 
made from the initial 2:1 ethanol preparation. This suggested that solvent environment had the potential 
to influence polymorphic or stoichiometric character for the system of sNPX and A. Furthermore, the 
thermal trace here demonstrated two consecutive endothermic events; at 86-90oC and 93-95oC, 
respectively, emphasising the presence of two multi-component forms. 
 
In the racemic case, for all the solvent environments used, each demonstrated precipitation of the same 
distinct phase seen from the initial preparations. The DSC plots for each of these, exclude those events 
corresponding to that of excess solvent being released, demonstrated a single endothermic phenomenon 
between 109-112oC. Together, this reinforced the notion that at racemic compositions, no structural 
variations were possible under the conditions used.    
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8.3.1.2 Combined evaporation & cooling crystallisation screening 
 
Parallel to that from mechanochemistry, individual crystals were grown from solution, so as to ascertain 
their crystalline structure. Figure 8.29 depicts the crystals grown for each of the novel multi-component 
materials found. In conjunction with the SCXRD analysis, individual crystals were taken and assessed 
for their thermal properties using HSM, the images of which can be found in Appendix A8.3. 
 
By first considering those grown from enantiopure solutions, where the API and co-former molecules 
were dissolved in a 1:1 molar ratio in ethanol, crystals with a long thin block, almost needle-like, 
morphologies were shown to form, collectively exhibiting bulk yellow colour. This material had a 
melting point between 101-104oC, higher than that of the novel material prepared via 
mechanochemistry. The SCXRD data showed that these crystals were of a different multi-component 




Figure 8. 29 - Microscope and mounted SCXRD images of crystals yielded from (a) 1:1 ethanol, (b) 1:1 acetonitrile and (c) 
seeded 1:1 ethanol enantiopure solutions, as well as that of (d) a racemic 1:1 solution in ethanol 
 
In an effort to generate the mechanochemically yielded material with ethanol, further crystallisations 
were established; those relying on spontaneous nucleation and growth from acetonitrile solutions, and 
those acting through secondary nucleation and growth from ethanol solutions. The second set of 
crystallisations were conducted with the aid of seeds obtained from the previous mechanochemical 
preparations. For both processes, the crystals produced showed elongated block morphologies and were 
yellow in colour. HSM showed that those formed from acetonitrile and via seeding each showed melting 
phenomena between 88-96oC and 93-98oC, broadly relating to those observed from the 1:1 DSC traces 
of sNPX and A ground with ethanol and isopropanol, respectively. As such, SCXRD investigations 
demonstrated that the crystals from the acetonitrile and seeded ethanol solutions correspond to that of 
the (1:1), Form I, and (2:3) co-crystals (see Section 8.3.2.3).  
 
The crystals grown from the racemic solutions of ethanol were shown to directly correspond to the 
material prepared from the 1:1 grinding of rsNPX and A. Based upon SCXRD, the structure of this 
material could be attributed to that of a (1:1) co-crystal of racemic NPX and the co-former. The images 
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produced over a range of temperatures using HSM highlighted a melting point from 110-112oC, 
corresponding to the findings from mechanochemistry. 
 
8.3.2 Material characterisation 
 
Thus far, the combination of mechanochemical and solution-based screening demonstrated that under 
given solvent environments, the API and co-former can interact to form a variety of different materials. 
From here, further analysis was conducted, emphasising any relationships towards that of a particular 
classification of chiral crystalline system.  
 
8.3.2.1 Phase, thermal and spectroscopic analysis 
 
As highlighted from the PXRD patterns highlighted in Figure 8.30, the three forms discovered for sNPX 
with A showed distinct diffraction peaks so as to make them discernible from each other, as well as that 
of the starting materials. To date, the three forms of enantiopure API and this given co-former 
demonstrated two (1:1) polymorphic phases and one (2:3) stoichiometric variation. In contrast, when 
both enantiomers were incorporated into the preparations, only one (1:1) co-crystal was shown to be 




Figure 8. 30 - PXRD patterns of the S-naproxen:acridine (1:1), Forms I & II, and (2:3) co-crystals, as well as that of the RS-
naproxen:acridine (1:1) co-crystal, as derived from SCXRD data, compared to that of the starting materials 
 
Thus far, the melting points of these novel multi-component materials were taken based upon thermal 
analysis of their respective individual crystals and, where possible, from their mechanochemical 
preparations. A comparison of the collected melting events from DSC and HSM studies are tabulated 
in Table 8.5. Based on this data, it was shown that the thermal stability of the respective multi-
component forms could be ranked as follows; (2:3) Form < (1:1) Form I < (1:1) Form II < (1:1) racemic 
co-crystal. With an initial focus on those phases made via mechanochemistry, the homochiral form was 
shown to have a lower melting point to that of the racemic, a sign of the enhanced stability of the solid-
state at racemic compositions. The discrepancy between the values taken from DSC compared to that 
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observed for HSM could be credited to the potential for mechanochemical techniques to also possess 
excess starting material as part of the bulk, altering the particle-particle interactions present. 
 
Table 8. 4 - Melting points for the four observed multi-component forms, incorporating either sNPX or rsNPX with A, as 
determined by DSC or HSM 
 
Co-crystal Form 
Melting Point (oC) 
DSC HSM 
S-naproxen:acridine (1:1) co-crystal, Form I 90-94 93-98 
S-naproxen:acridine (1:1) co-crystal, Form II N/A 101-104 
S-naproxen:acridine (2:3) co-crystal N/A 88-96 
RS-naproxen:acridine (1:1) co-crystal 107-110 110-112 
 
An initial assessment of the intermolecular interactions were made using IR spectroscopy, using ground 
up samples of the individual crystals prepared directly from solution. The spectra of each material can 
be found in Appendix A8.3. Broadly, all of the phases showed similar vibration and stretching modes, 
suggesting overall, similar set interactions were being used in the structure of each phase. The exception 
noted was that of the C=O stretch in the (1:1) Form I enantiopure co-crystal. In comparison to the other 
systems, where only one transmission peak was noted, here, two were observed, suggesting that this 
functionality displays some degree of variation in this structure.  
 
8.3.2.2 Binary (melting point) phase diagram analysis – Classification of chiral crystalline materials 
 
Focussing on the multi-component materials made via grinding, with varying enantiomeric 
composition, the melting points for the resultant samples could be taken and used for the construction 
of a binary phase diagram. Figure 8.31 depicts the change in the thermal phenomena as a function of 
enantiomeric composition. The corresponding PXRD patterns and DSC traces can be found in 
Appendix A8.3.  
 
With the changing contribution of sNPX to rNPX from racemic to enantiopure, it was shown that the 
(1:1) racemic co-crystal gradually morphed into that of the corresponding homochiral phase, with the 
melting point of the bulk steadily decreasing. For each sample, no eutectic phenomena were observed, 
suggesting that despite the significant changes in the diffraction, the mechanochemically prepared 
combination of NPX and A represented a racemic solid solution. With the racemic phase possessing the 
higher melting point, this system could be classified as a Roozeboom Type II solid solution. What was 
clear from this system was that a crystalline material that incorporated both enantiomers could 
precipitate towards racemic compositions, a phase with great thermal stability to that of any of the 
polymorphic or stoichiometry forms of the homochiral co-crystal. As such, the co-former, A, was shown 






Figure 8. 31 - Binary (melting) point phase diagram, with changing enantiomeric composition of rNPX and sNPX, for the 1:1 
co-crystals incorporating the co-former, A, highlighting the liquidus (○) point 
 
8.3.2.3 Crystallography – Crystal structure analysis 
 
The crystal structures for each of the discovered co-crystalline forms of NPX with A were determined 
using SCXRD. For all relevant crystallographic data, including hydrogen bond lengths and angles, as 
well as the relative occupancies for any disordered atoms, see Appendix A8.3. The corresponding CIF 
files (19-22) can be found on the accompanying CD-ROM. The unit cell parameters and details of the 
crystallographic refinement of both the (1:1) homochiral, Form I, and racemic phases can be found in 
Table 8.5. The arrangement of molecules and the relevant hydrogen bonding motifs for these materials 
are depicted in Figures 8.32 and 8.33, respectively.  
 
Upon assessing the crystals grown from the 1:1 enantiopure solution of ethanol, seeded with material 
prepared via mechanochemistry, it was shown that the API and the co-former molecules crystallised in 
an orthorhombic P212121 space group, a non-centrosymmetric space group. As such, the asymmetric 
unit was shown to consist of two sets of stoichiometrically related constituent starting materials, used 
to construct the whole unit cell (Z = 8, Z’ = 2). No proton transfer was evident, confirming the formation 
of a S-naproxen:acridine (1:1) co-crystal, Form I. 
 
The key interaction unit formed through a 𝐷1
1(3) hydrogen bond, acting through the O-H donor group 
of sNPX and the aromatic nitrogen atom of the A molecule (O-H···N), connecting the respective 
molecular entities. These moieties were then paired up with a corresponding interaction unit, with the 
co-former molecules parallel and slightly off-set, creating a zig-zag packing motif. Using these, as 
described by the symmetry operations, the whole crystal structure can be constructed, generating 
channels, the core of which was made up from a herring-bone spine of paired A molecules. Running in 
opposite directions either side of this central spine were the API molecules, with the relative positioning 
of each molecular entity alternating, so that the methyl group was pointing towards or away from the 
co-former. This co-crystal also demonstrated disorder about its carboxylic acid functionality, reflecting 
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the flexibility of the structure and the variability of the molecular positioning. This correlates with the 




Figure 8. 32 - Crystal structure of the S-naproxen:acridine (1:1) co-crystal, Form I, highlighting (a) the unit cell, (b) 
hydrogen bonding synthon, (c) packing unit and (d) overall packing arrangement (sNPX in red) 
 
Table 8. 5 - Unit cell and crystallographic parameters for the S-naproxen:acridine (1:1) co-crystal, Form I and the RS-
naproxen:acridine (1:1) co-crystal 
 
Material S-naproxen:acridine 
(1:1) co-crystal, Form I  
RS-naproxen:acridine 
(1:1) co-crystal 
Empirical formula C27H23NO3 C27H23NO3 
Formula weight 409.46 409.46 
Temperature (K) 150.00(10) 150.03(10) 
Crystal system orthorhombic orthorhombic 
Space group P212121 Pbca 
a (Å) 8.58630(10) 7.8445(2) 
b (Å) 17.3784(2) 18.8698(5) 
c (Å) 28.5664(3) 28.2197(7) 
α (°) 90 90 
β (°) 90 90 
γ (°) 90 90 
Volume (Å3) 4262.57(8) 4177.19(19) 
Z, Z’ 8, 2 8, 1 
ρcalc (g/cm3) 1.276 1.302 
μ (mm-1) 0.662 0.676 
F(000) 1728.0 1728.0 
Crystal size (mm3) 0.446 × 0.194 × 0.129 0.212 × 0.095 × 0.049 
Radiation CuKα (λ = 1.54184) CuKα (λ = 1.54184) 
2Θ range for data collection (°) 5.952 to 140.136 6.264 to 136.496 
Index ranges -8 ≤ h ≤ 10, -17 ≤ k ≤ 21, -34 ≤ l ≤ 34 -8 ≤ h ≤ 9, -22 ≤ k ≤ 22, -33 ≤ l ≤ 33 
Reflections collected 24472 42938 
Independent reflections 8102 [Rint = 0.0175, Rsigma = 0.0153] 3831 [Rint = 0.0479, Rsigma = 0.0172] 
Data/restraints/parameters 8102/509/576 3831/0/282 
Goodness-of-fit on F2 1.026 1.050 
Final R indexes [I>=2σ (I)] R1 = 0.0484, wR2 = 0.1361 R1 = 0.0502, wR2 = 0.1358 
Final R indexes [all data] R1 = 0.0502, wR2 = 0.1384 R1 = 0.0579, wR2 = 0.1430 
Largest diff. peak/hole  (e Å-3) 0.76/-0.36 0.23/-0.34 




Crystals obtained from the racemic solution again demonstrated the 1:1 stoichiometric relationship 
between NPX and A, with molecules crystallising in the centrosymmetric orthorhombic Pbca space 
group. Each unit cell was made up from eight asymmetric units, consisting of an API and co-former 
molecules, with both enantiomers being accounted for (Z = 8, Z’ = 1). As with the homochiral co-
crystal, no proton transfer was observed, allowing for this material to be described as a RS-
naproxen:acridine (1:1) co-crystal. The only hydrogen bonding interaction present within this structure 
was that of the 𝐷1
1(3) interaction, common to all the structures exploiting NPX and A. Upon building 
up the crystalline assembly, similarities were observed between this racemic species and that of the 
homochiral. The main body of each NPX molecule was noted to be directed in the same orientations in 
both cases, with the only difference arising from the relative positioning of the combined carboxylic 
acid and methyl functionalities. For the racemic co-crystal, both enantiomers were accounted for, with 
the channels either side of the co-former spine alternating between the enantiomers. Furthermore, these 




Figure 8. 33 - Crystal structure of the RS-naproxen:acridine (1:1) co-crystal, highlighting (a) the unit cell, (b) hydrogen 
bonding synthon, (c) packing unit and (d) overall packing arrangement (sNPX in red, rNPX in blue) 
 
Given the structural similarities between the enantiopure and racemic co-crystals, with both expressing 
similar structures, this combination of co-former and API was shown to generate a material that could 
allow for the composition of enantiomers to be continuous. However, given that the racemic form 
expressed a higher melting point and a calculated packing density (1.302 g/cm3 and 1.276 g/cm3 for 
racemic and homochiral, respectively), the packing efficiency was shown to be greater towards equal 
quantities of enantiomer. Hence, this system can be described as a Type II, racemic solid solution. 
 
The crystal structures for the (1:1) polymorphic and (2:3) stoichiometric co-crystal variants of sNPX 
with A are shown in Figures 8.34 and 35, with their unit cell parameters being shown in Tables 8.6 and 
7, respectively. In the polymorphic case, the molecules crystallised together in a 1:1 ratio in an 
orthorhombic P212121 space group, with the asymmetric units comprising of the API and co-former in 
a 1:1 molar ratio (Z = 4, Z’ = 1). Here, the same hydrogen bonding motif was used as before, but in this 
case, rather than forming pairs of these interaction units, individual units were stacked together, 
interlocking with neighbouring units, forming distinct channels of sNPX and A, with the each like 
molecule in these channels alternating in orientation, as described through the crystal symmetry. The 
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packing density of this polymorphic form was greater than that of Form I (1.324 g/cm3), highlighting 




Figure 8. 34 - Crystal structure of the S-naproxen:acridine (1:1) co-crystal, Form II, highlighting (a) the unit cell and (b) 
packing arrangement (sNPX in red) 
 
For the final form, the asymmetric unit consisted of two molecules of sNPX to three of A, a 
stoichiometric variant on that observed previous. With two of these making up the unit cell (Z = 2, Z’ 
= 1), these molecules were shown crystallise in the non-centrosymmetric monoclinic space group, P21, 
with the same hydrogen bonding motif being used as before. However, this interaction was not utilised 
by every co-former. For every two co-former molecules that formed hydrogen bonding interactions 
with two API molecules, a third non-bonding species of A was shown to be present. The hydrogen 
bonded entities were shown to pack in such a way so as produce rings, within which pores of sufficient 
size were generated, capable of accommodating two channels of co-formers.  
 
Table 8. 6 - Unit cell and crystallographic parameters for the S-naproxen:acridine (1:1) co-crystal, Form II 
 
Material S-naproxen:acridine 
(1:1) co-crystal, Form II 
Empirical formula C27H23NO3 
Formula weight 409.46 
Temperature (K) 150.00(10) 
Crystal system orthorhombic 
Space group P212121 
a (Å) 5.54150(10) 
b (Å) 12.5633(2) 
c (Å) 29.5070(4) 
α (°) 90 
β (°) 90 
γ (°) 90 
Volume (Å3) 2054.26(6) 
Z, Z’ 4, 1 
ρcalc (g/cm3) 1.324 
μ (mm-1) 0.687 
F(000) 864.0 
Crystal size (mm3) 0.05 × 0.05 × 0.05 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection (°) 5.99 to 146.24 
Index ranges -4 ≤ h ≤ 6, -15 ≤ k ≤ 15, -35 ≤ l ≤ 36 
Reflections collected 23848 
Independent reflections 4070 [Rint = 0.0314, Rsigma = 0.0193] 
Data/restraints/parameters 4070/0/283 
Goodness-of-fit on F2 1.057 
Final R indexes [I>=2σ (I)] R1 = 0.0386, wR2 = 0.1049 
Final R indexes [all data] R1 = 0.0416, wR2 = 0.1081 
Largest diff. peak/hole  (e Å-3) 0.23/-0.26 







Figure 8. 35 - Crystal structure of the S-naproxen:acridine (2:3) co-crystal, highlighting (a) the unit cell and (b) packing 
arrangement (sNPX in red) 
 




Empirical formula C67H55N3O6 
Formula weight 998.14 
Temperature (K) 150.00(10) 
Crystal system monoclinic 
Space group P21 
a (Å) 17.2022(8) 
b (Å) 5.9240(2) 
c (Å) 25.3678(11) 
α (°) 90 
β (°) 101.465(5) 
γ (°) 90 
Volume (Å3) 2533.54(19) 
Z, Z’ 2, 1 
ρcalc (g/cm3) 1.308 
μ (mm-1) 0.084 
F(000) 1052.0 
Crystal size (mm3) 0.32 × 0.126 × 0.124 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 5.272 to 51.362 
Index ranges -20 ≤ h ≤ 20, -7 ≤ k ≤ 7, -30 ≤ l ≤ 30 
Reflections collected 18594 
Independent reflections 9606 [Rint = 0.0281, Rsigma = 0.0488] 
Data/restraints/parameters 9606/1/691 
Goodness-of-fit on F2 1.078 
Final R indexes [I>=2σ (I)] R1 = 0.0433, wR2 = 0.0878 
Final R indexes [all data] R1 = 0.0529, wR2 = 0.0935 
Largest diff. peak/hole  (e Å-3) 0.15/-0.19 





8.4 Summary, conclusions and future work 
 
Following on from the previous work conducted with the NPX and the 2AP derivatives, further 
screening was carried out using co-formers exhibiting a different set of hydrogen bonding interactions. 
These included imidazole (I) and its derivative, benzimidazole (BI), as well as that of acridine (A). 
Whilst the first two species both exhibited the same hydrogen bond acceptor and donor functionalities, 
with the capability to facilitate proton transfer with NPX, the third co-former contained only one group 
that could form a contact with the API. Each of these co-formers, as single-component entities, were 
known to crystallise as a variety of forms, presenting the possibility of forming structurally varying 
multi-component forms.  
 
As with the 2AP derivatives, mechanochemistry was utilised as a first reference point and was shown 
to be capable of precipitating at least one novel crystalline multi-component phase for each of the co-
formers used. Whilst translation to solution crystallisation was not always directly possible, the solid 
prepared via grinding provided material that could be used as a seed into the necessary crystallisation 
media, allowing for the growth of the necessary crystals and hence, structural characterisation. As such, 
the combination of mechanochemical and crash cooling crystallisations allowed for the effective 
screening of the API with these co-formers, allowing for the discovery of eight novel multi-component 
complexes of varying enantiomeric and stoichiometric composition, with a several polymorphs being 
found.  
 
In the case of NPX with I, different salt forms were shown to precipitate at racemic and homochiral 
compositions, each expressing a (2:1) stoichiometry. For the enantiopure complex, a hydrogen bonded 
chain, alternating from NPX to I, formed the basis of the structure, with proton transfer occurring 
between the two molecular entities. An additional neutral API molecule was shown to interact with the 
chained NPX species, culminating in a branches protruding from the chain. In contrast, the racemic 
multi-component material demonstrated a zig-zagged chained structure, with the co-former molecule 
forming contacts, bridging between the protonated and deprotonated NPX molecules, each representing 
a different enantiomer. These in turn were shown to interact. Whilst the initial evidence suggested the 
crystallisation of a racemic compound system, the melting point of the homochiral salt was shown to 
be higher (124-127oC) than that of the heterochiral (113-117oC), highlighting similar characteristics to 
that of the NPX-2AP complex. Therefore, this system was deemed to have the properties of a metastable 
conglomerate and applications for chiral resolution methods, subject to further investigation. These 
would consist of probing the ability of the homochiral phase to crystallise at compositions towards that 
of racemic, hence, assessing its kinetic stability.  
 
Upon manipulating the structure of the first co-former with the introduction of a benzene functionality, 
BI was shown to generate a different set of crystalline materials at racemic and enantiopure 
contributions than that observed for I. Having been prepared reliably via mechanochemical means, both 
complexes were shown to not only possess the same diffraction patterns, but also broadly the same 
thermal phenomena from 128oC to 131oC. By assessing the crystal structures of the two materials, it 
was shown that both possessed the same arrangement of molecular entities, with the key interaction unit 
consisting of a ring of two co-former and two API molecules, all hydrogen bonded together. It was 
further shown that by changing the enantiomeric composition, the packing density did not vary, 
highlighting that the positioning of the NPX molecules within the structure did not depend upon its 
chirality. Hence, this system was defined as an ideal racemic solid solution and had no application 
towards a preferential crystallisation process.   
 
For the final system discussed in this chapter, the co-former A was selected owing to its lone 
functionality capable of forming a strong hydrogen bonding interaction, allowing for a greater number 
of molecular conformations and hence, polymorphic forms. The aim, alongside discovering structures 
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that are applicable to chiral resolution processes, was to explore the polymorphic landscape of multi-
component materials made in combination with NPX. As such, three different structural variations of 
the homochiral form of the API with the co-former were prepared; two polymorphic (1:1) and one (2:3) 
stoichiometric co-crystalline phases. In comparison, only one form was found, to date, with racemic 
compositions, that of a (1:1) co-crystal. The different materials were prepared either by 
mechanochemistry, through the direct crystallisation from ethanol or acetonitrile solutions or upon 
seeding said solutions. Upon comparing and contrasting the (1:1) structures of NPX and A, it was shown 
that both a conventional racemic compound and a racemic solid solution were possible, which showed 
little use for chiral resolution via crystallisation.  
 
With particular emphasis on the system incorporating the co-former A and whilst each of the multi-
component structures presented the same hydrogen bonding interaction, the polymorphic nature of this 
system could be attributed to different orientations the various molecular species could take about this 
contact. An interesting feature was that only the enantiopure preparations demonstrated polymorphism, 
whilst the racemic did not. It is plausible that the number of degrees of freedom exhibited by a racemic 
system would be less than that for the homochiral, owing to the need to find structures within which the 
three molecular components, i.e. the two enantiomers and the co-former, could interact and pack 
efficiently.  
 
Further to the work completed here, the polymorphic landscape of each case can still be explored to a 
greater extent. By using the crash cooling method, further solvent environments should be assessed, 
maintaining the different stoichiometric combinations of API to co-former and applying seeding where 
necessary. In addition, the potential of the NPX-I system should be explored further, confirming the 
metastability of the enantiomerically pure complex towards racemic compositions and designing 
cooling crystallisations accordingly that could have implications for a preferential process.   
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9 Selective preparation and crystallisation of stoichiometric co-crystals of 
oxalic acid and urea, driving towards continuous crystallisation 
 
As shown from previous studies, upon combining of oxalic acid (OA) and urea (U), two stoichiometric 
co-crystals were able to form, that of the oxalic acid:urea (1:2188, 189, 191, 193) and (1:1188, 191, 192) co-crystals 
(OAU-1:1 & OAU-1:2). These materials show different crystalline structures, highlighted in Chapter 3, 
each with their own stabilities. These are reflected by the thermal phenomena exhibited in Figure 9.1, 




Figure 9. 1 - DSC traces highlighting the thermal phenomena associated with urea (U), oxalic acid (OA) and oxalic acid 
dihydrate (OAD) starting materials, as well as that of the oxalic acid-urea (1:1) & (1:2) co-crystals 
 
These crystalline phases were produced via various and contrasting preparation methods, discussed in 
detail in the material literature review. These include mechanochemical192 methods, slurrying188, 191 and 
evaporation189, 190, 193 from solution. Each preparation method operates in a different area of the ternary 
phase diagram for a given system of components and solvent, as indicated in Figure 9.2 (a) and (b). For 
ground samples, a given stoichiometry of the starting components is selected and the materials are 
placed under mechanical stress. In certain cases, minimal solvent is added to facilitate the process of 
co-crystallisation. The role of the solvent is still debated, postulated to be either acting to facilitate the 
movement of molecules or aiding through the introduction of minor dissolution effects.  
 
Upon increasing the contribution of solvent and avoiding complete dissolution, slurrying can also be 
utilised as an effective multi-component material preparation method. Here, the starting components 
are mixed together in a given amount of solvent, whereby the molecules are constantly transitioning 
between the solid and solution states, thus aiding in the complexation of different crystalline forms. The 
phases yielded are dependent upon a variety of factors, each reliant on the location of the operation 
within the phase diagram at a given temperature. These include the degree of solid loading and the 






Figure 9. 2 - Simplified ternary phase diagrams, highlighting the areas utilised by different isothermal methods for co-crystal 
preparation, including (a) mechanochemical, slurrying and (b) evaporative techniques 
 
For both mechanochemical and slurrying methods, a given concentration or solid loading of the 
individual starting materials to solvent is selected and maintained through the time period of the 
experiment. In contrast, by evaporating off solvent at a specified temperature, the concentration 
constantly changes, moving from an undersaturated to a saturated to a supersaturated state. Once the 
supersaturation has been reached, nucleation and growth is then able to occur. As with grinding and 
slurrying, the initial stoichiometry plays a key role in determining which combination of phases are 
generated. 
 
These preparation methods, whilst operating in various areas of the ternary phase landscape, are each 
carried out under a single temperature environment. In cooling crystallisations, the inherent property 
that the solubility of the system changes with temperature, at a given composition, is utilised and upon 
altering the thermal conditions used, the system can transition to the supersaturated state necessary for 
crystallisation to occur. This is shown in the example ternary phase diagrams in Figure 9.3. To date, 
this method has not be used for the system of OA and U. 
 
Each of the methods discussed above can allow for the preparation of both the thermodynamically and 
kinetically stable phase, depending upon the conditions used. For the two methods reliant on excessive 
mixing and grinding, i.e. mechanochemistry and slurrying, the intensity of the processing and the time 
utilised can both play a key role for the nature of the end phases generated. In evaporative and cooling 
environments, the rate at which supersaturation is achieved is of great significance in this respect, with 
different temperatures and cooling rates influencing both these processes, respectively. 
 
Within this chapter, the system of OA and U will be examined, reassessing the initial crystallisation 
techniques used, exploring the important parameters of each method for the preparation of the 
individual co-crystals. Routes will be examined for the reproducible preparation of both these multi-
component phases, with a particular emphasis on their preparation in water. This focus on crystallisation 
from water will form the foundation for subsequent cooling crystallisation experiments, looking 
towards the preparation of the co-crystals in the batch environment. This will lead towards the specific 
preparation of the OAU-1:2 form through the continuous crystallisation rigs in operation at the 
University of Bath, assessing their capabilities and limitations. Where possible, material preparation 
was conducted towards room temperature conditions. For the cooling crystallisations, the predominant 
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aim was to attempt material precipitation between 20-30oC; such conditions would be ideal, for 




Figure 9. 3 - Simplified ternary phase diagrams, highlighting cooling crystallisation, the variability of solubility with 
temperature and some of the different solution stoichiometries to be probed 
 
9.1 Mechanochemical preparation 
 
Based upon the work conducted by Onija et al.192, mechanochemical methods were utilised for the 
generation of the OAU-1:1 co-crystal, whereby 1:1 combinations of OA and U were combined and 
ground with the aid of minimal quantities of water.  To date, grinding has not be used to prepare the 
OAU-1:2 stoichiometric form. In the work outlined in this section, mechanochemical preparations 
utilising different solvents will be assessed for their ability to yield the different co-crystalline forms. 
With a focus on liquid-assisted grinding with water, further preparations will be explored for the effect 
of starting materials used, grinding time and water quantity on complexation. Finally, 
mechanochemistry will be used to determine the ability of the two co-crystals to interconvert, providing 
an indication as to their relative stabilities.  
 
9.1.1 Variation in solvent  
 
Initial preparations were conducted whereby different stoichiometric amounts of OA and U (2:1, 1:1 
and 1:2) were ground together for 10 minutes, either neat or with the assistance of few drops of water, 
methanol, ethanol or isopropanol. Figures 9.4 and 9.5 outline the PXRD patterns for the 1:1 and 1:2 
preparations, with those of the 2:1 samples located in Appendix A9.1.  
 
For the equimolar preparation, both the neat and aqueous grindings demonstrated the formation of a 
mixture of the (1:2) co-crystal with OAD. It should be noted that under the atmospheric conditions used, 
the OA starting material, stored in a desiccated oven, readily took on water, forming the dihydrate. 
However, when utilising the alcohols, the (1:1) form could be obtained consistently, without excess 
starting material. These observations, particularly for the samples prepared from water, were in contrast 
to those made from the literature, where the (1:1) co-crystal could be accessed at the corresponding 






Figure 9. 4 - PXRD patterns highlighting the mechanochemical 1:1 combinations of OA and U, either neat or with minimum 
quantities of water, methanol, ethanol or isopropanol (top six patterns) 
 
When the grinding stoichiometry was changed to reflect the 1:2 molar ratio, it was shown (Figure 9.5) 
that the OAU-1:2 co-crystal could be generated across all preparations, with or without solvent. By 
considering the phases prepared across the three stoichiometries, where the 2:1 preparations 
demonstrated the formation of the (1:2) phase and excess OAD for the neat and water-based grindings, 
with the alcohols each showing that the (1:1) co-crystal could also be prepared with OAD, it was 
summarised that solvent environment and molar ratio of components each played an important role. 
Both co-crystals could be selectively accessed at their corresponding stoichiometries for the alcohol 
environments, whilst the only the (1:2) co-crystal could be obtained from the aqueous preparations. 






Figure 9. 5 - PXRD patterns highlighting the mechanochemical 1:2 combinations of OA and U, either neat or with minimum 
quantities of water, methanol, ethanol or isopropanol (top six patterns) 
 
9.1.2 Variation in the starting components (OA and OAD) and grinding times 
 
In order to determine a method for obtaining the OAU-1:1 phase, variations in the mechanochemical 
parameters were explored, each investigating the role of water. Firstly, neat grindings were conducted, 
whereby subtle changes in the starting material were examined alongside different grinding times. This 
change in the starting material was done by comparing grindings with anhydrous OA against those 
incorporating water already complexed within the structure, i.e. OAD. The PXRD patterns for the 
respective 2:1, 1:1 and 1:2 combinations can be found in Appendix A9.1.  
 
With an initial focus on the 1:2 mechanochemical samples, the OAU-1:2 co-crystal was shown to form 
rapidly, within two minutes, upon OAD and U being ground together neat in the corresponding 
stoichiometry. In contrast, upon using the dehydrated starting material, the same co-crystalline phase 
was shown to evolve slowly over time (greater than 20 minutes), with excess raw components being 
consumed or converted to the dihydrate before being used to generate the co-crystal. An initial 
suggestion would be that the water present as part of the complexed OA form was able to catalyse the 
co-crystallisation process, benefiting the interactions and structure of the (1:2) form. 
 
Continuing the study using a 1:1 ratio of starting materials, be it OAD or OA, both preparation types 
demonstrated the initial formation of the (1:2) multi-component phase along with excess OAD, OA (α), 
U or combinations thereof. As time progressed, it was shown that the contribution of the individual 
starting materials diminished, along with that of OAU-1:2. Through this, the relative proportions of the 
(1:1) co-crystal increased. Similar observations were made for the 2:1 samples, where the OAU-1:1 
complex was shown to develop over time, along with the presence of excess OA starting material, 
always developing into the dihydrate form. Owing to the similarity in observations for the anhydrous 
and hydrated preparations, the presence of water was not deemed the defining factor for the 




9.1.3 Variation in water quantity 
 
To further explore the role of water in the formation of the two respective co-crystals, further 
preparations were made, exploiting the same stoichiometries as before, but here utilising different 
aliquots of water (0 μL to 140 μL). Each sample was ground until all the solvent was deemed to have 
evaporated. The diffraction patterns for each preparation are outlined in the Appendix A9.1. 
 
As before, the OAU-1:2 co-crystal was shown to precipitate directly from its corresponding molar ratio 
with only a small quantity of water being added. In contrast, for the two ground sets of samples 
incorporating a greater molar contribution of OA, the OAU-1:2 co-crystal was again shown to be 
consistently produced, alongside excess OAD. The supported the findings from the previous 
experiments, suggesting that water was able to facilitate the formation of (1:2) form, whilst hindering 
that of the (1:1) at its related stoichiometric preparations. These collective observations raised questions 
as to the results previously reported192 for the selective preparation of the OAU-1:1 co-crystalline phase 
via mechanochemical means.  
 
9.1.4 Mechanochemical interconversion 
 
In addition to being utilised for the direct selective complexation of the different co-crystalline phases, 
mechanochemistry can also be used to probe the ability of these multi-component forms to interconvert. 
This, as a result, provides an indication as to the relative stability of the two materials under different 
grinding conditions. Hence, using the same preparation method used, initial 1:1 and 1:2 molar ratios of 
OA to U were combined together either neat or using water, methanol, ethanol or isopropanol, and 
ground for 10 minutes, or until sufficiently dry. From here, additional starting material was introduced 
so as to change the stoichiometries from 1:2 to 1:1 or 1:1 to 1:2, respectively. The samples were ground 
further, either neat or with solvent, and analysed using PXRD, the patterns of which are highlighted in 
Figures 9.6 and 9.7.  
 
Upon introducing excess U after the original complexation, the OAU-1:2 co-crystal was shown to form 
consistently from the 1:1 preparations across all solvent environments, along with additional U starting 
material. Likewise, with the addition of further OA to the 1:2 preparations, the (1:1) multi-component 
form was shown to precipitate dependably across all mechanochemical preparations. However, 
particularly in the alcohol samples, the (1:1) co-crystal was shown to be present in combination with 
the (1:2) phase. Whilst it was demonstrated that both co-crystalline forms could be accessed from their 
opposing stoichiometric variant, the PXRD patterns indicated that there was a greater barrier to 
conversion with that from the 1:2 to 1:1 phase. Together, the initial results taken from these 
mechanochemical experiments suggested that the OAU-1:2 co-crystalline system was marginally more 





Figure 9. 6 - PXRD patterns highlighting the mechanochemical conversion of the co-crystals of oxalic acid and urea, from a 





Figure 9. 7 - PXRD patterns highlighting the mechanochemical conversion of the co-crystals of oxalic acid and urea, from a 






9.2 Solvent-mediated (slurrying) preparations 
 
Solvent-mediation or slurrying is a popular method for generating different multi-component phases, 
as highlighted by the work carried out by Dalman et al.188 and Feng et al.191 for the preparation of the 
(1:1) and (1:2) co-crystalline phase, respectively. In the case of the OAU-1:1 phase, OA and U were 
combined in a 4.5 to 1 ratio, whilst the OAU-1:2 form was prepared from a 1:2 molar ratio, with both 
systems being suspended in water for 24 hours at 40oC. In this section, the preparation of the two co-
crystals will initially be assessed in different solvent environments, leading to a focus on their 
preparation exclusively from water at 20oC. By using various stoichiometries and solid loadings, 
different areas of the phase diagram were probed. As such, the stability of the different materials can 
be assessed, providing insights that could be translated towards cooling crystallisation preparations.  
 
9.2.1 Variation in solvent  
 
Using 2:1, 1:1 and 1:2 stoichiometries, OA and U were mixed for up to 24 hours in a range of solvents 
(water, methanol, ethanol and isopropanol) at 20oC. The samples were filtered and analysed for their 
phase composition using PXRD. Figures 9.8 and 9.9 show the patterns for the materials yielded from 
the 2:1 and 1:2 preparations, with that of the 1:1 samples in Appendix A9.2.  
 
For the preparations utilising the 2:1 molar ratio of OA to U, it was shown that the OAU-1:1 co-crystal 
could be accessed from all the solvent environments. However, unlike in the 1:2 samples where the 
(1:2) multi-component phase was prepared exclusively across all conditions, minimal traces of either 
the opposing (1:2) co-crystal or starting materials could be found in the 2:1 setups. It was also shown 
that for the equimolar preparations, the OAU-1:2 co-crystal could be consistently obtained from each 
of the solvent environments used, with the isopropanol case showing minimal amounts of the (1:1) 
phase in addition.  
 
 
Figure 9. 8 - PXRD patterns highlighting the solid product yielded from initial slurrying experiments of a 2:1 combination of 






Figure 9. 9 - PXRD patterns highlighting the solid product yielded from initial slurrying experiments of a 1:2 combination of 
OA and U, in a variety of solvents; water, methanol, ethanol and isopropanol (top four patterns) 
 
Collectively, these observations emphasised that under the conditions used, the (1:2) co-crystal was 
broadly the dominant phase at this temperature and in order to establish a route to the pure preparation 
of the alternative (1:1) form, particularly in water, further probing of the ternary phase diagram should 
be undertaken.  
 
9.2.2 Bulk preparation and solubility 
 
Due to the reproducible formation of the OAU-1:2 co-crystal across a number of solvent and 
stoichiometric environments, slurrying was used as a means of preparing bulk quantities of the material. 
Suspensions in water, consisting of a 1:2 combination of OA to U, were prepared and mixed at 20oC. 
As previously demonstrated, this particular co-crystalline phase could be yielded reliably and quickly 
from an aqueous environment. Hence, the slurries were mixed for only one hour. This method was 
consistently used for the preparation of the (1:2) form, as highlighted from the PXRD patterns shown 
in Figure 9.10.  
 
Having established a suitable means of preparing this specific multi-component material, its solubility 
could be determined across a given temperature range. Samples with a predetermined concentration of 
co-crystal in water were prepared and assessed for their clear points upon heating. These turbidity 
measurements are shown in comparison to that of OAD in Figure 9.11. The key saturations for OAD 
and the OAU-1:2 co-crystal at 20oC and 30oC are highlighted in Table 9.1. By considering the proportion 
of OA dissolved in solution as a contribution for the respective dihydrate and co-crystalline phases, 
dissolution from the hydrated phase was deemed to be four and five times greater than that of the co-








Figure 9. 10 - PXRD patterns highlighting the reproducible preparation of the oxalic acid:urea (1:2) co-crystal from a 1:2 




Figure 9. 11 - Solubility curves, as determined from turbidity measurements, of the oxalic acid:urea (1:2) co-crystal and the 





Table 9. 1 - Saturation points of OAD and the oxalic acid:urea (1:2) co-crystal in water, respectively, at 20oC and 30oC, with 
respect to the relative oxalic acid content 
 
Material 
Saturation at 20oC 
(OA mmol/mol) 
Saturation at 30oC 
(OA mmol/mol) 
Oxalic acid dihydrate 
(OAD) 
15.1 27.4 




9.2.3 Variation in suspension stoichiometry and solid loading 
 
Based upon the solid mass of the OAU-1:2 co-crystal required for complete dissolution at 30oC, various 
suspensions were prepared so as to assess the ternary phase diagram of OA and U in water at 20oC. By 
maintaining the overall mass of solid used, the stoichiometry of the constituent components was varied, 
so as to reflect the 5:1, 4:1, 3:1, 2:1, 1:1 and 1:2 ratios. Further to this, to probe different contributions 
of the solid starting materials with the solvent (water), different solid loadings were prepared, reflecting 
masses x2, x3, x4 and x5 that of the reference mass. Suspensions were then mixed for either 1, 4, 16 or 
64 hours, with the resultant material being analysed by PXRD. A summary of the solid phases yielded 
are tabulated in Tables 9.2, 9.3, 9.4 and 9.5, with the individual patterns located in Appendix A9.2. 
 
As emphasised below, the OAU-1:2 co-crystal could be selectively prepared across a number of degrees 
of solid loading, over a range of time scales, with particular prominence at its corresponding 
stoichiometry, 1:2. It was also noted that particularly at the lower loading levels (x2), i.e. closer to the 
solubility for a given molar ratio, this phase could be routinely accessed without excess starting material 
or opposing (1:1) co-crystal being present, even at higher suspension stoichiometries with high 
quantities of OA. This was particularly evident upon leaving the system to mix for longer time periods.  
 
In contrast, determining a route for the reproducible preparation of the (1:1) co-crystal via slurrying was 
by no means as straightforward. Though evidence for the formation of this phase was observed, there 
was limited opportunity for its pure precipitation. For samples made over short time scales and 
stoichiometries closer to that of 2:1, the OAU-1:1 form could be generated, though typically in 
combination with its related stoichiometric form or excess starting material. It was shown, however, 
that pure material of this co-crystal could be obtained at the 2:1 composition for the x4 and x5 solid 
loadings at the one and four hour timescales, respectively. 
 
A general trend was that over extending time periods of slurrying, the (1:2) co-crystal became the 
dominant phase, with limited opportunities to precipitate its stoichiometric counterpart. For the samples 
at short suspension times that did yield some of the equimolar co-crystalline phase, as the slurries were 
allowed to progress further, the system would evolve to reflect a greater contribution of the OAU-1:2 
form. Collectively, it could be stated that at molar ratios closer to 1:1 or 2:1, upon mixing the starting 
materials in water, particularly at higher solid loadings, the (1:1) phase could be kinetically stabilised 
and allowed to form. However, due to its enhanced stability in water, at many stoichiometries and solid 
loadings, the (1:2) co-crystal reflected the thermodynamically stable form and was able to evolve as the 




Table 9. 2 - Summary of the solid product, as determined by PXRD, yielded from suspensions of OA and U in water, at 
different stoichiometries (5:1, 4:1, 3:1, 2:1, 1:1 and 1:2) and solid loadings (x2, x3, x4 and x5 the solid mass of the oxalic 




x2 x3 x4 x5 





































1:2 OAU-1:2 OAU-1:2 OAU-1:2 OAU-1:2 
 
Table 9. 3 - Summary of the solid product, as determined by PXRD, yielded from suspensions of OA and U in water, at 
different stoichiometries (5:1, 4:1, 3:1, 2:1, 1:1 and 1:2) and solid loadings (x2, x3, x4 and x5 the solid mass of the oxalic 




x2 x3 x4 x5 










OAU-1:2, OAD,  
OA (α) 
OAU-1:2, OAD,  
OA (α) 





OA (α), U 
OAU-1:2, OAD,  
OA (α) 








1:1 OAU-1:2, OA (α) OAU-1:2 OAU-1:2 
OAU-1:2 
OAU-1:1 
1:2 OAU-1:2 OAU-1:2 OAU-1:2 OAU-1:2 
 
Table 9. 4 - Summary of the solid product, as determined by PXRD, yielded from suspensions of OA and U in water, at 
different stoichiometries (5:1, 4:1, 3:1, 2:1, 1:1 and 1:2) and solid loadings (x2, x3, x4 and x5 the solid mass of the oxalic 




x2 x3 x4 x5 
5:1 
OAU-1:2, OAD,  
OA (α) 
OAU-1:2, OAD,  
OA (α) 
OAU-1:2, OAD,  
OA (α) 
OA (α), OAD 
OAU-1:2 
4:1 OAU-1:2 OAD, OAU-1:2 
OAU-1:2, OAD 
OA (α) 
OA (α), OAD 
OAU-1:2, OAU-1:1 










1:1 OAU-1:2 OAU-1:2 OAU-1:2 OAU-1:2 





Table 9. 5 - Summary of the solid product, as determined by PXRD, yielded from suspensions of OA and U in water, at 
different stoichiometries (5:1, 4:1, 3:1, 2:1, 1:1 and 1:2) and solid loadings (x2, x3, x4 and x5 the solid mass of the oxalic 




x2 x3 x4 x5 
5:1 OAD, OA (α/β) 
OAD, OA (α/β) 
OAU-1:2 
OAD, OA (α/β) 
OAU-1:2 
OAD, OA (α/β) 
OAU-1:2 
4:1 
OAU-1:2, OAD,  
OA (α/β) 
OAD, OA (α/β) 
OAU-1:2 





OAU-1:2, OAD,  
OA (α) 






OAU-1:1, OA (α) 
OAU-1:2, OAD 




1:1 OAU-1:2 OAU-1:2 OAU-1:2 OAU-1:2, OA (α) 
1:2 OAU-1:2 OAU-1:2 OAU-1:2 OAU-1:2 
 
*Preparations that demonstrated the selective crystallisation of the oxalic acid:urea (1:2) co-crystal are highlighted in green 
** Preparations that demonstrated the selective crystallisation of the oxalic acid:urea (1:1) co-crystal are highlighted in yellow 
 
9.3 Evaporative crystallisation 
 
Thus far, both co-crystals of OA and U have been prepared through either mechanochemical or solvent 
mediated means, whereby complexation was dependent upon mechanochemical stress, solid-to-solid 
transitions or the gradual evolution based upon the equilibrium between the solution and solid states. 
However, despite demonstrating reliability in the selective formation of the respective co-crystals, the 
techniques discussed thus far present little control over other desirable properties, such as particle size 
and crystal morphology. As a first point of reference, the direct crystallisation from solution, exploiting 
spontaneous nucleation and growth, via initial evaporative crystallisations were examined. Both multi-
component phases were previous been studied and generated by evaporation, with both Harkema et 
al.189 and Chithambaram et al.193 crystallising the (1:2) phase from aqueous solutions of the 
corresponding stoichiometry, with further studies by Harkema et al.190 demonstrating the formation of 
the (1:1) co-crystal at higher molar ratios with respect to OA (5:1).  
 
In this section, the formation of respective co-crystals by evaporation will be explored. Firstly, the 
dependence on solvent, at given stoichiometries, will be assessed. Then, with a focus on crystallisation 
from water, further evaporative processes will be examined, evaluating the role of stoichiometry and 
the rate of nucleation as determined by the evaporation temperature.  
 
9.3.1 Variation in solvent 
 
Evaporative crystallisation experiments were first carried out at either 20oC or 40oC, using a range of 
solvent environments, including water, methanol, ethanol and isopropanol. Molar quantities of OA and 
U were dissolved in the respective solvents in either a 2:1, 1:1 or 1:2 ratio. The samples were then left 
to evaporate under their specified temperature until complete dryness had been achieved. From here, 
the resultant crystals grown were photographed under the microscope and analysed in terms of the 
phases present, using PXRD. Figure 9.12 depicts the individual crystals grown from solution, whilst 
Table 9.6 summaries the contribution of phases for each sample, the individual patterns of which can 




The aim of these experiments was to determine what crystalline materials could be yielded at given 
compositions, assessing the influence of evaporation temperature of the precipitation of the two co-
crystal forms of OA and U. As shown from the images shown in Figure 9.12, the crystal growth was 
most prevalent from the samples prepared from water across both temperatures used, where larger and 
more defined individual crystallites could be generated. In contrast, it was shown for the samples 
produced from the alcohol environments, that crystallisation was dominated by nucleation, resulting in 
smaller crystals. These initial observations suggested the favourability of the aqueous environment as a 
medium from which more sophisticated crystallisation procedures could developed. In addition, it was 
also emphasised that this solvent was the most appropriate from which single crystals could be selected 
for SCXRD analysis.  
 
Upon assessment of the diffraction data, particularly from the 1:2 samples from water, it was shown 
that the corresponding (1:2) co-crystal could be selectively crystallised using either of the two 
evaporation temperatures. In addition, this particular form could be accessed selectively when 
evaporating from isopropanol at 40oC, utilising the same stoichiometry. All of the other 1:2 preparations 
demonstrated the formation of the OAU-1:2 co-crystal along with excess starting material. These 
observations supported the findings from the other crystallisation techniques that at this composition, 




Figure 9. 12 - Images highlighting the crystals formed from the evaporative crystallisation, using 2:1, 1:1 and 1:2 





Table 9. 6 - Summary of the crystalline phases yielded from evaporative crystallisations of OA and U in either water, 
methanol, ethanol or isopropanol, utilising various solution stoichiometries (2:1, 1:1 and 1:2) and evaporation temperatures 


































Methanol OAU-1:2, OAD 
OAU-1:2, OAD 
other (26.5o) 
Ethanol OAU-1:2, OAD OAU-1:2, OAD 



















*Preparations that demonstrated the selective crystallisation of the oxalic acid:urea (1:2) co-crystal are highlighted in green 
 
Despite increasing the molar contribution of OA, the exclusive crystallisation of the OAU-1:1 co-crystal 
was found not to be possible under the conditions used. For the 1:1 stoichiometric samples, the (1:1) 
phase could only be accessed from water or isopropanol at the higher evaporation temperature, but only 
in combination with that the starting materials and the opposing (1:2) co-crystalline form. Although the 
proportion of this phase was greater at 40oC, this specific phase, again, could only be obtained as a 
mixture with the other solid state materials. It was noted that for all the samples prepared using the 2:1 
stoichiometry at 20oC the (1:2) form was consistently produced along with excess OAD.  
 
Collectively, these observations emphasised the stability of the OAU-1:2 co-crystal over a large 
composition range in the solvents used, with particular evidence at 20oC. Though further experiments 
would have to be conducted, accessing the (1:1) phase was only deemed possible towards higher molar 
contributions of OA and at higher temperatures, emphasising the existence of a higher temperature co-
crystalline form of OA and U. Further to this, given the observations made for the higher temperature 
evaporations at the 2:1 stoichiometry, the larger number of nucleation events at these compositions 
explained why both co-crystalline materials could crystallised, along with the additional starting 
materials.     
 
9.3.2 Variation in solution stoichiometry and evaporation temperature 
 
Continuing with the study into the preparation of two co-crystalline forms of OA and U via evaporation, 
further crystallisation samples were established in aqueous solutions, utilising a range of 
stoichiometries, ranging from 7:1 to 1:2. Each sample was prepared by dissolving the starting 
components in a given amount of water, from which the solvent was allowed to evaporate at different 
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evaporation rates. These rates controlled how quickly supersaturation was achieved and were 
determined through manipulations in the evaporation temperature. As such, the initial temperatures 
selected were 4oC (fridge), 20oC (room temperature) and 40oC (hotplate). Images for the resultant 
crystals are shown in Figure 9.13, with a summary of the phases obtained, as determined by PXRD, 




Figure 9. 13 - Images highlighting the crystals formed from the evaporative crystallisation, using 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 
1:1 and 1:2 stoichiometries of OA and U, from water over a range of evaporation temperatures 
 
Table 9. 7 - Summary of the crystalline phases yielded from evaporative crystallisations of OA and U in water, utilising 
various solution stoichiometries (5:1, 4:1, 3:1, 2:1, 1:1 and 1:2) and evaporation temperatures (4oC, 20oC and 40oC), 





4oC 20oC 40oC 























OAU-1:1, OA (α/β) 
2:1 OAU-1:2, OAD OAU-1:2, OAD 
OAU-1:2, OAD 
OAU-1:1, OA (α/β) 





1:2 OAU-1:2 OAU-1:2 OAU-1:2 
 
*Preparations that demonstrated the selective crystallisation of the oxalic acid:urea (1:2) co-crystal are highlighted in green 




Consistent with the observations made from mechanochemical and slurrying preparations, the OAU-
1:2 co-crystal, evident by its flat plate morphology, could be reliably prepared from solutions of the 
same stoichiometry, with no additional crystalline phases present. This observation was made over the 
three evaporation temperatures used, demonstrating the favourability in the formation of that particular 
multi-component material. Further to this, with increasing contributions of OA, the (1:2) co-crystal 
continued to crystallise at 4oC alongside excess OA in the form of its dihydrate. Despite the changes in 
the proportion of OAD to co-crystal with increasing quantities of OA starting material, the formation of 
this specific multi-component phase as opposed to the (1:1) form emphasised that with slow evaporation 
rates, supersaturation was achieved gradually. Hence, the more thermodynamically stable phase was 
shown to precipitate.  
 
As the temperature was increased, the rate at which supersaturation, and hence nucleation, was achieved 
increased. In particular at 40oC, the prevalence of the (1:1) co-crystal improved with the 1:1 preparation 
and those with greater quantities of OA, most notably in the 4:1 and 5:1 samples, where no (1:2) co-
crystal was noted within the detection limit of the diffractometer. These observations supported the 
findings made in the literature and emphasised that with faster nucleation rates and higher OA 
stoichiometries, the OAU-1:1 phase could be kinetically stabilised.  
 
It should also be noted that, with specific evidence at the higher evaporation rate and OA 
stoichiometries, the PXRD patterns demonstrated a distinct peak at 14.5o (2θ), with a greater than 
expected intensity to that otherwise associated with any of the known materials (See Appendix A9.3). 
As such, this could be associated with either the presence of an additional phase (‘other’) or of preferred 
orientation. 
 
Focusing on the 1:1 evaporative samples across the temperature range, both co-crystalline forms were 
shown to precipitate, with the (1:2) phase favoured. In order to confirm the metastability and kinetic 
favourability of the OAU-1:1 co-crystal, further evaporative crystallisations were prepared, utilising the 
1:1 stoichiometry and the solvent to dissipate at increasing temperatures from 60oC to 140oC. Table 9.7 
summaries the resultant crystalline phases, with the PXRD patterns displayed in Appendix A9.3. 
 
Table 9. 8 - Summary of the crystalline phases yielded from evaporative crystallisations of OA and U in water, utilising the 
1:1 solution stoichiometry and various evaporation temperatures (4oC, 20oC, 40oC, 60oC, 80oC, 100oC, 120oC and 140oC), 



























It was shown that as the temperature was raised for each evaporation, the proportion of the two co-
crystals precipitated changed in favour of the (1:1) form. This, once again, emphasised the fact that with 
rapid nucleation rates, both phases could crystallise. However, despite the stoichiometry, the fact that 
the 1:2 phase was still formed emphasised its thermodynamic stability when crystallising from aqueous 
conditions. Under the conditions explored here, the selective crystallisation the lone OAU-1:1 phase 
was deemed to not be possible via evaporation without the precipitation of a secondary phase. 
Therefore, prior structural analysis could only have been conducted by fortuitous selection of an 
individual crystal from a mixture of crystallites of various composition.  
 
Furthermore, it should be noted that whilst changing the rate of nucleation through increases in 
temperature can allow (limited) access to less stable phases, an obvious consequence is the effect on 
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crystallite size. With increasing temperatures, a greater degree of nucleation is possible, resulting in 
smaller crystals, that would impact on further processing steps.  
 
9.4 Batch cooling crystallisation 
 
To date, routes to the preparation of the two co-crystals of OA and U have been established through 
mechanochemical, slurrying or evaporative means, demonstrated either in the literature or from the 
work outlined here. In general, industrial crystallisation procedures do not utilise these methods owing 
to their limited ability to control the range of particle properties necessary for effective processing, such 
as particle size and shape. Hence, translating control over particle parameters like size distribution and 
morphology into a process whereby the phase can be selectively made, is greatly desirable.   
 
Cooling crystallisation, where solutions are able to transition to the supersatured state owing to the 
change in solubility with decreasing temperature, is a method regularly used within a variety of 
commercial environments. Through a knowledge of the solubility of a given crystalline system and by 
controlling factors such as cooling rate, mixing rate, seeding, etc., crystallisations can be designed to 
regulate an number of key outcomes. With phase selectivity remaining the goal, cooling crystallisation 
was applied to the system of OA and U, in a batch context, so as to derive pathways to the selective 
preparation of the individual co-crystalline forms. Cooling precipitations were carried out initially in 
isopropanol and subsequently in water. 
 
9.4.1 Cooling crystallisations from isopropanol 
 
Using gravimetric analysis, the solubility of OA starting material (taken as the α-polymorph) at 20oC in 
isopropanol was determined. Three preparations were prepared and assessed, from which an average 
solubility of 0.22 g/g was taken. The masses used to calculate this value can be found in Appendix A9.4. 
 
Based upon the amount of OA capable of dissolving in this given solvent system at 20oC, solutions of 
OA were established, to varying degrees of saturation. Molar quantities of U were then added so as to 
reflect the 4:1, 3:1, 2:1, 1:1 and 1:2 solution stoichiometries. The combinations of solutes and solvent 
were then heated and allowed to dissolve at 65oC and subsequently cooled to 20oC, at a rate of 
0.1oC/minute. The resultant solids were filtered and analysed by PXRD. The diffraction patterns for the 
individual compositions can be found in Appendix A9.4, with Table 9.8 summarising the findings.  
 
Table 9. 9 - Summary of the solid product, as determined by PXRD, yielded from the cooling crystallisations of solutions of 
OA and U in isopropanol, with varying solution stoichiometries (4:1, 3:1, 2:1, 1:1 and 1:2) and saturation levels (based upon 
x1, x0.5, x0.25, x0.125 & x0.0625 the saturation of the OA starting material at 20oC), heated to 65oC and cooled to 20oC at 




x1 x0.5 x0.25 x0.125 x0.0625 
























OAU-1:2 OAU-1:2 OAU-1:2 
1:2 U, OAU-1:2 U, OAU-1:2 OAU-1:2 OAU-1:2 OAU-1:2 
*Preparations that demonstrated the selective crystallisation of the oxalic acid:urea (1:2) co-crystal are highlighted in green 




Isopropanol was selected as a contrasting solvent system to water for cooling crystallisation due to the 
observations made from the previously used co-crystal preparation methods. With particular reference 
to the mechanochemical and slurrying techniques, when isopropanol was used as the mediating solvent, 
it was noted that both the respective multi-component phases of OA and U could be yielded to a greater 
degree of purity at the stoichiometries used.  
 
As shown from the diffraction data collected for the various samples prepared from the cooling 
crystallisations in isopropanol, depending upon the saturation level and solution stoichiometry 
employed, both co-crystals could accessed. At the higher contributions of OA, in terms of both loading 
and molar ratio with respect to U, it was shown that the OAU-1:1 phase could be generated, exclusively. 
Whilst this form could only be obtained purely above a certain saturation threshold (0.5 times 
saturation), it was demonstrated that the OAU-1:2 co-crystal could be crystallised consistently at its 
corresponding stoichiometry across all the saturations used. Furthermore, it was highlighted that this 
particular phase could also be generated across all the molar ratios utilised, with particular prevalence 
towards the lower saturations. 
 
Collectively, these results indicated that by using isopropanol as the crystallisation solvent, both co-
crystals could be selectively obtained. It was also made plain that the relative stability difference of the 
two phases in this given environment was smaller than that observed from aqueous systems, particularly 
when tending towards 20oC. However, given the fact that the OAU-1:2 co-crystal could be generated 
over a number of compositions at lower saturations, this provided another indication that, even in this 
alcohol system, this particular multi-component material was the more stable phase.   
 
9.4.2 Cooling crystallisations of the oxalic acid:urea (1:2) co-crystal from water 
 
Given the reliability of its formation at the corresponding stoichiometry through the other preparation 
techniques used and having established its solubility in water over a specified temperature range, 
cooling crystallisations were carried out so as to confirm the preparation of the (1:2) co-crystal. With 
the solubility of this multi-component form taken as 0.063 g/g (5.4 mmol/mol) at 30oC, solutions were 
prepared at the 2 g solvent (water) scale, heated to 45oC, ensuring complete dissolution, and cooled 
either 25oC or 20oC. The cooling rates used were 0.1oC/minute and 1oC/minute, with a constant mixing 
rate of 200 rpm. The end material in each case was filtered and analysed using PXRD, the patterns of 
which are shown in Figure 9.14. 
 
For each of the cooling rates used, the OAU-1:2 co-crystal was shown to form consistently, with no 
other phases present. With the saturation level set at 30oC with respect to this multi-component material, 
nucleation was shown to occur between 30oC and 25oC for each preparation, emphasising the relatively 
small metastable zone generated under the conditions used.  
 
Selecting the faster cooling rate (1oC/minute), so as to reflect the more rapid rate of cooling utilised in 
later continuous crystallisation processes, further crystallisations were conducted at increasing volumes 
of solvent. Cooling from 45oC to 20oC, mixing at 200 rpm, solutions were setup at increasing scales, 
reflecting that of 10 g, 30 g and 100 g of water with the corresponding quantities of OA and U. The 
resultant solid yielded was analysed, the PXRD patterns of which are highlighted in Appendix A9.4. 
As before, each of the preparations demonstrated the reliable crystallisation of the (1:2) co-crystal, 
emphasising the use of cooling for multi-component material formation, a process capable of yielding 






Figure 9. 14 - PXRD patterns highlighting the preparation of the oxalic acid:urea (1:2) co-crystal via cooling crystallisation, 
assessing different cooling rates (0.1oC/min & 1oC/min) and end temperatures (20oC & 25oC) (top four patterns) 
 
9.4.3 Cooling crystallisations of the oxalic acid:urea (1:1) co-crystal from water 
 
Having established from the slurrying experiments in water, both those conducted at 20oC here and 
those at 30oC (as explored in the literature188, 191), that the OAU-1:1 co-crystal could be accessed at 
stoichiometries with higher proportions of OA and at higher solid loadings, cooling crystallisation 
experiments were designed that exploited similar compositions. Once again, the solid mass of the OAU-
1:2 co-crystal required for complete saturation in water at 30oC was used as a reference mass, from 
which solutions that reflected the 5:1, 4:1, 3:1 and 2:1 molar ratios of OA to U were prepared. The 
relative saturation levels were also changed, constituting x2.5, x3 and x3.5 that of the original, used to 
achieve higher supersaturations. These samples were heated to 75oC and allowed to completely 
dissolve. From here, the solutions were cooled to 20oC at 1oC/minute or 0.1oC/minute, with a constant 
mixing rate of 200 rpm. Once filtered from the mother liquor and dried, the resultant solids were 
analysed using PXRD. Tables 9.9 and 9.10 summarise the crystalline products yielded for the different 
cooling rates, with the individual diffraction patterns shown in Appendix A9.4. 
 
From the higher degrees of saturation under the 0.1oC/minute rate of cooling, it was noted that the (1:1) 
multi-component form was able to precipitate. As the proportion of OA was increased, along with the 
overall saturation level, the proportion of the OAU-1:1 form increased, though still in combination with 
excess starting material. This suggested that upon crystallising material out at these compositions, the 
conditions were such that this particular phase was able to nucleate pseudo-selectively and be stabilised 
sufficiently till filtration, without the crystallisation of its stoichiometric relative. Consistent for both 
cooling rates, the (1:2) co-crystal could be accessed selectively at the stoichiometries using the lowest 
proportion of OA and towards lower solution saturations, with particular evidence at the 2:1 molar 
combination. 
 
Utilising the same conditions but cooling at the faster cooling rate, it was shown that both multi-
component phases could precipitate, along with additional starting materials. This was rationalised 
based upon how supersaturation was achieved. With increasing rates of cooling, a system can reach 
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higher proportions of supersaturation more quickly, increasing the likelihood of a greater number of 
nucleation events. Here, as supersaturation was reached and surpassed, a greater degree of nucleation 
events were able to occur, a consequence of which was the formation of multiple crystalline phases, 
including both the stoichiometric co-crystals. Given the previous observations made from slurrying and 
the inherent thermodynamic stability of the (1:2) phase over a wide composition range, it was therefore 
expected that, if the resultant solid mixture was left, over time, the OAU-1:1 crystal would be suppressed 
and convert to that of either the starting materials or the (1:2) phase, depending upon the composition.  
 
Table 9. 10 -Summary of the solid product, as determined by PXRD, yielded from the cooling crystallisations of solutions of 
OA and U in water, with varying solution stoichiometries (5:1, 4:1, 3:1 and 2:1) and saturation levels (x2.5, x3 & x3.5 the 
solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC), heated to 75oC and cooled to 20oC at 0.1oC/min, emphasising the 





































Table 9. 11 - Summary of the solid product, as determined by PXRD, yielded from the cooling crystallisations of solutions 
of OA and U in water, with varying solution stoichiometries (5:1, 4:1, 3:1 and 2:1) and saturation levels (x2.5, x3 & x3.5 the 
solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC), heated to 75oC and cooled to 20oC at 1oC/min, emphasising the 




x2.5 x3 x3.5 
5:1 
OAD 
OAU-1:2, OA (α/β) 
OAD 
OAU-1:2, OA (α/β) 
OAD 
OAU-1:1, OAU-1:2, OA (α) 
4:1 OAU-1:1, OAU-1:2 
OAU-1:2, OAD 






OAU-1:2, OAD,  
OAU-1:1 
OA (α) 
2:1 OAU-1:2 OAU-1:2 OAU-1:2 
 
*Preparations that demonstrated the selective crystallisation of the oxalic acid:urea (1:2) co-crystal are highlighted in green 
** Preparations that demonstrated the pseudo-selective crystallisation of the oxalic acid:urea (1:1) co-crystal are highlighted in yellow 
 
Having shown access to the OAU-1:1 co-crystal (with excess starting material) without the precipitation 
of the (1:2) phase towards higher degrees of saturation and contributions of OA (5:1, 4:1 and 3:1) 
through the slow cooling (0.1oC/minute) to 20oC, further crystallisations were prepared utilising the 
same experimental procedures, but here cooling to 30oC. Upon immediate filtration, the solid materials 




As the stoichiometry was altered to reflect decreasing quantities of OA, crystallisation was only shown 
to occur towards the higher saturation levels, with only the x3.5 saturation demonstrating consistent 
precipitation across the molar ratios used. Whilst preparations at the 5:1 and 3:1 molar ratios for the 
x3.5 saturation demonstrated the additional formation of either excess OAD or the (1:2) phase, it was 
shown that OAU-1:1 co-crystal could be crystallised to high proportions of purity from all the 
experiments conducted. This was particularly evident for the x3.5 saturated samples at the 5:1 and 4:1 
stoichiometries, as well as that at the x3 4:1 preparation, where this specific co-crystal could be accessed 
with complete selectivity. 
 
To ensure the reproducible crystallisation of the (1:1) multi-component phase, five repeats were carried 
out, saturating 4:1 solutions to 3.5 times the solid loading of the OAU-1:2 co-crystal at 30oC, heating to 
75oC and cooling to 30oC, filtering of the solid phase straight after reaching the end temperature. As 
shown in the PXRD patterns in Figure 9.15, using this method the corresponding OAU-1:1 co-crystal 
could be generated, via cooling crystallisation, to high levels of purity, with no evidence of the excess 
starting material or the opposing co-crystalline form. This reliability in the crystallisation of the (1:1) 
form at higher temperature supported the findings from other crystallisations from water, demonstrating 




Figure 9. 15 - PXRD patterns highlighting the reproducible preparation of the oxalic acid:urea (1:1) co-crystal via cooling 
crystallisation, cooling from 75oC to 30oC at 0.1oC/min, with a solution concentration and stoichiometry of x3.5 the solid 
mass of the oxalic acid:urea (1:2) co-crystal at 30oC and 4:1, respectively (top five patterns) 
 
9.5 Continuous cooling crystallisation 
 
As highlighted in the introduction, despite the general robustness of batch processing, the ability to 
control a wide spectrum of solid properties via these techniques is limited. In recent years, continuous 
methods have offered a route to the fine tuning of particle parameters, owing to the heightened control 
over process environments. The development of continuous crystallisation platforms has been one of 
the core remits of the Bath Continuous Crystallisation Laboratory, based at the University of Bath. 
Within this final section, two of the continuous cooling crystallisation setups used within the group, the 
Continuous Oscillatory Baffled Crystalliser (COBC) and the Kinetically Regulated Automated Input 




As shown from the previous section, both co-crystalline forms of OA and U could be selectively yielded 
through batch cooling crystallisation methods. In the case of the OAU-1:1 form, crystallisation of the 
correct phase was shown to occur only from solutions with increased saturations and higher OA content. 
In addition, these systems had to be cooled to temperatures above that of the laboratory norm, i.e. 30oC. 
Given the issues with filtration at higher temperatures, the continuous platforms were designed to 
operate primarily so that the end cooling temperature was that of ambient. As such, the selective and 
pure crystallisation of the (1:1) multi-component phase of OA and U was deemed an unsuitable target 
for such setups. 
 
9.5.1 Continuous oscillatory baffled crystalliser (COBC) 
 
Crystallisation of the OAU-1:2 co-crystal was first conducted via continuous means using the COBC, 
the design of which is outlined in Figure 9.16. The general setup consisted of six temperature controlled 
baffled straights (1-6) into which a high temperature saturated solution could be fed. The solution was 
flowed through the platform through the action of a peristatic pump, with mixing being enabled by the 
oscillatory motion of a bellows pump. Moving through the crystalliser, different temperature conditions 
were experienced by the crystallisation medium, with the temperature dropping from straight to straight, 
with the final section residing at 20oC. This allowed for stepwise cooling, raising the supersaturation 
and encouraging nucleation and growth. For each run, the residence time (the theoretical time frame 
required for a given volume of solution to move through the crystalliser) was taken as approximately 
35 minutes. Five continuous crystallisation runs were carried out, each using a different combination of 
straight temperatures for either a 30oC or 35oC saturated solution with respect to the solubility of the 
(1:2) co-crystal in water. The parameters used for these runs, as well as the nature of the end solid 
product, can be found in Table 9.12. The individual PXRD patterns from the resulting products can be 
found in Appendix A9.5. 
 
Table 9. 12 - Summary of the key parameters and outcomes of the COBC runs, 1-5, conducted with 1:2 solutions of OA and 







Straight Temperature (oC) 
Solid product 
1 2 3 4 5 6 
1 30 50 40 40 30 30 20 No crystallisation* 
2 30 50 40 40 25 25 20 No crystallisation* 
3 30 50 30 30 25 25 20 No crystallisation* 
4 30 50 20 20 20 20 20 OAU 1:2 
5 35 50 20 20 20 20 20 OAU 1:2 
 






Figure 9. 16 - Schematic diagram of the continuous oscillatory baffled crystalliser (COBC), highlighting the six temperature 
controlled tubular straights (1-6), solution feed, bellows and filtration point 
 
For the first three continuous runs, the temperature of the straights were set so as to implement a steady 
decrease in temperature, observing the point of any nucleation within the body of the crystalliser. Run 
1 maintained an undersaturated solution until the final straight, whilst runs 2 and 3 exploited a more 
gradual temperature change, with the latter transitioning from the undersaturated to the supersaturated 
state via a more severe temperature profile. For each of these procedures, no crystallisation was noted 
within the straights within the first residence time. Precipitation was noted, however, at the end piece 
of the platform, once the volume of solution necessary for one residence time had passed through the 
entire crystalliser, moving from the glass straights through a PTFE tube to the filtration unit. For each 
of the initial experiments, the precipitation at this point in the crystalliser was taken to have occurred 
around 48-51 minutes after starting the run, well within the second residence time. Leaving each of 
these runs to complete a second and third residence time (occurring approximately 35-70 minutes and 
70-105 minutes after initiating the crystalliser), crystallisation ensued, propagating from the end piece 
backwards through straights 6, 5 and 4. The initial crystallisation of material was put down to the 
interaction of the supersaturated solution with the walls of the PTFE tubing at the end piece, aiding in 
heterogeneous nucleation. This allowed for nuclei or ‘seeds’ to facilitate secondary nucleation that 
propagated back through the straights owing to the oscillatory mixing employed. Phase analysis of the 
solid product yielded demonstrated the consistent formation of OAU-1:2 co-crystal for each of these 
runs. 
 
To force primary nucleation to occur within the body of the crystalliser, the temperature for straights 2-
6 were reduced and set to 20oC, with the first being maintained at 50oC to ensure complete dissolution. 
This precaution was taken so as to minimise the possibility of crystallisation occurring within the 
oscillation bellows and thus damaging the pump. Given the unique type of mixing utilised within the 
COBC, the metastable zone for the crystallisation of the desired co-crystal, when saturated at 30oC, was 
deemed to be much wider than that observed during batch processing methods. Hence for this 
experiment, supersaturation was established much earlier stage within the crystalliser, allowing more 
time for nucleation to occur as the solution flows through the system. 
 
As with the previous runs, no crystallisation was observed until the second residence time, 48 minutes 
after initiation. However, rather than occurring at the end piece, precipitation was first witnessed 
midway through straight 4. Again, owing the oscillatory motion inherent to this crystallisation platform, 
with 10 minutes, further nucleation events were noted in straights 3, 5 and 6. After filtration and 
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subsequent analysis, the solid product was shown to be that of the (1:2) multi-component material of 
OA and U. Figure 9.17a depicts the moment when the first crystals were seen in straight 4, with Figure 




Figure 9. 17 - Images of the COBC straights in run 4, highlighting (a) the initial crystallites observed in straight 4, compared 
to straight 5, and (b) the growth of the crystals of the oxalic acid-urea (1:2) co-crystal in straight 4 
 
Whilst run 4 exemplified that the desired co-crystal could be formed via an initial primary nucleation 
process, only a small quantity of material was collected for a given residence time, with the third 
residency yielding solid with an overall mass of 2.55g. In an effort to improve the amount of solid 
obtained for a given residence time, a further continuous run was carried out at a higher saturation level, 
with solutions prepared to an OAU-1:2 co-crystal 35oC saturation. Exploiting the same temperature 
profile as in run 4 and upon commencing the run, crystallisation was originally shown to occur within 
the first residence time in straight 4 after 30 minutes. After a further 23 minutes, additional nucleation 
events had proliferated to straights 3, 5 and 6. The process was continued till the end of the second 
residence time, with the solid collected demonstrating a total mass of 8.26g, a substantially greater 
quantity than taken from previous runs. Figures 9.18a, b and c demonstrate the initial crystallites and 




Figure 9. 18 - Images for COBC run 5 highlighting (a) the initial crystallites observed in straight 4, (b) the accumulation and 
growth of crystals in straight 4 and (c) the propagation of crystallisation for the oxalic acid-urea (1:2) co-crystal from straight 




Although solid product could be generated in a larger yield with the same co-crystalline consistency, it 
was deemed not possible to produce material beyond a second residence time under the conditions used 
for run 5. This was as a result of the uncontrolled build-up of crystals at various points within the 
crystalliser. As demonstrated in Figure 9.19a, as well as primary homogenous nucleation occurring 
within the body of the platform, further nucleation phenomena were shown to ensue on the inner surface 
of the baffled straights. This encrustation developed over time, impacting on the flow dynamics inside 
the platform, as well as having implications towards the possible phases present in the end solid product. 
Furthermore, due to the vertical orientation of this particular setup, crystals were shown to accumulate 
at the bends connecting consecutive straights. Given the set flow and oscillation rates, the solid product 
could not overcome these connections and move up through the crystalliser, presenting issues in terms 
of obtaining material at the end of the process for filtration and that of blockages. The latter 
consideration presented problems upon transitioning from the second to the third residence time, with 
the blockages causing increases in pressure, presenting a safety hazard. An example of this build up is 
shown in Figure 9.19b.  
 
The final issue concerned preventing crystallisation occurring within the bellows utilised for the 
oscillatory motion exploited within the platform (Figure 9.19c). The bellows themselves were 
connected to the main straights via an L-unit of unjacketed, unbaffled glass piping which was filled 
with water and in contact with the solution medium. Despite the higher temperature of the first straight 
and given the back mixing generated upon oscillation, solution was able to enter the connecting piece 
and become supersaturated upon cooling to room temperature. Hence, crystallisation was able to occur, 
with the possibility of precipitation occurring within the bellows themselves. As such, upon noticing 
the initial crystal formation within this component, the crystalliser was stopped so as to avoid damage. 
Despite these issues, the COBC was shown to allow for the selective continuous crystallisation of the 




Figure 9. 19 - Images from COBC run 5, highlighting (a) encrustation in straight 4, (b) crystal build up in the bend between 





9.5.2 Kinetically regulated automated input crystalliser (KRAIC) 
 
Further continuous crystallisations were carried out using the KRAIC platform, whereby a solution of 
OA and U was progressively cooled through a mesotubular segmented flow reactor to room 
temperature, with solution within the slugs created by phase segmentation and mixed by bolus flow 
action. The starting components were combined in a 1:2 stoichiometry and saturated with respect to the 
corresponding co-crystal at 35oC, heated to 40oC to ensure complete dissolution. The degree of 
saturation was selected based upon the observations made from the previous COBC runs. Given the 
inherently gentle type of mixing exploited within this crystalliser, the metastable zone was expected to 
be larger than that generated under oscillatory homogenisation, justifying the heightened saturation 
level. The heated feed solution was then fed to the mixing piece and upon contact with the carrier fluid 
and air, segmentation was generated. The resultant solution slugs, coated with the immiscible fluid 
(minimise heterogeneous nucleation with the tube walls) and supported against the air segment 
(maximising efficient flow through the system), were able to move through the consecutive coils, 
gradually being cooled. The slugs were analogous to micro-batch units, with the solution being mixed 
by the generation of internal vortices. Upon reaching the end of the cooling tubing, the phases were 
separated and the solid filtered off. Figure 9.20 outlines the general setup for the KRAIC platform, 




Figure 9. 20 - Schematic diagram of the Kinetically Regulated Automated Input Crystalliser (KRAIC), highlighting cooling 
coils, the heated mixing piece and segmented flow in operation 
 
For the flow rates used, the residence time was estimated to be 17 minutes from the mixing piece to the 
filtration unit. Crystallisation was first noted towards the end of the third coil, 16 minutes after starting 
the run. Individual crystals were shown to have grown within specific slugs, though precipitation was 
observed only in a few of the segments initially. Continuing into the second residence time, 
crystallisation was shown to occur earlier in the process, with crystallites found in the midst of the 
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second cooling coil. Towards the end of this period (38 minutes), crystals were present in nearly every 
solution segment, with solid precipitating from the early stage of the second coil.  
 
Whilst this platform showed consistent crystallisation within the body of the tubing for a whole 
residence time, issues manifested themselves increasingly as time progressed. Entering into the third 
time period (40 minutes), a blockage was noted at the end piece to the filtration unit. Subsequently, 
further obstructions were observed within the body of the crystalliser, in the first coil. This caused a 
slowing of the flow rate, affecting the time over which crystallisation could occur. For each such issue 
found, the process had to be stopped.  
 
Figure 9.21 shows the crystals obtained from the first three residences, demonstrating the particular 
success of residence time two. As shown, the KRAIC was used to generate individual crystals in 
individual solution slugs, with crystals growing beyond 1 mm in length. Phase analysis of the solid 
obtained (PXRD patterns shown in Appendix A9.5) showed, once again, the successful and consistent 
preparation of the (1:2) co-crystalline phase of OA and U at this given solution composition. 
Furthermore, this setup also demonstrated the potential for segmented flow crystallisers to allow for 




Figure 9. 21 - Images of the crystals yielded from residence times 1-3 (a-c), with a close up view of those obtained for the 






9.6 Summary, conclusions and future work 
 
Within this chapter, a variety of preparation methods were examined, assessing their ability to allow for 
the selective crystallisation of the stoichiometrically diverse OAU-1:1 and OAU-1:2 co-crystals, 
respectively. By using different quantities of solvent, ranging from the minimal, via mechanochemical 
or solvent-mediated means, to those reliant on complete dissolution, i.e. evaporative or cooling 
crystallisation, routes were devised for discerning between the two co-crystalline forms. For each 
preparatory method used, key parameters were explored, with particular emphasis on solvent 
environment, sample stoichiometry and solid loading.  
 
In terms of the (1:1) form, this phase could be accessed across the different preparation methods utilised, 
either in pure form or in combination with excess starting material. By using non-aqueous solvent 
environments, in particular that of isopropanol, this co-crystal could be prepared selectively at 20oC 
when utilising larger molar proportions of OA. This suggested an enhanced stabilisation effect with 
respect to this solvent when compared to the equivalent preparations from water. As such, the formation 
of this multi-component material via these methods in water was shown to be hindered across a number 
of stoichiometries at lower solid loadings at 20oC. However, by maintaining higher solid to solvent 
ratios and larger molar ratios of OA, this co-crystal could be kinetically stabilised under ambient 
conditions. Given this metastability towards room temperatures, cooling crystallisations were 
developed, again using higher quantities of OA (4:1) and saturation levels, with the temperature being 
held at 30oC. As suggested by these initial results, the OAU-1:1 form represented a less stable material 
at room temperature with respect to the (1:2) co-crystal, though it could be kinetically stabilised and 
accessed under given conditions. The stability of this phase was shown to increase with temperature, 
highlighting the existence of a co-crystalline material with a relatively reduced stability difference with 
respect to that of the opposing multi-component phase at higher temperatures.    
 
In contrast, the OAU-1:2 form represented the formation of the more thermodynamically stable multi-
component phase under laboratory conditions, demonstrating consistent selectivity over a range of 
stoichiometries, with particular emphasis on the 1:2 combination of starting materials. In aqueous 
conditions, this specific phase could be stabilised with respect to its stoichiometric counterpart, with 
mechanochemical, slurrying, evaporative and cooling methods all exhibiting pathways to its 
reproducible preparation. Due to its reliable formation at 20oC, this co-crystal embodied the necessary 
characteristics for trials through the continuous cooling crystallisation platforms available at the 
University of Bath; the COBC and KRAIC. Both setups could be used successfully to prepare the (1:2) 
form, though further optimisation, in terms of the crystallisation parameters used and the design of the 
crystallisers, was necessary, with the aim of enhancing the yield of the OAU-1:2 phase in these runs.  
 
Drawing on the work outlined here, the system of OA and U can be explored further, with particular 
emphasis on continuing to design cooling crystallisations where the (1:1) co-crystal could potentially 
be accessed at room temperature. Using the appropriate techniques, complete ternary phase diagrams 
can be developed for the temperatures ranges of interest, focussing on that of 20oC and 30oC. Given the 
metastability in the aqueous environment of this phase, the kinetic parameters for its generation should 
be explored further. This could be conducted through the manipulation of the cooling profile used or 
through the introduction of the necessary seed. Building upon this, methods could be established for the 
continuous crystallisation of this phase, reconfiguring the platforms available so as to access materials 
with a reduced metastability at higher temperatures. For crystallisation experiments carried out using 
the COBC, the orientation of the platform could be altered, laying it flat, minimising the obstructions 
caused by the build-up of solid at the bend units. Furthermore, future designs of this particular rig should 
explore the possibility of using different materials for the construction of the individual baffled 
straights. At present, the glass surface utilised presents an opportunity for uncontrolled heterogeneous 
nucleation to occur. By coating this surface with a compatible substance to reduce this effect, more 
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efficient processes can be designed. As for the KRAIC, the main issues arise from blockages 
manifesting at the end piece as well as in the body of the crystalliser. Again, these issues can be 
overcome through the careful consideration of the material used for the coil tubing, as well as the design 




10 Conclusions  
 
When developing species such as salts and co-crystals, initial screening ought to be conducted, outlining 
early routes for the reproducible preparation of material, allowing for characterisation to take place. 
Depending upon the method used, various properties can be assessed, defining the phase behaviour, 
melting phenomena and crystal structure for a particular form. In addition, the potential for polymorphic 
and stoichiometric variations can be explored. To this end, comparisons can be made with the starting 
materials so as to determine whether the novel entity demonstrates any particular advantages. Upon the 
discovery of such a system, processes can be designed for the efficient crystallisation for the preferred 
multi-component phase, taking advantage of more robust methods, such as cooling crystallisation. In 
the research outlined in this thesis, two projects relating to the preparation, characterisation and 
application of multi-component materials is discussed. The first was centred on the API, naproxen 
(NPX), exploring the potential of salt or co-crystal formation in the alteration of the chiral crystalline 
class yielded, with uses towards preferential crystallisation processes. In the second, various 
crystallisation methods were considered for the selective preparation of the stoichiometric co-crystals 
of oxalic acid (OA) and urea (U), driving towards the design of cooling crystallisation pathways, in 
either a batch or continuous setup. 
 
NPX at racemic compositions forms a racemic compound, where opposing enantiomers crystallise 
preferentially within the same crystalline lattice. By introducing the complementary molecule, 2-
aminopyridine (2AP), novel salts can be generated at both racemic and homochiral compositions, where 
the enantiopure phase demonstrated metastability under certain conditions. This material was defined 
as a metastable conglomerate. By characterising this system using binary and ternary phase diagrams, 
crystallisations were developed that showed that complexes of homogeneous chirality could be obtained 
at compositions that tended towards the formation of the racemic multi-component phase. These 
crystallisations utilised faster cooling rates that allowed for the kinetic stabilisation of the 
enantiomerically pure phase. This emphasised that through the introduction of an appropriate secondary 
molecular entity, systems could be obtained that allow for the preferential precipitation of a desired 
enantiomer near racemic contributions.  
 
Based upon these findings, further multi-component material screening was conducted for NPX with a 
range of co-formers, using a combined approach of mechanochemical and crash cooling crystallisation 
techniques. The molecules selected were based on derivatives of 2AP, as well as those utilising different 
functional groups, and were combined with the API at both racemic and enantiopure combinations. By 
using grinding, either with or without solvent, it was shown that an efficient initial assessment could be 
made as to whether or no co-crystal or salt formation was possible. In addition, this preparative method 
also lent itself to the development of binary (melting point) phase diagrams, aiding in the 
characterisation of the chiral crystalline material present. Moreover, by using mechanochemistry, seed 
could be readily made for input into solution crystallisations, allowing for consistency in the crystalline 
product made across the different methods. 
 
For all the molecules used, a range of co-crystals and salts were found at racemic or homochiral 
compositions. In the majority of cases, no change was noted when compared to that of single-component 
component NPX in terms of the chiral crystalline material developed. Upon combination with the 2AP 
derivatives 2-aminopyrimidine (2APM), 2-amino-3-chloropyridine (2A3CP), 2-amino-4-
chloropyridine (2A3CP) and 2-amino-5-chloropyridine (2A5CP), as well as the co-former acridine (A), 
distinct crystalline phases were shown to precipitate at both enantiopure and racemic contributions, with 
evidence to suggest the formation of stable racemic compounds. Further to this, with particular 
emphasis on the preparations with A, additional polymorphic or stoichiometric forms were also 
discovered, whereby the chiral composition within the racemic co-crystal was shown to be continuous. 
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This demonstrated the formation of a racemic solid solution. Likewise, this was also shown to occur 
upon multi-component material formation with 2-amino-4,6-dimethylpyrimidine (2ADMP) and 
benzimidazole (BI). Whilst each of the solid solutions displayed different packing efficiencies at the 
two key enantiomeric compositions, like with the racemic compound forming systems, these types of 
material were deemed to not be suitable for future preferential crystallisation processes.  
 
Two other systems of interest were those incorporating imidazole (I) and 2-amino-6-chloropyridine 
(2A6CP). As observed with 2AP, upon combining NPX with I, discrete salt forms were shown to 
crystallise at racemic and enantiopure compositions, with the racemic phase exhibiting a lower melting 
point than that of its homochiral counterpart. This demonstrated a degree of stability in the solid state 
for the enantiomerically pure form, again providing an initial indication of a metastable conglomerate, 
with applicability towards a preferential crystallisation process. In the case of the 2A6CP, whereas the 
homochiral co-crystal could be freely made at the corresponding API compositions, to date no evidence 
has been found from early screening that any novel material, let alone a racemic phase, could be 
prepared at the 50:50 molar ratio of API enantiomers. By considering the location of the halogen 
substituent about the aromatic ring of the co-former, it could be suggested that no efficient packing was 
possible to accommodate both chiral forms of NPX within the same multi-component crystalline 
structure. As such, this system was deemed to have potential in the design of processes for the separation 
of enantiomers.  
 
Collectively, it was shown that by combining secondary components with a target API, novel co-
crystals or salts could be accessed with the potential of changing the chiral crystalline nature with 
respect to the starting components. By first considering what interactions were likely and selecting the 
appropriate co-former, new materials could be screened for with ease, through mechanochemical and 
solution-based means.  
 
Multi-component systems can show a variety of structural variations, be they polymorphic or 
stoichiometric. Depending upon the method of preparation used and the conditions thereof, different 
phases can be obtained. By exploiting diverse compositions of the two starting components at varying 
solvent contributions, the pathways to the selective preparation of the two respective co-crystals of OA 
and U (OAU-1:1 and OAU-1:2) were examined. The methods used included mechanochemical, 
slurrying, evaporative and cooling crystallisation techniques.   
 
With emphasis on grinding and slurrying, it was shown that both co-crystalline forms could be accessed 
from different alcohol environments (methanol, ethanol and isopropanol), although the (1:1) phase 
could only be prepared at higher molar quantities of OA, especially in samples utilising isopropanol. 
Likewise, when using solution crystallisation methods, such as cooling and evaporation, the OAU-1:1 
co-crystal was only shown to form when OA was in a greater proportion or when the degree of saturation 
was higher. This, again, was particularly prevalent for experiments conducted from isopropanol. Across 
all the preparation methods and solvents used, the OAU-1:2 co-crystal could be reliably made at its 
corresponding stoichiometry.  
 
When water was applied as the crystallisation medium of choice, over all the preparations used, the 
(1:2) phase demonstrated the greatest degree of stability at room temperature (20oC). The opposing 
equimolar co-crystal could only be generated by using larger molar contributions of OA, increasing the 
over saturation level and by crystallising this given form at higher temperatures. By considering all the 
observations made, it was suggested that under ambient conditions the OAU-1:2 phase had the greater 
thermodynamic stability over the composition range, with the only opportunity to crystallise the OAU-




Given the comparative stability and ease of crystallisation of the (1:2) form, this system was applied to 
the continuous crystallisation rigs based at the University of Bath; the COBC and KRAIC. As such, the 
OAU-1:2 co-crystal was shown to crystallise consistently within both platforms. As both of these 
methods utilise a gentler type of mixing than used in batch processing, the metastable zone was observed 
to be much wider, with spontaneous nucleation only occurring after a lengthy induction period. 
Furthermore, whilst methods demonstrated the consistent preparation of the correct co-crystalline 
phase, additional platform optimisation needs to be conducted so as to achieve the production of the 
necessary material beyond a few residence times. In the case of the COBC, this requires re-evaluating 
the inner surface of the crystalliser, to minimise the possibility of undesired heterogeneous nucleation 
that could cause encrustation, as well as changing the orientation of the crystalliser to the horizontal 
geometry. The aim of this being to stop blockages at the bend units between the straights. For the 
KRAIC, further development needs to be conducted to reduce the likelihood of blockages at the end 
piece, with additional investigations into the homogeneity of the crystallisation coil tubing, again to 
minimise the possibility of heterogeneous primary nucleation.  
 
10.1 Future work 
 
The specific aspects of future work to be carried out are outlined in detail at the end of each research 
chapter (Chapters 6-9). Broadly, all research to be conducted focusses on two main areas; further 
material screening and crystallisation development. 
 
In terms of material screening with NPX, co-formers should be selected based on functionalities that 
are deemed likely to interact with the API. Consideration should also be given to other groups that may 
influence these intermolecular interactions, with the eventual aim of generating multi-component 
materials that are able to preferentially form the enantiopure phase towards racemic compositions, i.e. 
a racemic conglomerate. Supposing that a conglomerate was found, further work should be conducted 
into the development of processes that can apply these materials in the resolution of the different chiral 
forms. In order for a robust preferential crystallisation to be developed, additional work should be done 
to explore methods for the in-line assessment of solution enantiomeric composition. Circular dichroism 
offers a unique opportunity to achieve this, given its ability to monitor solution concentration, as well 
as chiral compositions. These ideas form the basis of the on-going collaboration between the Wilson 
(University of Bath) and ter Horst (University of Strathclyde) groups, as part of the EPSRC Future 
Manufacturing Hub, aiming to develop methods for the complete resolution of enantiomers via 
crystallisation. 
 
Furthermore, additional work should be carried out into the optimisation of the continuous 
crystallisation platforms based at the University of Bath; the COBC and the KRAIC. By changing the 
setup orientation of the COBC and improving the filtration unit within the KRAIC, these systems can 
be vastly improved. Through the implementation of enhanced temperature control, particularly for the 
segmented flow crystalliser, crystallisations can be developed that could allow for the selective 
preparation of the less stable co-crystalline form of OA and U, that of the (1:1) phase. Collectively, the 
observations made from the study with OA and U could benefit other systems in terms of developing 
methods for the selective preparation of structurally variant (polymorphic or stoichiometric) multi-
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Appendix (A3) Chapter 3 
 
 Table A3. 1 - CSD search for single and multi-component materials of NPX, highlighting crystallographic parameters 
 
















BEXGUI 13.122 5.898 24.075 90 95.56 90 P21 293 
C14 H14 O3 








BEYTUW 6.1054 12.475 49.1664 90 90 90 Pbca 293 
C14 H14 O3 






COYRUD 13.315 5.7765 7.8732 90 93.88 90 P21 295 C14 H14 O3 
N/A 
4 COYRUD01 7.855 5.783 13.349 90 93.9 90 P21 295 C14 H14 O3 
5 COYRUD11 13.375 5.793 7.914 90 93.91 90 P21 295 C14 H14 O3 
6 COYRUD12 7.7354 5.7181 13.3641 90 93.737 90 P21 102 C14 H14 O3 
7 COYRUD13 7.8759 5.7834 13.323 90 93.877 90 P21 298 C14 H14 O3 
8 COYRUD14 7.7162 5.7022 13.371 90 93.73 90 P21 100 C14 H14 O3 
9 
Co-former + sNPX 
(1:2) 







2(C14 H14 O3) 





DEQYIH 11.1692 6.3276 12.898 90 93.33 90 P21 295 
C14 H13 O3 1- 




Co-former + sNPX 
monohydrate 
EZEKUP 12.568 11.93 16.956 90 102.4 90 P21 295 
C23 H32 N4 O1 
2(C14 H14 O3) 








FEVZOX 5.7713 6.252 23.8346 90 92.047 90 P21 293 
C14 H14 O3 






FEVZUD 5.6999 6.5428 23.1874 90 94.835 90 P21 293 
C14 H14 O3 





14 Co-former + sNPX FIWYUH 15.9309 6.3941 18.8138 90 107.606 90 P21 296 
C14 H13 O3 1- 
C6 H14 N1 1+ 
Cyclohexanaminium  
15 Co-former + sNPX FIWZOC 11.632 5.9372 13.377 90 90.327 90 P21 296 
C7 H10 N1 1+ 
C14 H13 O3 1- 
Benzylammonium  
16 Co-former + sNPX FIWZUI 5.7688 8.478 48.065 90 90 90 P212121 296 
C14 H16 N1 1+ 
C14 H13 O3 1- 
Dibenzylammonium  
17 Co-former + sNPX GIPTIJ 9.5594 5.8786 29.704 90 96.345 90 P21 293 
C5 H6 N1 1+ 
C14 H13 O3 1- 
Pyridinium  
18 
Co-former + sNPX 
(JULEH) 1:2 
HEGGAD 5.96338 15.1283 32.5411 90 90 90 P212121 223 
2(C14 H14 O3) 
C6 H6 N2 O1 
Nicotinamide 
19 HEGGAD01 5.96338 15.1283 32.5411 90 90 90 P212121 223 
2(C14 H14 O3) 




HIFRIX 11.6395 5.9814 13.6907 90 94.462 90 P21 295 
C8 H12 N1 1+ 





JASHOB 14.662 9.225 17.129 90 113.865 90 C2 295 
C6 H15 N4 O2 1+ 
C14 H13 O3 1- 
(S)-Arginine  
22 
Co-former + rsNPX 
(HEGGAD) 1:2 
JULJEH 16.0822 5.7965 32.892 90 99.314 90 P21/c 293 
2(C14 H14 O3) 












C14 H14 O3 
C14 H31 N1 O5 
N-octyl-D-(-)-glucamine 
24 




NABMAH 26.87 5.4794 15.955 90 102.335 90 C2 200 
C13 H14 N1 O1 1+ 







OKIQAA 12.32 5.854 13.929 90 97.971 90 P21 293 
C9 H12 N1 O1 1+ 








PAMPIF 23.818 5.5862 15.671 90 113.803 90 C2 150 
C8 H12 N1 O1 1+ 





27 Co-former + sNPX PAMQAX 5.8146 6.2269 49.37 90 90.531 90 P21 293 
C14 H14 O3 
C6 H6 N2 O1 
Isonicotinamide 
28 rsNPX PAPTUX 25.8301 15.4939 5.9465 90 90 90 Pbca 298 C14 H14 O3 N/A 
29 Co-former + sNPX POPVAR 5.8526 16.166 26.694 90 90 90 P212121 295 
C14 H19 N2 O2 S1 
1+ 








QANPEB 9.145 9.145 43.307 90 90 120 P3221 295 
C6 H15 N4 O2 1+ 





RODSEK 5.05836 7.1121 45.2723 90 90 90 P212121 100 
C14 H14 O3 
C3 H7 N1 O2 




RODSIO 5.3366 6.9013 44.227 90 90 90 P212121 150 
C14 H14 O3 
C3 H7 N1 O2 




RODSOU 5.88418 11.3844 34.6863 90 90 90 P212121 150 
C14 H14 O3 








RODSUA 9.4508 5.9725 18.9525 90 103.814 90 P21 295 
C14 H14 O3, 




35 Co-former + sNPX SAJCOY 5.3048 31.891 10.508 90 98.184 90 P21 120 
C14 H14 O3 
C6 H6 N2 O1 
Pyridine-2-carboxamide 
36 
Co-former + sNPX 
monohydrate 
TAMDAP 10.0057 5.9515 15.3212 90 99.389 90 P21 296 
C14 H13 O3 1- 




37 Co-former + sNPX TAMDET 9.7396 6.11 14.6168 90 95.383 90 P21 296 
C5 H7 N2 1+ 






TERYEU 12.688 11.894 16.876 90 101.78 90 P21 295 
C23 H31 N4 O1 1+ 
C14 H13 O3 1- 
C14 H14 O3 









Co-former + rsNPX 
(TOBMAA) (1:2) 
TOBLUT 7.624 5.8 36.02 90 90.017 90 P21/c 173 
2(C14 H14 O3) 
C10 H8 N2 
4,4'-bipyridine 
40 
Co-former + sNPX 
(TOBLUT) (1:2) 
TOBMAA 15.206 5.766 19.37 90 111.189 90 P21 173 
2(C14 H14 O3) 
C10 H8 N2 
41 
Co-former + sNPX 
(TOBMII) (1:2) 
TOBMEE 7.966 6.012 28.985 90 91.739 90 P21/c 173 
2(C14 H14 O3) 
C4 H10 N2 
Piperazine 
42 
Co-former + sNPX 
(TOBMEE) (1:2) 
TOBMII 8.029 6.118 28.045 90 93.99 90 P21 173 
2(C14 H14 O3) 




YALWEO 5.301 15.006 28.421 90 90 90 P212121 298 
C13 H14 N1 O1 1+ 
C14 H13 O3 1- 
(1S,2S)-trans-1-
Aminobenz[f]indan-2-ol  
44 Co-former + sNPX YOCZUL 8.538 10.596 6.815 
106.8
4 
108.6 99.84 P1 295 
C14 H14 O3 
C10 H2 N4 
1,2,4,5-tetracyanobenzene 
45 Co-former + sNPX ZIFQOU 15.179 21.407 27.67 90 90 90 P212121 258 
C63 H112 O35 





46 Co-former + sNPX TEQCAW 6.312 8.531 33.196 90 90 90 P212121 296 
C14 H13 O3 1- 




47 Co-former + rNPX TEQDIF 9.239 6.523 14.92 90 101.94 90 P21 120 
C14 H13 O3 1- 





NIFGOB 9.978 6.0394 16.685 90 101.711 90 P21 90 
C14 H13 O3 1- 




















OXALAC03 6.548(5) 7.844(5) 6.086(5) 90 90 90 312.592 Pbca 
Oxalic acid 
(OA-β) 




OXACDH01 6.102(<1) 3.497(<1) 11.959(<1) 90 105.77(<1) 90 245.612 P21/n 
Urea 
(U-I) 
UREAXX30 5.638(4) 5.638(4) 4.714(3) 90 90 90 149.844 P–4 21 m 
Urea 
(U-III) 
UREAXX37 3.420(1) 8.145(3) 8.758(4) 90 90 90 243.969 P212121 
Urea 
(U-IV) 
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Table A5. 1 – The CIF files corresponding to the multi-component materials prepared during this research, found on the 
accompanying CD-ROM 
  
File number File name Multi-component material 
1 1_sNPX_2AP_11.cif S-naproxen:2-aminopyridine (1:1) salt 
2 2_rsNPX_2AP_11.cif RS-naproxen:2-aminopyridine (1:1) salt 
3 3_sNPX_2APM_21.cif S-naproxen:2-aminopyrimidine (2:1) co-crystal 
4 4_sNPX_2APM_11.cif S-naproxen:2-aminopyrimidine (1:1) co-crystal 
5 5_rsNPX_2APM_11.cif RS-naproxen:2-aminopyrimidine (1:1) co-crystal 
6 6_sNPX_2ADMP_11.cif S-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal 
7 7_rsNPX_2ADMP_11.cif RS-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal 
8 8_sNPX_2A3CP_11.cif S-naproxen:2-amino-3-chloropyridine (1:1) co-crystal 
9 9_rsNPX_2A3CP_11.cif RS-naproxen:2-amino-3-chloropyridine (1:1) co-crystal 
10 10_sNPX_2A4CP_21.cif S-naproxen:2-amino-4-chloropyridine (2:1) salt 
11 11_rsNPX_2A4CP_11.cif RS-naproxen:2-amino-4-chloropyridine (1:1) co-crystal 
12 12_sNPX_2A5CP_11.cif S-naproxen:2-amino-5-chloropyridine (1:1) co-crystal 
13 13_rsNPX_2A5CP_11.cif RS-naproxen:2-amino-5-chloropyridine (1:1) co-crystal 
14 14_sNPX_2A6CP_11.cif S-naproxen:2-amino-6-chloropyridine (1:1) co-crystal 
15 15_sNPX_I_21.cif S-naproxen:imidazole (2:1) salt 
16 16_rsNPX_I_21.cif RS-naproxen:imidazole (2:1) salt 
17 17_sNPX_BI_11.cif S-naproxen:benzimidazole (1:1) co-crystal 
18 18_rsNPX_BI_11.cif RS-naproxen:benzimidazole (1:1) co-crystal 
19 19_sNPX_A_11_FormI.cif S-naproxen:acridine (1:1) co-crystal Form I 
20 20_sNPX_A_11_FormII.cif S-naproxen:acridine (1:1) co-crystal Form II 
21 21_sNPX_A_23.cif S-naproxen:acridine (2:3) co-crystal 
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Figure A6. 2 - PXRD patterns, highlighting the change in phase from the racemic to the enantiopure NPX, with increasing 






Figure A6. 3 - DSC traces, highlighting the change in phase from the racemic to the enantiopure NPX, with increasing molar 
contributions of sNPX 
 
Table A6. 1 - Saturation of ethanol solutions with varying compositions of sNPX and rNPX (excess sNPX) at 20oC and 30oC, 
respectively, utilised for the construction of a ternary phase diagram 
 
Mole fraction of 
sNPX 
Saturation of NPX 
at 20oC 
(mmol/mol) 
Saturation of NPX 
at 30oC 
(mmol/mol) 
0.5 7.7 11.5 
0.6 8.4 12.2 
0.7 10.1 13.8 
0.75 11.4 15.8 
0.8 13.1 16.7 
0.85 13.4 17.5 
0.9 13.6 18.4 
0.95 13.1 18.5 






Figure A6. 4 - Molar ellipticity, taken over a range of wavelengths, for 0.75mM, 0.5mM and 0.25mM ethanol solutions of 





A6.2 Materials of racemic and enantiopure naproxen with 2-aminopyridine (2AP) 
 





































Figure A6. 5 - PXRD patterns from mechanochemically prepared samples of sNPX and 2AP, ground with minimum ethanol 




Figure A6. 6 - DSC traces from mechanochemically prepared samples of sNPX and 2AP, ground with minimum ethanol in 






Figure A6. 7 - PXRD patterns from mechanochemically prepared samples of sNPX and 2AP, ground in a 1:1 molar ratio 







Figure A6. 8 - DSC traces corresponding to the mechanochemical combination of rsNPX and sNPX, in different 




Figure A6. 9 - DSC traces corresponding to the mechanochemical combination of rNPX and sNPX, in different enantiomeric 







Figure A6. 10 - Key functional groups of the S-naproxen:2-aminopyridine (1:1) salt, with the atoms associated with 
hydrogen bonding and proton transfer highlighted 
 
Table A6. 3 - Hydrogen bonding interactions with the S-naproxen:2-aminopyridine (1:1) salt, highlighting the key 
interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N2 H2A O2 0.86 1.73 2.583(3) 169.1 
N1 H1A O1 0.86 2.01 2.850(4) 166.3 









Figure A6. 11 - Key functional groups of the RS-naproxen:2-aminopyridine (1:1) salt, with the atoms associated with 
hydrogen bonding and proton transfer highlighted 
 
Table A6. 4 - Hydrogen bonding interactions with the RS-naproxen:2-aminopyridine (1:1) salt, highlighting the key 
interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N2 H2A O2 0.86 1.76 2.6130(17) 174.3 
N1 H1A O1 0.86 2.04 2.8452(17) 155.5 









Figure A6. 12 - PXRD patterns of three iterations of solid material produced via the 1:1 slurrying of sNPX and 2AP at 20oC, 




Figure A6. 13 - DSC traces of three iterations of solid material produced via the 1:1 slurrying of sNPX and 2AP at 20oC, 200 






Figure A6. 14 - PXRD patterns of three iterations of solid material produced via the 1:1 slurrying of rsNPX and 2AP at 20oC, 




Figure A6. 15 - DSC traces of three iterations of solid material produced via the 1:1 slurrying of rsNPX and 2AP at 20oC, 






Figure A6. 16 - Solubility data of the S-naproxen:2-aminopyridine (1:1) and RS-naproxen:2-aminopyridine (1:1) salts in 
isopropanol, as determined from turbidity measurements (concentration taken with respect to NPX) (% error less than 1%) 
 
Table A6. 5 - Clear points of the S-naproxen:2-aminopyridine (1:1) and RS-naproxen:2-aminopyridine (1:1) salts in 
isopropanol, at 20oC and 30oC (concentration taken with respect to NPX) 
 
Material Solvent 
Clear point at 20oC 
(NPX mmol/mol) 
Clear point at 30oC 
(NPX mmol/mol) 
S-naproxen:2-












Figure A6. 17 - PXRD patterns of the solid yielded from the slurrying of varying enantiomeric compositions of sNPX and 




Figure A6. 18 - PXRD patterns of the solid yielded from the slurrying of varying enantiomeric compositions of sNPX and 







Table A6. 6 - Saturation of ethanol solutions with varying compositions of sNPX and rNPX (excess sNPX), in a 1:1 




Saturation of NPX-2AP 
(1:1) at 20oC 
(NPX mmol/mol) 
Saturation of NPX-2AP 
(1:1) at 30oC 
(NPX mmol/mol) 
0.5 13.3 30.7 
0.6 13.3 23.1 
0.7 14.2 26.7 
0.75 15.5 29.3 
0.8 16.9 32.4 
0.85 18.3 33.7 
0.9 18.1 31.7 
0.95 - 28.4 








Figure A6. 19 - PXRD patterns of the solid yielded from cooling crystallisations, utilising 1:1 ethanol solutions of NPX to 
2AP, with varying enantiomeric compositions (80:20, 75:25 and 70:30, excess sNPX), cooled at 0.1oC/min from 45oC to 




Figure A6. 20 - PXRD patterns of the solid yielded from cooling crystallisations, utilising 1:1 ethanol solutions of NPX to 
2AP, with varying enantiomeric compositions (80:20, 75:25 and 70:30, excess sNPX), cooled at 0.1oC/min from 45oC to 5oC, 








Figure A6. 21 - PXRD patterns of the solid yielded from cooling crystallisations, utilising 1:1 ethanol solutions of NPX to 
2AP, with varying enantiomeric compositions (80:20, 75:25 and 70:30, excess sNPX), cooled at 0.1oC/min from 45oC to 0oC, 




Figure A6. 22 - PXRD patterns of the solid yielded from cooling crystallisations, utilising 1:1 ethanol solutions of NPX to 
2AP, with varying enantiomeric compositions (80:20, 75:25 and 70:30, excess sNPX), cooled at 0.1oC/min from 45oC to 5oC, 






Figure A6. 23 - PXRD patterns of the solid yielded from cooling crystallisations, utilising 1:1 ethanol solutions of NPX to 
2AP, with varying enantiomeric compositions (80:20, 75:25 and 70:30, excess sNPX), cooled at 0.1oC/min from 45oC to 0oC, 







Figure A6. 24 - PXRD patterns of the solid yielded from cooling crystallisations, utilising 1:1 ethanol solutions of NPX to 
2AP, with varying enantiomeric compositions (80:20, 75:25 and 70:30, excess sNPX), cooled at 1oC/min from 45oC to 5oC, 




Figure A6. 25 - PXRD patterns of the solid yielded from cooling crystallisations, utilising 1:1 ethanol solutions of NPX to 
2AP, with varying enantiomeric compositions (80:20, 75:25 and 70:30, excess sNPX), cooled at 1oC/min from 45oC to 0oC, 







Figure A6. 26 - PXRD patterns of the solid yielded from cooling crystallisations, utilising 1:1 ethanol solutions of NPX to 
2AP, with varying enantiomeric compositions (80:20, 75:25 and 70:30, excess sNPX), cooled at 1oC/min from 45oC to 10oC, 




Figure A6. 27 - PXRD patterns of the solid yielded from cooling crystallisations, utilising 1:1 ethanol solutions of NPX to 
2AP, with varying enantiomeric compositions (80:20, 75:25 and 70:30, excess sNPX), cooled at 1oC/min from 45oC to 5oC, 







Figure A6. 28 - PXRD patterns of the solid yielded from cooling crystallisations, utilising 1:1 ethanol solutions of NPX to 
2AP, with varying enantiomeric compositions (80:20, 75:25 and 70:30, excess sNPX), cooled at 1oC/min from 45oC to 0oC, 
mixing at 600 rpm 
295 
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Table A7. 1 - Crystallographic data for the co-formers 2-aminopyrimidine (2APM), 2-amino-4,6-dimethylpyrimdine (2ADMP), 2-amino-3-chloropyridine (2A3CP), 2-amino-4-chloropyridine 
(2A4CP), 2-amino-5-chloropyridine (2A5CP) and  2-amino-6-chloropyridine (2A6CP), as found from the CSD 
 































XONQAU 11.934(1) 4.699(<1) 11.225(1) 90 112.60(<1) 90 581.178 P21 /c 100 C5H5ClN2 
*No previously published structures of 2-amino-4-chloropyridine (2A4CP) could be found in the CSD as of July 2018
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Figure A7. 1 - HSM images of the S-naproxen:2-aminopyrimidine (1:1) co-crystal, prepared via seeded crash cooling 




Figure A7. 2 - HSM images of the RS-naproxen:2-aminopyrimidine (1:1) co-crystal, prepared via crash cooling 






Figure A7. 3 - IR spectra of the S-naproxen:2-aminopyrimidine (2:1) & (1:1) co-crystals, the RS-naproxen:2-







Figure A7. 4 - PXRD patterns, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystal of NPX 




 Figure A7. 5 - DSC traces, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystal of NPX and 








Figure A7. 6 - Asymmetric unit of S-naproxen:2-aminopyrimidine (2:1) co-crystal, highlighting labelling of atoms involved 
in key intermolecular interactions 
 
Table A7. 2 - Hydrogen bonding interactions with the S-naproxen:2-aminopyrimidine (2:1) co-crystal, highlighting the key 
interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N1 H1A O1 0.86 2.16 2.941(4) 150.9 
N1 H1C O1' 0.86 2.08 2.921(4) 167.3 
N1A H1AA O1A 0.86 2.02 2.879(4) 173.3 
O2' H2' N3 1.006(14) 1.698(15) 2.701(4) 174(5) 
O2 H2 N2 1.003(14) 1.696(16) 2.691(4) 171(4) 
O2A H2AA N2A 1.001(14) 1.75(3) 2.725(4) 163(7) 







Figure A7. 7 - Asymmetric unit of S-naproxen:2-aminopyrimidine (1:1) co-crystal, highlighting labelling of atoms involved 
in key intermolecular interactions 
 
Table A7. 3 - Hydrogen bonding interactions with the S-naproxen:2-aminopyrimidine (1:1) co-crystal, highlighting the key 
interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
O2' H2' N2' 0.82 1.80 2.602(3) 164.8 
N1 H1A O1 0.86 2.07 2.919(3) 167.7 
N1 H1B O1'1 0.86 2.28 3.001(4) 142.0 
N1' H1'A O12 0.86 2.22 2.930(4) 140.0 
N1' H1'B O1' 0.86 2.16 3.007(3) 169.0 











Figure A7. 8 - Asymmetric unit of RS-naproxen:2-aminopyrimidine (1:1) co-crystal, highlighting labelling of atoms 
involved in key intermolecular interactions 
 
Table A7. 4 - Hydrogen bonding interactions with the RS-naproxen:2-aminopyrimidine (1:1) co-crystal, highlighting the key 
interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N1 H1A O11 0.86 2.23 2.9967(17) 148.2 
N1 H1B O1 0.86 2.13 2.9748(17) 168.3 












Figure A7. 9 - PXRD patterns from mechanochemically prepared samples of sNPX and 2ADMP, ground neat in either 2:1, 




Figure A7. 10 - DSC traces from mechanochemically prepared samples of sNPX and 2ADMP, ground neat in either 2:1, 1:1 




Figure A7. 11 - PXRD patterns from mechanochemically prepared samples of rsNPX and 2ADMP, ground neat in either 2:1, 




Figure A7. 12 - DSC traces from mechanochemically prepared samples of rsNPX and 2ADMP, ground neat in either 2:1, 1:1 






Figure A7. 13 - HSM images of the S-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal, prepared via crash cooling 




Figure A7. 14 - HSM images of the RS-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal, prepared via crash 




Figure A7. 15 - IR spectra of the S-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) and RS-naproxen:2-amino-4,6-





Figure A7. 16 - PXRD patterns, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystal of 




Figure A7. 17 - DSC traces, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystal of NPX 








Figure A7. 18 - Asymmetric unit of S-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal, highlighting labelling of 
atoms involved in key intermolecular interactions 
 
Table A7. 5 - Hydrogen bonding interactions with the S-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal, 
highlighting the key interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
O2' H2' N2'1 0.82 1.82 2.629(4) 168.7 
N1' H1'A N32 0.86 2.18 3.040(4) 178.9 
N1' H1'B O1'3 0.86 2.14 2.976(4) 163.5 
O2 H2 N24 0.82 1.88 2.683(4) 165.8 
N1 H1A N3'5 0.86 2.10 2.962(4) 177.3 



















Figure A7. 19 - Asymmetric unit of RS-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal, highlighting labelling of 
atoms involved in key intermolecular interactions 
 
Table A7. 6 - Hydrogen bonding interactions with the RS-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal, 
highlighting the key interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N1 H1A N31 0.86 2.14 3.002(3) 178.4 
N1 H1B O12 0.86 2.12 2.957(3) 163.7 










Figure A7. 20 - Labelled atoms, highlighting disorder in the RS-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal 
 
Table A7. 7 - Atomic occupancy of disordered atoms in the RS-naproxen:2-amino-4,6-dimethylpyrimidine (1:1) co-crystal 
 
Atom Occupancy Atom Occupancy Atom Occupancy 
C13 0.913(5) H13 0.913(5) C25 0.913(5) 
H25A 0.913(5) H25B 0.913(5) H25C 0.913(5) 
C13A 0.087(5) H13A 0.087(5) C25A 0.087(5) 









Figure A7. 21 - IR spectra of the S-naproxen:2-amino-3-chloropyridine (1:1) and RS-naproxen:2-amino-3-chloropyridine 



























Figure A7. 22 - PXRD patterns, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystal of 




Figure A7. 23 - DSC traces, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystal of NPX 
















Figure A7. 24 - Asymmetric unit of S-naproxen:2-amino-3-chloropyridine (1:1) co-crystal, highlighting labelling of atoms 
involved in key intermolecular interactions 
 
Table A7. 8 - Hydrogen bonding interactions with the RS-naproxen:2-amino-3-chloropyridine (1:1) co-crystal, highlighting 
the key interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
O2 H2 N2 0.82 1.82 2.636(2) 170.5 
N1 H1A O1 0.86 2.11 2.948(2) 163.9 









Figure A7. 25 - Asymmetric unit of RS-naproxen:2-amino-3-chloropyridine (1:1) co-crystal, highlighting labelling of atoms 
involved in key intermolecular interactions 
 
Table A7. 9 - Hydrogen bonding interactions with the RS-naproxen:2-amino-3-chloropyridine (1:1) co-crystal, highlighting 
the key interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N1 H1A O11 0.86 2.22 3.016(6) 154.5 
N1 H1B O1 0.86 2.16 2.991(7) 161.3 









Figure A7. 26 - Labelled atoms, highlighting disorder in the RS-naproxen:2-amino-3-chloropyridine (1:1) co-crystal (sNPX 
in red, rNPX in blue) 
 
Table A7. 10 - Atomic occupancy of disordered atoms in the RS-naproxen:2-amino-3-chloropyridine (1:1) co-crystal 
 
Atom Occupancy Atom Occupancy Atom Occupancy 
C2 0.813(10) H2A 0.813(10) C3 0.813(10) 
H3A 0.813(10) H3B 0.813(10) H3C 0.813(10) 
C2A 0.187(10) H2AA 0.187(10) C3A 0.187(10) 









Figure A7. 27 - PXRD patterns of mechanochemical preparations of sNPX with 2A4CP in a 1:1 molar ratio, ground either 




Figure A7. 28 - DSC traces of mechanochemical preparations of sNPX with 2A4CP in a 1:1 molar ratio, ground either neat, 






Figure A7. 29 - IR spectra of the S-naproxen:2-amino-4-chloropyridine co-crystal (mechanochemically prepared) and RS-






Figure A7. 30 - PXRD patterns, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystal of 
NPX and 2A4CP, with increasing molar contributions of sNPX, prepared mechanochemically with ethanol (100:0, 90:10, 




Figure A7. 31 - DSC traces, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystal of NPX 







Figure A7. 32 - Asymmetric unit of S-naproxen:2-amino-4-chloropyridine (2:1) salt, highlighting labelling of atoms 
involved in key intermolecular interactions 
 
Table A7. 11 - Hydrogen bonding interactions with the S-naproxen:2-amino-4-chloropyridine (2:1) salt, highlighting the key 
interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N1 H1 O11 0.86 1.86 2.717(7) 172.1 
N2 H2A O21 0.86 1.89 2.741(8) 173.3 
N2 H2B O2 0.86 1.99 2.773(8) 150.9 









Figure A7. 33 - Asymmetric unit of RS-naproxen:2-amino-4-chloropyridine (1:1) co-crystal, highlighting labelling of atoms 
involved in key intermolecular interactions 
 
Table A7. 12 - Hydrogen bonding interactions with the RS-naproxen:2-amino-4-chloropyridine (1:1) co-crystal, highlighting 
the key interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N1 H1A O1 0.86 2.11 2.946(3) 163.8 
N1 H1B O11 0.86 2.23 2.866(3) 131.1 












Figure A7. 34 - IR spectra of the S-naproxen:2-amino-5-chloropyridine (1:1) and RS-naproxen:2-amino-5-chloropyridine 






Figure A7. 35 - PXRD patterns, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystal of 
NPX and 2A5CP, with increasing molar contributions of sNPX, prepared mechanochemically with ethanol (100:0, 90:10, 




Figure A7. 36 - DSC traces, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystal of NPX 






Figure A7. 37 - Asymmetric unit of S-naproxen:2-amino-5-chloropyridine (1:1) co-crystal, highlighting labelling of atoms 
involved in key intermolecular interactions 
 
Table A7. 13 - Hydrogen bonding interactions with the S-naproxen:2-amino-5-chloropyridine (1:1) co-crystal, highlighting 
the key interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N1 H1A O1 0.86 2.13 2.928(2) 154.8 
N1 H1B O11 0.86 2.13 2.944(2) 158.5 









Figure A7. 38 - Asymmetric unit of RS-naproxen:2-amino-5-chloropyridine (1:1) co-crystal, highlighting labelling of atoms 
involved in key intermolecular interactions 
 
Table A7. 14 - Hydrogen bonding interactions with the RS-naproxen:2-amino-5-chloropyridine (1:1) co-crystal, highlighting 
the key interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N1 H1A O1 0.86 2.10 2.948(3) 167.7 
N1 H1B O11 0.86 2.15 2.942(3) 152.9 












Figure A7. 39 - PXRD patterns of mechanochemical preparations of sNPX with 2A6CP in a 1:1 molar ratio, ground with 




Figure A7. 40 - DSC traces of mechanochemical preparations of sNPX with 2A6CP in a 1:1 molar ratio, ground with 





Figure A7. 41 - PXRD patterns of the S-naproxen:2-amino-6-chloropyridine (1:1) co-crystal, as derived from SCXRD, 











Figure A7. 43 - IR spectra of 1:1 mechanochemically prepared samples of either sNPX or rsNPX with 2A6CP, compared to 





Figure A7. 44 - PXRD patterns, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystal of 
NPX and 2A6CP, with increasing molar contributions of sNPX, prepared mechanochemically with ethanol (100:0, 90:10, 





Figure A7. 45 - Asymmetric unit of S-naproxen:2-amino-6-chloropyridine (1:1) co-crystal, highlighting labelling of atoms 
involved in key intermolecular interactions 
 
Table A7. 15 - Hydrogen bonding interactions with the S-naproxen:2-amino-6-chloropyridine (1:1) co-crystal, highlighting 
the key interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N1 H1A O1 0.86 2.11 2.936(4) 160.7 
N1 H1B O11 0.86 2.09 2.917(3) 161.4 
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IMAZOL21 7.326(7) 4.997(4) 9.556(9) 90 122.68(7) 90 294.449 P21/c 283-303 C3H4N2 
Imidazole (I) 
Form β 
IMAZOL22 14.250(8) 8.623(4) 5.399(4) 90 90 90 663.417 Aba2 283-303 C3H4N2 
Benzimidazole (BI) 
Form α 
BZDMAZ02 13.492(3) 6.805(1) 6.939(1) 90 90 90 637.101 Pna21 283-303 C7H6N2 
Benzimidazole (BI) 
Form β 
BZDMAZ03 9.726(1) 16.688(1) 7.606(1) 90 90 90 1234.400 Pccn 283-303 C7H6N2 
Benzimidazole (BI) 
Form γ 
BZDMAZ05 9.782(6) 7.859(4) 12.967(8) 90 90 90 996.861 Pbca 283-303 C7H6N2 
Acridine (A) hydrate 
Form I 





ACRDIN01 11.375(3) 5.988(3) 13.647(3) 90 98.97 90 918.177 P21/n 283-303 C13H9N 
Acridine (A) 
Form III 
ACRDIN 16.292 18.831 6.072 90 95.07 90 1855.569 P21/a 283-303 C13H9N 
Acridine (A) 
Form IV 
ACRDIN03 15.610 29.340 6.220 90 90 90 2848.744 P212121 283-303 C13H9N 
Acridine (A) 
Form V* 
ACRDIN02 20.040 5.950 16.370 90 110.63 90 1826.759 Aa 283-303 C13H9N 
Acridine (A) 
Form VI 
ACRDIN05 6.174(2) 23.497(8) 12.868(4) 90 96.48(<1) 90 1854.830 Cc 187 C13H9N 
Acridine (A) 
Form VII 
ACRDIN06 6.057(1) 22.813(4) 13.204(2) 90 95.94(<1) 90 1814.687 P21/n 185 C13H9N 
*Only unit cell parameters have been determined, no atomic coordinates available
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Figure A8. 1 - PXRD patterns from mechanochemically prepared samples of sNPX and I, ground neat in either 2:1, 1:1 or 










Figure A8. 3 - PXRD patterns from mechanochemically prepared samples of rsNPX and I, ground neat in either 2:1, 1:1 or 











Figure A8. 5 - IR spectra of the S-naproxen:imidazole & RS-naproxen:imidazole (2:1) salts, prepared mechanochemically, 







Figure A8. 6 - PXRD patterns, highlighting the change in phase from the racemic to the enantiopure (2:1) salts of NPX and I, 




Figure A8. 7 - DSC traces, highlighting the change in phase from the racemic to the enantiopure (2:1) salts of NPX and I, 








Figure A8. 8 - Key functional groups and disordered atoms of the S-naproxen:imidazole (2:1) salt, highlighting labelled 
atoms of the (a) carboxylate and (b) carboxylic acid groups of sNPX, as well as that for (c) the co-former, I 
 
Table A8. 2 - Hydrogen bonding interactions with the S-naproxen:imidazole (2:1) salt, highlighting the key interaction 
lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N1 H1 O1 0.86 1.85 2.662(9) 156.8 
N2 H2A O21 0.86 1.87 2.710(5) 165.3 
N1A H1A O1 0.86 1.83 2.68(2) 174.2 
O1' H1' O2 1.002(14) 1.513(16) 2.509(6) 172(2) 
O1'A H1'A O2 1.001(14) 1.64(3) 2.612(12) 161(6) 




Table A8. 3 - Atomic occupancy of disordered atoms in the S-naproxen:imidazole (2:1) salt 
 
Atom Occupancy Atom Occupancy Atom Occupancy 
C15 0.705(5) H15 0.705(5) C16 0.705(5) 
H16 0.705(5) C17 0.705(5) H17 0.705(5) 
N1 0.705(5) H1 0.705(5) N2 0.705(5) 
H2A 0.705(5) C15A 0.295(5) H15A 0.295(5) 
C16A 0.295(5) H16A 0.295(5) C17A 0.295(5) 
H17A 0.295(5) N1A 0.295(5) H1A 0.295(5) 
N2A 0.295(5) H2AA 0.295(5) O1' 0.624(5) 
O2' 0.624(5) O1'A 0.376(5) O2'A 0.376(5) 








Figure A8. 9 - Key functional groups and disordered atoms of the RS-naproxen:imidazole (2:1) salt, highlighting labelled 
atoms of the (a) carboxylate and (b) carboxylic acid groups of NPX, as well as that for (c) the co-former, I 
 
Table A8. 4 - Hydrogen bonding interactions with the RS-naproxen:imidazole (2:1) salt, highlighting the key interaction 
lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N2 H2B O21 0.848(10) 1.834(11) 2.677(3) 173(3) 
N1 H1A O1'2 0.851(10) 1.854(13) 2.696(3) 170(4) 








 Table A8. 5 - Atomic occupancy of disordered atoms in the RS-naproxen:imidazole (2:1) salt 
 
Atom Occupancy Atom Occupancy Atom Occupancy 
C2' 0.910(3) H2'A 0.910(3) C3' 0.910(3) 
H3'A 0.910(3) H3'B 0.910(3) H3'C 0.910(3) 
C2 0.910(3) H2 0.910(3) C3 0.910(3) 
H3A 0.910(3) H3B 0.910(3) H3C 0.910(3) 
C3'A 0.090(3) H3'D 0.090(3) H3'E 0.090(3) 
H3'F 0.090(3) C2'A 0.090(3) H2'B 0.090(3) 
C2A 0.090(3) H2A 0.090(3) C3A 0.090(3) 










 Figure A8. 10 - PXRD patterns from mechanochemically prepared samples of sNPX and BI, ground neat in either 2:1, 1:1 or 











Figure A8. 12 - PXRD patterns from mechanochemically prepared samples of rsNPX and BI, ground neat in either 2:1, 1:1 




Figure A8. 13 - DSC traces from mechanochemically prepared samples of rsNPX and BI, ground neat in either 2:1, 1:1 or 







Figure A8. 14 - IR spectra of the S-naproxen:benzimidazole & RS-naproxen:benzimidazole (1:1) co-crystals, prepared 







Figure A8. 15 - PXRD patterns, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystals of 
NPX and BI, with increasing molar contributions of sNPX, prepared in a 1:1 API to co-former stoichiometry (100:0, 90:10, 




Figure A8. 16 - DSC traces, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystals of NPX 








Figure A8. 17 - Key functional groups and disordered atoms of the S-naproxen:benzimidazole (1:1) co-crystal, highlighting 
labelled atoms of the carboxylic acid functions that make up the key interaction unit, (a) and (b), as well as that for (c) the 
co-former, BI 
 
Table A8. 6 - Hydrogen bonding interactions with the S-naproxen:benzimidazole (1:1) co-crystal, highlighting the key 
interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
N1 H1 O1'1 0.963(13) 2.33(3) 2.934(3) 120(2) 
N1' H1' O1 0.965(14) 2.37(3) 2.973(3) 120(2) 
O2' H2' N2'2 1.001(14) 1.631(15) 2.623(3) 171(4) 






Table A8. 7 - Atomic occupancy of disordered atoms in the S-naproxen:benzimidazole (1:1) co-crystal 
 
Atom Occupancy Atom Occupancy Atom Occupancy 
C2' 0.599(6) H2'A 0.599(6) C3' 0.599(6) 
H3'A 0.599(6) H3'B 0.599(6) H3'C 0.599(6) 
C2'A 0.401(6) H2'B 0.401(6) C3'A 0.401(6) 








Figure A8. 18 - Key functional groups and disordered atoms of the RS-naproxen:benzimidazole (1:1) co-crystal, highlighting 
labelled atoms of the carboxylic acid functions that make up the key interaction unit, (a), as well as that for (b) the co-
former, BI 
 
Table A8. 8 - Hydrogen bonding interactions with the RS-naproxen:benzimidazole (1:1) co-crystal, highlighting the key 
interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
O2 H2 N21 0.998(10) 1.635(11) 2.6279(18) 173(3) 




Table A8. 9 - Atomic occupancy of disordered atoms in the RS-naproxen:benzimidazole (1:1) co-crystal 
 
Atom Occupancy Atom Occupancy Atom Occupancy 
C2 0.583(4) H2A 0.583(4) C3 0.583(4) 
H3A 0.583(4) H3B 0.583(4) H3C 0.583(4) 
C2A 0.417(4) H2AA 0.417(4) C3A 0.417(4) 










Figure A8. 19 - PXRD patterns from mechanochemically prepared samples of sNPX and A, ground neat in either 2:1, 1:1 or 











Figure A8. 21 - PXRD patterns from mechanochemically prepared samples of rsNPX and A, ground neat in either 2:1, 1:1 or 











Figure A8. 23 - PXRD patterns from mechanochemically prepared samples of sNPX and A, ground a 1:1 molar ratio, either 




Figure A8. 24 - DSC traces from mechanochemically prepared samples of sNPX and A, ground a 1:1 molar ratio, either neat 





Figure A8. 25 - PXRD patterns from mechanochemically prepared samples of rsNPX and A, ground a 1:1 molar ratio, either 




Figure A8. 26 - DSC traces from mechanochemically prepared samples of rsNPX and A, ground a 1:1 molar ratio, either neat 





Figure A8. 27 - HSM images of individual crystals obtained from homochiral ethanol solutions, with 1:1 molar ratio of NPX 




Figure A8. 28 - HSM images of individual crystals obtained from homochiral acetonitrile solutions, with 1:1 molar ratio of 





Figure A8. 29 - HSM images of individual crystals obtained from seeded homochiral ethanol solutions, with 1:1 molar ratio 




Figure A8. 30 - HSM images of individual crystals obtained from racemic ethanol solutions, with 1:1 molar ratio of NPX to 





 Figure A8. 31 - IR spectra of the S-naproxen:acridine (1:1), Forms I & II, and (2:3) co-crystals, as well as the RS-








Figure A8. 32 - PXRD patterns, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystals of 




Figure A8. 33 - DSC traces, highlighting the change in phase from the racemic to the enantiopure (1:1) co-crystals of NPX 








Figure A8. 34 - Key functional groups and disordered atoms of the S-naproxen:acridine (1:1) co-crystal, Form I, highlighting 
the atoms involved in the two hydrogen bonding interactions, (a) and (b) 
 
  Table A8. 10 - Hydrogen bonding interactions with the S-naproxen:acridine (1:1) co-crystal, Form I, highlighting the key 
interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
O2' H2'A N1' 0.82 2.00 2.77(2) 155.3 
O1 H1 N1 0.996(14) 1.73(2) 2.677(3) 158(4) 
O2'A H2'B N1' 0.82 1.94 2.74(2) 166.1 
O2' H2'A N1' 0.82 2.00 2.77(2) 155.3 
 
Table A8. 11 - Atomic occupancy of disordered atoms in the S-naproxen:acridine (1:1) co-crystal, Form I 
 
Atom Occupancy Atom Occupancy Atom Occupancy 
O2' 0.504(8) H2'A 0.504(8) O1' 0.504(8) 








Figure A8. 35 - Key functional groups of the RS-naproxen:acridine (1:1) co-crystal, highlighting the atoms involved in 
hydrogen bonding 
 
Table A8. 12 - Hydrogen bonding interactions with the RS-naproxen:acridine (1:1) co-crystal, highlighting the key 
interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 









Figure A8. 36 - Key functional groups of the S-naproxen:acridine (1:1) co-crystal, Form II, highlighting atoms involved in 
hydrogen bonding 
 
Table A8. 13 - Hydrogen bonding interactions with the S-naproxen:acridine (1:1) co-crystal, Form II, highlighting the key 
interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 









Figure A8. 37 - Key functional groups of the S-naproxen:acridine (2:3) co-crystal, highlighting the atoms involved in 
hydrogen bonding, (a) and (b) 
 
  Table A8. 14 - Hydrogen bonding interactions with the S-naproxen:acridine (2:3) co-crystal, highlighting the key 
interaction lengths and angles 
 
D H A d(D-H) (Å) d(H-A) (Å) d(D-A) (Å) D-H-A (o) 
O002 H002 N007 0.82 2.02 2.809(3) 161.5 
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Table A9. 1 - Major endothermic thermal events (melting points) exhibited by the prepared and starting materials of OA and 
U, as determined by DSC 
 
Material Major thermal event (oC) 
Urea 
(U) 
133.9 – 135.3 
Oxalic acid 
(OA) 
190.8 – 192.0 
Oxalic acid dihydrate 
(OAD) 
99.4 – 102.6 
Oxalic acid:urea (1:1) co-crystal 
(OAU-1:1) 
175.4 – 175.7 
Oxalic acid:urea (1:2) co-crystal 
(OAU-1:2) 










Figure A9. 1 - PXRD patterns highlighting the mechanochemical 2:1 combinations of OA and U, either neat or with 







Figure A9. 2 - PXRD patterns highlighting the neat mechanochemical 2:1 combinations of OAD and U, ground for different 
time periods (top five patterns) 
 
 
Figure A9. 3 - PXRD patterns highlighting the neat mechanochemical 1:1 combinations of OAD and U, ground for different 






Figure A9. 4 - PXRD patterns highlighting the neat mechanochemical 1:2 combinations of OAD and U, ground for different 
time periods (top four patterns) 
 
 
Figure A9. 5 - PXRD patterns highlighting the neat mechanochemical 2:1 combinations of OA and U, ground for different 






Figure A9. 6 - PXRD patterns highlighting the neat mechanochemical 1:1 combinations of OA and U, ground for different 
time periods (top five patterns) 
 
 
Figure A9. 7 - PXRD patterns highlighting the neat mechanochemical 1:2 combinations of OA and U, ground for different 






Figure A9. 8 - PXRD patterns highlighting the mechanochemical 2:1 combinations of OA and U, ground with different 




Figure A9. 9 - PXRD patterns highlighting the mechanochemical 1:1 combinations of OA and U, ground with different 





Figure A9. 10 - PXRD patterns highlighting the mechanochemical 1:2 combinations of OA and U, ground with different 
volumes of water (top six patterns)  
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Figure A9. 11 - PXRD patterns highlighting the solid product yielded from initial slurrying experiments of a 1:1 combination 






Figure A9. 12 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x2 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 1 hour, utilising a range of 




Figure A9. 13 -PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x3 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 1 hour, utilising a range of 





Figure A9. 14 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x4 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 1 hour, utilising a range of 




Figure A9. 15 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x5 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 1 hour, utilising a range of 






Figure A9. 16 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x2 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 4 hours, utilising a range of 




Figure A9. 17 -PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x3 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 4 hours, utilising a range of 




Figure A9. 18 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x4 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 4 hours, utilising a range of 




Figure A9. 19 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x5 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 4 hours, utilising a range of 





Figure A9. 20 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x2 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 16 hours, utilising a range of 




Figure A9. 21 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x3 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 16 hours, utilising a range of 






Figure A9. 22 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x4 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 16 hours, utilising a range of 




Figure A9. 23 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x5 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 16 hours, utilising a range of 





Figure A9. 24 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x2 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 64 hours, utilising a range of 




Figure A9. 25 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x3 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 64 hours, utilising a range of 





Figure A9. 26 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x4 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 64 hours, utilising a range of 




Figure A9. 27 - PXRD patterns highlighting the solid product yielded from slurrying experiments in water, with a solid 
loading of x5 that of the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC, mixed for 64 hours, utilising a range of 
suspension stoichiometries (top six patterns)  
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Figure A9. 28 - PXRD patterns highlighting the crystalline phases yielded from evaporative crystallisations at 20oC, from 




Figure A9. 29 - PXRD patterns highlighting the crystalline phases yielded from evaporative crystallisations at 20oC, from 





Figure A9. 30 - PXRD patterns highlighting the crystalline phases yielded from evaporative crystallisations at 20oC, from 




Figure A9. 31 - PXRD patterns highlighting the crystalline phases yielded from evaporative crystallisations at 40oC, from 






Figure A9. 32 - PXRD patterns highlighting the crystalline phases yielded from evaporative crystallisations at 40oC, from 
water, methanol, ethanol and isopropanol, with oxalic acid and urea in a 1:1 stoichiometry 
 
 
Figure A9. 33 - PXRD patterns highlighting the crystalline phases yielded from evaporative crystallisations at 40oC, from 






Figure A9. 34 - PXRD patterns highlighting the crystalline phases yielded from evaporative crystallisations at 4oC, from 




Figure A9. 35 - PXRD patterns highlighting the crystalline phases yielded from evaporative crystallisations at 20oC, from 





Figure A9. 36 - PXRD patterns highlighting the crystalline phases yielded from evaporative crystallisations at 40oC, from 




Figure A9. 37 - PXRD patterns highlighting the crystalline phases yielded from evaporative crystallisations over a range of 
temperatures, from water, with oxalic acid and urea in a 1:1 stoichiometry (top eight patterns)  
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A9.4 Batch cooling crystallisation 
 
Table A9. 2 - Summary of the gravimetric analysis of the OA starting material in isopropanol, highlighting its solubility at 
20oC  
 





Solution (g) Solid (g) Solvent (g) Conc. (g/g) 
1 6.6172 7.565 6.7794 0.9478 0.1622 0.7856 0.2064 
2 6.6505 7.7001 6.8471 1.0496 0.1966 0.853 0.2304 
3 6.5888 7.6885 6.7921 1.0997 0.2033 0.8964 0.2267 







Figure A9. 38 - PXRD patterns highlighting the solid product yielded from cooling crystallisations from isopropanol over a 
number of OA to U stoichiometries (4:1, 3:1, 2:1, 1:1 and 1:2), with a solid loading of x1 that of the saturation of the OA 





Figure A9. 39 - PXRD patterns highlighting the solid product yielded from cooling crystallisations from isopropanol over a 
number of OA to U stoichiometries (4:1, 3:1, 2:1, 1:1 and 1:2), with a solid loading of x0.5 that of the saturation of the OA 




Figure A9. 40 - PXRD patterns highlighting the solid product yielded from cooling crystallisations from isopropanol over a 
number of OA to U stoichiometries (4:1, 3:1, 2:1, 1:1 and 1:2), with a solid loading of x0.25 that of the saturation of the OA 






Figure A9. 41 - PXRD patterns highlighting the solid product yielded from cooling crystallisations from isopropanol over a 
number of OA to U stoichiometries (4:1, 3:1, 2:1, 1:1 and 1:2), with a solid loading of x0.125 that of the saturation of the OA 




Figure A9. 42 - PXRD patterns highlighting the solid product yielded from cooling crystallisations from isopropanol over a 
number of OA to U stoichiometries (4:1, 3:1, 2:1, 1:1 and 1:2), with a solid loading of x0.0625 that of the saturation of the 





Figure A9. 43 - PXRD patterns highlighting the preparation of the oxalic acid:urea (1:2) co-crystal via cooling crystallisation 
at a variety of scales of water content (2g, 10g, 30g and 100g), saturated with respect to the co-crystal at 30oC, heated to 





Figure A9. 44 - PXRD patterns highlighting the solid product yielded from 5:1 preparations of the oxalic acid and urea 
cooling crystallisation, at three saturation levels (x2.5, x3 & x3.5 the solid mass of the oxalic acid:urea (1:2) co-crystal at 




Figure A9. 45 - PXRD patterns highlighting the solid product yielded from 4:1 preparations of the oxalic acid and urea 
cooling crystallisation, at three saturation levels (x2.5, x3 & x3.5 the solid mass of the oxalic acid:urea (1:2) co-crystal at 





Figure A9. 46 - PXRD patterns highlighting the solid product yielded from 3:1 preparations of the oxalic acid and urea 
cooling crystallisation, at three saturation levels (x2.5, x3 & x3.5 the solid mass of the oxalic acid:urea (1:2) co-crystal at 




Figure A9. 47 - PXRD patterns highlighting the solid product yielded from 2:1 preparations of the oxalic acid and urea 
cooling crystallisation, at three saturation levels (x2.5, x3 & x3.5 the solid mass of the oxalic acid:urea (1:2) co-crystal at 





Figure A9. 48 - PXRD patterns highlighting the solid product yielded from 5:1 preparations of the oxalic acid and urea 
cooling crystallisation, at three saturation levels (x2.5, x3 & x3.5 the solid mass of the oxalic acid:urea (1:2) co-crystal at 




Figure A9. 49 -PXRD patterns highlighting the solid product yielded from 4:1 preparations of the oxalic acid and urea 
cooling crystallisation, at three saturation levels (x2.5, x3 & x3.5 the sold mass of the oxalic acid:urea (1:2) co-crystal at 






Figure A9. 50 - PXRD patterns highlighting the solid product yielded from 3:1 preparations of the oxalic acid and urea 
cooling crystallisation, at three saturation levels (x2.5, x3 & x3.5 the solid mass of the oxalic acid:urea (1:2) co-crystal at 




Figure A9. 51 - PXRD patterns highlighting the solid product yielded from 2:1 preparations of the oxalic acid and urea 
cooling crystallisation, at three saturation levels (x2.5, x3 & x3.5 the solid mass of the oxalic acid:urea (1:2) co-crystal at 






Figure A9. 52 - PXRD patterns highlighting the solid product yielded from 5:1 preparations of the oxalic acid and urea 
cooling crystallisation, at three saturation levels (x3 & x3.5 the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC), 





Figure A9. 53 - PXRD patterns highlighting the solid product yielded from 4:1 preparations of the oxalic acid and urea 
cooling crystallisation, at three saturation levels (x3 & x3.5 the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC), 





Figure A9. 54 - PXRD patterns highlighting the solid product yielded from 3:1 preparations of the oxalic acid and urea 
cooling crystallisation, at three saturation levels (x3.5 the solid mass of the oxalic acid:urea (1:2) co-crystal at 30oC), heated 









Figure A9. 55 - PXRD patterns highlighting the solid material obtained from COBC runs 1-5, collected either as precipitate 




Figure A9. 56 - PXRD patterns, highlighting the phase of the solid product yielded from the second residence time as 
collected from the KRAIC 
